0001564590-21-015962.txt : 20210329 0001564590-21-015962.hdr.sgml : 20210329 20210329080042 ACCESSION NUMBER: 0001564590-21-015962 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 86 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210329 DATE AS OF CHANGE: 20210329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SCYNEXIS INC CENTRAL INDEX KEY: 0001178253 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 562181648 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36365 FILM NUMBER: 21779510 BUSINESS ADDRESS: STREET 1: 1 EVERTRUST PLAZA STREET 2: 13TH FLOOR CITY: JERSEY CITY STATE: NJ ZIP: 07302-6548 BUSINESS PHONE: 201-884-5485 MAIL ADDRESS: STREET 1: 1 EVERTRUST PLAZA STREET 2: 13TH FLOOR CITY: JERSEY CITY STATE: NJ ZIP: 07302-6548 10-K 1 scyx-10k_20201231.htm 10-K scyx-10k_20201231.htm
0001178253 --12-31 FY false 0.1 true true us-gaap:AccountingStandardsUpdate201813Member true 0.1 2037-12-31 0.21 0.1 P5Y P1Y P3Y6M P371D P5Y P2Y6M P10M24D P8Y7M2D P9Y7M2D P5Y11M19D P6Y10D P5Y6M P5Y6M14D P7Y7M13D P7Y8M15D P6Y8M26D P7Y8M15D 0 0 0001178253 2020-01-01 2020-12-31 xbrli:shares 0001178253 2021-03-01 iso4217:USD 0001178253 2020-06-30 0001178253 2020-12-31 0001178253 2019-12-31 iso4217:USD xbrli:shares 0001178253 2019-01-01 2019-12-31 0001178253 us-gaap:CommonStockMember 2018-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001178253 us-gaap:RetainedEarningsMember 2018-12-31 0001178253 2018-12-31 0001178253 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001178253 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001178253 us-gaap:CommonStockMember 2019-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001178253 us-gaap:RetainedEarningsMember 2019-12-31 0001178253 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001178253 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001178253 us-gaap:CommonStockMember 2020-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001178253 us-gaap:RetainedEarningsMember 2020-12-31 0001178253 us-gaap:SubsequentEventMember scyx:JanuaryTwentyThousandAndTwentyOneShelfRegistrationMember 2021-01-06 2021-01-08 0001178253 scyx:OctoberTwentyThousandAndTwentyShelfRegistrationMember 2020-09-29 2020-10-01 0001178253 scyx:SalesAgreementProspectusMember us-gaap:CommonStockMember scyx:OctoberTwentyThousandAndTwentyShelfRegistrationMember 2020-09-29 2020-10-01 xbrli:pure 0001178253 2020-07-14 2020-07-16 0001178253 2020-07-16 0001178253 2020-07-17 0001178253 2020-07-15 2020-07-17 0001178253 scyx:SixPercentAprilTwoThousandAndTwentyAndMarchTwoThousandAndNineteenConvertibleSeniorNotesMember 2020-12-31 0001178253 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001178253 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001178253 scyx:June2016PublicOfferingMember us-gaap:WarrantMember 2020-01-01 2020-12-31 0001178253 scyx:June2016PublicOfferingMember us-gaap:WarrantMember 2019-01-01 2019-12-31 0001178253 scyx:March2018PublicOfferingSeries2Member us-gaap:WarrantMember 2020-01-01 2020-12-31 0001178253 scyx:March2018PublicOfferingSeries2Member us-gaap:WarrantMember 2019-01-01 2019-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember us-gaap:WarrantMember 2020-01-01 2020-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember us-gaap:WarrantMember 2019-01-01 2019-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember scyx:OptionToPurchaseCommonStockMember 2020-01-01 2020-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember scyx:OptionToPurchaseCommonStockMember 2019-01-01 2019-12-31 0001178253 scyx:December2020PublicOfferingSeries1Member us-gaap:WarrantMember 2020-01-01 2020-12-31 0001178253 scyx:December2020PublicOfferingSeries1Member us-gaap:WarrantMember 2019-01-01 2019-12-31 0001178253 scyx:December2020PublicOfferingSeries2Member us-gaap:WarrantMember 2020-01-01 2020-12-31 0001178253 scyx:December2020PublicOfferingSeries2Member us-gaap:WarrantMember 2019-01-01 2019-12-31 0001178253 scyx:ConversionOfMarch2019NotesMember 2020-01-01 2020-12-31 0001178253 scyx:ConversionOfMarch2019NotesMember 2019-01-01 2019-12-31 0001178253 scyx:ConversionOfApril2020NotesMember 2020-01-01 2020-12-31 0001178253 scyx:ConversionOfApril2020NotesMember 2019-01-01 2019-12-31 0001178253 scyx:WarrantsAssociatedWithSolarLoanAgreementMember us-gaap:WarrantMember 2020-01-01 2020-12-31 0001178253 scyx:WarrantsAssociatedWithSolarLoanAgreementMember us-gaap:WarrantMember 2019-01-01 2019-12-31 scyx:Segment 0001178253 us-gaap:AccountingStandardsUpdate201813Member 2020-12-31 0001178253 us-gaap:AccountingStandardsUpdate201813Member 2020-01-01 2020-12-31 0001178253 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001178253 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0001178253 scyx:OvernightRepurchaseAgreementsMember 2019-12-31 0001178253 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001178253 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001178253 us-gaap:ComputerEquipmentMember 2020-12-31 0001178253 us-gaap:ComputerEquipmentMember 2019-12-31 0001178253 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2020-12-31 0001178253 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2019-12-31 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-03-10 2020-04-09 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-04-09 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-01-01 2020-12-31 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-12-31 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-06-01 2020-06-30 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-12-01 2020-12-31 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember us-gaap:SubsequentEventMember 2021-01-02 2021-01-31 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-06-30 utr:D 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-03-07 2019-03-07 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-03-07 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-01-01 2019-12-31 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-12-31 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2020-12-31 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2020-01-01 2020-12-31 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-04-01 2019-04-30 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-04-30 0001178253 us-gaap:SecuredDebtMember scyx:TermLoanMember 2016-09-29 2016-09-30 0001178253 us-gaap:SecuredDebtMember scyx:TermLoanMember 2016-09-30 0001178253 us-gaap:SecuredDebtMember scyx:TermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-09-29 2016-09-30 utr:sqft 0001178253 2018-03-01 0001178253 2018-02-28 2018-03-01 0001178253 srt:MaximumMember 2020-01-01 2020-12-31 0001178253 scyx:CypralisLimitedMember scyx:AssetPurchaseAgreementMember 2020-01-01 2020-12-31 0001178253 scyx:CypralisLimitedMember scyx:AssetPurchaseAgreementMember 2019-01-01 2019-12-31 0001178253 scyx:WaterstonePharmaceuticalHKLimitedMember scyx:LicenseAgreementMember 2020-01-01 2020-12-31 0001178253 scyx:WaterstonePharmaceuticalHKLimitedMember scyx:LicenseAgreementMember 2019-01-01 2019-12-31 0001178253 2019-06-17 0001178253 2019-06-18 0001178253 us-gaap:EmployeeStockOptionMember 2020-12-31 0001178253 us-gaap:EmployeeStockOptionMember 2019-12-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001178253 scyx:June2016PublicOfferingMember us-gaap:WarrantMember 2020-12-31 0001178253 scyx:June2016PublicOfferingMember us-gaap:WarrantMember 2019-12-31 0001178253 scyx:March2018PublicOfferingMember scyx:SeriesTwoWarrantMember 2020-12-31 0001178253 scyx:March2018PublicOfferingMember scyx:SeriesTwoWarrantMember 2019-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember us-gaap:WarrantMember 2020-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember us-gaap:WarrantMember 2019-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember scyx:OptionToPurchaseCommonStockMember 2020-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember scyx:OptionToPurchaseCommonStockMember 2019-12-31 0001178253 scyx:December2020PublicOfferingSeries1Member us-gaap:WarrantMember 2020-12-31 0001178253 scyx:December2020PublicOfferingSeries1Member us-gaap:WarrantMember 2019-12-31 0001178253 scyx:December2020PublicOfferingSeries2Member us-gaap:WarrantMember 2020-12-31 0001178253 scyx:December2020PublicOfferingSeries2Member us-gaap:WarrantMember 2019-12-31 0001178253 scyx:December2020PublicOfferingMember 2020-12-31 0001178253 scyx:December2020PublicOfferingMember 2019-12-31 0001178253 scyx:WarrantsAssociatedWithSolarLoanAgreementMember us-gaap:WarrantMember 2020-12-31 0001178253 scyx:WarrantsAssociatedWithSolarLoanAgreementMember us-gaap:WarrantMember 2019-12-31 0001178253 scyx:SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember 2020-12-31 0001178253 scyx:SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember 2019-12-31 0001178253 scyx:SixPointZeroPercentageSeniorConvertibleNotesDueTwoThousandAndTwentySixMember 2020-12-31 0001178253 scyx:SixPointZeroPercentageSeniorConvertibleNotesDueTwoThousandAndTwentySixMember 2019-12-31 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2019-12-31 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2019-12-31 0001178253 scyx:TwoThousandAndFifteenInducementAwardPlanMember 2020-12-31 0001178253 scyx:TwoThousandAndFifteenInducementAwardPlanMember 2019-12-31 0001178253 2014-05-07 0001178253 scyx:December2020PublicOfferingMember 2020-12-17 2020-12-17 0001178253 scyx:December2020PublicOfferingMember 2020-12-17 0001178253 scyx:December2020PublicOfferingMember scyx:PrefundedWarrantsMember 2020-12-17 0001178253 scyx:December2020PublicOfferingMember scyx:SeriesOneWarrantMember srt:MaximumMember 2020-12-17 0001178253 scyx:December2020PublicOfferingMember scyx:SeriesTwoWarrantMember srt:MinimumMember 2020-12-17 0001178253 scyx:December2020PublicOfferingMember scyx:SeriesOneWarrantMember 2020-12-17 2020-12-17 0001178253 scyx:December2020PublicOfferingMember scyx:SeriesOneWarrantMember 2020-12-17 0001178253 scyx:December2020PublicOfferingMember scyx:SeriesTwoWarrantMember 2020-12-17 2020-12-17 0001178253 scyx:December2020PublicOfferingMember scyx:SeriesTwoWarrantMember 2020-12-17 0001178253 scyx:December2020PublicOfferingMember us-gaap:CommonStockMember 2020-12-17 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember 2019-12-12 2019-12-12 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember 2019-12-12 0001178253 us-gaap:OverAllotmentOptionMember srt:MaximumMember 2019-12-12 2019-12-12 0001178253 us-gaap:OverAllotmentOptionMember us-gaap:WarrantMember 2019-12-12 0001178253 scyx:OptionToPurchaseCommonStockMember srt:MaximumMember 2019-12-12 0001178253 scyx:OptionToPurchaseCommonStockMember 2019-12-12 2019-12-12 0001178253 2018-03-07 2018-03-08 0001178253 scyx:March2018PublicOfferingMember us-gaap:WarrantMember srt:MaximumMember 2018-03-08 0001178253 scyx:March2018PublicOfferingMember 2018-03-08 0001178253 scyx:March2018PublicOfferingMember scyx:SeriesOneWarrantMember 2018-03-08 0001178253 scyx:March2018PublicOfferingMember scyx:SeriesTwoWarrantMember 2018-03-08 0001178253 scyx:March2018PublicOfferingMember scyx:SeriesOneWarrantMember srt:MaximumMember 2018-03-08 0001178253 scyx:March2018PublicOfferingMember scyx:SeriesOneWarrantMember 2018-03-07 2018-03-08 0001178253 scyx:March2018PublicOfferingMember scyx:SeriesTwoWarrantMember srt:MaximumMember 2018-03-08 0001178253 scyx:March2018PublicOfferingMember scyx:SeriesTwoWarrantMember 2018-03-07 2018-03-08 0001178253 scyx:SeriesOneWarrantMember 2018-12-31 0001178253 scyx:SeriesOneWarrantMember 2018-01-01 2018-12-31 0001178253 scyx:SeriesOneWarrantMember 2018-03-07 2018-03-08 0001178253 2016-06-21 2016-06-21 0001178253 scyx:June2016PublicOfferingMember us-gaap:WarrantMember srt:MaximumMember 2016-06-21 0001178253 scyx:June2016PublicOfferingMember 2016-06-21 0001178253 scyx:June2016PublicOfferingMember 2016-06-21 2016-06-21 0001178253 scyx:December2020PublicOfferingMember 2020-01-01 2020-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember 2020-01-01 2020-12-31 0001178253 scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommonStockPurchaseAgreementMember srt:MaximumMember 2020-04-10 2020-04-10 0001178253 scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommonStockPurchaseAgreementMember 2020-04-10 2020-04-10 0001178253 scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommonStockPurchaseAgreementMember 2020-04-10 0001178253 scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommonStockPurchaseAgreementMember 2020-01-01 2020-12-31 0001178253 scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommonStockPurchaseAgreementMember srt:MaximumMember 2020-04-10 0001178253 scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommonStockPurchaseAgreementMember scyx:CommitmentSharesMember 2020-04-10 2020-04-10 0001178253 scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommonStockPurchaseAgreementMember scyx:CommitmentSharesMember us-gaap:OtherExpenseMember 2020-01-01 2020-12-31 0001178253 scyx:WarrantAssociatedWithSolarLoanAgreementsMember 2016-09-30 0001178253 scyx:WarrantAssociatedWithSolarLoanAgreementsMember 2016-09-29 2016-09-30 0001178253 us-gaap:DomesticCountryMember 2020-12-31 0001178253 us-gaap:DomesticCountryMember 2019-12-31 0001178253 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001178253 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001178253 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001178253 us-gaap:StateAndLocalJurisdictionMember stpr:NJ 2020-04-01 2020-04-30 0001178253 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001178253 us-gaap:StateAndLocalJurisdictionMember stpr:NJ 2020-01-01 2020-12-31 0001178253 srt:MaximumMember 2017-01-01 2017-12-31 0001178253 scyx:TwoThousandAndNineStockOptionPlanMember srt:MinimumMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndNineStockOptionPlanMember srt:MaximumMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndNineStockOptionPlanMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2014-05-02 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember srt:MinimumMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember srt:MaximumMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember srt:MaximumMember 2014-05-01 2014-05-02 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2014-05-01 2014-05-02 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2019-01-01 2019-12-31 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2015-03-26 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2019-06-08 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2019-06-09 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2020-12-31 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2019-01-01 2019-12-31 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2019-12-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2014-05-02 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2014-05-01 2014-05-02 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001178253 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001178253 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001178253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001178253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:DerivativeMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:DerivativeMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:DerivativeMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:DerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:DerivativeMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:DerivativeMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:DerivativeMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:DerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001178253 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001178253 us-gaap:MeasurementInputPriceVolatilityMember srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001178253 us-gaap:MeasurementInputExpectedTermMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001178253 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001178253 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001178253 us-gaap:MeasurementInputExpectedTermMember us-gaap:FairValueInputsLevel3Member srt:MaximumMember 2019-12-31 0001178253 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001178253 us-gaap:MeasurementInputCreditSpreadMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001178253 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001178253 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember scyx:SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001178253 us-gaap:WarrantMember 2019-12-31 0001178253 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001178253 us-gaap:WarrantMember 2020-12-31 0001178253 us-gaap:DerivativeMember 2019-12-31 0001178253 us-gaap:DerivativeMember 2020-01-01 2020-12-31 0001178253 us-gaap:DerivativeMember 2020-12-31 scyx:hour 0001178253 us-gaap:SubsequentEventMember scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2020-12-02 2021-01-01 0001178253 us-gaap:SubsequentEventMember scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2020-12-02 2021-01-01 0001178253 us-gaap:SubsequentEventMember scyx:AmplityIncMember 2021-02-01 2021-02-28 0001178253 scyx:ExclusiveLicenseAndCollaborationAgreementMember us-gaap:SubsequentEventMember 2021-02-11 2021-02-11 0001178253 srt:MaximumMember scyx:ExclusiveLicenseAndCollaborationAgreementMember us-gaap:SubsequentEventMember 2021-02-11 2021-02-11

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

(Mark One)

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED December 31, 2020

OR

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM                      TO

Commission File Number 001-36365

 

SCYNEXIS, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

56-2181648

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1 Evertrust Plaza, 13th Floor

Jersey City, NJ

 

07302 - 6548

(Address of principal executive offices)

 

(Zip Code)

 

(201) 884-5485

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.001 per share

SCYX

Nasdaq Global Market

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐   No  ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  ☐    No  ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒   No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

☐

 

Accelerated filer

 

☐

 

 

 

 

Non-accelerated filer

 

☒  

 

Smaller reporting company

 

☒

 

 

 

 

 

 

 

Emerging growth company

 

☐ 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐ 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.   ☐ 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based upon the closing price of its Common Stock on the Nasdaq Global Market on June 30, 2020 was $77,935,551.  Excludes 99,975 shares of the registrant's Common Stock held by executive officers and directors outstanding at June 30, 2020. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.

As of March 1, 2021, there were 20,622,778 shares of the registrant’s Common Stock outstanding.

Documents Incorporated by Reference

Portions of the registrant’s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s 2021 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant’s fiscal year ended December 31, 2020.

 

 

 

 

 

SCYNEXIS, INC.

ANNUAL REPORT ON FORM 10-K

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020

TABLE OF CONTENTS

 

PART I.

 

3

Item 1.

Business

5

Item 1A.

Risk Factors

17

Item 1B.

Unresolved Staff Comments

39

Item 2.

Properties

39

Item 3.

Legal Proceedings

39

Item 4.

Mine Safety Disclosures

39

 

 

 

PART II.

 

40

Item 5.

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

40

Item 6.

Selected Financial Data

40

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

41

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

50

Item 8.

Consolidated Financial Statements and Supplementary Data

51

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

77

Item 9A.

Controls and Procedures

77

Item 9B.

Other Information

77

 

 

 

PART III.

 

78

Item 10.

Directors, Executive Officers and Corporate Governance

78

Item 11.

Executive Compensation

78

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters

78

Item 13.

Certain Relationships and Related Transactions, and Director Independence

78

Item 14.

Principal Accounting Fees and Services

78

 

 

 

PART IV.

 

79

Item 15.

Exhibits and Financial Statement Schedules

79

Item 16.

Form 10-K Summary

81

 

 

 

Signatures

 

82

 

 

 

 

 

 

 

 

 

 

 

PART I

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “potential” and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. We discuss many of these risks, uncertainties and other factors in this Annual Report on Form 10-K in greater detail under the heading “Risk Factors.” Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

RISK FACTOR SUMMARY

Risks and uncertainties we face are set forth in this Annual Report on Form 10-K in greater detail under the heading “Risk Factors.” The following is a summary of these risk factors:

Risks Relating to Our Financial Condition and Need for Additional Capital

 

•

We have never been profitable, we have no products approved for commercial sale, and to date we have not generated any revenue from product sales. As a result, our ability to curtail our losses and reach profitability is unproven, and we may never achieve or sustain profitability.

 

•

We will continue to require substantial additional capital, and if we are unable to raise capital when needed we would be forced to delay, reduce or eliminate our development program for ibrexafungerp.

 

•

Our operating activities may be restricted as a result of covenants related to the indebtedness under our senior convertible notes and we may be required to repay the notes in an event of default, which could have a materially adverse effect on our business.

Risks Relating to the Development, Regulatory Approval and Commercialization of Our Product Candidates For Human Use

 

•

We cannot be certain that ibrexafungerp will receive regulatory approval, and without regulatory approval we will not be able to market ibrexafungerp. Regulatory approval is a lengthy, expensive and uncertain process, and there is no guarantee that ibrexafungerp will ultimately be approved by the FDA.

 

•

Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate we or our current or potential future partners advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval.

 

•

We have limited experience in conducting clinical trials and have only submitted one NDA before, and we may be unable to do so for ibrexafungerp in additional indications or any future product candidate we may seek to develop.

 

•

If ibrexafungerp or any other future product candidates for which we receive regulatory approval do not achieve broad market acceptance, the revenue that is generated from their sales will be limited.

 

•

If resistance to ibrexafungerp develops quickly or cross-resistance with echinocandins becomes more common, our business will be harmed.

 

3

 

 

 

•

If we are unable to obtain regulatory approval of both the oral and IV formulations of ibrexafungerp, ibrexafungerp may not achieve broad market acceptance and sales will be limited.

 

•

Our product candidates may have undesirable side effects that may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market or otherwise limit their sales.

 

•

We have never marketed a drug before, and if we are unable to establish an effective sales force and marketing infrastructure or enter into acceptable third-party sales and marketing or licensing arrangements, we may not be able to successfully commercialize ibrexafungerp and any future product candidates we may seek to develop.

 

•

We expect that ibrexafungerp and any future product candidates we may seek to develop will face competition, and most of our competitors have significantly greater resources than we do.

 

•

Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance in the United States. If there is not sufficient reimbursement for our products, it is less likely that our products will be purchased by patients and/or providers.

Risks Related to Our Dependence on Third Parties

 

•

We are dependent on our existing third-party collaborations for drug development and to commercialize ibrexafungerp, and if these third-parties do not perform well under these collaborations, or our prospects may be harmed.

 

•

As we do not intend to own or operate facilities for manufacturing, storage and distribution of drug substance or drug product we are and will be dependent on third parties for the manufacture of ibrexafungerp. If we experience problems with any of these third parties, the commercial manufacturing of ibrexafungerp could be delayed.

Risks Relating to Our Intellectual Property

 

•

We were dependent on Merck for the establishment of our intellectual property rights related to ibrexafungerp, and if Merck did not establish our intellectual property rights with sufficient scope to protect ibrexafungerp, we may have limited or no ability to assert intellectual property rights to ibrexafungerp.

 

•

It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.

 

•

We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to enforce or protect our rights to, or use, our technology.

Risks Related to Employee Matters and Managing Growth

 

•

We may not be able to manage our business effectively if we are unable to attract and retain key personnel.

 

•

We may need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth.

Other Risks Relating to Our Business

 

•

We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization.

 

•

Our internal computer systems, or those used by our contract research organizations or other contractors or consultants, may fail or suffer security breaches.

 

•

Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities.

 

•

Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.

 

•

U.S. and foreign privacy and data protection laws and regulations may impose additional liabilities on us.

 

•

Our business could be adversely affected by the COVID-19 outbreak, in regions where we or third parties on which we rely have significant concentrations of clinical trial sites, manufacturing facilities, or other business operations.

 

 

 

4

 

 

Risks Relating to Owning Our Common Stock

 

•

The market price of our common stock may be highly volatile.

 

•

Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

 

•

Sales of our common stock to Aspire Capital may cause substantial dilution to our existing stockholders and the sale of the shares of our common stock acquired by Aspire Capital could cause the price of our common stock to decline.

REVERSE STOCK SPLIT

On July 16, 2020, we implemented a 1-for-10 reverse stock split of our common stock and decreased the number of authorized shares of our common stock from 250,000,000 shares to 100,000,000 shares.  All share and per share amounts presented in this Annual Report on Form 10-K have been retroactively adjusted for the reverse stock split.

ITEM 1.

BUSINESS

Overview

SCYNEXIS, Inc. is pioneering innovative medicines to potentially help millions of patients worldwide in need of new options to overcome and prevent difficult-to-treat and drug-resistant infections.  We are developing our lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. In December 2020, we announced that we had received the acceptance letter from the U.S. Food and Drug Administration (FDA) for our New Drug Application (NDA) for oral ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection) with a Prescription Drug User Fee Act (PDUFA) action goal date of June 1, 2021.  The FDA has conditionally approved “Brexafemme” as the brand name for oral ibrexafungerp for vaginal yeast infections. We are also continuing late-stage clinical development for the prevention of recurrent VVC as well as the treatment of life-threatening invasive fungal infections in hospitalized patients.

Ibrexafungerp, the first representative of a novel class of antifungal agents called triterpenoids and designated by the suffix “-fungerp”, is a structurally distinct glucan synthase inhibitor and has shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in the United States (U.S.) and Europe. To date, we have characterized the antifungal activity, pharmacokinetics, and safety profile of the oral and IV formulations of ibrexafungerp in multiple in vitro, in vivo, and clinical studies. The FDA has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to ibrexafungerp for the indications of VVC (including the treatment of VVC episodes and the prevention of recurrent VVC), invasive candidiasis (IC) (including candidemia), and invasive aspergillosis (IA), and has granted Orphan Drug designations for the IC and IA indications. These designations may provide us with additional market exclusivity and expedited regulatory paths.

5

 

Our Platform of Indications

Oral Ibrexafungerp Development Program

We continue to actively advance our clinical programs, leveraging the potential of ibrexafungerp to be a suitable treatment for multiple indications with significant unmet medical needs and considerable commercial opportunities. The following illustration summarizes the status of the indications for oral ibrexafungerp currently being pursued, and the potential NDA approval for the treatment of VVC in June 2021:

Vaginal Yeast Infections — Our most advanced stage of clinical development, targeting both treatment of VVC and prevention of recurrent VVC.

The Phase 3 registration program for the treatment of VVC and prevention of recurrent VVC comprises three multi-center, randomized, double-blind, placebo-controlled trials designed according to FDA guidance to demonstrate superiority of oral ibrexafungerp vs. placebo, as detailed below:

 

•

Treatment of VVC (VANISH Phase 3 Program)

In December 2020, we announced that we had received the acceptance letter from the FDA for our NDA for ibrexafungerp for the treatment of VVC, also known as vaginal yeast infection, with a PDUFA action goal date of June 1, 2021.  The NDA is supported by positive results from two Phase 3, randomized, double-blind, placebo-controlled, multi-center studies (VANISH-303 and VANISH-306), in which oral ibrexafungerp demonstrated statistically superior efficacy and a favorable tolerability profile in women with VVC.  Additionally, the FDA has communicated that it is not currently planning to hold an advisory committee meeting to discuss the application.  The FDA has conditionally approved “Brexafemme” as the brand name for ibrexafungerp for the treatment of vaginal yeast infections.  

 

•

Prevention of Recurrent VVC

In March 2021, we completed enrollment in the CANDLE study, a Phase 3, multi-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of oral ibrexafungerp compared to placebo in preventing an acute episode in women with recurrent VVC (defined at least three or more episodes of VVC in the past 12 months, including the episode at screening).  We expect the last-patient/last-visit for the CANDLE study by the end of 2021.  As a result of the COVID-19 pandemic, our timelines for reaching our targeted enrollment size in the CANDLE study were slightly extended and we now anticipate both top-line data and a potential supplemental NDA submission for the prevention of recurrent VVC in the first half of 2022, resulting in a potential approval in late 2022.

The CANDLE study, which is being conducted in female patients age 12 years and older living with recurrent VVC, enrolled 441 subjects from approximately 50 global centers. The primary endpoint of the study is efficacy as measured by the percentage of patients with no recurrences of an acute episode of VVC, up through their test-of-cure (TOC) evaluation at week 24. Secondary endpoints of the study include evaluation of VVC recurrences at other time points up to week 36, time to first recurrence, mycological eradication and quality of life assessments. All patients in the CANDLE study initially received three doses of oral fluconazole to treat their acute VVC episode present at screening. Patients who responded to oral fluconazole for their acute VVC episode were enrolled in the prevention of recurrence

6

 

phase of the study and randomized to oral ibrexafungerp (300mg BID for one day) or placebo, given one day per month for six months. Patients who failed to sufficiently respond to fluconazole treatment for their acute VVC episode were included in a nested open-label sub-study, in which they were offered a single day of oral ibrexafungerp treatment (300mg BID) for their unresolved VVC infection.  The CANDLE study is being conducted in accordance with an agreement with the FDA under a Special Protocol Assessment (SPA) on the design, trial population, endpoints and statistical analysis of the study.  This SPA provides agreement with the FDA that the Phase 3 protocol design adequately addresses efficacy objectives that, if met, would form the primary basis of a regulatory submission for approval of oral ibrexafungerp for the prevention of recurrent VVC, an indication with no FDA-approved therapies.

Refractory Invasive Fungal Infections (rIFI) —Potential for streamlined development pathway.

Enrollment is ongoing in our rIFI program, which comprises two open-label Phase 3 studies (FURI and CARES) designed to support a potential future NDA submission through the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).

In March 2021, we announced that a Data Review Committee (DRC) of independent experts assessed the efficacy of oral ibrexafungerp in a third cohort of 33 patients from the FURI study and a first cohort of ten patients from the CARES study. The third interim analysis of the FURI study showed that antifungal activity was consistently positive across all interim analyses with oral ibrexafungerp showing clinical benefit in 30 out 33 patients, and no patients with progression of disease. On an aggregate basis, oral ibrexafungerp showed clinical benefits in 86.5% of patients (64 out 74), with 46 patients achieving a complete or partial response and 18 patients achieving a stable disease response. Of the 74 treated patients, only five did not respond to ibrexafungerp treatment, one patient died of an underlying condition unrelated to the treatment or fungal infection, and four patients were considered indeterminate.  Analysis of the CARES study found that 80% (8 out 10) patients with invasive candidiasis and candidemia due to Candida auris experienced a complete response, one patient died of an underlying condition unrelated to the treatment or fungal infection and one patient was considered indeterminate.  Oral ibrexafungerp exhibited a positive safety profile and was well-tolerated, with gastrointestinal issues cited as the most common treatment-related adverse events. There were no safety signals warranting changes to the studies.  Below is the summary of the aggregate interim analysis for FURI and CARES:

Global Response

Aggregate (FURI) n=74 (%)

CARES n=10 (%)

Aggregate (FURI+CARES) n=84 (%)

Complete or Partial Response or Clinical Improvement

46 (62)

8 (80)

54 (64)

Stable Disease

18 (24)

0 (0)

18 (21)

Total

64 (87)

8 (80)

72 (86)

No Response

6 (8)

1 (10)

7 (8)

Indeterminate

4 (5)

1 (10)

5 (6)

The FURI study is evaluating oral ibrexafungerp as a salvage treatment in patients with a variety of difficult-to-treat mucocutaneous and invasive fungal infections that are refractory to or intolerant of current standards of care, or require a non-azole oral step-down therapy for treatment of azole-resistant species. The CARES study is focused on hospitalized patients with invasive candidiasis caused by the multidrug-resistant Candida auris organism, which is associated with high mortality, and the interim analysis was the first clinical trial data of an investigational treatment against infections caused by Candida auris.  Candida auris has been recently declared an “Urgent Threat” to public health by the Centers for Disease Control and Prevention (CDC) in its report, Antibiotic Resistance Threats in the United States, 2019, as it can be multidrug-resistant, has resulted in high mortality rates (up to 60%), and can be spread from patients (and surfaces) to patients, resulting in hospital outbreaks. The CARES study is intended to provide rapid access to oral ibrexafungerp for patients suffering from this life-threatening infection.  

The open-label designs of the FURI and CARES studies permit evaluation of the data on an interim basis to further inform subsequent regulatory steps of the development program. We believe that compelling data from the FURI and/or CARES studies could allow ibrexafungerp to become eligible for the regulatory LPAD, potentially resulting in an NDA submission based on streamlined development. The LPAD was established under the 21st Century Cures Act of 2016, and FDA draft guidance issued in June 2019 suggests smaller, shorter or fewer clinical trials may be appropriate to support approval to treat a serious or life-threatening infection in a limited population with unmet needs. We plan to continue to advance enrollment in the FURI and CARES studies, both in the U.S. and globally. Positive clinical findings from these studies have so far reinforced the potential role of oral ibrexafungerp as a novel therapy to combat severe and difficult-to-treat fungal infections, including multidrug-resistant Candida auris.

Invasive Pulmonary Aspergillosis—Ibrexafungerp in combination with standard of care may represent a significant opportunity to improve outcomes for this high-mortality infection.

Based on promising pre-clinical data from combination use of ibrexafungerp with SoC vs. Aspergillus spp., we are conducting a Phase 2 study (SCYNERGIA study) of oral ibrexafungerp in combination with voriconazole (SoC) in patients

7

 

with IA. This study is a randomized, double-blind trial with the objective of assessing the safety and efficacy of oral ibrexafungerp in combination with voriconazole, compared to voriconazole alone. We believe that ibrexafungerp’s broad activity against Aspergillus spp., including azole-resistant strains, along with its minimal drug-drug interactions, high tissue penetration into the lungs, and oral formulation allowing for long-term administration, may make it an ideal candidate for use as combination therapy to provide improved outcomes vs. SoC.  Pending successful completion of this study, we anticipate top-line data by the end of 2021.

 

 

IV Ibrexafungerp Development Program

Based on promising pre-clinical data of our liposomal IV formulation of ibrexafungerp, we are conducting a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of the IV liposomal formulation of ibrexafungerp in healthy subjects. The study is being conducted in South Africa and dosing started in March 2021.  We expect to provide further updates as the study advances.

Key Milestones

We believe we will potentially achieve the following key milestones in the next 12 months:

 

 

•

receive approval of ibrexafungerp for the treatment of VVC by the FDA on the expected PDUFA target action date of June 1, 2021;

 

 

•

commercially launch ibrexafungerp in the U.S. for the treatment of vaginal yeast infections, if approved, in the second half of 2021;

 

 

 

 

•

report development updates on our Phase 1 study of the IV liposomal formulation of ibrexafungerp;

 

 

•

provide both top-line data of the Phase 3 CANDLE study and a potential supplemental NDA submission for the prevention of recurrent VVC in the first half of 2022 with a potential approval in late 2022; and

 

 

•

provide top-line data of the Phase 2 SCYNERGIA study by the end of 2021.

 

Our Strategy

Key elements of our strategy include:

 

 

•

to further develop ibrexafungerp and obtain regulatory approval in major commercial markets for our key initial indications: treatment of VVC, prevention of recurrent VVC, invasive candidiasis and invasive aspergillosis;

 

 

•

to commercialize ibrexafungerp for selected indications in the U.S. through a dedicated commercial team, including field force;

 

 

•

to contract with commercial partners to develop and commercialize ibrexafungerp outside of the U.S.;

 

 

•

to assess external opportunities for in-licensing to expand our development pipeline and add products for commercialization; and

 

 

•

to leverage our strong scientific team to pursue the development of other internal proprietary compounds.

Market Opportunity

Vaginal Yeast Infections

VVC, commonly known as a vaginal yeast infection due to Candida, is the second most common cause of vaginitis. Although these infections are frequently caused by Candida albicans, infections caused by fluconazole-resistant and non-albicans Candida strains, such as Candida glabrata, have been reported to be on the rise.  An estimated 70-75% of women worldwide will have at least one episode of VVC in their lifetime, and 40-50% of them will experience multiple episodes. VVC can be associated with substantial morbidity, including significant genital discomfort (pain, itching, burning), reduced sexual pleasure and activity, psychological distress (stress, depression, anxiety), embarrassment, reduced physical activity, and loss of productivity. Typical VVC symptoms include pruritus, vaginal soreness, irritation, excoriation of vaginal mucosa and abnormal vaginal discharge.

Current treatments for VVC include several topical azole antifungals and oral fluconazole, which is the only orally administered antifungal currently approved for the treatment of VVC in the U.S. and which accounts for over 90% of the prescriptions for VVC written each year, primarily by obstetrician and gynecologist (OGBYN) offices. Fluconazole reported a 55% therapeutic cure rate in its label, which now also includes warnings of potential fetal harm, illustrating the need for new

8

 

oral alternatives. In addition, there are many women with persistent (chronic) infections, recurrent infections (four or more recurrences in a 12-month period), non-albicans / azole-resistant Candida strains (e.g., Candida glabrata), diabetic patients, especially with poorly controlled glycemia, and obese patients that could potentially benefit from a non-azole treatment.  Currently, there are only azole class treatments available for women suffering from VVC with no approved alternative class in the U.S.  When a patient fails fluconazole therapy, patients typically are treated with more fluconazole or a topical azole.  Women with VVC could benefit from a non-azole, and preferably oral, treatment option.  

We believe ibrexafungerp has the potential to address vaginal yeast infections across a broad range of patients and could be an ideal treatment option for many patients for whom current treatment options are suboptimal. Despite yeast infections being so common and prevalent, with millions of women suffering from it every year, it is still an under-appreciated, under-reported, and under-served women’s health condition. There are over 18 million prescriptions written for VVC in the U.S. annually, all of which belong to a single drug class, the azoles.  Additionally, of the 9.5 million women in the U.S. who received a prescription for VVC in the previous year, about 40% of them required multiple prescriptions, illustrating that many patients’ symptoms are not adequately addressed by existing azole treatments.  There has been no new oral treatment for VVC in over 25 years, and we believe health care providers are eager for a novel oral alternative to treat their patients.

Ibrexafungerp, if approved, would be the first and only oral, non-azole treatment for vaginal yeast infections. We believe that ibrexafungerp’s unique combination of features, including being from a novel class with a different mechanism of action, single-day oral dosing, broad spectrum, and fungicidal activity in all Candida species (albicans and non-albicans) including fluconazole-resistant strains, will differentiate it from competing products.

Invasive Aspergillosis

Current treatment guidelines for IA in the U.S. and in Europe recommend the use of azoles (itraconazole, voriconazole or isavuconazole) as the initial first-line therapy. However, patients face unsatisfactory clinical outcomes with mortality rates ranging from 30% to 80% (depending on the stage of infection and the host underlying disease) and long treatment durations. Additionally, current azole therapies often exhibit drug-drug interactions, and the recent emergence of A. fumigatus azole-resistance is increasingly becoming of clinical concern worldwide.  

Due to the significant rate of resistance in some countries, combination antifungal therapy as first-line treatment for patients suspected of IA is recommended. The combination of voriconazole or isavuconazole with a glucan synthesis inhibitor agent (IV echinocandin) is recommended at least until results of resistance testing are obtained. A previous study, by Marr et al., in IA patients demonstrated that the combination of an IV echinocandin and an IV/oral azole for two weeks followed by an oral azole alone for four additional weeks improved outcomes in certain patient subgroups. In this study, the combination regimen was given for only two weeks because of the limitations of using an IV echinocandin long-term in the outpatient setting. We believe that oral ibrexafungerp, if approved in combination with standard of care for the treatment of IA, would allow patients to receive the desired combination treatment of two agents with different mechanisms of action for the full six to twelve weeks of therapy, potentially leading to better outcomes.

Invasive Candidiasis / rIFI

Treatment options for invasive candidiasis are limited to three main drug classes: echinocandins, azoles, and amphotericin B. The echinocandins are considered the first line recommended therapy in most invasive candidiasis settings. Because the echinocandins can be administered only intravenously, orally administered azoles are often used as step-down agents after initial IV echinocandin therapy. However, antifungal treatment duration for invasive candidiasis typically extends for several weeks and patients for whom the azoles are not a suitable therapy due to resistance, intolerance, or risk of drug-to-drug interaction are restricted to use IV therapy for several weeks. Amphotericin B is also only available via IV administration and is associated with a significant risk of renal toxicity and infusion reactions, making it an unsuitable option in settings where there is underlying, or high risk of, renal impairment. Due to significant monitoring issues, Amphotericin B is also less desirable for outpatient parenteral administration. The echinocandins are typically well tolerated but clinical resistance is rising in many centers, due to development of mutations in the fks genes leading to echinocandin resistance and shift species with natural resistance as well as the rise of novel drug resistant species, such as Candida auris. When resistance develops, the available treatment options may be less efficacious or more toxic. The phenomenon of multi-drug resistance is also reported among Candida species, making the management of patients suffering from these infections extraordinarily challenging, considering the very limited treatment options available. Specifically, 90% of Candida auris isolates have been reported to be resistant to at least one antifungal agent and 30% isolates resistant to at least two antifungals.

There is a clear need for new antifungal treatment options for patients with invasive candidiasis that are refractory or intolerant to available therapies as well as for those who would benefit from oral therapy. We believe ibrexafungerp has the potential to address many of these unmet needs by providing a well-tolerated oral antifungal agent, with low risk for drug-drug interactions that has activity against azole-resistant and most echinocandin-resistant strains.

9

 

Ibrexafungerp Target Product Profile

Ibrexafungerp, the first agent in a novel antifungal class, acts through the inhibition of the glucan synthase complex, an established target in antifungal therapeutics. Ibrexafungerp is being developed as oral and IV formulations and has demonstrated potent activity against a large collection of medically relevant strains of Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces species.  Additionally, ibrexafungerp has shown in vitro, in vivo and clinical activity against multidrug-resistant organisms such as Candida auris and synergistic/additive activity in combination with isavuconazole against Aspergillus strains.  Ibrexafungerp has unique attributes that define its potential to address significant unmet medical needs and provide considerable commercial opportunities, including:

 

•

oral bioavailability, unlike other glucan synthase inhibitors, allowing for convenient long-term outpatient use;

 

•

broad activity against Candida, Aspergillus, Pneumocystis, Coccidioides, Histoplasma and Blastomyces strains;

 

•

distinct chemical structure from other glucan synthase inhibitors, providing a unique spectrum of activity and pharmacokinetic profile;

 

•

activity against azole-resistant and most echinocandin-resistant Candida strains, including Candida auris and multidrug-resistant strains;

 

•

activity against azole-resistant Aspergillus strains;

 

•

fungicidal (i.e., killing the fungi) capabilities against Candida species compared to azoles, which are fungistatic (i.e., only inhibiting the growth of fungi);

 

•

high tissue penetration, allowing high concentrations in the organs commonly affected by fungal infections;

 

•

generally well tolerated with over 1,200 subjects and patients exposed; and

 

•

20-hour half-life with a low risk of drug-drug interactions.

We believe that ibrexafungerp, if approved, has the potential to address significant gaps with commercially available therapies in the following indications:

 

•

treatment of vaginal yeast infections, including prevention of recurrent infections;

 

•

invasive candidiasis (including resistant infections);

 

•

invasive aspergillosis (including resistant infections); and

 

•

refractory invasive fungal infections.

In the future, we may also consider other indications for ibrexafungerp for which longer oral antifungal regimens are typically needed and would benefit from the broad-spectrum activity, favorable safety profile and low potential for drug-drug interactions, including for the treatment of chronic fungal infections and for prophylaxis.

Given our stage of development, we have not yet established an operational commercial organization or distribution capabilities and we are in the process of assessing our global commercial strategy.  Given the June 1, 2021 PDUFA date for the treatment VVC indication, we have been rapidly building the commercial organization including talent, operational infrastructure, processes and IT and data capabilities. We have also been putting in place an ecosystem of key sales, marketing, market access, distribution, and patient support partners to ensure an agile, omnichannel commercial model that will provide a positive experience for both patients and healthcare providers.

For the treatment and prevention of vaginal yeast infections, we anticipate that prescribing physicians will mostly be obstetricians, gynecologists, and nurse practitioners. In February 2021, we partnered with a third-party commercial sales organization, Amplity, Inc., for the potential upcoming commercial launch of ibrexafungerp for the treatment of VVC in the U.S.  We will utilize Amplity’s commercial execution expertise and resources for sales force, remote engagement, training, market access and select operation services.  Amplity is deferring a portion of its direct service costs in the first two years (2021 and 2022), up to a cap, which we will repay over three years starting in 2023. Amplity has the potential to earn a performance-based success fee, up to a cap, in the 2023-2025 timeframe by exceeding certain revenue targets. Each party retains the right to terminate the agreement upon notice to the other party.

For the treatment of invasive fungal infections, we expect that prescribing physicians will be located at major medical centers, where physicians specializing in critical care, infectious disease specialists, and physicians treating immune compromised or immuno-suppressed patients, such as oncologists and those performing solid organ transplants and stem cell transplants, are likely to be found.  For these indications, we intend to form our own focused hospital-based field force to target physicians in the U.S. Outside of the U.S., subject to obtaining necessary marketing approvals, we will likely seek to commercialize ibrexafungerp through distribution or other collaboration arrangements.

10

 

Competition for Ibrexafungerp

Our competitors include large pharmaceutical and biotechnology companies, and specialty pharmaceutical and generic drug companies. The leading antifungal drugs representing each main class are as follows:

Azoles. Noxafil® (posaconazole) marketed by Merck and Cresemba® (isavuconazole), approved in the U.S. and other global markets and marketed by Astellas in the U.S.; Diflucan® (fluconazole), Pfizer, off-patent with multiple generics, Terazol (terconazole), Jannsen, off-patent with multiple generics, Gynazole (butoconazole), Perrigo, off patent with multiple generics

Echinocandins.  Cancidas® (caspofungin), a product that became generic in March 2017.  Pfizer also markets the echinocandin Eraxis® (anidulafungin) and Astellas markets the echinocandin Mycamine® (micafungin); and

Polyenes.  AmBisome® (liposomal amphotericin B), a product sold by Gilead in Europe, by Astellas in the U.S. and by Dainippon-Sumitomo in Japan.

Pfizer, Merck, Astellas, and Gilead are all large pharmaceutical companies with significant experience and financial resources in the marketing and sale of specialty pharmaceuticals. Various other producers market and sell generic oral voriconazole, fluconazole and itraconazole.

The VVC market has three generic prescription agents, fluconazole (oral), terconazole and butoconazole (topical), manufactured by multiple generic companies. There is limited to no marketing to support these generic products.

Further, we expect that product candidates currently in clinical development may represent significant competition, if approved. These include the azole Oteseconazole (VT-1161) being developed by Mycovia Pharmaceuticals, Inc., formerly Viamet Pharmaceuticals, Inc. (assets acquired by NovaQuest Capital Management, LLC), the long-acting IV echinocandin Rezafungin (CD101) being developed by Cidara Therapeutics, Inc., Fosmanogepix (APX-001) being developed by Amplyx Pharmaceuticals Inc., the polyene amphotericin B oral formulation MAT2203 being developed by Matinas BioPharma Holdings Inc., and Olorofim (F901318) being developed by F2G Limited.  These companies may have greater resources than ours.

We believe that ibrexafungerp has the ability to perform well in the future fungal infection market given the sparse competitive marketplace, the unmet medical need, and the often high mortality rate of many of these infections.  The key competitive factors affecting the success of ibrexafungerp, if approved, are likely to be its efficacy, safety, convenience, use in outpatient settings, the level of generic competition and the availability of reimbursement from government and other third-party payors. If approved, we believe that ibrexafungerp’s unique features, including being from a novel antifungal class, broad-spectrum of activity including resistant strains, IV and oral formulations, fungicidal activity versus Candida, high tissue penetration, and favorable safety profile, will differentiate it from competing products and allow premium pricing to generics and other competing products.

Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA, or other regulatory, approval for their products more rapidly than we may obtain approval for ours. In addition, our ability to compete may be affected because in many cases insurers or other third-party payors seek to encourage the use of generic products. In the azole class, fluconazole, itraconazole, posaconazole, and oral voriconazole are generic. Caspofungin, the largest selling echinocandin, is now available on a generic basis.  If approved, we believe ibrexafungerp will be capable of delivering value supportive of premium pricing over competitive generic products.

Manufacturing and Supply of Ibrexafungerp

We have agreements with external vendors that are capable of supplying drug substance and of producing drug product to support ongoing and planned clinical trials, as well as for planned commercial launch. However, we do not own or operate and do not intend to own or operate facilities for manufacturing, storage and distribution, or testing of drug substance or drug product. We have relied on third-party contract manufacturers for synthesis of our clinical compounds and manufacture of drug product. We expect to continue to rely on either existing or alternative third-party manufacturers to supply ibrexafungerp for ongoing and planned clinical trials and for commercial production.

Ibrexafungerp is a semi-synthetic compound. Thus, the manufacturing process for ibrexafungerp involves fermentation and synthetic chemical steps. The synthetic process does not require any specialized equipment and uses readily sourced intermediates. At commercial scale, we expect cost of goods for ibrexafungerp to be similar to that of other small molecule drugs. We have negotiated agreements with our primary contract manufacturers to produce both drug product and drug substance for our current clinical and commercial needs. In the future, we plan to qualify secondary suppliers to establish a secure supply chain to support commercialization.

We estimate our supplies on hand as well as those we plan to produce for the oral formulation of ibrexafungerp are sufficient to supply our ongoing and planned clinical trials as well as our anticipated commercial launch for the treatment of VVC, if approved, in the second half of 2021.  Manufacture of additional supplies of ibrexafungerp drug substance is planned

11

 

to support any further optimization of either the oral or IV formulations, if needed. Additional batches of both oral and IV ibrexafungerp drug product will be manufactured as needed to support the subsequent stages of our clinical development plan and commercial supply requirements.

A drug manufacturing program subject to extensive governmental regulations requires robust quality assurance systems and experienced personnel with the relevant technical and regulatory expertise as well as strong project management skills. We believe we have a team that is capable of managing these activities.

The primary third-party vendors  with which we have agreements in place to support manufacturing and supply both for clinical development and commercial launch have the required capabilities with respect to facilities, equipment and technical expertise, quality systems that meet global regulatory and compliance requirements, satisfactory regulatory inspection history from relevant health authorities and proven track records in supplying drug substance and drug product for late-stage clinical and commercial use.

Collaborations and Licensing Agreements Associated with Our Core Drug Development Operations

We have a number of licensing and collaboration agreements associated with our core drug development operations, including the following:

Merck

We initially discovered and developed ibrexafungerp through a research collaboration with Merck Sharp & Dohme Corp. (Merck), a subsidiary of Merck & Co., Inc. In May 2013, Merck transferred to us all development and commercialization rights for ibrexafungerp (also known as MK-3118). This decision was made following a review and prioritization of Merck’s infectious disease portfolio. Under the terms of the agreement, we received all human health rights to ibrexafungerp, including all related technical documents, preclinical data, data from the seven Phase 1 trials conducted by Merck, and drug product and drug substance.  The agreement continues until expiration of all royalty obligations. The agreement may be terminated if either party is in material breach and fails to remedy the breach after receiving written notice. In January 2014, Merck assigned the patents to us related to ibrexafungerp that it had exclusively licensed to us. Under the terms of the patent assignment, Merck no longer has responsibility to maintain the patents. Merck was originally eligible to receive milestones upon initiation of a Phase 3 clinical study, NDA submission and marketing approvals in each of the U.S., major European markets and Japan that could total up to $19 million.  In addition, Merck will receive tiered royalties based on worldwide sales of ibrexafungerp. The aggregate royalties are mid- to high-single digits of net sales, and we expect to pay royalties on net sales of ibrexafungerp to Merck for no more than ten years from first commercial launch, on a country-by-country basis.

In December 2014, we entered into an amendment to the license agreement with Merck that defers the remittance of a milestone payment due to Merck, such that no amount will be due upon initiation of the first phase 2 clinical trial of a product containing the ibrexafungerp compound (the Deferred Milestone). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that will be due upon initiation of the first Phase 3 clinical trial of a product containing the ibrexafungerp compound.  In December 2016 and January 2019, we entered into second and third amendments to the license agreement with Merck which clarified what would constitute the initiation of a Phase 3 clinical trial for the purpose of a milestone payment.  In January 2019, a milestone payment became due to Merck as a result of the initiation of the VANISH Phase 3 VVC program and it was paid in March 2019.  

On December 2, 2020, we entered into a fourth amendment to the license agreement with Merck. The amendment eliminates two cash milestone payments that we would have paid to Merck upon the first filing of a NDA, triggered by the FDA acceptance for filing of our NDA for ibrexafungerp for the treatment of VVC, and first marketing approval in the U.S., anticipated in June 2021 for our NDA for ibrexafungerp for the treatment of VVC.  These cash milestone payments would have been creditable against future royalties owed to Merck on net sales of ibrexafungerp. With the amendment, these milestones will not be paid in cash and, accordingly, credits will not accrue. Pursuant to the amendment, we will also forfeit the credits against future royalties that had accrued from a prior milestone payment already paid to Merck. All other key terms of the license agreement are unchanged.  

Hansoh

In February 2021, we entered into an Exclusive License and Collaboration Agreement (the Agreement) with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, Hansoh), pursuant to which we granted to Hansoh an exclusive license to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the Agreement, Hansoh shall be responsible for the development, regulatory approval and commercialization of ibrexafungerp in Greater China. We received a $10.0 million upfront payment and will also be eligible to receive up to $112.0 million in development and commercial milestones, plus low double-digit royalties on net product sales. The obligation to pay royalties with respect to sales in a specified region will continue until the later of the date of expiration of all intellectual property and regulatory exclusivity for the product in the region and ten years from the first commercial sale, unless earlier terminated by Hansoh with advanced notice for convenience or under other specified circumstances.

12

 

R-Pharm

In August 2013, we entered into an agreement with R-Pharm, CJSC (R-Pharm), a leading supplier of hospital drugs in Russia, granting them exclusive rights to develop and commercialize ibrexafungerp in the field of human health in Russia, Turkey, and certain Balkan, Central Asian, Middle Eastern and North African countries. We retained the right to commercialize ibrexafungerp in the Americas, Europe, and Asia.  In November 2014, we entered into a supplemental arrangement with R-Pharm, whereby R-Pharm was informed of the modified IV formulation development plan and R-Pharm agreed to reimburse us for specifically identified IV formulation development and manufacturing costs incurred by us.  We received a non-refundable upfront payment of $1.5 million from R-Pharm in August 2013 which was recognized over a period of 70 months and is fully amortized.

Government Regulation

Government Regulation

Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, including any manufacturing changes, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.

U.S. Drug Approval Process

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA), and implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA’s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recall requests, product seizures, total or partial suspension of production or distribution, injunctions, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.

The process required by the FDA before a drug may be marketed in the United States generally involves the following:

 

•

completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA’s good laboratory practice (GLP) regulations;

 

•

submission to the FDA of an investigational new drug application (IND) which must become effective before human clinical trials may begin;

 

•

approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated;

 

•

performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (GCP) to establish the safety and efficacy of the proposed drug for each indication, subject to on-going IRB review;

 

•

submission to the FDA of an NDA;

 

•

satisfactory completion of an FDA advisory committee review, if applicable;

 

•

satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current Good manufacturing practice (cGMP) regulations and guidance, and to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity; and

 

•

FDA review and approval of the NDA.

After evaluating the NDA and all related information, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the application.

Preclinical Studies

Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any

13

 

outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.

Clinical Trials

Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health (NIH) for public dissemination on their ClinicalTrials.gov website.

Human clinical trials are typically conducted in three sequential phases, which in some cases may overlap or be combined:

Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.

Phase 2: The drug is administered to a limited patient population with the target disease to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.

Phase 3: The drug is administered to an expanded patient population with the target disease, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.

Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur.  Phase 1, Phase 2 and Phase 3 clinical trials sometimes cannot be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients.

In some cases, the FDA may condition approval of an NDA for a product candidate on the sponsor’s agreement to conduct additional clinical trials to further assess the drug’s safety and effectiveness after NDA approval. Such post-approval trials are typically referred to as Phase 4 studies.

In some circumstances, the FDA may also order a sponsor to conduct post-approval clinical trials if new safety information arises raising questions about the drug’s risk-benefit profile. Those clinical trials are typically referred to as Post-Marketing Requirements (PMRs).

GAIN Act

The FDA has various expedited development programs, including break-through therapy, fast track designation and priority review, that are intended to expedite or simplify the process for the development and FDA review of drugs that meet certain qualifications. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.

The GAIN Act is intended to encourage development of new antibacterial and antifungal drugs for the treatment of serious or life-threatening infections by providing certain benefits to sponsors, including extended exclusivity periods, fast track and priority review. To be eligible for these benefits a product in development must seek and be awarded designation as a Qualified Infectious Disease Product (QIDP).

To qualify as a QIDP according to the criteria established in the GAIN Act, a product must be an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections, including, those:

 

•

caused by an antifungal resistant pathogen, including novel or emerging infectious pathogens; or

 

•

qualifying pathogens listed by the FDA in accordance with the GAIN Act.

Fast Track Designation

14

 

The FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the Fast Track program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for Fast Track designation within 60 days of receipt of the sponsor's request.

If a drug candidate is granted Fast Track designation, the sponsor may engage in more frequent interactions with the FDA, and the FDA may review sections of the NDA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA's time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.

Post Approval Requirements

Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications, manufacturing changes or other labeling claims, are subject to further testing requirements and prior FDA review and approval. There also are continuing annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as application fees for supplemental applications with clinical data.

Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, including a boxed warning, require that post‑approval studies, including Phase 4 clinical trials, be conducted to further assess a drug’s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post‑marketing studies or surveillance programs.

In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third‑party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.

The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label, although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications. However, pharmaceutical companies may share truthful and not misleading information that is otherwise consistent with the labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting their promotion of off‑label uses, and a company that is found to have improperly promoted off‑label uses may be subject to significant civil, criminal and administrative liability.

In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.

Pediatric Exclusivity

Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of regulatory protection to the term of any existing exclusivity, including the non-patent exclusivity periods described above, and to the regulatory term of any patent that has been submitted to FDA for the approved drug product. This six-month exclusivity may be granted based on the voluntary completion of a pediatric study or studies in accordance with an FDA-issued “Written Request” for such a study or studies.

Qualified Infectious Disease Product Exclusivity

If the NDA for a QIDP is approved by the FDA, the FDA will extend by an additional five years any non-patent marketing exclusivity period awarded, such as a five-year exclusivity period awarded for a new chemical entity. This extension

15

 

is in addition to any pediatric exclusivity extension awarded. Eligibility for the extension will be denied if the product is approved for uses that would not meet the definition of a QIDP.

Other U.S. Healthcare Laws and Compliance Requirements

In the United States our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare & Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (HHS) such as the Office of Inspector General, the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant programs must comply with the federal and state anti-fraud and abuse laws, false claims laws, the privacy provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and payment transparency laws. If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including civil, criminal and administrative sanctions, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity oversight and reporting obligations, and contractual damages.

Foreign Regulation

To market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.

Pharmaceutical Coverage, Pricing and Reimbursement and Health Care Reform

Our ability to commercialize our product candidates successfully will depend in part on the extent to which the United States and foreign governmental authorities, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our product candidates and related treatments. In many of the markets where we would commercialize a product following regulatory approval, the prices of pharmaceutical products are subject to direct price controls (by law) and to drug reimbursement programs with varying price control mechanisms.  In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. One third-party payor’s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly.

Public and private health care payors control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others within a therapeutic class. Payors also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered. In particular, many public and private health care payors limit reimbursement and coverage to the uses of a drug that are either approved by the FDA or that are supported by other appropriate evidence (for example, published medical literature) and appear in a recognized drug compendium. Drug compendia are publications that summarize the available medical evidence for particular drug products and identify which uses of a drug are supported or not supported by the available evidence, whether or not such uses have been approved by the FDA.

In the United States and some foreign jurisdictions there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare system to contain costs, improve quality, and expand access to care. For example, in the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Affordable Care Act, substantially changed the way healthcare is financed by both governmental and private insurers, and continues to significantly impact the U.S. pharmaceutical industry. There have been executive, judicial and congressional challenges to certain aspects of the Affordable Care Act. For example, the United States Supreme Court is currently reviewing the constitutionality of the Affordable Care Act. There also has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there have been several recent executive orders, Congressional inquiries and proposed federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.

Intellectual Property

16

 

We strive to protect the proprietary technology that we believe is important to our business, including seeking and maintaining patents intended to cover our product candidates and compositions, and their methods of use and other inventions that are commercially important to the development of our business. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.

As of March 1, 2021, we are the owner of ten issued U.S. patents and more than 125 issued non-U.S. patents with claims to novel compounds, compositions containing them, processes for their preparation, and their uses as pharmaceutical agents, with terms expiring between 2027 and 2035. Of these patents, four U.S. patents relate to ibrexafungerp. We are actively pursuing six U.S. patent applications and many non-U.S. patent applications in multiple jurisdictions worldwide.

Ibrexafungerp is protected by an issued composition of matter patent (U.S. Patent No. 8,188,085) in the United States, which expires in 2030, and we will have ten to twelve years of regulatory exclusivity in the U.S.  Based on our current development plan, we believe that an additional term of up to five years for the ibrexafungerp composition of matter U.S. patent may result from the patent term extension provision of the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). The composition of matter is covered by a patent in more than 60 jurisdictions, with 10 patent applications pending, worldwide.  Three patents related to ibrexafungerp salts and polymorphs, including the citrate salt currently under development, have issued, with expiration expected in 2035.  Additional patent applications related to ibrexafungerp’s formulations and use as an antifungal agent have been filed and are currently pending. If granted, the new patent families could extend the patent protection for certain ibrexafungerp formulations or uses up to 2040.  For this and more comprehensive risks related to our proprietary technology and processes, please see the section on “Risk Factors-Risks Relating to Our Intellectual Property.”

Employees

As of March 1, 2021, we had 38 employees, all of whom were employed on a full-time basis. Our employees are engaged in administration, accounting and finance, research, clinical development, manufacturing, and business development functions. We believe our relations with our employees are good.

Corporate Information

We were incorporated in the State of Delaware on November 4, 1999. Our corporate headquarters are located at 1 Evertrust Plaza, 13th Floor, Jersey City, New Jersey 07302.

Our corporate website address is www.scynexis.com. Our Annual Report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge on our website. The information contained on, or that can be accessed through, our website is not part of this Annual Report, and the inclusion of our website address in this Annual Report is an inactive textual reference only.

ITEM 1A.

RISK FACTORS

In evaluating our business, you should carefully consider the following risks, as well as the other information contained in this Annual Report on Form 10-K. These risk factors could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report on Form 10-K and those we may make from time to time. If any of the following risks actually occurs, our business, financial condition and operating results could be harmed. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business.

Risks Relating to Our Financial Condition and Need for Additional Capital

We have never been profitable, we have no products approved for commercial sale, and to date we have not generated any revenue from product sales. As a result, our ability to curtail our losses and reach profitability is unproven, and we may never achieve or sustain profitability.

We are not profitable and do not expect to be profitable in the foreseeable future. We have incurred net losses in each year since our inception, including a net loss of $55.2 million for the year ended December 31, 2020.  As of December 31, 2020, we had an accumulated deficit of approximately $326.6 million.  On a prospective basis, our strategic focus, along with the commitment of our financial resources, will be directed towards the development and potential commercialization of ibrexafungerp, our lead product candidate.  We had cash and cash equivalents of $93.0 million as of December 31, 2020.  Based upon our existing operating plan, we believe that our existing cash and cash equivalents, the sale of a portion of our New Jersey NOLs, the upfront payment from Hansoh, and anticipated sales of Brexafemme will enable us to fund our operating requirements into 2023, although there can be no assurances that we will be able to continue our operations on a long-term basis.  We have suffered substantial losses from operations since inception and will require additional financing.

We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially as we:

17

 

 

•

continue the development of ibrexafungerp for treatment of multiple indications;

 

•

conduct ongoing and initiate new clinical trials for ibrexafungerp;

 

•

seek marketing approvals for ibrexafungerp;

 

•

establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;

 

•

maintain, expand and protect our intellectual property portfolio;

 

•

hire additional clinical, quality control and scientific personnel;

 

•

maintain and create additional infrastructure to support our operations as a public company; and

 

•

develop in-house product candidates or seek to in-license product candidates from third-parties.

In addition, our expenses could increase if we are required by the U.S. Food and Drug Administration, or the FDA, to perform studies in addition to, or that are larger than, those that we currently expect.

As a result of the foregoing, we expect to experience net losses and negative cash flows from operations for the foreseeable future, and we are unable to predict when, or if, we will be able to achieve profitability. Our losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity, financial position and working capital.

We expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance.

Our financial condition and operating results have varied significantly in the past and will continue to fluctuate from quarter to quarter or year to year due to a variety of factors, many of which are beyond our control. The following factors relating to our business, as well as factors described elsewhere in this report, may contribute to these fluctuations:

 

•

the costs associated with developing ibrexafungerp, which are difficult for us to predict;

 

•

any delays in regulatory review and approval of ibrexafungerp;

 

•

delays in the timing of submission of any new drug application, or NDA, or supplement thereto, as well as commencement, enrollment and the timing of clinical testing, of ibrexafungerp or any other product candidates we may seek to develop;

 

•

our ability to commercialize product candidates, both in the United States and overseas, if we are able to obtain regulatory approval to do so;

 

•

the costs associated with obtaining and maintaining regulatory approval and ongoing company compliance and product compliance for ibrexafungerp;

 

•

market acceptance of ibrexafungerp and any future product candidates we may seek to develop;

 

•

changes in regulations and regulatory policies;

 

•

competition from existing products or new products that may emerge;

 

•

the ability of patients or healthcare providers to obtain coverage of, or sufficient reimbursement for, any products we are able to develop;

 

•

our ability to establish or maintain collaborations, licensing or other arrangements;

 

•

costs related to, and outcomes of, potential litigation;

 

•

potential product liability claims; and

 

•

potential liabilities associated with hazardous materials.

Due to the various factors mentioned above, and others, the results of any quarterly or annual periods should not be relied upon as indications of future operating performance.  Further, any financial projections we make are made as of the date we make them are subject to these risks and uncertainties, and these financial projections may not be realized.

We will continue to require substantial additional capital, and if we are unable to raise capital when needed we would be forced to delay, reduce or eliminate our development program for ibrexafungerp.

Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. If the FDA requires that we perform additional studies beyond those that we currently expect, our expenses could increase beyond what we currently anticipate, the timing of the submission of our planned NDAs could be delayed, and any potential product approval could be delayed. Based upon our existing operating plan, we believe that our existing cash and cash equivalents, the sale of a

18

 

portion of our New Jersey NOLs, the upfront payment from Hansoh, and anticipated sales of Brexafemme will enable us to fund our operating requirements into 2023; provided, however, that changing circumstances may cause us to consume cash more rapidly than we currently anticipate. We may need to raise additional funds from additional issuances of equity and/or debt securities or otherwise obtain funding through strategic alliances or collaborations with third parties. In any event, we will require additional capital to complete development of, to seek regulatory approval for and, if approval is obtained, to commercialize ibrexafungerp and any future product candidates we may seek to develop.

When we are required to secure additional financing, the additional fundraising efforts may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize ibrexafungerp and any future product candidates we may seek to develop. In addition, we cannot guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to:

 

•

significantly delay, scale back or discontinue the development or commercialization of ibrexafungerp and any future product candidates we may seek to develop;

 

•

seek strategic alliances for research and development programs at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or

 

•

relinquish or license on unfavorable terms our rights to any product candidates that we otherwise would seek to develop or commercialize ourselves.

If we are required to conduct additional fundraising activities and we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects.

Our operating activities may be restricted as a result of covenants related to the indebtedness under our senior convertible notes and we may be required to repay the notes in an event of default, which could have a materially adverse effect on our business.

On March 7, 2019, we entered into a senior convertible note purchase agreement with Puissance Life Science Opportunities Fund VI (Puissance), pursuant to which we issued and sold to Puissance $16 million of our 6.0% senior convertible notes due 2025, and on April 9, 2020, we entered into a senior convertible note purchase agreement with Puissance pursuant to which we issued and sold to Puissance $10 million of our 6.0% senior convertible notes due 2026.

We may be required to repay the outstanding notes if an event of default occurs under the note purchase agreements.  Under the note purchase agreements, an event of default will occur if, among other things: we fail to make payments under the note purchase agreement; we breach any of our covenants under the note purchase agreements, subject to specified cure periods with respect to certain breaches; or we or our subsidiaries become subject to bankruptcy, insolvency or reorganization proceedings.  We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In this case, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant to others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.

Risks Relating to the Development, Regulatory Approval and Commercialization of Our Product Candidates For Human Use

We cannot be certain that ibrexafungerp will receive regulatory approval, and without regulatory approval we will not be able to market ibrexafungerp. Regulatory approval is a lengthy, expensive and uncertain process.

Our ability to generate significant revenue related to ibrexafungerp sales will depend on the successful development and regulatory approval of ibrexafungerp. We expect that the earliest that we could obtain regulatory approval of ibrexafungerp and commence commercialization of ibrexafungerp will be in June 2021, if at all.

We currently have no products approved for sale and we cannot guarantee that we will ever have marketable products. The development and commercialization of a product candidate, including preclinical and clinical testing, manufacturing, quality systems, labeling, approval, record-keeping, selling, promotion, marketing and distribution of products, is subject to extensive regulation by the FDA in the United States and regulatory authorities in other countries, with regulations differing from country to country. We are not permitted to market product candidates in the United States until and unless we receive approval of an NDA from the FDA. Although we have submitted an NDA for ibrexafungerp for the treatment of VVC, have not yet received regulatory approval of our NDA for this indication.  We have not submitted an NDA for ibrexafungerp for the prevention of recurrent VVC or for the treatment of refractory invasive fungal infections, invasive pulmonary aspergillosis or any other indications. Obtaining approval of an NDA is a lengthy, expensive and uncertain process. An NDA must include extensive preclinical and clinical data and supporting information to establish the product candidate’s safety and effectiveness for each indication. The approval application must also include significant information regarding the chemistry, manufacturing

19

 

and controls for the product. The product development and regulatory review process typically takes years to complete, involves numerous uncertainties and the potential for concerns to emerge late in the development process, and approval is never guaranteed. Even if a product is approved, as we expect will occur for our NDA for ibrexafungerp for the treatment of VVC, the FDA may limit the indications for which the product may be used, require extensive warnings on the product labeling or require costly ongoing requirements for post-marketing clinical studies and surveillance or other risk management measures to monitor the safety or efficacy of the product candidate, including the imposition of a Risk Evaluation and Mitigation Strategy, or REMS. Markets outside of the United States also have requirements for approval of drug candidates with which we must comply prior to marketing. Obtaining regulatory approval for marketing of a product candidate in one country does not ensure we will be able to obtain regulatory approval in other countries, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries. Also, any regulatory approval of a product candidate, once obtained, may be withdrawn. If ibrexafungerp or any of our other wholly-owned or partnered product candidates do not receive timely regulatory approval, or fail to maintain that regulatory approval, we may not be able to generate sufficient revenue to become profitable or to continue our operations. Moreover, the submission of our NDA or the receipt of regulatory approval does not assure commercial success of any approved product.

Although both the oral and IV formulations of ibrexafungerp have been granted Qualified Infectious Disease Product status and Fast Track designation, this does not guarantee that the length of the FDA review process will be significantly shorter than otherwise, or that ibrexafungerp will ultimately be approved by the FDA.

We applied to the FDA for, and received, the designation of the oral tablet and the IV formulations of ibrexafungerp for vulvovaginal candidiasis, invasive candidiasis and invasive aspergillosis as Qualified Infectious Disease Product (QIDP) under the Generating Antibiotic Incentives Now Act (GAIN Act). We also applied to the FDA for, and were granted, Fast Track designation for ibrexafungerp for these indications.  Receipt of QIDP status and Fast Track designation in practice may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA or related GAIN Act exclusivity benefits.

Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for ibrexafungerp or any future product candidates.

We do not know whether our current clinical trials of ibrexafungerp will be completed on schedule or at all, or whether any future clinical trials of ibrexafungerp or any future product candidates we may seek to develop will be allowed to commence or, if commenced, will be completed on schedule or at all. The commencement, enrollment and completion of clinical trials can be delayed for a variety of reasons, including:

 

•

inability to reach agreements on acceptable terms with prospective clinical research organizations, or CROs, and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

 

•

difficulty identifying and engaging qualified clinical investigators;

 

•

regulatory objections to commencing a clinical trial or proceeding to the next phase of investigation, including inability to reach agreement with the FDA or non-U.S. regulators regarding the scope or design of our clinical trials or for other reasons such as safety concerns that might be identified during preclinical development or early stage clinical trials;

 

•

inability to identify and maintain a sufficient number of eligible trial sites, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our product candidates;

 

•

withdrawal of clinical trial sites from our clinical trials as a result of changing standards of care;

 

•

inability to obtain institutional review board (or ethics review committee) approval to conduct a clinical trial at prospective sites;

 

•

difficulty identifying, recruiting and enrolling eligible patients to participate in clinical trials for a variety of reasons, including meeting the enrollment criteria for our study and competition from other clinical trial programs for the same indication as product candidates we seek to commercialize;

 

•

inability to retain patients in clinical trials due to the treatment protocol, personal issues, side effects from the therapy or lack of efficacy;

 

•

inability to produce and/or obtain in a timely manner sufficient quantity of our products to satisfy the requirements of the clinical trials;

 

•

inability to enroll patients, or slow down in the rate of enrolling patients, in clinical trials due to unforeseen natural disasters, public health crises, political crises and other catastrophic events or other events outside of our control, such as the recent emergence and spread of COVID-19, a coronavirus, which may cause participants to not want to participate in these trials or otherwise have any unnecessary contact with the medical community; and

20

 

 

•

inability to obtain sufficient funding to commence a clinical trial.

In addition, a clinical trial may be suspended or terminated by us, our current or any future partners, an institutional review board, the FDA or other regulatory authorities due to a number of factors, including:

 

•

failure by us, CROs or clinical investigators to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;

 

•

failed inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities;

 

•

safety or efficacy issues or any determination that a clinical trial presents unacceptable health risks.  During an extension of our Phase 1 program for the intravenous formulation in healthy volunteers, aimed to expand the safety margin that would allow greater flexibility of dosing options in patients, we observed adverse events secondary to thrombi formation at site of IV infusion; or

 

•

lack of adequate funding to continue the clinical trial due to unforeseen costs resulting from enrollment delays, requirements to conduct additional trials and studies, increased expenses associated with the services of our CROs and other third parties, or other reasons.

If we are required to conduct additional clinical trials or other testing of ibrexafungerp or any future product candidates we may seek to develop, we may be delayed in obtaining, or may not be able to obtain, marketing approval for these product candidates.

In addition, if our current or any future partners have rights to and responsibility for development of ibrexafungerp or any future product candidates, they may fail to meet their obligations to develop and commercialize the product candidates, including clinical trials for these product candidates.

Changes in regulatory requirements and guidance may occur and we or any of our partners may be required by appropriate regulatory authorities to amend clinical trial protocols to reflect these changes. Amendments may require us or any of our partners to resubmit clinical trial protocols to independent review boards for re-examination, which may impact the costs, timing or successful completion of a clinical trial. If we or any of our partners experience delays in the completion of, or if we or our partners terminate, clinical trials, the commercial prospects for ibrexafungerp and any future product candidates we may seek to develop will be harmed, and our ability to generate revenue from sales of these product candidates will be prevented or delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate.

Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate we or our current or potential future partners advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval.

Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or our partners may decide, or regulators may require us, to conduct additional clinical or preclinical testing. In addition, data obtained from tests are susceptible to varying interpretations, and regulators may not interpret data as favorably as we do, which may delay, limit or prevent regulatory approval. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Frequently, product candidates that have shown promising results in early clinical trials have subsequently suffered significant setbacks in later clinical trials. In addition, the design of a clinical trial can determine whether its results will support approval of a product application, or approval of a supplemental application to add a new indication or other changes, and flaws or shortcomings in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval, or approval of supplemental applications for new indications or other changes. Further, clinical trials of potential products often reveal that it is not practical or feasible to continue development efforts. If ibrexafungerp or any future product candidates are found to be unsafe or lack efficacy, we or our collaborators will not be able to obtain regulatory approval for them and our business would be harmed. For example, if the results of our completed, ongoing or planned Phase 2 and Phase 3 clinical trials of ibrexafungerp do not achieve, to the satisfaction of regulators, the primary efficacy endpoints and demonstrate an acceptable level of safety, the prospects for approval of ibrexafungerp would be materially and adversely affected. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in Phase 2 and Phase 3 clinical trials, even after seeing promising results in earlier clinical trials.

In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including differences in trial protocols and design, differences in size and type of the patient populations, adherence to the dosing regimen and the rate of dropout among clinical trial participants. Further, the patients taking ibrexafungerp often have other significant medical issues, such as organ transplants, cancer or other conditions in which their immune systems are suppressed, which makes it difficult to measure the effect of ibrexafungerp in the presence of these medical issues. We do not know whether our NDA for ibreaxfungerp for the treatment of VVC will be approved, or

21

 

whether any Phase 2, Phase 3 or other clinical trials we or any partners may conduct will demonstrate consistent and/or adequate efficacy and safety to obtain regulatory approval to market ibrexafungerp and any future product candidates we may seek to develop.

We have limited experience in conducting clinical trials and have only submitted one NDA before, and we may be unable to do so for ibrexafungerp in additional indications or any future product candidate we may seek to develop.

Merck completed seven Phase 1 clinical trials of ibrexafungerp and we have completed 13 Phase 1 clinical trials, four Phase 2 trials, and have initiated five Phase 3 trials, two of which have been completed and three of which are ongoing. We are planning to conduct additional Phase 1, Phase 2, and Phase 3 clinical trials of ibrexafungerp. The conduct of successful Phase 2 and Phase 3 clinical trials is essential in obtaining regulatory approval, and the submission of a successful NDA is a complicated process. We have limited experience in preparing and submitting regulatory filings, have previously only sponsored four Phase 2 clinical trials and five Phase 3 clinical trials, and we have only submitted one NDA. Consequently, we may be unable to successfully and efficiently execute and complete our ongoing and planned clinical trials in a way that is acceptable to the FDA and leads to an approval of ibrexafungerp or any future product candidate we may seek to develop. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we may seek to develop. In addition, failure to commence or complete, or delays in, our planned clinical trials would prevent us from or delay us in commercializing ibrexafungerp or any future product candidate we may develop.

The environment in which our regulatory submissions may be reviewed changes over time, which may make it more difficult to obtain regulatory approval of any of our product candidates we may seek to develop or commercialize.

The environment in which regulatory submissions are reviewed changes over time. For example, average review times at the FDA for NDAs have fluctuated over the last ten years, and although we have PDUFA date for our NDA submission for ibrexafungerp for the treatment of VVC, we cannot predict the review time for any other submission with any regulatory authorities. Review times can be affected by a variety of factors, including budget and funding levels and statutory, regulatory and policy changes. Moreover, in light of widely publicized events concerning the safety risks of certain drug products, regulatory authorities, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and establishment of risk evaluation and mitigation strategies that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials. Data from preclinical studies and clinical trials may receive greater scrutiny with respect to safety, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense, a delay or failure in obtaining approval or approval for a more limited indication or conditions of use than originally sought.

In addition, data obtained from preclinical studies and clinical trials are subject to different interpretations, which could delay, limit or prevent regulatory review or approval of product candidates. Changes in FDA personnel responsible for review of our submissions could also impact the manner in which our data are viewed. Furthermore, regulatory attitudes towards the data and results required to demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence of new information, including information on other products, policy changes and agency funding, staffing and leadership. We do not know whether future changes to the regulatory environment will be favorable or unfavorable to our business prospects.

If ibrexafungerp or any other future product candidates for which we receive regulatory approval do not achieve broad market acceptance, the revenue that is generated from their sales will be limited.

The commercial success of ibrexafungerp or any other product candidates we may seek to develop will depend upon the acceptance of these product candidates among physicians, patients, the medical community and healthcare payors. The degree of market acceptance of product candidates will depend on a number of factors, including:

 

•

limitations or warnings contained in the FDA-approved labeling;

 

•

changes in the standard of care for the targeted indications;

 

•

limitations in the approved indications;

 

•

availability of alternative therapies with potentially advantageous results, or other products with similar results at similar or lower cost, including generics and over-the-counter products;

 

•

lower demonstrated clinical safety or efficacy compared to other products;

 

•

occurrence of significant adverse side effects;

 

•

ineffective sales, marketing and distribution support;

22

 

 

 

•

lack of availability of coverage and adequate reimbursement from governmental health care programs, managed care plans and other third-party payors;

 

•

timing of market introduction and perceived effectiveness of competitive products;

 

•

lack of cost-effectiveness;

 

•

adverse publicity about our product candidates or favorable publicity about competitive products;

 

•

lack of convenience and ease of administration; and

 

•

potential product liability claims.

If ibrexafungerp or any future product candidates we may seek to develop are approved, but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, sufficient revenue may not be generated from these product candidates, and we may not become or remain profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful.

A significant use of antifungal drugs consists of treatment due to the presence of symptoms before diagnosis of the invasive fungal infections, and if recently approved diagnostic tools, or additional tools currently under development, for the quick diagnosis of invasive fungal infections are broadly used in the marketplace, the number of treatments using antifungal drugs may decrease significantly, decreasing the potential market for ibrexafungerp.

We believe that a large portion of the treatments using antifungal drugs are administered when symptoms of invasive fungal infections are present but a diagnosis of the infection has not yet been made, due to the rapid and potentially fatal progression of invasive fungal infections. Diagnostic tools recently approved by the FDA, or currently under development, for the rapid diagnosis of invasive fungal infections may significantly diminish the need to treat patients in advance of diagnosis of invasive fungal infections, which will reduce the potential market for ibrexafungerp in the event that we are able to obtain FDA approval of ibrexafungerp. Moreover, if a rapid and accurate test of the susceptibility of a fungal infection to generically available treatments is developed and widely adopted, the market for ibrexafungerp may suffer.

If resistance to ibrexafungerp develops quickly or cross-resistance with echinocandins becomes more common, our business will be harmed.

We recognize that, over time, resistance develops against every antibacterial and antifungal drug. One or more strains of fungal pathogens may develop resistance to ibrexafungerp more rapidly than we currently expect, either because our hypothesis of the mechanism of action is incorrect or because a strain of fungi undergoes some unforeseen genetic mutation that permits it to survive. Since we expect lower resistance relative to other antifungal drug classes to be a major factor in the commercialization of ibrexafungerp, rapid development of such resistance or development of cross resistance with echinocandins would have a major adverse impact on the acceptability and sales of ibrexafungerp.

If we are unable to obtain regulatory approval of both the oral and IV formulations of ibrexafungerp, ibrexafungerp may not achieve broad market acceptance and sales will be limited.

Current treatment regimens for invasive fungal infections typically involve initial administration of treatments as an IV infusion, with a switch to an oral formulation of the same or a similar medication to complete the course of treatment on an out-patient basis. We believe that providing both the IV and oral formulations will be beneficial to doctors who prefer to start treatment of patients in a hospital setting with an IV therapy and then switch them to an oral formulation of the same medication. If we are unable to successfully develop and achieve regulatory approval for either the oral or IV formulation of ibrexafungerp, our lead product candidate may not achieve, or may be delayed in achieving, broad market acceptance and sales will be limited.

Our product candidates may have undesirable side effects that may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market or otherwise limit their sales.

Although we have a PDUFA date for our NDA submission for ibrexafungerp for the treatment of VVC, it is impossible to predict when or if ibrexafungerp for other indications or any other product candidate we may seek to develop will prove effective or safe, or whether we will receive marketing approval for ibrexafungerp for the treatment of VVC or other indications, or for any other products we may seek to develop. Unforeseen side effects from any product candidates could arise either during clinical development or, if approved, after the product has been marketed. The most commonly reported adverse events after oral administration of ibrexafungerp have been gastrointestinal (GI) events (i.e., nausea, diarrhea, vomiting).  The gastrointestinal events reported have typically been transient (i.e., short duration), mild or moderate and not leading to discontinuation.  The most commonly reported adverse events after IV administration of ibrexafungerp have been local reactions at the site of infusion.  During our Phase 1 IV program in healthy volunteers, aimed to expand the safety margin that would allow greater flexibility of dosing options in patients, we observed three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of ibrexafungerp at the highest doses and highest concentrations in a Phase 1 study.  These events were reported to FDA as 15-day alert reports because they were unexpected and required anticoagulant therapy.  

23

 

The potential contribution of the IV formulation of ibrexafungerp to these events cannot be ruled out even though rates of thrombotic events due to intravenous catheters reported in the literature are comparable to those observed in the Phase 1 study.  

Serious adverse events (SAEs) are common when conducting clinical trials in a seriously ill population such as patients experiencing invasive candidiasis. Several SAEs have been reported in our clinical trials but only four of the events have been deemed by the investigator to be potentially related to ibrexafungerp, although other contributing factors could not be ruled out.  These four serious adverse events include: one event of elevation of liver function tests in a subject who received a single dose of oral ibrexafungerp (resolved) and three events secondary to thrombi formation at site of IV infusion with the cyclodextrin-based IV formulation.

On March 2, 2017, we announced that the FDA had placed a clinical hold on our IV formulation, instructing us to hold the initiation of any new clinical studies with our IV formulation until the FDA completes a review of all available pre-clinical and clinical data of the IV formulation of ibrexafungerp.  In January 2018, we announced encouraging pre-clinical results for the prototype liposomal IV formulation of ibrexafungerp, showing improved local tolerability profile at the infusion site in head-to-head pre-clinical evaluations with the cyclodextrin-based IV formulation. In August 2018, we announced that as part of our development plans, the process for the liposomal formulation was transferred for scale-up purposes at a manufacturing site intended to provide clinical supplies. Additional preclinical evaluations were performed with the scaled-up formulation, which unexpectedly revealed differences in tolerability at the injection site, delaying advancement of the IV product into human trials. As it is generally recognized that changes to manufacturing processes and/or scale-up can impact the characteristics of drug products, particularly for more technically complex formulations such as liposomal products, we are currently working with our vendors and CMC experts to enable us to resume the pre-IND pre-clinical activities for the IV formulation of ibrexafungerp in the U.S.  If the FDA does not permit us to initiate new clinical studies with our IV formulation, we will not be able to develop and commercialize an IV formulation of ibrexafungerp, which would harm our business prospects.  We are currently conducting a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of the IV liposomal formulation of ibrexafungerp in healthy subjects. The study is being conducted in South Africa and dosing started in March 2021.  

Preclinical findings in the future could trigger the need to evaluate or monitor for specific potential safety concerns in clinical trials. The results of our Phase 1 clinical trial in South Africa and any future clinical trials may show that ibrexafungerp and any future product candidates we may seek to develop cause undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, resulting in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or may lead us to abandon their development altogether.

Even if ibrexafungerp or any future product candidate we may seek to develop receives marketing approval, we or others may subsequently identify undesirable or unacceptable side effects caused by these products, in which case:

 

•

regulatory authorities may require the addition of labeling statements, specific warnings, precautions, contraindications or field alerts to physicians and pharmacies;

 

•

we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;

 

•

we may have limitations on how we promote the product;

 

•

sales of the product may decrease significantly;

 

•

regulatory authorities may require us to take our approved product off the market;

 

•

we may be subject to litigation or product liability claims; and

 

•

our reputation may suffer.

Any of these events could prevent us or our current or potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of products.

We have never marketed a drug before, and if we are unable to establish an effective sales force and marketing infrastructure or enter into acceptable third-party sales and marketing or licensing arrangements, we may not be able to successfully commercialize ibrexafungerp and any future product candidates we may seek to develop.

We currently do not have any sales, distribution and marketing capabilities, the development of which will require substantial resources and will be time consuming. The costs incurred in the development of these capabilities, either internally or through a third-party contract sales organization, would be incurred in advance of any approval of a product candidate. In addition, we may not be able to hire a sales force in the United States that is sufficient in size or has adequate expertise in the medical markets that we intend to target. If we are unable to establish our sales force and marketing capability, our operating results may be adversely affected. In addition, in February 2021 we entered into an agreement with Amplity, Inc., for the potential upcoming commercial launch of ibrexafungerp for the treatment of VVC in the U.S., and will utilize Amplity’s

24

 

commercial execution expertise and resources for sales force, remote engagement, training, market access and select operation services.  However, if Amplity does not perform under this agreement in the manner we expect, or Amplity were to terminate this agreement, this would significantly impair or delay our ability to commercialize ibrexafungerp for the treatment of VVC in the U.S. if approved.  Further, we currently have a development license and supply agreement with R-Pharm, a leading supplier of hospital drugs in Russia, pursuant to which we license to R-Pharm rights to develop and commercialize ibrexafungerp in the field of human health in Russia and certain smaller non-core markets. We plan to enter into additional sales and marketing or licensing arrangements with third parties for international sales of any approved products. If we are unable to enter into or maintain any such arrangements on acceptable terms, or at all, or these entities fail to perform as we intend under these agreements, we may be unable to market and sell ibrexafungerp or any future product candidates we may seek to develop in these markets.

We expect that ibrexafungerp and any future product candidates we may seek to develop will face competition, and most of our competitors have significantly greater resources than we do.

The pharmaceutical industry is highly competitive, with a number of established, large pharmaceutical companies, as well as many smaller companies. There are many foreign and domestic pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations actively engaged in research and development of products that may target the same markets as ibrexafungerp and any future product candidates we may seek to develop. We expect any products we develop to compete on the basis of, among other things, product efficacy, lack of significant adverse side effects and convenience and ease of treatment. For example, ibrexafungerp will compete against current leading antifungal drugs, including voriconazole from the azole class, caspofungin from the echinocandin class, and liposomal amphotericin B from the polyenes class, many of which are currently available in generic form, or expected to be available in generic form at the time ibrexafungerp might be approved.

Compared to us, many of our competitors in the antifungal market have, and potential competitors for any future product candidates we may seek to develop may have, substantially greater:

 

•

resources, including capital, personnel and technology;

 

•

research and development capability;

 

•

clinical trial expertise;

 

•

regulatory expertise;

 

•

intellectual property portfolios;

 

•

expertise in prosecution of intellectual property rights;

 

•

manufacturing and distribution expertise; and

 

•

sales and marketing expertise.

As a result of these factors, our competitors and potential competitors may obtain regulatory approval of their products more rapidly than we do. Our competitors and potential competitors may also develop drugs that are more effective, more widely used and less costly than ours and may also be more successful than us in manufacturing and marketing their products and maintaining compliance with ongoing regulatory requirements.

Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance in the United States. If there is not sufficient reimbursement for our products, it is less likely that our products will be purchased by patients and/or providers.

Successful commercialization of pharmaceutical products usually depends on the availability of coverage and adequate reimbursement from third-party payors, including commercial insurers and federal and state healthcare programs. Patients and/or healthcare providers who purchase drugs generally rely on third-party payors to reimburse all or part of the costs associated with such products. As such, coverage and adequate reimbursement from third-party payors can be essential to new product acceptance and may have an effect on pricing.

Because ibrexafungerp is not currently commercially available, we do not know the extent to which it will be able to obtain favorable coverage and adequate reimbursement from third-party payors if it is approved by the FDA. If we choose to bring other product candidates to market, they will be subject to similar uncertainty. We believe that ibrexafungerp and any other product candidates that are brought to market are less likely to be purchased by patients and/or providers if they are not adequately reimbursed by third-party payors.

In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors.  As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Furthermore, the market for our product candidates may depend on access to third-

25

 

party payors’ drug formularies, or lists of medications for which third-party payors provide coverage and reimbursement. Industry competition to be included in such formularies results in downward pricing pressures on pharmaceutical companies. Third-party payors may refuse to include a particular branded drug in their formularies when a competing generic product is available. The adoption of certain payment methodologies by third-party payors may limit our ability to profit from the sale of ibrexafungerp. For example, under Medicare, hospitals are reimbursed under an inpatient prospective payment system. This pricing methodology provides a single payment amount to hospitals based on a given diagnosis-related group. As a result, with respect to Medicare reimbursement for services in the hospital inpatient setting, hospitals could have a financial incentive to use the least expensive drugs for the treatment of invasive fungal infections, particularly the IV formulations of these drugs, as they are typically administered in the hospital, which may significantly impact our ability to charge a premium for ibrexafungerp.

All third-party payors, whether governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs, including mechanisms to encourage the use of generic drugs. Congress has also considered policies to lower the reimbursement formulas in federal and state healthcare programs. Furthermore, coverage of, and reimbursement for, drugs can differ significantly from payor to payor and may require significant time and resources to obtain. In addition, new laws or regulations could impact future coverage and reimbursement.

Healthcare policy changes, including the Affordable Care Act, or changes or repeal of the Affordable Care Act, may have a material adverse effect on us.

In recent years, there have been numerous initiatives on the federal and state levels for comprehensive reforms affecting healthcare industry, including reforms related to the payment for, the availability of and reimbursement for healthcare services in the United States, including pharmaceutical products. These initiatives have ranged from proposals to fundamentally change federal and state healthcare reimbursement programs, including providing comprehensive healthcare coverage to the public under governmental funded programs, to minor modifications to existing programs.

In March 2010, Congress enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the Affordable Care Act. The Affordable Care Act is designed to expand access to affordable health insurance, control healthcare spending, and improve healthcare quality. The law included provisions to, among other things, tie Medicare provider reimbursement to healthcare quality and incentives, mandatory compliance programs, enhanced transparency disclosure requirements, increased funding and initiatives to address fraud and abuse, and incentives to state Medicaid programs to expand their coverage and services. It also imposed an annual tax on pharmaceutical manufacturers or importers who sell “branded prescription drugs.” There have been executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act.  For example, President Trump signed several executive orders and other directives designed to delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the Affordable Care Act.  Concurrently, Congress considered legislation to replace or repeal and replace all or part of the Affordable Care Act.  While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. For example, the Tax Cuts and Jobs Act of 2017 included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the Affordable Care Act-mandated “Cadillac” tax on certain high cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. Further, the Bipartisan Budget Act of 2018 (BBA) among other things, amended the Affordable Care Act, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole”.

On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unclear when a decision will be made or how the Supreme Court will rule. Although the Supreme Court has not yet ruled on the constitutionality of the Affordable Care Act, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden Administration will impact the Affordable Care Act and our business.

Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and

26

 

enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.  For example, at the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration’s proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021. On November 20, 2020, CMS issued an interim final rule implementing President Trump’s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. However, it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives.

We cannot predict what healthcare reform initiatives may be adopted in the future, particularly in light of the new presidential administration. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing, which could have a negative impact on our sales of any future approved products. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.

We expect that a portion of the market for ibrexafungerp and any other product candidates we may seek to develop will be outside the United States. However, our product candidates may never receive approval or be commercialized outside of the United States.

Before we or any commercial partners can market and commercialize any product candidates outside of the United States, there are numerous and varying regulatory requirements of other countries that will apply. Research and marketing authorization procedures vary among countries and can involve additional product testing and administrative review periods. The marketing authorization process in other countries may include all of the risks detailed above regarding failure to obtain FDA approval in the United States as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country, or identification of potential safety concerns in one country, may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. As described above, such effects include the risks that:

 

•

ibrexafungerp and any future product candidates we may seek to develop may not generate preclinical or clinical data that are deemed sufficient by regulators in a given jurisdiction;

 

•

ibrexafungerp may not be approved for all indications requested, or any indications at all, in a given jurisdiction which could limit the uses of ibrexafungerp and any future product candidates we may seek to develop and have an adverse effect on product sales and potential royalties; and

 

•

such approval in a given jurisdiction may be subject to limitations on the indicated uses for which the product may be marketed or require costly post-marketing follow-up studies.

Foreign countries may have requirements for marketing authorization holders or distributors to have a legal or physical presence in that country, and consideration of and compliance with these requirements may result in additional time and expense before we can pursue or obtain marketing authorization in foreign jurisdictions. If we do receive approval in other countries, we may enter into sales and marketing arrangements with third parties for international sales of any approved products.

Even if ibrexafungerp or any other future product candidates we may seek to develop receive regulatory approval, we may still face future development and regulatory difficulties.

Even if regulatory approval is obtained for ibrexafungerp or any other future product candidates we may seek to develop, regulatory authorities may still impose significant restrictions on a product’s indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. Given the number of high profile adverse events with certain drug products, regulatory authorities may require, as a condition of approval, costly risk evaluation and mitigation strategies, which may include safety surveillance, restricted distribution and use, patient education, enhanced labeling, expedited reporting of certain adverse events, pre-approval of promotional materials and restrictions on direct-to-consumer advertising. For example, any labeling approved for any of our product candidates may include a restriction on the term of its use, or it may not include one or more intended indications. Furthermore, any new legislation addressing drug safety issues could result in delays or

27

 

increased costs during the period of product development, clinical trials and regulatory review and approval, as well as increased costs to assure compliance with any new post-approval regulatory requirements. Any of these restrictions or requirements could force us or our partners to conduct costly studies.

Ibrexafungerp and any other future product candidates we may seek to develop will also be subject to ongoing regulatory requirements for the packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information on the drug. In addition, approved products, manufacturers and manufacturers’ facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices (cGMP). As such, we and our contract manufacturers, which we will be responsible for overseeing and monitoring for compliance, are subject to continual review and periodic inspections to assess compliance with cGMP. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. The FDA may hold us responsible for any deficiencies or noncompliance of our contract manufacturers in relation to ibrexafungerp and any other future product candidates we may seek to develop. Failure to follow cGMP can result in products being deemed adulterated, which carries significant legal implications. We will also be required to engage in pharmacovigilance activities and report certain adverse reactions and production problems, if any, to the FDA and to comply with certain requirements concerning advertising and promotion for products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved label. As such, we may not promote products for indications or uses for which they do not have approval. Failure to comply with FDA advertising and promotion standards, which are often subject to interpretation by regulators, may result in a wide range of exposure and liability for us.

If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or disagrees with the promotion, marketing or labeling of a product, a regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If the manufacturing or marketing of products fail to comply with applicable regulatory requirements, a regulatory agency may:

 

•

issue warning letters;

 

•

mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;

 

•

require us or our partners to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;

 

•

impose other civil or criminal penalties;

 

•

suspend regulatory approval;

 

•

suspend any ongoing clinical trials;

 

•

refuse to approve pending applications or supplements to approved applications filed by us, our partners or our potential future partners;

 

•

impose restrictions on operations, including costly new manufacturing requirements; or

 

•

seize or detain products or require a product recall.

Non-compliance may also open a company to potential whistleblower lawsuits and the potential for liability under the False Claims Act.

Pharmaceutical companies are subject to significant ongoing regulatory obligations and oversight, which may result in significant additional expense and limit our ability to commercialize our products.

We are subject to regulation by other regional, national, state and local agencies, including the Department of Justice, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies. Violations of any of such laws and regulations could result in significant penalties being assessed against us.

The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical companies on one hand and prescribers, purchasers and formulary managers on the other. The Affordable Care Act, among other things, clarified that a person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it, in order to have committed a violation.  In addition, the Affordable Care Act amended the federal civil False Claims Act to provide that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute, constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. There are a number of statutory exceptions and regulatory safe harbors

28

 

protecting certain common activities from prosecution or other regulatory sanctions, however, the exceptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exception or safe harbor may be subject to scrutiny.

The federal civil and criminal false claims laws, including the federal civil False Claims Act, and civil monetary penalties law, prohibit any person from, among other things, knowingly presenting, or causing to be presented, claims for payment of government funds that are false or fraudulent or knowingly making, or causing to be made, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. Many pharmaceutical and other healthcare companies have been investigated and have reached substantial financial settlements with the federal government under these laws for a variety of alleged marketing activities, including providing free product to customers with the expectation that the customers would bill federal programs for the product; providing consulting fees, grants, free travel, and other benefits to physicians to induce them to prescribe the company’s products; and inflating prices reported to private price publication services, which are used to set drug payment rates under government healthcare programs. Companies have been prosecuted for causing false claims to be submitted because of the marketing of their products for unapproved uses and have also been prosecuted on other legal theories of Medicare and Medicaid fraud.

The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, regardless of the payor (e.g., public or private). Similar to the federal Anti-Kickback Statute, a person or entity need not have actual knowledge the statute or specific intent to violate it, in order to have committed a violation.

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their implementing regulations, which impose certain obligations with respect to safeguarding the privacy, security and transmission of individually identifiable health information on “covered entities,” such as certain healthcare providers, health plans, and healthcare clearinghouses and their respective “business associates,” as well as their covered subcontractors, that perform services for them, which involve the creation, receipt, use, maintenance, transmission or disclosure of, individually identifiable health information for or on behalf of a covered entity.

The Physician Payments Sunshine Act, created under the Affordable Care Act, which require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare and Medicaid Services information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding its payments and other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year.

The majority of states also have statutes or regulations similar to these laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Some of these states also prohibit certain marketing related activities including the provision of gifts, meals, or other items to certain health care providers. In addition, certain states, including California, Connecticut, Nevada, and Massachusetts, require pharmaceutical companies to implement compliance programs or marketing codes.  Certain states also require pharmaceutical companies to file periodic reports with the state on sales, marketing, pricing, clinical trials and/or other activities, and/or register their sales and medical representatives.

Compliance with various federal and state laws is difficult and time consuming, and companies that violate them may face substantial penalties. The potential sanctions include significant administrative, civil and criminal penalties, including monetary fines, exclusion from participation in federal health care programs, integrity oversight and reporting obligations to resolve allegations of non-compliance with these laws, disgorgement, criminal fines, imprisonment, contractual damage, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Because of the breadth of these laws and the lack of extensive legal guidance in the form of regulations or court decisions, it is possible that some of our business activities or those of our commercial partners could be subject to challenge under one or more of these laws. Such a challenge could have a material adverse effect on our business and financial condition and growth prospects.

We could become subject to government investigations and related subpoenas. Such subpoenas are often associated with previously filed qui tam actions, or lawsuits filed under seal under the federal civil False Claims Act. Qui tam actions are brought by private plaintiffs suing on behalf of the federal government for alleged federal civil False Claims Act violations. The time and expense associated with responding to such subpoenas, and any related qui tam or other actions may be extensive, and we cannot predict the results of our review of the responsive documents and underlying facts or the results of such actions. Responding to government investigations, defending any claims raised, and any resulting fines, restitution, damages and penalties, settlement payments or administrative actions, as well as any related actions brought by stockholders or other third parties, could have a material impact on our reputation, business and financial condition and divert the attention of our management from operating our business.

29

 

The number and complexity of both federal and state laws continues to increase, and additional governmental resources are being added to enforce these laws and to prosecute companies and individuals who are believed to be violating them. In particular, the Affordable Care Act includes a number of provisions aimed at strengthening the government’s ability to pursue federal Anti-Kickback Statute and federal False Claims Act cases against pharmaceutical manufacturers and other healthcare entities, including substantially increased funding for healthcare fraud enforcement activities, enhanced investigative powers, and amendments to the federal civil False Claims Act that make it easier for the government and whistleblowers to pursue cases for alleged kickback and false claim violations. Responding to a government investigation or enforcement action would be expensive and time-consuming and could have a material adverse effect on our business and financial condition and growth prospects.

If we fail to comply with applicable federal, state, or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our ability to commercialize our products and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of commercializing and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business.

Regulations, guidelines and recommendations published by various government agencies and organizations may affect the use of ibrexafungerp and any future product candidates we may seek to develop.

Government agencies may issue regulations and guidelines directly applicable to us, our partners or our potential future partners and our product candidates. In addition, professional societies, practice management groups, private health/science foundations and organizations involved in various diseases from time to time publish guidelines or recommendations to the healthcare and patient communities. These various sorts of recommendations may relate to such matters as product usage, dosage, and route of administration and use of related or competing therapies. Changes to these recommendations or other guidelines advocating alternative therapies could result in decreased use of ibrexafungerp and any future product candidates we may seek to develop, which may adversely affect our results of operations.

Risks Related to Our Dependence on Third Parties

We are dependent on our existing third-party collaboration with Amplity, Inc. to commercialize ibrexafungerp for the treatment of VVC in the U.S., and if Amplity is not successful in commercializing ibrexafungerp in the U.S., we may not be successful in commercializing ibrexafungerp in the U.S.

In February 2021, we entered into an agreement with Amplity, Inc., for the potential upcoming commercial launch of ibrexafungerp for the treatment of VVC in the U.S., and will utilize Amplity’s commercial execution expertise and resources for sales force, remote engagement, training, market access and select operation services.  However, if Amplity does not perform under this agreement in the manner we expect, or Amplity were to terminate this agreement, this would significantly impair or delay our ability to commercialize ibrexafungerp for the treatment of VVC in the U.S. if approved.  

We are dependent on our existing third-party collaboration with Hansoh to commercialize ibrexafungerp in the Greater China region, and if Hansoh is not successful in commercializing ibrexafungerp in these areas, we will lose a significant source of potential revenue.

We currently have an exclusive license and collaboration agreement with Hansoh who will pay us milestone payments upon the achievement of specified development and commercial milestones.  In addition, Hansoh will pay us royalties upon sales of ibrexafungerp by Hansoh. We are relying on Hansoh to commercialize ibrexafungerp in the Greater China area, including mainland chaina, Hong Kong, Macau, and Taiwan, and if Hansoh is not able to commercialize ibrexafungerp in those countries, or determines not to pursue commercialization of ibrexafungerp in those countries, we will not receive any milestone or royalty payments under the agreement.

We are dependent on our existing third-party collaboration with R-Pharm to commercialize ibrexafungerp in the Russian Federation and certain other countries, and if R-Pharm is not successful in commercializing ibrexafungerp in those countries, we will lose a significant source of potential revenue.

We currently have a development license and supply agreement with R-Pharm, a leading supplier of hospital drugs in Russia, pursuant to which we license to R-Pharm rights to develop and commercialize ibrexafungerp in the field of human health in Russia and certain smaller non-core markets. R-Pharm will pay us milestone payments upon the achievement of specified milestones, including registration of ibrexafungerp in a country and upon the achievement of specified levels of sales. In addition, R-Pharm will pay us royalties upon sales of ibrexafungerp by R-Pharm. We are relying on R-Pharm to commercialize ibrexafungerp in the countries covered by our agreement with it, and if R-Pharm is not able to commercialize ibrexafungerp in those countries, or determines not to pursue commercialization of ibrexafungerp in those countries, we will not receive any milestone or royalty payments under the agreement.

30

 

We may not be successful in establishing and maintaining development and commercialization collaborations, which could adversely affect our ability to develop and commercialize product candidates.

Developing pharmaceutical products, conducting clinical trials, obtaining regulatory approval, establishing manufacturing capabilities and marketing approved products is expensive. Consequently, a portion of our strategy is to license to third parties rights to develop and commercialize product candidates, including candidates we have discovered other than ibrexafungerp, and if these third parties do not perform under our agreements with them, we will not receive any revenue from these collaborations. For example, we currently have a development license and supply agreement with R-Pharm, pursuant to which we license to R-Pharm rights to develop and commercialize ibrexafungerp in the field of human health in Russia and certain smaller non-core markets, and if ibrexafungerp receives marketing approval, we may enter into additional sales and marketing arrangements with third parties for international sales. If we are unable to enter into any of these arrangements on acceptable terms, or at all, we may be unable to market and sell ibrexafungerp and any future product candidates we may seek to develop in certain markets. We expect to face competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement and they may require substantial resources to maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements for the development of product candidates. When we partner with a third party for development and commercialization of a product candidate, we can expect to relinquish to the third party some or all of the control over the future success of that product candidate. Our collaboration partner may not devote sufficient resources to the commercialization of product candidates or may otherwise fail in their commercialization. The terms of any collaboration or other arrangement that we establish may not be favorable to us. In addition, any collaboration that we enter into may be unsuccessful in the development and commercialization of product candidates. In some cases, we may be responsible for continuing preclinical and initial clinical development of a partnered product candidate or research program, and the payment we receive from our collaboration partner may be insufficient to cover the cost of this development. If we are unable to reach agreements with suitable collaborators for product candidates, we could face increased costs, we may be forced to limit the number of product candidates we can commercially develop or the territories in which we commercialize them and we might fail to commercialize products or programs for which a suitable collaborator cannot be found. If we fail to achieve successful collaborations, our operating results and financial condition will be materially and adversely affected.

We depend on third-party contractors for a substantial portion of our drug development activities and may not be able to control their work as effectively as if we performed these functions ourselves.

We outsource, and intend to continue to outsource, substantial portions of our drug development activities to third-party service providers, including manufacturing and the conduct of our clinical trials and various preclinical studies. Our agreements with third-party service providers and CROs are and will be on a study-by-study basis and typically short-term. In all cases, we expect to be able to terminate the agreements with notice and be responsible for the supplier’s previously incurred costs.

Because we rely on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. Even if we outsource activities, in most cases regulators will hold us responsible for the compliance of the activities performed, and hold us responsible for oversight and monitoring of the activities. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. There are a limited number of third-party service providers that have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult and time consuming and could cause delays in our development programs. We currently have a small number of employees devoted to clinical development activities, which limits the internal resources we have available to identify and monitor our third-party providers. To the extent we are unable to identify, retain and successfully manage the performance of third-party service providers in the future, our business may be adversely affected.

As we do not intend to own or operate facilities for manufacturing, storage and distribution of drug substance or drug product we are and will be dependent on third parties for the manufacture of ibrexafungerp. If we experience problems with any of these third parties, the commercial manufacturing of ibrexafungerp could be delayed.

If ibrexafungerp is approved, the inability to manufacture sufficient commercial supplies of the drug product could adversely affect product commercialization. We do not currently have any agreements with third-party manufacturers for the long-term commercial supply of ibrexafungerp. We may encounter technical difficulties or delays in the transfer of ibrexafungerp manufacturing on a commercial scale to a third-party manufacturer, or may be unable to enter into agreements for commercial supply with third-party manufacturers, or may be unable to do so on acceptable terms.  

We may not be able to establish additional sources of supply for ibrexafungerp and any future product candidates we may seek to develop. These suppliers are subject to regulatory requirements covering manufacturing, testing, quality control and record keeping relating to product candidates and are also subject to ongoing inspections by the regulatory agencies. Failure by any of our suppliers to comply with applicable regulations may result in long delays and interruptions to our product candidate supply while we seek to secure another supplier that meets all regulatory requirements.

31

 

Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including:

 

•

the possible breach of the manufacturing agreements or violation of regulatory standards by the third parties because of factors beyond our control;

 

•

the possibility of termination or nonrenewal of the agreements by the third parties because of our breach of the manufacturing agreement or based on their own business priorities; and

 

•

the possibility of unforeseen natural disasters, public health crises, political crises and other catastrophic events or other events outside of our control impacting our third parties, such as the recent emergence and spread of COVID-19, a coronavirus, which may cause delays in the ability of our suppliers to provide us with supplies on a timely basis.

Any of these factors could result in delays or higher costs in connection with our clinical trials, regulatory submissions, required approvals or commercialization of ibrexafungerp and any future product candidates we may seek to develop.

If we fail to establish or lose our relationships with CROs, our drug development efforts could be delayed.

We are substantially dependent on third-party vendors and CROs for preclinical studies and clinical trials related to our drug discovery and development efforts. If we fail to establish or lose our relationship with any one or more of these providers, we could experience a significant delay in both identifying another comparable provider and then contracting for its services, which could adversely affect our development efforts. We may be unable to retain an alternative provider on reasonable terms, or at all. Even if we locate an alternative provider, it is likely that this provider will need additional time to respond to our needs and may not provide the same type or level of services as the original provider. In addition, any contract research organization that we retain will be subject to the FDA’s regulatory requirements and similar foreign standards and we do not have control over compliance with these regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of ibrexafungerp and any future product candidates we may seek to develop could be delayed, which could severely harm our business and financial condition.

Risks Relating to Our Intellectual Property

We were dependent on Merck for the establishment of our intellectual property rights related to ibrexafungerp, and if Merck did not establish our intellectual property rights with sufficient scope to protect ibrexafungerp, we may have limited or no ability to assert intellectual property rights to ibrexafungerp.

Under our agreement with Merck, Merck was responsible for establishing the intellectual property rights to ibrexafungerp. As we were not responsible for the establishment of our intellectual property rights to ibrexafungerp, we have less visibility into the strength of our intellectual property rights to ibrexafungerp than if we had been responsible for the establishment of these rights. If Merck did not establish those rights such that they are of sufficient scope to protect ibrexafungerp, then we may not be able to prevent others from using or commercializing ibrexafungerp, and others may be able to assert intellectual property rights in ibrexafungerp and prevent us from further pursuing the development and commercialization of ibrexafungerp.

It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.

Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of ibrexafungerp and any future product candidates we may seek to develop and the methods used to manufacture them, as well as successfully defending these patents against third-party challenges. Our ability to stop third parties from making, using, selling, offering to sell or importing ibrexafungerp and any future product candidates we may seek to develop is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.

The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No absolute policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. Changes in either the patent laws or in interpretations of patent laws in the United States and foreign jurisdictions may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be enforced in the patents that we currently own or that may be issued from the applications we have filed or may file in the future or that we have licensed or may license from third parties, including Merck for ibrexafungerp. Further, if any patents we obtain or license are deemed invalid or unenforceable, it could impact our ability to commercialize or license our technology.

The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:

32

 

 

•

others may be able to make compounds that are similar to ibrexafungerp and any future product candidates we may seek to develop but that are not covered by the claims of our patents;

 

•

if we encounter delays in our clinical trials, the period of time during which we could market our drug candidates under patent protection would be reduced;

 

•

we might not have been the first to conceive, make or disclose the inventions covered by our patents or pending patent applications;

 

•

we might not have been the first to file patent applications for these inventions;

 

•

any patents that we obtain may be invalid or unenforceable or otherwise may not provide us with any competitive advantages; or

 

•

the patents of others may have a material adverse effect on our business.

Due to the patent laws of a country, or the decisions of a patent examiner in a country, or our own filing strategies, we may not obtain patent coverage for all of the product candidates that may be disclosed or methods involving these candidates that may be disclosed in the parent patent application. We plan to pursue divisional patent applications and/or continuation patent applications in the United States and many other countries to obtain claim coverage for inventions that were disclosed but not claimed in the parent patent application, but may not succeed in these efforts.

Composition of matter patents on the active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents generally provide protection without regard to any method of use. We cannot be certain that the claims in our patent applications covering composition-of-matter of our drug candidates will be considered patentable by the U.S. Patent and Trademark Office (USPTO) courts in the United States or by the patent offices and courts in foreign countries. Method of use patents protect the use of a product for the method recited in the claims. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products “off-label.” Although off-label prescriptions may infringe or contribute to or induce the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute. Interference or derivation proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our collaborators or licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation, interference, or derivation proceedings may fail, resulting in harm to our business, and, even if successful, may result in substantial costs and distract our management and other employees.

We also rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, licensees, licensors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information such that our competitors may obtain it. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how, such as new therapies, including therapies for the indications we are targeting. If others seek to develop similar therapies, their research and development efforts may inhibit our ability to conduct research in certain areas and to expand our intellectual property portfolio, and also have a material adverse effect on our business.

We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to enforce or protect our rights to, or use, our technology.

If we choose to go to court to stop another party from using the inventions claimed in any patents we obtain, that individual or company has the right to ask the court to rule that such patents are invalid or should not be enforced. These lawsuits are expensive and would consume time and resources and divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such patents or sustaining their validity and enforceability. In addition, there is a risk that the court will decide that such patents are not valid or that we do not have the right to enforce them. There is also the risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the grounds that such other party’s activities do not infringe such patents. In addition, the United States Court of Appeals for the Federal Circuit and the Supreme Court of the United States continue to address issues under the United States patent laws, and the decisions of those and other courts could adversely affect our ability to sustain the validity of our issued or licensed patents and obtain new patents.

Furthermore, a third party may claim that we or our manufacturing or commercialization partners or customers are using inventions covered by the third party’s patent rights and may go to court to stop us or our partners and/or customers from engaging in our operations and activities, including making or selling ibrexafungerp and any future product candidates we may

33

 

seek to develop. These lawsuits are costly and could affect our results of operations and divert the attention of managerial and scientific personnel. There is a risk that a court would decide that we or our commercialization partners or customers are infringing the third party’s patents and would order us or our partners or customers to stop the activities covered by the patents. In that event, we or our commercialization partners or customers may not have a viable way around the patent and may need to halt commercialization or use of the relevant product. In addition, there is a risk that a court will order us or our partners or customers to pay the other party damages for having violated the other party’s patents or obtain one or more licenses from third parties, which may be impossible or require substantial time and expense. We cannot predict whether any license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our drug candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In such events, we would be unable to further develop and commercialize one or more of our drug candidates, which could harm our business significantly. In the future, we may agree to indemnify our commercial partners and/or customers against certain intellectual property infringement claims brought by third parties which could increase our financial expense, increase our involvement in litigation and/or otherwise materially adversely affect our business.

Because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation, which could adversely affect our intellectual property rights and our business. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.

The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform.  If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity or unenforceability is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents.

Because some patent applications in the United States may be maintained in secrecy until the patents are issued, because patent applications in the United States and many foreign jurisdictions are typically not published until eighteen months after filing, because searches and examinations of patent applications by the USPTO and other patent offices may not be comprehensive, and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our patents or pending applications. Our competitors may have filed, and may in the future file, patent applications and may have obtained patents covering technology similar to ours. Any such patents or patent application may have priority over our patent applications, which could further require us to obtain or license rights to issued patents covering such technologies. If another party has obtained a U.S. patent or filed a U.S. patent application on inventions similar to ours, we may have to participate in a proceeding before the USPTO or in the courts to determine which patent or application has priority. The costs of these proceedings could be substantial, and it is possible that our application or patent could be determined not to have priority, which could adversely affect our intellectual property rights and business.

We have received confidential and proprietary information from collaborators, prospective licensees and other third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have improperly used or disclosed confidential information of these third parties or our employees’ former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. If we are not successful, our ability to continue our operations and our business could be materially, adversely affected.

Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations, on our ability to hire or retain employees, or otherwise on our business.

Risks Related to Employee Matters and Managing Growth

We may not be able to manage our business effectively if we are unable to attract and retain key personnel.

We may not be able to attract or retain qualified management, finance, scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses.  Stock-based awards are critical to our ability to recruit, retain and motivate highly skilled talent. However, the trading price of our common stock as listed on the Nasdaq Global Market has traded at or below the exercise price of a significant portion of the stock options currently held by our executive officers and key employees. This may reduce the retention value of these options and

34

 

we may need to grant additional stock options, make further amendments to the terms of existing option awards, or provide alternative compensation and retention programs to continue to retain our employees, especially our key employees and executive officers. If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.  If we are unable to retain our current executive officers and key employees our ability to implement our business strategy successfully could be seriously harmed.

We may need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth.

As of March 1, 2021, we had 38 employees.  If the FDA approves our NDA for ibrexafungerp for the treatment of VVC, as we expect to occur in June 2021, we will need to increase our marketing, sales and administrative headcount to manage the commercialization of ibrexafungerp for the treatment of VVC. Further, as we advance ibrexafungerp through preclinical studies, clinical trials and commercialization for other indications, we will need to increase our product development, scientific, marketing, sales and administrative headcount to manage these efforts. Our management, personnel and systems currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and various projects requires that we:

 

•

successfully attract and recruit new employees with the expertise and experience we will require;

 

•

manage our clinical programs effectively, which we anticipate being conducted at numerous clinical sites;

 

•

develop a marketing and sales infrastructure; and

 

•

continue to develop our operational, financial and management controls, reporting systems and procedures.

If we are unable to successfully manage this growth, our business may be adversely affected.

Other Risks Relating to Our Business

We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization.

The use of product candidates in clinical trials and the sale of any products for which we may obtain marketing approval expose us to the risk of product liability claims. Product liability claims may be brought against us or our partners by participants enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling products. If we cannot successfully defend ourselves against any such claims, we would incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:

 

•

withdrawal of clinical trial participants;

 

•

termination of clinical trial sites or entire trial programs;

 

•

costs of related litigation;

 

•

substantial monetary awards to patients or other claimants;

 

•

decreased demand for product candidates and loss of revenue;

 

•

impairment of our business reputation;

 

•

diversion of management and scientific resources from our business operations; and

 

•

the inability to commercialize product candidates.

We have obtained limited product liability insurance coverage for our clinical trials domestically and in selected foreign countries where we are conducting clinical trials. Our coverage is currently limited to $10.0 million per occurrence and $10.0 million in the aggregate per year, as well as additional local country product liability coverage for trials conducted outside of the United States as required by the local country regulations. As such, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to product liability. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain marketing approval for product candidates, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash available to develop ibrexafungerp and any future product candidates we may seek to develop and adversely affect our business.

35

 

Our internal computer systems, or those used by our contract research organizations or other contractors or consultants, may fail or suffer security breaches.

Despite the implementation of security measures, our internal computer systems and those of our contract research organizations and other contractors and consultants are vulnerable to damage, data leakage and security breaches from computer viruses, unauthorized access, social engineering, the acts or omissions of our workforce or others with authorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we are not aware of the occurrence of any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our or other contractors or consultants’ operations, it could result in a material disruption of our product candidate development programs. For example, the loss of clinical study data from completed or ongoing clinical studies for a product candidate could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of any product candidates could be delayed.

Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities.

We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, property, auto, workers’ compensation, products liability and directors’ and officers’ insurance. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.

Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.

Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive.

U.S. and foreign privacy and data protection laws and regulations may impose additional liabilities on us.

U.S. federal and state privacy and data security laws and regulations regulate how we and our partners collect, use and share certain information.  For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations, impose certain obligations with respect to safeguarding the privacy, security and transmission of individually identifiable health information on “covered entities,” such as certain healthcare providers, health plans, and healthcare clearinghouses and their respective “business associates” that perform services for them.  State security breach notification laws, state health information privacy laws, and other state privacy laws also impose requirements regarding the collection, use, disclosure, and protection of personal information.  In addition, in June 2018, California enacted the California Consumer Privacy Act of 2018 (CCPA) which became effective January 1, 2020. The CCPA gives California residents the right to access and require deletion of their personal information, the right to opt out of certain personal information sharing, and the right to detailed information about how their personal information is collected, used, and disclosed. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although the CCPA includes exemptions for certain clinical trials data and data collected pursuant to HIPAA, the law may increase our compliance costs and potential liability with respect to other personal information we collect about California residents. The CCPA has prompted a wave of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs, and adversely affect our business.

We may also be subject to or affected by foreign laws and regulations, including regulatory guidance, governing the collection, use, disclosure, security, transfer, and storage of personal data, such as information that we collect about patients in connection with clinical trials and our other operations abroad. The global legislative and regulatory landscape for privacy and data protection continues to evolve, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, result in liability, or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future.

For example, the EU implemented the General Data Protection Regulation (GDPR) a broad data protection framework that expands the scope of EU data protection law to include certain non-European Union entities that process the personal data of EU residents, including clinical trial data. The GDPR increases our compliance burden with respect to data protection, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and protect information about them. The processing of sensitive personal data, such as information about health conditions, leads to heightened compliance burdens under the GDPR and is a topic of active

36

 

interest among EU regulators. In addition, the GDPR provides for breach reporting requirements, more robust regulatory enforcement and fines of up to the greater of 20 million euros or 4% of annual global revenue. The GDPR increases our responsibility and liability in relation to personal data that we process, including in clinical trials, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management’s attention and increase our cost of doing business.  

A data security breach or other privacy violation that compromises the confidentiality, integrity or availability of the personal information of our clinical trials participants, collaborators or employees could harm our reputation, compel us to comply with U.S. or international breach notification laws, subject us to mandatory corrective action, and otherwise subject us to liability under U.S. or foreign laws and regulations.  Data breaches or other security incidents could also compromise our trade secrets or other intellectual property.  If we are unable to prevent such data security breaches and security incidents or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer reputational harm, financial loss or other regulatory penalties. In addition, such events can be difficult to detect, and any delay in identifying them may lead to increased harm. While we have implemented security measures designed to protect our information technology systems, such measures may not prevent such events.

Finally, it is possible that these privacy laws may be interpreted and applied in a manner that is inconsistent with our practices. Any failure or perceived failure by us to comply with federal, state, or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort, and proceedings against us by governmental entities or others. If we expand into other foreign countries and jurisdictions, we may be subject to additional privacy and data protection laws and regulations that may affect how we conduct business.

Risks Relating to Owning Our Common Stock

The market price of our common stock may be highly volatile.

The trading price of our common stock may be volatile. The following factors, in addition to other factors described in this “Risk Factors” section and elsewhere in this report, may have a significant impact on the market price of our common stock:

 

•

whether or not our NDA for ibrexafungerp for the treatment of VVC is approved, denied or delayed by the FDA;

 

•

the results of our preclinical testing or clinical trials;

 

•

the ability to obtain additional funding;

 

•

any delay in submitting an NDA or similar foreign applications for ibrexafungerp and any future product candidate we may seek to develop or any adverse development or perceived adverse development with respect to the FDA’s review of that NDA or a foreign regulator’s review of a similar applications;

 

•

maintenance of our existing collaborations or ability to enter into new collaborations;

 

•

our collaboration partners’ election to develop or commercialize product candidates under our collaboration agreements or the termination of any programs under our collaboration agreements;

 

•

any intellectual property infringement actions in which we or our licensors and collaboration partners may become involved;

 

•

our ability to successfully develop and commercialize future product candidates;

 

•

changes in laws or regulations applicable to future products;

 

•

adverse regulatory decisions;

 

•

introduction of new products, services or technologies by our competitors;

 

•

achievement of financial projections we may provide to the public;

 

•

achievement of the estimates and projections of the investment community;

 

•

the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;

 

•

changes in the structure of healthcare payment systems;

 

•

announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our collaboration partners or our competitors;

 

•

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

 

•

legislation or regulation that mandates or encourages the use of generic products;

37

 

 

 

•

additions or departures of key scientific or management personnel;

 

•

significant lawsuits, including patent or stockholder litigation;

 

•

changes in the market valuations of similar companies;

 

•

general economic and market conditions and overall fluctuations in the U.S. equity markets;

 

•

sales of our common stock by us, our executive officers and directors or our stockholders in the future; and

 

•

trading volume of our common stock.

In addition, companies trading in the stock market in general, and the Nasdaq Global Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.

Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. These sales may also result in new investors gaining rights superior to our existing stockholders.  For example, in March 2019 and April 2020, we issued and sold $16 million and $10 million, respectively, of 6.0% convertible senior notes. The holders may convert their convertible notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 (for the notes issued in March 2019) and April 15, 2026 (for the notes issued in April 2020). Upon conversion of the convertible notes by a holder, the holder will receive shares of our common stock, together, if applicable, with cash in lieu of any fractional share. Holders who convert may also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of common stock.  In addition, following certain corporate events that occur prior to the maturity date, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its convertible notes in connection with such a corporate event.  To the extent holders of these notes convert the notes, our stockholders may experience substantial dilution.

Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us, including the ability of our board of directors to establish new series of preferred stock and issue shares of these new series, which could be used by our board of directors to oppose a hostile takeover attempt, which some stockholders may believe would be in the best interests of stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management, including the elimination of cumulative voting, inability of our stockholders to call special meetings or take action by written consent, ability of our board of directors to fill board vacancies, and ability of our board of directors to determine the size of the board of directors. In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Finally, our charter documents establish advance notice requirements for nominations for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings. Although we believe these provisions together provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders.

Sales of our common stock to Aspire Capital may cause substantial dilution to our existing stockholders and the sale of the shares of our common stock acquired by Aspire Capital could cause the price of our common stock to decline.

We may issue and sell to Aspire Capital from time to time pursuant to the common stock purchase agreement an aggregate amount of up to $20.0 million of shares of common stock. It is anticipated that shares offered to Aspire Capital will be sold over a period of up to 30 months from April 2020. The number of shares ultimately offered for sale to Aspire Capital is dependent upon the number of shares we elect to sell to Aspire Capital under the common stock purchase agreement. Depending upon market liquidity at the time, sales of shares of our common stock under the common stock purchase agreement may cause the trading price of our common stock to decline.

Aspire Capital may ultimately purchase all, some or none of the shares of common stock that, together with the 70,910 commitment shares. After Aspire Capital has acquired shares under the common stock purchase agreement, it may sell all, some or none of those shares. Sales to Aspire Capital by us pursuant to the common stock purchase agreement may result in substantial dilution to the interests of other holders of our common stock. The sale of a substantial number of shares of our

38

 

common stock to Aspire Capital in this offering, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales. However, we have the right to control the timing and amount of any sales of our shares to Aspire Capital and the common stock purchase agreement may be terminated by us at any time at our discretion without any cost to us.

We have a right to sell up to 25,000 purchase shares per day under our common stock purchase agreement with Aspire Capital, which total may be increased by mutual agreement up to an additional 200,000 purchase shares per day. The extent to which we rely on Aspire Capital as a source of funding will depend on a number of factors, including the prevailing market price of our common stock and the extent to which we are able to secure working capital from other sources. The aggregate number of shares that we can sell to Aspire Capital under the common stock purchase agreement may in no case exceed 1,956,547 shares of our common stock (which is equal to approximately 19.99% of the common stock outstanding on the date of the common stock purchase agreement), including the 70,910 commitment shares (the Exchange Cap), unless either (a) shareholder approval is obtained to issue more, in which case the Exchange Cap will not apply, or (b) the average purchase price of all shares sold under the common stock purchase agreement exceeds $8.461; provided that at no time shall Aspire Capital (together with its affiliates) beneficially own more than 19.99% of our common stock.

Our business could be adversely affected by the COVID-19 outbreak, in regions where we or third parties on which we rely have significant concentrations of clinical trial sites, manufacturing facilities, or other business operations.

Our business could be adversely affected by the COVID-19 outbreak, in regions where we or third parties on which we rely have significant concentrations of clinical trial sites, manufacturing facilities, or other business operations. We have a significant number of clinical trial sites in countries that have been directly affected by COVID-19, and depend on manufacturing operations for various stages of our supply chain in countries affected by COVID-19.  The ultimate impact of the COVID-19 health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our activities dependent on regulatory authorities, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.

ITEM 1B.

UNRESOLVED STAFF COMMENTS

None.

ITEM 2.

PROPERTIES

On March 1, 2018, we entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey.  The lease term is until July 2029, and we have the option to renew for two consecutive five-year periods from the end of the first term. We believe that our facilities under this lease are adequate for our purposes for the foreseeable future.  

ITEM 3.

We are not party to any legal proceedings for which disclosure is required under this item.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

39

 

PART II

ITEM 5.

MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our common stock trades on the Nasdaq Global Market under the symbol “SCYX.”  

Stockholders

As of March 1, 2021, there were approximately 51 stockholders of record of our common stock, which excludes stockholders whose shares were held in nominee or street name by brokers. The actual number of common stockholders is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

Dividend Policy

We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.  

Recent Sales of Unregistered Securities

None.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

We did not purchase any of our securities during the fourth quarter of 2020.

ITEM 6.

SELECTED FINANCIAL DATA

This item is not applicable to smaller reporting companies.

 

40

 

ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Operating results for the year ended December 31, 2020, are not necessarily indicative of results that may occur in future fiscal years. Some of the statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management and involve significant elements of subjective judgment and analysis. Words such as “expects,” “will,” “anticipates,” “targets,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “potential,” “should,” “could,” variations of such words, and similar expressions are intended to identify forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed under the caption “Special Note Regarding Forward Looking Statements” and in “Risk Factors” and elsewhere in this Annual Report on Form 10-K. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this Annual Report.

Overview

SCYNEXIS, Inc. is pioneering innovative medicines to potentially help millions of patients worldwide in need of new options to overcome and prevent difficult-to-treat and drug-resistant infections.  We are developing our lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. In December 2020, we announced that we had received the acceptance letter from the U.S. Food and Drug Administration (FDA) for our New Drug Application (NDA) for oral ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection) with a Prescription Drug User Fee Act (PDUFA) action goal date of June 1, 2021.  The FDA has conditionally approved “Brexafemme” as the brand name for oral ibrexafungerp for vaginal yeast infections. We are also continuing late-stage clinical development for the prevention of recurrent VVC as well as the treatment of life-threatening invasive fungal infections in hospitalized patients.

Ibrexafungerp, the first representative of a novel class of antifungal agents called triterpenoids and designated by the suffix “-fungerp”, is a structurally distinct glucan synthase inhibitor and has shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in the United States (U.S.) and Europe. To date, we have characterized the antifungal activity, pharmacokinetics, and safety profile of the oral and IV formulations of ibrexafungerp in multiple in vitro, in vivo, and clinical studies. The FDA has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to ibrexafungerp for the indications of VVC (including the treatment of VVC episodes and the prevention of recurrent VVC), invasive candidiasis (IC) (including candidemia), and invasive aspergillosis (IA), and has granted Orphan Drug designations for the IC and IA indications. These designations may provide us with additional market exclusivity and expedited regulatory paths.

Ibrexafungerp Update

We recently announced that the FDA has accepted for filing our NDA for ibrexafungerp for the treatment of VVC, also known as vaginal yeast infections. The FDA has granted this application Priority Review, a designation which is granted to applications for potential drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment of serious conditions when compared to standard applications.  Under the PDUFA, the FDA has set a target action date of June 1, 2021. Additionally, the FDA has communicated that it is not currently planning to hold an advisory committee meeting to discuss the application.  The NDA is supported by positive results from two Phase 3, randomized, double-blind, placebo-controlled, multi-center studies (VANISH-303 and VANISH-306), in which oral ibrexafungerp demonstrated statistically superior efficacy and a favorable tolerability profile in women with VVC.

Enrollment is complete in the CANDLE study, a Phase 3, multi-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of oral ibrexafungerp for the prevention of recurrent VVC, for which there is no approved therapy in the U.S.  As a result of the COVID-19 pandemic, our timelines for reaching our targeted enrollment size in the CANDLE study were slightly extended and we now anticipate both top-line data and a potential supplemental NDA submission for the prevention of recurrent VVC in the first half of 2022, resulting in a potential approval in late 2022.

Enrollment is ongoing in our refractory invasive fungal infections (rIFI) program, which comprises two open-label Phase 3 studies (FURI and CARES) designed to support a potential future NDA submission through the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), as well as our Phase 2 study (SCYNERGIA study) of oral ibrexafungerp in combination with voriconazole (SoC) in patients with IA.  Similar to interim analyses of data previously reported, we intend to analyze the data of patients that have completed the treatment course in our FURI and CARES studies and announce these findings when complete.  

41

 

We have successfully completed preclinical testing of our liposomal IV formulation of ibrexafungerp and we are advancing the program into human trials in healthy volunteers. The first trial is being conducted as a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of the IV liposomal formulation of ibrexafungerp in healthy subjects. The study is being conducted in South Africa and dosing started in March 2021.

Corporate Update

On December 2, 2020, we amended our license agreement with Merck Sharp & Dohme Corp. (Merck), dated May 24, 2013.  The amendment eliminates two cash milestone payments that we would have paid to Merck upon the first filing of a NDA, triggered by the FDA acceptance for filing of our NDA for ibrexafungerp for the treatment of VVC, and first marketing approval in the U.S., anticipated in June 2021 for our NDA for ibrexafungerp for the treatment of VVC.  Such cash milestone payments would have been creditable against future royalties owed to Merck on net sales of ibrexafungerp. With the amendment, these milestones will not be paid in cash and, accordingly, credits will not accrue. Pursuant to the amendment, we will also forfeit the credits against future royalties that it had accrued from a prior milestone payment already paid to Merck. All other key terms of the license agreement are unchanged.

On December 17, 2020, we completed a public offering (the December 2020 Public Offering) of our common stock and warrants pursuant to our effective shelf registration.  We sold an aggregate of (a) 8,340,000 shares of our common stock, par value $0.001 per share, (b) pre-funded warrants, in lieu of common stock, to purchase 5,260,000 shares of our common stock, par value $0.001 per share, and (c) two series of warrants, which will accompany the common stock or pre-funded warrants, to purchase up to an aggregate of 13,600,000 shares of our common stock and received approximately $79.5 million in net proceeds.

In February 2021, we partnered with Amplity Inc. (Amplity) for the potential upcoming commercial launch of ibrexafungerp for the treatment of VVC.  Under the terms of the 5-year agreement, we will utilize Amplity’s commercial execution expertise and resources for sales force, remote engagement, training, market access and select operations services.  We will maintain full ownership of ibrexafungerp and control of all strategic aspects of the launch. Amplity is deferring a portion of its direct service costs in the first two years (2021 and 2022), which we will repay over three years starting in 2023.  Amplity has the potential to earn a performance-based success fee in the 2023-2025 time frame by exceeding certain revenue targets.

On February 11, 2021, we entered into an Exclusive License and Collaboration Agreement (the Agreement) with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, Hansoh), pursuant to which Hansoh obtains an exclusive license from us to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the Agreement, Hansoh shall be responsible for the development, regulatory approval and commercialization of ibrexafungerp in Greater China. We received a $10.0 million upfront payment and will also be eligible to receive up to $112.0 million in development and commercial milestones, plus low double-digit royalties on net product sales. The obligation to pay royalties with respect to sales in a specified region will continue until the later of the date of expiration of all intellectual property and regulatory exclusivity for the product in the region and ten years from the first commercial sale, unless earlier terminated by Hansoh with advanced notice for convenience or under other specified circumstances.

Impact of COVID-19 Pandemic on Our Business

A novel strain of coronavirus (COVID-19) was first identified in December 2019, and subsequently declared a global pandemic by the World Health Organization on March 11, 2020.  The full extent of the future impacts of COVID-19 on our operations is uncertain and a prolonged outbreak could have an adverse effect on our business. 

We continue to see enrollment across our ongoing studies but have observed that the pandemic has resulted in some delays to some of our clinical studies, particularly in our CANDLE study, with top-line data now expected in the first half of 2022, as the initiation of new investigational sites can be delayed due to the diversion of their resources away from necessary start-up activities, and by limiting the ability of investigational sites to conduct all activities associated with our ongoing studies. For example, the circumstances can hinder the investigational sites’ ability to screen patients for enrollment. We are collaborating with our investigational sites to implement measures to minimize disruptions to patients and ensure continued access to treatment, in accordance with health authority guidance.

With respect to manufacturing and supply, we currently have sufficient drug supply for our ongoing clinical studies. Our third-party contract manufacturers continue to operate at or near normal levels and, at this time and subject to further COVID-19 implications, we do not anticipate any disruptions to our drug supply chain.  Additionally, our employees have been transitioned to a work-from-home policy and this has not had any material impact on our internal operating abilities.

The extent of the impact of COVID-19 on our business, financial results, liquidity and cash flows will depend largely on future developments.  Any potential delays in clinical studies as a result of the impact of COVID-19, particularly on our CANDLE study, could result in the recognition of research and development expense for these studies in periods later than

42

 

originally anticipated and could potentially further extend our cash runway.  As of December 31, 2020, we had $93.0 million in cash and cash equivalents, and we may utilize our common stock purchase agreement entered into on April 10, 2020 with Aspire Capital Fund, LLC (Aspire Capital) in order to provide additional liquidity.  Our ability to acquire necessary capital may be negatively impacted by the economic environment if the pandemic is prolonged. 

The ultimate impact of the COVID-19 health pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential impacts on our business, our clinical trials, our activities dependent on regulatory authorities, healthcare systems or the global economy as a whole. We will continue to monitor the COVID-19 situation closely. 

Liquidity

We have operated as a public entity since we completed our initial public offering in May 2014, which we refer to as our IPO. We also completed a follow-on public offering of our common stock in April 2015 and public offerings of our common stock and warrants in June 2016, March 2018, December 2019, and December 2020.  We have received an aggregate of $253.2 million in net proceeds from the issuance of our common stock in these six offerings.  Our principal source of liquidity is cash and cash equivalents, which totaled $93.0 million as of December 31, 2020.  In addition, during the year ended December 31, 2020, we sold 691,304 shares of our common stock and received net proceeds of $4.8 million under our at-the-market (ATM) facility, sold 125,000 shares of our common stock and received net proceeds of $0.6 million under our common stock purchase agreement with Aspire Capital, and in April 2020, we received a cash receipt of $3.1 million from a third party for the sale of a portion of our unused New Jersey Net Operating Losses (NOLs) and research and development credits.

We have incurred net losses since our inception, including the year ended December 31, 2020.  As of December 31, 2020, our accumulated deficit was $326.6 million. We expect we will continue to incur significant research and development expense as we continue to execute our research and drug development strategy, but that our research and development expenses will decrease primarily given the completion of the VANISH Phase 3 registration program.  Consistent with our operating plan, we also expect that we will continue to incur significant selling, general and administrative expenses to support our public reporting company operations, and that our selling, general and administrative expenses will increase to support a potential commercial launch for the VVC indication and our ongoing operations. As a result, we will need additional capital to fund our operations, which we may obtain through one or more of equity offerings, debt financings, other non-dilutive third-party funding (e.g., grants, and New Jersey Technology Business Tax Certificate Transfer (NOL) Program), strategic alliances and licensing or collaboration arrangements. We may offer shares of our common stock pursuant to our effective shelf registrations and the common stock purchase agreement with Aspire Capital.

Components of Operating Results

Revenue

Revenue consists of the amortization of a non-refundable upfront payment received under our collaboration arrangement with R-Pharm.  

Research and Development Expense

Research and development expense consists of expenses incurred while performing research and development activities to discover, develop, or improve potential product candidates we seek to develop. This includes conducting preclinical studies and clinical trials, manufacturing and other development efforts, and activities related to regulatory filings for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily consists of:

 

•

costs related to executing preclinical studies and clinical trials, including related drug formulation, manufacturing and other development;

 

•

salaries and personnel-related costs, including benefits and any stock-based compensation for personnel performing research and development functions;

 

•

fees paid to clinical research organizations (CROs), vendors, consultants and other third parties who support our product candidate development and intellectual property protection;

 

•

other costs in seeking regulatory approval of our products; and

 

•

allocated overhead.

Ibrexafungerp was the only key research and development project during the periods presented. We expect to continue to incur significant research and development expense for the foreseeable future as we continue our effort to develop ibrexafungerp, and to potentially develop our other product candidates, subject to the availability of additional funding.  

The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates.

43

 

Selling, General and Administrative Expense

Selling, general and administrative expense consists primarily of salaries and personnel-related costs, including employee benefits and any stock-based compensation. This includes personnel in executive, accounting and finance, commercial, human resources, business development, and administrative support functions. Other expenses include facility-related costs not otherwise allocated to research and development expense, professional fees for accounting, auditing, tax and legal services, consulting costs for general and administrative purposes, information systems maintenance and marketing efforts.

Other Expense (Income)

Substantially all of our other expense (income) during the periods reported consists of costs associated with:

 

•

fair value adjustments to our warrant and derivative liabilities;

 

•

interest expense;

 

•

amortization of debt issuance costs and discount;

 

•

other income associated with research and development tax credits;

 

•

interest income associated with our held-to-maturity short-term investments

 

•

other expense and;

 

•

the expense recognized for the extinguishment of debt.

Income Tax Benefit

Income tax benefit consists of U.S. federal and state income taxes. To date, we have not been required to pay U.S. federal income taxes because of our current and accumulated net operating losses.  For the year ended December 31, 2020, we recognized $3.1 million in income tax benefit associated with the sale of our NOLs and research and development credits.

Results of Operations for the Years Ended December 31, 2020 and 2019

The following table summarizes our results of operations for the years ended December 31, 2020 and 2019, and period-to-period percentage change (dollars in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

Period-to-Period Change

 

Revenue

 

$

—

 

 

$

121

 

 

$

(121

)

 

 

(100.0

)%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

36,522

 

 

 

38,394

 

 

 

(1,872

)

 

 

(4.9

)%

Selling, general and administrative

 

 

14,627

 

 

 

10,648

 

 

 

3,979

 

 

 

37.4

%

Total operating expenses

 

 

51,149

 

 

 

49,042

 

 

 

2,107

 

 

 

4.3

%

Loss from operations

 

 

(51,149

)

 

 

(48,921

)

 

 

(2,228

)

 

 

4.6

%

Other expense (income):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss on extinguishment of debt

 

 

1,766

 

 

 

1,045

 

 

 

721

 

 

 

69.0

%

Amortization of debt issuance costs and discount

 

 

1,201

 

 

 

1,171

 

 

 

30

 

 

 

2.6

%

Interest income

 

 

(189

)

 

 

(805

)

 

 

616

 

 

 

(76.5

)%

Interest expense

 

 

1,181

 

 

 

986

 

 

 

195

 

 

 

19.8

%

Other income

 

 

(334

)

 

 

(538

)

 

 

204

 

 

 

(37.9

)%

Other expense

 

 

602

 

 

 

—

 

 

 

602

 

 

 

—

 

Warrant liabilities fair value adjustment

 

 

5,214

 

 

 

4,497

 

 

 

717

 

 

 

15.9

%

Derivative liabilities fair value adjustment

 

 

(2,257

)

 

 

(1,567

)

 

 

(690

)

 

 

44.0

%

Total other expense:

 

 

7,184

 

 

 

4,789

 

 

 

2,395

 

 

 

50.0

%

Loss before taxes

 

 

(58,333

)

 

 

(53,710

)

 

 

(4,623

)

 

 

8.6

%

Income tax benefit

 

 

3,148

 

 

 

—

 

 

 

3,148

 

 

 

—

 

Net Loss

 

$

(55,185

)

 

$

(53,710

)

 

$

(1,475

)

 

 

2.7

%

Revenue. For the year ended December 31, 2019, revenue consisted of the amortization of a non-refundable upfront payment received under our collaboration arrangement with R-Pharm and was fully amortized in 2019.

Research and Development. For the year ended December 31, 2020, research and development expenses decreased to $36.5 million from $38.4 million for the year ended December 31, 2019. The decrease of $1.9 million, or 4.9%, was primarily driven by a milestone payment made in 2019 to Merck upon initiation of the Phase 3 VVC registration study, a decrease of $4.2 million in clinical development expense, a decrease of $1.0 million in preclinical expense, offset in part by an increase of

44

 

$4.5 million in chemistry, manufacturing, and controls (CMC), an increase of $1.1 million in salary and consulting related expense, an increase of $1.1 million in regulatory expense, and a net increase in other research and development expense of $0.6 million.

The $4.2 million decrease in clinical development expense for the year ended December 31, 2020, was primarily driven by a decrease of $9.2 million in costs associated with the VANISH Phase 3 VVC program that was substantially complete by the beginning of the third quarter of 2020, a decrease of $0.8 million in expense associated with the SCYNERGIA study, a decrease of $0.4 million in expense associated with two drug-drug interaction clinical studies to support the NDA submission for the treatment of VVC indication, offset in part by an increase of $4.6 million in costs associated with the CANDLE Phase 3 study, an increase of $0.5 million in expense associated with certain Phase 1 studies to support the NDA submission for the treatment of VVC indication, a $0.6 million increase in expense associated with the FURI and CARES studies, and a net increase in other clinical expenses of $0.5 million.  The $4.5 million increase in CMC for the year ended December 31, 2020, was primarily driven by increased costs associated with the development and manufacture of drug product for ongoing and planned clinical studies as well as commercial batches necessary for a potential commercial launch of ibrexafungerp in the second half of 2021.  The $1.1 million increase in salary and consulting related expense is primarily due to the increase in full time employees from the comparable prior period.  The $1.1 million increase in regulatory expense was primarily due to the additional costs incurred during the period for the preparation and filing of the NDA submission for the treatment of VVC.

Selling, General and Administrative. For the year ended December 31, 2020, selling, general and administrative expenses increased to $14.6 million from $10.6 million for the year ended December 31, 2019.  The increase of $4.0 million, or 37.4%, was primarily driven by a $1.5 million increase in commercial and business development expense, a $1.3 million increase in other professional service expense, a $0.9 million increase in salary and other compensation related costs, and a net increase in other selling, general and administrative expenses of $0.3 million.  The $1.5 million increase in commercial and business development expense is primarily due to the costs incurred in preparation of the potential commercial launch of ibrexafungerp for the treatment of VVC in the second half of 2021.

Loss on Extinguishment of Debt.  For the year ended December 31, 2020, we recognized a $1.8 million loss on extinguishment of debt associated with the conversion of a portion of our April 2020 6.0% Convertible Senior Notes (April 2020 Notes) and, with respect to the 2019 period, a $0.8 million loss on extinguishment of debt associated with the repayment of the term loan with Solar and a $0.2 million loss on debt extinguishment upon the conversion of a portion of our March 2019 6.0% Convertible Senior Notes (March 2019 Notes).

Amortization of Debt Issuance Costs and Discount. For the years ended December 31, 2020 and 2019, amortization of debt issuance costs and discount was $1.2 million.  The 2020 and 2019 debt issuance costs and discount comprised an allocated portion of the advisory fee and other issuance costs associated with our convertible debt and the fair value of the bifurcated derivative liability.  

Interest Income.  For the years ended December 31, 2020 and 2019, we recognized $0.2 million and $0.8 million, respectively, in interest income associated with our short-term investments.  The decrease in interest income was primarily due to the decrease in interest rate returns earned in comparison to the comparable period and the maturity of all our short-term investments during the current period.

Interest Expense.  For the years ended December 31, 2020 and 2019, we recognized $1.2 million and $1.0 million, respectively, in interest expense associated with our convertible debt.  The increase from the prior comparable period is primarily due to the additional interest expense recognized for the April 2020 Notes.

Other Income.  For the years ended December 31, 2020 and 2019, we recognized $0.3 million and $0.5 million in other income associated with certain research and development tax credits.

Other Expense.  For the year ended December 31, 2020, we recognized $0.6 million in expense associated with the noncash consideration associated with the common stock purchase agreement entered into with Aspire Capital in April 2020.

Warrant Liabilities Fair Value Adjustment.  For the years ended December 31, 2020 and 2019, we recognized losses of $5.2 million and $4.5 million, respectively, for the fair value adjustment for warrant liabilities primarily due to the increase in our stock price during the periods.

Derivative Liabilities Fair Value Adjustment.  For the years ended December 31, 2020 and 2019, we recognized gains of $2.3 million and $1.6 million, respectively, in the fair value adjustment related to the derivative liabilities primarily due to the decrease in our stock price during the period.  

Income Tax Benefit.  For the year ended December 31, 2020, we recognized a $3.1 million income tax benefit associated with the sale of a portion of our NOLs and research and development credits. This sale was structured through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program.

45

 

Liquidity and Capital Resources

Sources of Liquidity

As of December 31, 2020, we had cash and cash equivalents of approximately $93.0 million, compared to cash, cash equivalents, and short-term investments of $48.4 million as of December 31, 2019. The increase in our cash and cash equivalents was primarily due to the funds raised in our December 2020 Public Offering of our common stock and warrants and through our ATM and Aspire facilities, the sale of our April 2020 Notes, the cash receipt of $3.1 million received in 2020 for the sale of a portion of our New Jersey NOLs, offset in part by the continued development costs associated with our lead product candidate, ibrexafungerp.

We have incurred net losses since our inception, including the year ended December 31, 2020. As of December 31, 2020, our accumulated deficit was $326.6 million. We anticipate that we will continue to incur losses for at least the next several years.  As a result, we will need additional capital to fund our operations, which we may obtain through one or more of equity offerings, debt financings, or other non-dilutive third-party funding (e.g., grants, New Jersey Technology Business Tax Certificate Transfer (NOL) Program), strategic alliances and licensing or collaboration arrangements. We may offer shares of our common stock pursuant to our Form S-3 shelf registration statements.  For the year ended December 31, 2020, we received net proceeds of $4.8 million, under our ATM facility.

In April 2020 and March 2019, we sold to Puissance Life Science Opportunities Fund VI (Puissance) $10.0 million and $16.0 million aggregate principal amount of our convertible senior notes (Notes), respectively.  See Note 7 to our consolidated financial statements for the year ended December 31, 2020, included in this Annual Report for further details.

Cash Flows

The following table sets forth the significant sources and uses of cash for the years ended December 31, 2020 and 2019 (dollars in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

Cash, cash equivalents, and restricted cash, January 1

 

$

42,193

 

 

$

11,767

 

Net cash used in operating activities

 

 

(49,354

)

 

 

(38,119

)

Net cash provided by investing activities

 

 

6,474

 

 

 

26,240

 

Net cash provided by financing activities

 

 

94,001

 

 

 

42,305

 

Net increase in cash, cash equivalents, and restricted cash

 

 

51,121

 

 

 

30,426

 

Cash, cash equivalents, and restricted cash, December 31

 

$

93,314

 

 

$

42,193

 

Operating Activities

The $11.2 million increase in net cash used in operating activities for the year ended December 31, 2020, as compared to the year ended December 31, 2019, was primarily due to increases in costs associated with ibrexafungerp development efforts. Consistent with our operating plan, we expect that our research and development expenses will decrease primarily given the completion of the VANISH Phase 3 registration program and we expect our selling, general and administrative expenses to increase to support a potential commercial launch for the treatment of VVC and our ongoing operations.

Net cash used in operating activities of $49.4 million for the year ended December 31, 2020, primarily consisted of the  $55.2 million net loss adjusted for non-cash charges that included the loss on change in fair value of the warrant liabilities of $5.2 million and stock-based compensation expense of $2.2 million, the gain on change in fair value of the derivative liabilities of $2.3 million, the loss on extinguishment of debt of $1.8 million, and the amortization of debt issuance costs and discount of $1.2 million, plus a net unfavorable change in operating assets and liabilities of $3.2 million.  The net unfavorable change in operating assets and liabilities included a decrease in accounts payable and accrued expenses of $2.3 million and an increase in prepaid expenses, other assets, and deferred costs of $0.9 million.  The $2.3 million decrease in accounts payable and accrued expenses was primarily due to the decrease in accounts payable of $2.5 million as of December 31, 2020.  The $0.9 million increase in prepaid expenses, other assets, and deferred costs is primarily due to a $2.9 million increase for a receivable that was fully collected in February 2021, offset in part by a $1.2 million decrease in prepaid research and development costs associated with drug product shipped during the period.

Net cash used in operating activities of $38.1 million for the year ended December 31, 2019, primarily consisted of the  $53.7 million net loss adjusted for non-cash charges that included the loss on change in fair value of the warrant liabilities of $4.5 million and stock-based compensation expense of $1.8 million, the gain on change in fair value of the derivative liability of $1.6 million, the loss on extinguishment of debt of $1.0 million, and the amortization of debt issuance costs and discount of $1.2 million, plus a net favorable change in operating assets and liabilities of $8.3 million.  The net favorable change in operating assets and liabilities included an increase in accounts payable and accrued expenses of $5.2 million primarily due to the increase in accounts payable and a decrease in prepaid expenses, other assets, and deferred costs of $3.3

46

 

million.  The $3.3 million decrease in prepaid expenses, other assets, and deferred costs is primarily due the cash receipt of $6.7 million received in 2019 for the sale of a portion of our NOLs through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program.

Investing Activities

Net cash provided by investing activities of $6.5 million for the year ended December 31, 2020, consisted primarily of purchases and maturities of short-term investments of $14.2 million and $20.7 million, respectively.  

Net cash provided by investing activities of $26.2 million for the year ended December 31, 2019, consisted of purchases and maturities of short-term investments of $39.5 million and $65.7 million, respectively.  

Financing Activities

Net cash provided by financing activities of $94.0 million for the year ended December 31, 2020, consisted primarily of gross proceeds from common stock of $90.6 million, primarily as a result of our December 2020 public offering of common stock and warrants in addition to the gross proceeds from common stock sold under our ATM and Aspire facilities, partially offset by related underwriting discounts and commissions and offering expenses totaling $5.9 million.  Additionally, pursuant to the April 2020 Notes, we issued and sold to Puissance $10.0 million aggregate principal amount of our April 2020 Notes, resulting in $9.5 million in net proceeds after deducting an advisory fee and other issuance costs.  

Net cash provided by financing activities of $42.3 million for the year ended December 31, 2019, consisted primarily of gross proceeds from common stock of $46.3 million, primarily as a result of our December 2019 public offering of common stock and warrants in additional to the gross proceeds from common stock sold under our ATM facilities, partially offset by related underwriting discounts and commissions and offering expenses totaling $2.9 million.  Additionally, pursuant to the note purchase agreement, we issued and sold to Puissance $16.0 million aggregate principal amount of our March 2019 Notes, resulting in $14.7 million in net proceeds after deducting an advisory fee and other issuance costs, and we used the net proceeds to pay the remaining outstanding Solar term loan in full.  As part of the payment of the outstanding balance of the Solar term loan, we paid $0.8 million in debt extinguishment costs which comprised the remaining unamortized discount and issuance costs associated with the Solar term loan prior to repayment.

Future Funding Requirements

To date, we have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize ibrexafungerp. In addition, we expect to incur expenses in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our product candidates. We anticipate that we will need substantial additional funding in connection with our continuing future operations.

Based upon our existing operating plan, we believe that our existing cash and cash equivalents, the sale of a portion of our New Jersey NOLs, the upfront payment from Hansoh, and anticipated sales of Brexafemme will enable us to fund our operating requirements into 2023.  These funds will also be sufficient to enable us to commercially launch Brexafemme for the treatment of vaginal yeast infections, if approved, and complete the development activities for the CANDLE study.  However, we are continually evaluating our operating plan and assessing the optimal cash utilization for our ibrexafungerp development strategy. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenses necessary to complete the development of product candidates.

Our future capital requirements will depend on many factors, including:

 

•

the progress, costs, and the clinical research and development of ibrexafungerp;

 

•

the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;

 

•

the ability of our product candidates to progress through clinical development successfully;

 

•

our need to expand our research and development activities;

 

•

the costs associated with securing, establishing and maintaining commercialization and manufacturing capabilities;

 

•

our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;

 

•

our need and ability to hire additional management and scientific and medical personnel;

47

 

 

 

•

our need to implement additional, as well as to enhance existing, internal systems and infrastructure, including financial and reporting processes and systems; and

 

•

the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future.

Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of net proceeds from equity offerings, debt financings, or other non-dilutive third-party funding (e.g., grants, New Jersey Technology Business Tax Certificate Transfer (NOL) Program), strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, similar to our previous loan agreement with Solar or the convertible senior notes we sold in March 2019 and April 2020, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through sales of assets, other third-party funding, strategic alliances and licensing or collaboration arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.

Off-Balance Sheet Arrangements

During the periods presented we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our consolidated financial statements, as well as the reported revenues and expenses during the reported periods. We evaluate these estimates and judgments on an ongoing basis. We base our assumptions and estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements for the year ended December 31, 2020, included in this Annual Report, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our consolidated financial statements and understanding and evaluating our reported financial results.

Research and Development Accruals

We are required to estimate our expenses resulting from our obligations under contracts with CROs, clinical site agreements, vendors, and consultants in connection with conducting ibrexafungerp clinical trials and preclinical studies and other development activities. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate development and trial expenses in our consolidated financial statements by matching those expenses with the period in which the services and efforts are expended by our service providers.

For clinical trials, we account for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, we determine accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with our knowledgeable internal personnel and service provider personnel. During the course of a clinical trial or preclinical study or development project, we adjust our rate of trial or project expense recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date within our consolidated financial statements based on the facts and circumstances known to us at that time. Our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in our reporting changes in estimates in any particular period. We have not experienced any significant adjustments to our estimates to date.

48

 

Stock-Based Compensation

We record the fair value of stock options issued as of the grant date as compensation expense. We recognize compensation expense over the requisite service period, which is equal to the vesting period.

Stock-based compensation expense has been reported in our statements of operations as follows (dollars in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

Research and development, net

 

$

806

 

 

$

604

 

Selling, general and administrative

 

 

1,414

 

 

 

1,224

 

Total

 

$

2,220

 

 

$

1,828

 

On December 31, 2020, the aggregate intrinsic value of outstanding options to purchase shares of our common stock was $0.1 million, based upon the $7.65 closing sales price per share of our common stock as reported on the Nasdaq Global Market on that date.

Determination of the Fair Value of Stock-based Compensation Grants

We calculate the fair value of stock-based compensation arrangements using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of subjective assumptions, including volatility of our common stock, the expected term of our stock options, the risk free interest rate for a period that approximates the expected term of our stock options, and the fair value of the underlying common stock on the date of grant. In applying these assumptions, we considered the following factors:

 

•

we estimate expected volatility based on the volatility of our own common stock trading history;

 

•

the assumed dividend yield is based on our expectation of not paying dividends on our underlying common stock for the foreseeable future;

 

•

we determine the average expected life of stock options based on the simplified method in accordance with SEC Staff Accounting Bulletin Nos. 107 and 110, as our common stock has a limited trading history. We expect to use the simplified method until we have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term;

 

•

we determine the risk-free interest rate by reference to implied yields available from U.S. Treasury securities with a remaining term equal to the expected life assumed at the date of grant; and

 

•

we recognize forfeitures as they are incurred.

The assumptions used in the Black-Scholes option-pricing model for the years ended December 31, 2020 and 2019 are set forth below:

 

Employee Stock Options

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

Weighted average risk-free interest rate

 

 

1.18

%

 

 

2.47

%

Weighted average expected term (in years)

 

 

5.97

 

 

 

6.03

 

Weighted average expected volatility

 

 

64.67

%

 

 

66.47

%

 

Non-Employee Director Stock Options

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

Weighted average risk-free interest rate

 

 

0.36

%

 

 

2.11

%

Weighted average expected term (in years)

 

 

5.50

 

 

 

5.54

 

Weighted average expected volatility

 

 

66.55

%

 

 

65.36

%

Warrant Liabilities

We account for the outstanding warrants associated with the June 2016, March 2018, December 2019, and December 2020 public offerings as liabilities measured at fair value.  The fair values of these warrants have been determined using the Black-Scholes valuation model.  We determine the risk-free interest rate by reference to implied yields available from U.S. Treasury securities and utilize the remaining term of the warrant as the expected term.  We estimate expected volatility using the historical volatility of our common stock given we have sufficient history to support the expected terms of the warrants.  See Note 2 to our consolidated financial statements on this Annual Report for further details.

49

 

Convertible Debt and Derivative Liabilities

For the convertible notes, we account for the bifurcated embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, as long-term derivative liabilities in our consolidated balance sheet. The derivative liabilities are remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the consolidated statements of operations in other (income) expense.  We used the binomial lattice valuation model to value the derivative liabilities at inception and on subsequent valuation dates.  This model incorporates transaction details such as stock price, contractual terms, dividend yield, risk-free rate, historical volatility, credit rating, market credit spread, and estimated yield.  See Note 2 to our consolidated financial statements on this Annual Report for further details.

ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

This item is not applicable to smaller reporting companies.

 

50

 

ITEM 8.

CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

 

 

51

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of SCYNEXIS, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of SCYNEXIS, Inc. and subsidiaries (the "Company") as of December 31, 2020 and 2019, the related consolidated statements of operations, changes in stockholders’ equity, and cash flows, for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Convertible Debt and Derivative Liabilities – April 2020 Note Purchase Agreement – Refer to “Note 2 – Summary of Significant Accounting Policies” and “Note 7 – Borrowings” to the financial statements

Critical Audit Matter Description

In April 2020, the Company entered into a Senior Convertible Note Purchase Agreement pursuant to which it issued and sold $10.0 million aggregate principal amount of 6.0% Convertible Senior Notes (the “April 2020 Notes”), each of which are convertible into shares of the Company’s common stock. Upon issuance of the April 2020 Notes, the Company bifurcated the fair value of the embedded conversion option from the April 2020 Notes and recorded it as a derivative liability in accordance with ASC 815, Derivatives and Hedging. Both the April 2020 Notes and the derivative liability have been classified as long-term and presented as “Convertible debt and derivative liabilities” in the Company’s consolidated balance sheet. Prospectively, the convertible debt is required to be carried at amortized cost, while the derivative liability component is remeasured at each reporting period with changes in fair value recorded in the Company’s consolidated statements of operations as other (income) expense. The calculation of the fair value of the derivative liability includes items subject to management’s judgment including the valuation model used in determining the fair value, as well as individual inputs to the valuation model.

52

 

We identified the initial accounting for and valuation of the April 2020 Notes as a critical audit matter because of the complexity in applying the accounting framework for the April 2020 Notes and the significant estimates and judgments made by management in the determination of the fair value of the derivative liability component. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the appropriateness of the accounting framework and to assess the reasonableness of the fair value estimates and assumptions, including the involvement of our fair value specialists.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the accounting for and valuation of the April 2020 Notes included the following, among others:

•     With the assistance of professionals in our firm having expertise in the accounting treatment for financial instruments, we evaluated the Company’s conclusions regarding the accounting treatment applied to the April 2020 Notes including the bifurcation of the embedded conversion option.

•   With the assistance of our fair value specialists, we evaluated the reasonableness of the valuation methodology and the significant assumptions used to determine the fair value of the derivative liability by:

 

o

Testing the source information underlying the fair value of the derivative liability and the mathematical accuracy of the calculation.

 

o

Developing a range of independent estimates and comparing those to the fair value of the derivative liability determined by management.

 

/s/ DELOITTE & TOUCHE LLP

Parsippany, New Jersey
March 29, 2021

We have served as the Company's auditor since 2000.

 

 

 

 

53

 

 

SCYNEXIS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

 

 

December 31, 2020

 

 

December 31, 2019

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

93,041

 

 

$

41,920

 

Short-term investments

 

 

—

 

 

 

6,494

 

Prepaid expenses and other current assets

 

 

5,165

 

 

 

3,988

 

Total current assets

 

 

98,206

 

 

 

52,402

 

Other assets

 

 

573

 

 

 

812

 

Deferred offering costs

 

 

187

 

 

 

70

 

Restricted cash

 

 

273

 

 

 

273

 

Property and equipment, net

 

 

298

 

 

 

405

 

Operating lease right-of-use asset (Note 8)

 

 

2,999

 

 

 

3,191

 

Total assets

 

$

102,536

 

 

$

57,153

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

4,639

 

 

$

7,177

 

Accrued expenses

 

 

4,141

 

 

 

3,801

 

Warrant liabilities

 

 

17,564

 

 

 

—

 

Operating lease liability, current portion (Note 8)

 

 

52

 

 

 

36

 

Total current liabilities

 

 

26,396

 

 

 

11,014

 

Warrant liabilities

 

 

33,592

 

 

 

18,396

 

Convertible debt and derivative liabilities (Note 7)

 

 

16,516

 

 

 

11,522

 

Operating lease liability (Note 8)

 

 

3,274

 

 

 

3,326

 

Total liabilities

 

 

79,778

 

 

 

44,258

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, authorized 5,000,000 shares as of December 31, 2020 and December 31, 2019; 0 shares issued and outstanding as of December 31, 2020 and December 31, 2019

 

 

—

 

 

 

—

 

Common stock, $0.001 par value, 100,000,000 shares authorized as of December   31, 2020, and December 31, 2019; 19,663,698 and 9,741,372 shares issued and outstanding as of December 31, 2020, and December 31, 2019, respectively

 

 

20

 

 

 

10

 

Additional paid-in capital

 

 

349,351

 

 

 

284,313

 

Accumulated deficit

 

 

(326,613

)

 

 

(271,428

)

Total stockholders’ equity

 

 

22,758

 

 

 

12,895

 

Total liabilities and stockholders’ equity

 

$

102,536

 

 

$

57,153

 

 

The accompanying notes are an integral part of the financial statements.

 

 

 

54

 

 

SCYNEXIS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

Revenue

 

$

—

 

 

$

121

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

36,522

 

 

 

38,394

 

Selling, general and administrative

 

 

14,627

 

 

 

10,648

 

Total operating expenses

 

 

51,149

 

 

 

49,042

 

Loss from operations

 

 

(51,149

)

 

 

(48,921

)

Other expense (income):

 

 

 

 

 

 

 

 

Loss on extinguishment of debt

 

 

1,766

 

 

 

1,045

 

Amortization of debt issuance costs and discount

 

 

1,201

 

 

 

1,171

 

Interest income

 

 

(189

)

 

 

(805

)

Interest expense

 

 

1,181

 

 

 

986

 

Other income

 

 

(334

)

 

 

(538

)

Other expense

 

 

602

 

 

 

—

 

Warrant liabilities fair value adjustment

 

 

5,214

 

 

 

4,497

 

Derivative liability fair value adjustment

 

 

(2,257

)

 

 

(1,567

)

Total other expense:

 

 

7,184

 

 

 

4,789

 

Loss before taxes

 

 

(58,333

)

 

 

(53,710

)

Income tax benefit

 

 

3,148

 

 

 

—

 

Net loss

 

$

(55,185

)

 

$

(53,710

)

Net loss per share – basic and diluted

 

$

(5.15

)

 

$

(9.58

)

Weighted average common shares outstanding – basic and diluted

 

 

10,720,211

 

 

 

5,608,138

 

 

The accompanying notes are an integral part of the financial statements.

 

 

 

55

 

 

SCYNEXIS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except share data)

 

 

 

 

Shares of

Common

Stock

 

 

 

Common

Stock

 

 

Additional

Paid-in

Capital

 

 

Accumulated

Deficit

 

 

Total Stockholders’ Equity

 

Balances as of December 31, 2018

 

 

 

4,797,198

 

 

 

$

5

 

 

$

248,938

 

 

$

(217,718

)

 

$

31,225

 

Net loss

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

(53,710

)

 

 

(53,710

)

Stock-based compensation expense

 

 

 

—

 

 

 

 

—

 

 

 

1,828

 

 

 

—

 

 

 

1,828

 

Common stock issued through employee stock purchase plan

 

 

 

3,684

 

 

 

 

—

 

 

 

37

 

 

 

—

 

 

 

37

 

Common stock issued, net of expenses

 

 

 

4,773,692

 

 

 

 

5

 

 

 

30,525

 

 

 

—

 

 

 

30,530

 

Common stock issued for conversion of March 2019 Notes

 

 

 

162,600

 

 

 

 

—

 

 

 

2,984

 

 

 

—

 

 

 

2,984

 

Common stock issued for exercise of stock options

 

 

 

2,252

 

 

 

 

—

 

 

 

12

 

 

 

—

 

 

 

12

 

Common stock issued for vested restricted stock units

 

 

 

1,946

 

 

 

 

—

 

 

 

(11

)

 

 

—

 

 

 

(11

)

Balances as of December 31, 2019

 

 

 

9,741,372

 

 

 

$

10

 

 

$

284,313

 

 

$

(271,428

)

 

$

12,895

 

Net loss

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

(55,185

)

 

 

(55,185

)

Stock-based compensation expense

 

 

 

—

 

 

 

 

—

 

 

 

2,220

 

 

 

—

 

 

 

2,220

 

Common stock issued through employee stock purchase and stock option plans

 

 

 

4,652

 

 

 

 

—

 

 

 

28

 

 

 

—

 

 

 

28

 

Common stock issued, net of expenses

 

 

 

9,156,304

 

 

 

 

9

 

 

 

57,175

 

 

 

—

 

 

 

57,184

 

Common stock issued for conversion of April 2020 Notes

 

 

 

638,809

 

 

 

 

1

 

 

 

5,221

 

 

 

—

 

 

 

5,222

 

Common stock issued for Commitment Shares

 

 

 

70,910

 

 

 

 

—

 

 

 

602

 

 

 

—

 

 

 

602

 

Common stock issued for vested restricted stock units

 

 

 

51,651

 

 

 

 

—

 

 

 

(208

)

 

 

—

 

 

 

(208

)

Balances as of December 31, 2020

 

 

 

19,663,698

 

 

 

$

20

 

 

$

349,351

 

 

$

(326,613

)

 

$

22,758

 

 

The accompanying notes are an integral part of the financial statements.

 

 

 

56

 

 

SCYNEXIS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(55,185

)

 

$

(53,710

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation

 

 

111

 

 

 

111

 

Stock-based compensation expense

 

 

2,220

 

 

 

1,828

 

Accretion of investment discount

 

 

—

 

 

 

(16

)

Amortization of debt issuance costs and discount

 

 

1,201

 

 

 

1,171

 

Change in fair value of warrant liabilities

 

 

5,214

 

 

 

4,497

 

Change in fair value of derivative liabilities

 

 

(2,257

)

 

 

(1,567

)

Noncash operating lease expense for right-of-use asset

 

 

192

 

 

 

174

 

Loss on extinguishment of debt

 

 

1,766

 

 

 

1,045

 

Noncash consideration associated with common stock purchase agreement

 

 

602

 

 

 

—

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses, other assets, and deferred costs

 

 

(922

)

 

 

3,254

 

Accounts payable and accrued expenses

 

 

(2,296

)

 

 

5,215

 

Deferred revenue

 

 

—

 

 

 

(121

)

Net cash used in operating activities

 

 

(49,354

)

 

 

(38,119

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Maturities of investments

 

 

20,713

 

 

 

65,740

 

Purchases of property and equipment

 

 

(4

)

 

 

—

 

Purchase of investments

 

 

(14,235

)

 

 

(39,500

)

Net cash provided by investing activities

 

 

6,474

 

 

 

26,240

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from common stock issued

 

 

90,554

 

 

 

46,337

 

Payments of offering costs and underwriting discounts and commissions

 

 

(5,879

)

 

 

(2,855

)

Proceeds from employee stock purchase plan issuances

 

 

28

 

 

 

49

 

Repurchase of shares to satisfy tax withholdings

 

 

(208

)

 

 

—

 

Proceeds from senior convertible notes

 

 

10,000

 

 

 

16,000

 

Payments of senior convertible notes issuance costs

 

 

(494

)

 

 

(1,253

)

Payment of loan payable expected to be refinanced

 

 

—

 

 

 

(15,973

)

Net cash provided by financing activities

 

 

94,001

 

 

 

42,305

 

Net increase in cash, cash equivalents, and restricted cash

 

 

51,121

 

 

 

30,426

 

Cash, cash equivalents, and restricted cash at beginning of period

 

 

42,193

 

 

 

11,767

 

Cash, cash equivalents, and restricted cash at end of period

 

$

93,314

 

 

$

42,193

 

Supplemental cash flow information:

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

1,088

 

 

$

850

 

Cash received for interest

 

$

186

 

 

$

898

 

Noncash financing and investing activities:

 

 

 

 

 

 

 

 

Operating lease liabilities arising from obtaining right-of-use assets

 

$

—

 

 

$

3,365

 

Deferred offering and issuance costs included in accounts payable

 

$

62

 

 

$

—

 

Deferred offering costs reclassified to additional paid-in capital

 

$

153

 

 

$

36

 

Common stock issued for settlement of senior convertible notes

 

$

5,221

 

 

$

2,984

 

Common stock issued for Commitment Shares

 

$

602

 

 

$

—

 

 

The accompanying notes are an integral part of the financial statements.

 

 

 

 

57

 

SCYNEXIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

1.

Description of Business and Basis of Preparation

Organization

SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections.  The Company is developing its lead product candidate, ibrexafungerp, as the first representative of a novel oral and intravenous triterpenoid antifungal family for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.

The Company has incurred significant losses and negative cash flows from operations since its initial public offering in May 2014 and expects to continue to incur losses and negative cash flows for the foreseeable future. As a result, the Company had an accumulated deficit of $326.6 million at December 31, 2020 and limited capital resources to fund ongoing operations.   These capital resources primarily comprised cash and cash equivalents of $93.0 million at December 31, 2020. While the Company believes its capital resources are sufficient to fund the Company’s on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying consolidated financial statements, the Company's liquidity could be materially affected over this period by, among other things: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding; (2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events or unanticipated costs related to its development of ibrexafungerp; (4) its ability to potentially commercialize ibrexafungerp for the treatment of vaginal yeast infections and; (5) any other unanticipated material negative events or costs.  One or more of these events or costs could materially affect the Company’s liquidity.  If the Company is unable to meet its obligations when they become due, the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to its operating plan.  The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.  Intercompany balances and transactions are eliminated in consolidation.

Shelf Registration Filings

On December 31, 2020 and September 11, 2020, the Company filed shelf registration statements on Form S-3 (File No. 333-251851 and File No. 333-248751, respectively) with the Securities and Exchange Commission (“SEC”), which were declared effective on January 8, 2021 and October 1, 2020, respectively (the “January 2021 Shelf Registration” and “October 2020 Shelf Registration”).  Both shelf registrations contain a base prospectus which covers the offering, issuance and sale of such indeterminate number of shares of common stock and preferred stock, such indeterminate principal amount of debt securities, and such indeterminate number of warrants to purchase common stock, preferred stock and/or debt securities, which together shall have an aggregate initial offering price not to exceed $200.0 million.  

A prospectus is included in the October 2020 Shelf Registration covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $50.0 million of the Company’s common stock that may be issued and sold under a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. (“Cantor”) and/or Controlled Equity OfferingSM Sales Agreement with Ladenburg Thalmann & Co. Inc. (such agreements, the “Sales Agreements”).  These Sales Agreements were cancelled in December 2020.

As of December 31, 2020, approximately $437.0 million of the securities registered under the Company’s effective shelf registrations, which include the January 2021 Shelf Registration, October 2020 Shelf Registration, and the Form S-3 shelf registration filed by the Company in August 2018 (effective September 14, 2018), are available to be offered, issued and sold by the Company.

Reverse Stock Split

On July 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”), which became effective on Friday, July 17, 2020, (a) implementing a 1-for-10 reverse stock split of the Company’s common stock and (b) decreasing the number of authorized shares of the Company’s common stock from 250,000,000 shares to 100,000,000 shares.  On the effective date of July 17, 2020, the number of the Company’s issued and outstanding shares of common stock was decreased from 105,083,291 to 10,508,302 and the par value per common share remained unchanged.  No fractional shares were issued as a result of the reverse stock split.  Stockholders who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof.  All share and per share amounts presented in these consolidated financial statements have been retroactively adjusted for the reverse stock split and certain items in the prior period financial statements have been revised to conform to the current presentation.

58

 

The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of outstanding convertible notes or upon the exercise of stock options or warrants outstanding.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: determination of the fair value of stock-based compensation grants; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimates and assumptions utilized in measuring the fair values of the warrant and derivative liabilities each reporting period.

2.

Summary of Significant Accounting Policies

Concentration of Credit Risk

Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents.  The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any significant losses in the account.

Cash and Cash Equivalents

The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents.  The Company reported cash, cash equivalents, and restricted cash of $93.3 million and $42.2 million as of December 31, 2020 and 2019, respectively.  See Note 8 for further details on the nature of the restricted cash.

Short-Term Investments

The Company's held-to-maturity investments in U.S. government securities, commercial paper, and its overnight repurchase agreement are carried at amortized cost and any premiums or discounts are amortized or accreted through the maturity date of the investment.  Any impairment that is not deemed to be temporary is recognized in the period identified.

Warrant Liabilities

The Company accounts for the outstanding warrants associated with the June 2016 public offering, March 2018 Public Offering, December 2019 Public Offering and December 2020 Public Offering as liabilities measured at fair value. The fair values of these warrants have been determined using the Black-Scholes valuation model ("Black-Scholes"). The warrants are subject to remeasurement at each balance sheet date, using Black-Scholes, with any changes in the fair value of the outstanding warrants recognized in the accompanying consolidated statements of operations. See Notes 9 and 12 for further details.

Convertible Debt and Derivative Liabilities

In connection with the Company’s issuance of its April 2020 and March 2019 6.0% Convertible Senior Notes (the “April 2020 Notes” and the “March 2019 Notes”), the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as long-term derivative liabilities in the Company’s balance sheet in accordance with FASB Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging.  The convertible debt and the derivative liabilities associated with the April 2020 Notes and March 2019 Notes are presented in total on the consolidated balance sheet as the convertible debt and derivative liabilities.  The convertible debt is carried at amortized cost.  The derivative liabilities will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the consolidated statements of operations in other expense (income).  See Notes 7 and 12 for further details.

Research and Development

Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance.

The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting ibrexafungerp clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its consolidated

59

 

financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel.  

Patent Expenses

Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows:

 

•

Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

 

•

Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

 

•

Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.

Amortization of Debt Issuance Costs and Discount

The Company’s convertible debt is recorded net of debt issuance costs which comprised issuance costs and an advisory fee.  The portion of the debt issuance costs allocated to the convertible debt, based on the amount of proceeds allocated between the convertible debt and the derivative liability, is being amortized over the term of the convertible debt using the effective interest method in addition to the discount initially recognized for the fair value of the bifurcated derivative liability from the convertible debt.  Debt issuance costs allocated to the derivative liabilities were included in other expense as a component of the fair value adjustment for the year ended December 31, 2020.  The Company’s previous term loan with Solar Capital Ltd. (“Solar”), which was paid in full in March 2019 (see Note 7), was recorded net of debt discount which comprised issuance costs, customary closing and final fees, and the fair value of the warrants issued in conjunction with the term loan. The resulting debt discount was being amortized over the term of the term loan using the straight-line method, which approximated the effective interest method.  The amortization of debt issuance costs and discount is included in other expense within the accompanying consolidated statements of operations.

Income Taxes

The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions.

Stock-Based Compensation

The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date.  The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods.

Basic and Diluted Net Loss per Share of Common Stock

The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period.

60

 

The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive:

 

 

December 31,

 

 

 

2020

 

 

2019

 

Outstanding stock options

 

 

830,343

 

 

 

526,070

 

Outstanding restricted stock units

 

 

29,087

 

 

 

96,637

 

Warrants to purchase common stock associated with June 2016 Public Offering

 

 

421,867

 

 

 

421,867

 

Warrants to purchase common stock associated with March 2018 Public Offering - Series 2

 

 

798,810

 

 

 

798,810

 

Warrants to purchase common stock associated with December 2019 Public Offering

 

 

4,472,205

 

 

 

4,472,205

 

Option to purchase common stock associated with December 2019 Public Offering

 

 

—

 

 

 

583,333

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 1

 

 

6,800,000

 

 

 

—

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 2

 

 

6,800,000

 

 

 

—

 

For possible future issuance for the conversion of the March 2019 Notes

 

 

1,138,200

 

 

 

1,138,200

 

For possible future issuance for the conversion of the April 2020 Notes

 

 

1,299,790

 

 

 

—

 

Warrants to purchase common stock associated with Solar loan agreement

 

 

12,243

 

 

 

12,243

 

          Total

 

 

22,602,545

 

 

 

8,049,365

 

Segment and Geographic Information

Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. The material assets of the Company were held in the United States for the years ended December 31, 2020 and 2019.  In July 2019, the Company incorporated SCYNEXIS Pacific Pty Ltd, a wholly-owned subsidiary, in Sydney, Australia, for the initial purpose of conducting certain clinical trials and other research and development activities.

Although all operations are primarily based in the United States, the Company generated a portion of its revenue from R-Pharm outside of the United States for the year ended December 31, 2019.  All of the Company's revenue in 2019 was generated from a non-refundable upfront payment received under a licensing and collaboration arrangement with a partner located in Russia.  All sales, including sales outside of the United States, are denominated in United States dollars.

 

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) (“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted.  As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its consolidated financial statements.

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company is currently evaluating the impact ASU 2019-12 will have on its consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity (“ASU 2020-06”). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share.  The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years.  As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its consolidated financial statements.

61

 

 

Recently Adopted Accounting Pronouncements

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). ASU 2018-13 removes, modifies and adds certain disclosure requirements in ASU 2018-13, Fair Value Measurement. ASU 2018-13 eliminates certain disclosures related to transfers and the valuation process, modifies disclosures for investments that are valued based on net asset value, clarifies the measurement uncertainty disclosure, and requires additional disclosures for Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The Company adopted ASU 2018-13 during the year ended December 31, 2020 and as a result, included the required additional disclosures for its Level 3 fair value measurements in its consolidated financial statements (see Note 12).  The Company did not identify any other material impacts of ASU 2018-13 on its consolidated financial statements.

 

3.

Short-term Investments

The following table summarizes the held-to-maturity securities held at December 31, 2019 (in thousands):

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair Value

 

As of December 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government securities

 

$

1,996

 

 

$

15

 

 

$

(14

)

 

$

1,997

 

Commercial paper

 

 

998

 

 

 

—

 

 

 

—

 

 

 

998

 

Overnight repurchase agreement

 

 

3,500

 

 

 

—

 

 

 

—

 

 

 

3,500

 

Total short-term investments

 

$

6,494

 

 

$

15

 

 

$

(14

)

 

$

6,495

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2019, the Company had $6.5 million of held-to-maturity investments which all matured as of December 31, 2020.  The gross unrealized gains and losses for the Company's commercial paper and overnight repurchase agreement are not significant.  The Company carries short-term investments at amortized cost. The fair value of the short-term investments is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets.

4.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

December 31,

 

 

 

2020

 

 

2019

 

Prepaid research and development services

 

$

1,535

 

 

$

3,043

 

Prepaid insurance

 

 

362

 

 

 

252

 

Other prepaid expenses

 

 

19

 

 

 

19

 

Other receivable

 

 

2,876

 

 

 

—

 

Other current assets

 

 

373

 

 

 

674

 

Total prepaid expenses and other current assets

 

$

5,165

 

 

$

3,988

 

 

5.

Property and Equipment

Property and equipment consisted of the following (in thousands):

 

 

December 31,

 

 

 

2020

 

 

2019

 

Furniture and fixtures

 

$

406

 

 

$

406

 

Computer equipment

 

 

76

 

 

 

73

 

Other

 

 

98

 

 

 

98

 

 

 

 

580

 

 

 

577

 

Less: accumulated depreciation and amortization

 

 

(282

)

 

 

(172

)

Total property and equipment, net

 

$

298

 

 

$

405

 

 

62

 

 

6.

Accrued Expenses

Accrued expenses consisted of the following (in thousands):

 

 

December 31,

 

 

 

2020

 

 

2019

 

Accrued research and development expenses

 

$

991

 

 

$

1,296

 

Accrued employee bonus compensation

 

 

2,190

 

 

 

1,798

 

Other accrued expenses

 

 

960

 

 

 

707

 

Total accrued expenses

 

$

4,141

 

 

$

3,801

 

 

7.

Borrowings

April 2020 Note Purchase Agreement

On April 9, 2020, the Company entered into a Senior Convertible Note Purchase Agreement (the “April 2020 Note Purchase Agreement”) and issued and sold to Puissance Life Science Opportunities Fund VI (“Puissance”) $10.0 million aggregate principal amount of its April 2020 Notes, resulting in net proceeds of approximately $9.5 million after deducting $0.5 million for an advisory fee and other issuance costs  The April 2020 Notes were issued and sold for cash at a purchase price equal to 100% of their principal amount, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), due to the April 2020 Notes being issued to one financially sophisticated investor.

The April 2020 Notes will bear interest at a rate of 6.0% per annum, payable semiannually in arrears on April 15 and October 15 of each year, beginning October 15, 2020. The April 2020 Notes will mature on April 15, 2026, unless earlier converted, redeemed or repurchased.  The April 2020 Notes constitute general, senior unsecured obligations of the Company.

As of December 31, 2020, the Company’s April 2020 Notes consists of the convertible debt balance of $1.2 million, presented net of the unamortized debt issuance costs allocated to the convertible debt of $0.1 million, and the bifurcated embedded conversion option derivative liability of $3.3 million.  In connection with the Company’s issuance of its April 2020 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, Derivatives and Hedging, at its initial fair value of $8.1 million as the interest make-whole provision is settled in shares of common stock.  Debt issuance costs of $0.4 million initially allocated to the derivative liability were written off upon issuance of the April 2020 Notes and were recognized in the gain on the fair value adjustment for the derivative liability for the year ended December 31, 2020.  For the year ended December 31, 2020, the Company recognized a gain of $1.7 million on the fair value adjustment for the derivative liability and recognized $0.2 million in amortization of debt issuance costs and discount for the year ended December 31, 2020, related to the April 2020 Notes.

In June 2020, Puissance converted $2.0 million of the April 2020 Notes for 316,461 shares of common stock.  Upon conversion of the $2.0 million of the April 2020 Notes, the Company recognized a $0.8 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $2.0 million and the fair value of the consideration issued of $2.8 million.  In December 2020 and January 2021, Puissance converted the remaining $2.0 million and $6.0 million of the April 2020 Notes for 322,348 and 959,080 shares of common stock, respectively.  Upon conversion of the $2.0 million of the April 2020 Notes in December 2020, the Company recognized a $1.0 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $1.4 million and the fair value of the consideration issued of $2.4 million.

The Company estimated the fair value of the convertible debt and derivative liability for the April 2020 Notes using a binomial lattice valuation model and Level 3 inputs. At December 31, 2020, the fair value of the April 2020 Notes is $7.4 million.

The holders of the April 2020 Notes may convert their April 2020 Notes at their option at any time prior to the close of business on the business day immediately preceding April 15, 2026 into shares of the Company’s common stock. The initial conversion rate is 111.1108 shares of common stock per $1,000 principal amount of the April 2020 Notes, which is equivalent to an initial conversion price of approximately $9.00 per share, and is subject to adjustment in certain events described in the April 2020 Note Purchase Agreement. Holders who convert may also be entitled to receive, under certain circumstances, an “interest make-whole payment” (as defined in the April 2020 Note Purchase Agreement) payable in shares of common stock. In addition, following certain corporate events that occur prior to the maturity date, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its April 2020 Notes in connection with such a corporate event. Unless the Company seeks and receives stockholder approval, the number of shares that the Company may deliver in connection with a conversion of the April 2020 Notes, including those delivered in connection with an “interest make-whole payment” or a “make-whole fundamental change” (each as defined in the April 2020 Note Purchase Agreement), will not exceed a cap of 1,938,600 shares of common stock.

63

 

On or after April 15, 2023, the Company has the right, at its election, to redeem all or any portion of the April 2020 Notes not previously converted if the last reported sale price per share of common stock exceeds 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. The redemption price will be 100% of the principal amount of the April 2020 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

If a “fundamental change” (as defined in the April 2020 Note Purchase Agreement) occurs, then, subject to certain exceptions, the Company must offer to repurchase the April 2020 Notes for cash at a repurchase price of 100% of the principal amount of the April 2020 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date.  

March 2019 Note Purchase Agreement

On March 7, 2019, the Company entered into a Senior Convertible Note Purchase Agreement (the “March 2019 Note Purchase Agreement”) with Puissance.  Pursuant to the March 2019 Note Purchase Agreement, on March 7, 2019, the Company issued and sold to Puissance $16.0 million aggregate principal amount of its March 2019 Notes, resulting in $14.7 million in net proceeds after deducting $1.3 million for an advisory fee and other issuance costs.  The Company used the net proceeds to pay the remaining outstanding Solar term loan in full and recorded a loss on debt extinguishment of $0.8 million during the year ended December 31, 2019.  The loss on debt extinguishment of $0.8 million for the year ended December 31, 2019 was recognized as the difference between the reacquisition price of the outstanding Solar debt of $15.9 million and the $15.1 million net carrying value of the Solar debt obligation prior to repayment.

As of December 31, 2020 and 2019, the Company’s March 2019 Notes consists of the convertible debt balance of $9.4 million and $8.3 million, presented net of the unamortized debt issuance costs allocated to the convertible debt of $0.4 million and $0.5 million, and the bifurcated embedded conversion option derivative liability of $2.7 million and $3.2 million, respectively.  In connection with the Company’s issuance of its March 2019 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, Derivatives and Hedging, at its initial fair value of $7.0 million as the interest make-whole provision is settled in shares of common stock.  Debt issuance costs of $0.6 million initially allocated to the derivative liability were written off upon issuance of the March 2019 Notes and were recognized in the gain on the fair value adjustment for the derivative liability for the year ended December 31, 2019.  For the years ended December 31, 2020 and 2019, the Company recognized gains of $0.5 million and $1.6 million, respectively, on the fair value adjustment for the derivative liability.   For the years ended December 31, 2020 and 2019, the Company recognized $1.0 million and $1.1 million, respectively, in amortization of debt issuance costs and discount, related to the March 2019 Notes.

In April 2019, Puissance converted $2.0 million of the March 2019 Notes for 162,600 shares of common stock.  Upon conversion of the $2.0 million of the March 2019 Notes, the Company recognized a $0.2 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $2.8 million and the fair value of the consideration issued of $3.0 million.  

The Company estimated the fair value of the convertible debt and derivative liability for the March 2019 Notes using a binomial lattice valuation model and Level 3 inputs. At December 31, 2020 and 2019, the fair value of the convertible debt and derivative liability for the March 2019 Notes is $12.9 million and $11.7 million, respectively.

The March 2019 Notes were issued and sold for cash at a purchase price equal to 100% of their principal amount, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), due to the March 2019 Notes being issued to one financially sophisticated investor. The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased. The March 2019 Notes constitute general, senior unsecured obligations of the Company.

The holder of the March 2019 Notes may convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company’s common stock. The initial conversion rate is 73.9096 shares of common stock per $1,000 principal amount of March 2019 Notes, which is equivalent to an initial conversion price of approximately $13.53 and is subject to adjustment in certain events described in the March 2019 Note Purchase Agreement. The Holder upon conversion may also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of common stock. In addition, following certain corporate events that occur prior to the maturity date, the Company will, in certain circumstances, increase the conversion rate if the holder elects to convert its March 2019 Notes in connection with such a corporate event. Subject to adjustment in the conversion rate, the number of shares that the Company may deliver in connection with a conversion of the March 2019 Notes, including those delivered in connection with an interest make-whole payment, will not exceed a cap of 81 shares of common stock per $1,000 principal amount of the March 2019 Notes.  

64

 

On or after March 15, 2022, the Company has the right, at its election, to redeem all or any portion of the March 2019 Notes not previously converted if the last reported sale price per share of common stock exceeds 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. The redemption price will be 100% of the principal amount of the March 2019 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.  If a “fundamental change” (as defined in the March 2019 Note Purchase Agreement) occurs, then, subject to certain exceptions, the Company must offer to repurchase the March 2019 Notes for cash at a repurchase price of 100% of the principal amount of the March 2019 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date.

Solar Loan Agreement

On September 30, 2016, the Company entered into a loan agreement with Solar Capital Ltd. (“Solar”), in its capacity as administrative and collateral agent and as lender. Pursuant to the loan agreement, Solar was providing the Company with a 48-month secured term loan in the amount of $15.0 million.  The term loan bore interest at a floating rate equal to the LIBOR rate in effect plus 8.49%.  The Solar term loan was paid in full in March 2019.

8.

Commitments and Contingencies

Leases

On March 1, 2018, the Company entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey, that the Company identified as an operating lease under ASC 842 (the “Lease”). The lease term is eleven years from August 1, 2018, the commencement date, with total lease payments of $7.3 million over the lease term. The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which will be reduced by fifty-five thousand dollars every two years for ten years after the commencement of the lease.  The security deposit is classified as restricted cash in the accompanying consolidated balance sheets.  

The consideration in the Lease allocated to the single lease component includes the fixed payments for the right to use the office space as well as common area maintenance.  The Lease also contains costs associated with certain expense escalation, property taxes, insurance, parking, and utilities which are all considered variable payments and are excluded from the operating lease liability.  The incremental borrowing rate utilized approximated the prevailing market interest rate the Company would incur to borrow a similar amount equal to the total Lease payments on a collateralized basis over the term of the Lease.  The following table summarizes certain quantitative information associated with the amounts recognized in the accompanying consolidated financial statements for the Lease (dollars in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

Operating lease cost

 

$

664

 

 

$

664

 

Variable lease cost

 

 

51

 

 

 

41

 

Total operating lease expense

 

$

715

 

 

$

705

 

 

 

 

 

 

 

 

 

 

Cash paid for amounts included in the measurement of operating lease liability

 

$

507

 

 

$

497

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2020

 

 

December 31, 2019

 

Remaining Lease term (years)

 

 

8.59

 

 

 

9.59

 

Discount rate

 

 

15

%

 

 

15

%

 

Future minimum lease payments for all operating leases as of December 31, 2020 are as follows (in thousands):

 

 

 

December 31, 2020

 

2021

 

$

517

 

2022

 

 

527

 

2023

 

 

715

 

2024

 

 

730

 

2025

 

 

744

 

Thereafter

 

 

2,789

 

Total

 

$

6,022

 

65

 

 

The presentation of the operating lease liability and right-of-use asset as of December 31, 2020 are as follows (in thousands):

 

 

December 31, 2020

 

Present value of future minimum lease payments

 

$

3,326

 

 

 

 

 

 

Operating lease liability, current portion

 

$

52

 

Operating lease liability, long-term portion

 

 

3,274

 

Total operating lease liability

 

$

3,326

 

 

 

 

 

 

Difference between future minimum lease payments and discounted cash flows

 

$

2,696

 

 

 

 

 

 

Operating lease right-of-use asset

 

$

2,999

 

License Arrangements with Potential Future Expenditures

As of December 31, 2020, the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, as amended, that involves potential future expenditures. Under the license arrangement, executed in May 2013, the Company exclusively licensed from Merck its rights to ibrexafungerp in the field of human health.  In January 2014, Merck assigned the patents related to ibrexafungerp that it had exclusively licensed to the Company.  Ibrexafungerp is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck was originally eligible to receive milestone payments from the Company that could total $19.0 million upon occurrence of specific events, including initiation of a Phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets, and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of ibrexafungerp. The aggregate royalties are mid- to high-single digits.

In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first Phase 2 clinical trial of a product containing the ibrexafungerp compound (the “Deferred Milestone”). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the ibrexafungerp compound.  In December 2016 and January 2018, the Company entered into second and third amendments to the license agreement with Merck which clarified what would constitute the initiation of a Phase 3 clinical trial for the purpose of milestone payment.  In January 2019, a milestone payment became due to Merck as a result of the initiation of the VANISH Phase 3 VVC program and was paid in March 2019. The milestone payment was recognized in the consolidated statement of operations in research and development expense for the year ended December 31, 2019 and is included in cash used in operating activities on the consolidated statement of cash flows.  On December 2, 2020, the Company entered into a fourth amendment to the license agreement with Merck.  The amendment eliminates two cash milestone payments that the Company would have paid to Merck upon the first filing of a NDA, triggered by the FDA acceptance for filing of its NDA for ibrexafungerp for the treatment of VVC, and first marketing approval in the U.S., anticipated in June 2021 for the Company’s NDA for ibrexafungerp for the treatment of VVC.  Such cash milestone payments would have been creditable against future royalties owed to Merck on net sales of ibrexafungerp. With the amendment, these milestones will not be paid in cash and, accordingly, credits will not accrue. Pursuant to the amendment, the Company will also forfeit the credits against future royalties that it had accrued from a prior milestone payment already paid to Merck.  All other key terms of the license agreement are unchanged.

Clinical Development Arrangements

The Company has entered into, and expects to continue to enter into, contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.

Other License Arrangements

In July 2016, the Company entered into an asset purchase agreement with UK-based Cypralis Limited (or "Cypralis"), a life sciences company, for the sale of its cyclophilin inhibitor assets. Cypralis also acquired all patents, patent applications and know-how related to the acquired portfolio. In connection with the asset purchase agreement, the Company is eligible to receive milestone payments upon the successful progression of Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. The Company retains the right to repurchase the portfolio assets from Cypralis if abandoned or deprioritized.  For the years ended December 31, 2020 and 2019, there was no revenue recognized associated with this agreement given the variable consideration associated with the sale of intellectual property to Cypralis was fully constrained.  Additionally, in October 2014 the Company entered into a license agreement with Waterstone Pharmaceutical HK Limited (or “Waterstone”) and granted Waterstone an exclusive, worldwide license to develop and commercialize certain non-strategic compounds.  The Company is entitled to receive potential milestones and royalties from Waterstone and for the years ended December 31, 2020 and 2019, there was no revenue recognized by the Company associated with this agreement given the variable consideration was fully constrained.

66

 

9.

Stockholders’ Equity

Authorized, Issued, and Outstanding Common Shares

The Company’s authorized common stock has a par value of $0.001 per share and consists of 100,000,000 shares as of December 31, 2020 and 2019; 19,663,698 and 9,741,372 shares were issued and outstanding at December 31, 2020, and December 31, 2019, respectively.  On June 18, 2019, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 125,000,000 to 250,000,000.  On July 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, which became effective on Friday, July 17, 2020, (a) implementing a 1-for-10 reverse stock split of the Company’s common stock and (b) decreasing the number of authorized shares of the Company’s common stock from 250,000,000 shares to 100,000,000 shares.  

The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of outstanding convertible notes or upon the exercise of stock options or warrants outstanding. No fractional shares were issued as a result of the reverse stock split.

Shares Reserved for Future Issuance

The Company had reserved shares of common stock for future issuance as follows:

 

 

December 31,

 

 

 

2020

 

 

2019

 

Outstanding stock options

 

 

830,343

 

 

 

526,070

 

Outstanding restricted stock units

 

 

29,087

 

 

 

96,637

 

Warrants to purchase common stock associated with June 2016 Public Offering

 

 

421,867

 

 

 

421,867

 

Warrants to purchase common stock associated with March 2018 Public Offering - Series 2

 

 

798,810

 

 

 

798,810

 

Warrants to purchase common stock associated with December 2019 Public Offering

 

 

4,472,205

 

 

 

4,472,205

 

Option to purchase common stock associated with December 2019 Public Offering

 

 

—

 

 

 

583,333

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 1

 

 

6,800,000

 

 

 

—

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 2

 

 

6,800,000

 

 

 

—

 

Prefunded warrants to purchase common stock associated with December 2020 Public Offering

 

 

5,260,000

 

 

 

—

 

Warrants to purchase common stock associated with Solar loan agreement

 

 

12,243

 

 

 

12,243

 

For possible future issuance for the conversion of the March 2019 Notes

 

 

1,138,200

 

 

 

1,138,200

 

For possible future issuance for the conversion of the April 2020 Notes

 

 

1,299,790

 

 

 

—

 

For possible future issuance under 2014 Equity Incentive Plan  (Note 11)

 

 

146,488

 

 

 

55,478

 

For possible future issuance under Employee Stock Purchase Plan (Note 11)

 

 

5,895

 

 

 

7,423

 

For possible future issuance under 2015 Inducement Award Plan (Note 11)

 

 

14,050

 

 

 

31,550

 

Total common shares reserved for future issuance

 

 

28,028,978

 

 

 

8,143,816

 

 

Liquidation Rights

In the event of any liquidation or dissolution of the Company, the holders of the common stock are entitled to the remaining assets of the Company legally available for distribution.

Dividends and Voting Rights

The holders of the common stock are entitled to receive dividends if and when declared by the Company.  

Preferred Stock

On May 7, 2014, the Company amended and restated its articles of incorporation relating to its approved capital structure. The Company’s board of directors has authorized the Company, subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of preferred stock with a par value of $0.001 per share in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions. The Company’s board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series

67

 

then outstanding, without any further vote or action by the stockholders. The Company’s board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. There were no shares of preferred stock issued and outstanding as of December 31, 2020 and 2019.

December 2020 Public Offering

On December 17, 2020, the Company completed a public offering (the “December 2020 Public Offering”) of its common stock and warrants pursuant to the Company’s effective shelf registration.  The Company sold an aggregate of (a) 8,340,000 shares of the Company’s common stock, par value $0.001 per share, (b) pre-funded warrants, in lieu of common stock, to purchase 5,260,000 shares of the Company’s common stock, par value $0.001 per share, and (c) two series of warrants, which will accompany the common stock or pre-funded warrants, to purchase up to an aggregate of 13,600,000 shares of the Company’s common stock.  The pre-funded warrants entitle the holders to purchase up to 5,260,000 shares of common stock and have an unlimited term and an exercise price of $0.001 per share. Each of the two series of warrants entitle the holders to purchase up to an aggregate of 6,800,000 shares of common stock.

The prefunded warrants are classified as equity in accordance with ASC 815, Derivatives and Hedging given the prefunded warrants are indexed to the Company’s own shares of common stock and meet the requirements to be classified in equity.  The prefunded warrants were recorded at their relative fair value at issuance in the stockholders’ equity section of the balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per share calculation for the year ended December 31, 2020 given their nominal exercise price. 

The Series 1 warrants have a one-year term and an exercise price of $7.33 per share, and Series 2 warrants have a three-and-a-half-year term and an exercise price of $8.25 per share.  There is not expected to be any trading market for the pre-funded warrants, the Series 1 warrants or the Series 2 warrants issued in the offering. Each warrant is exercisable immediately upon issuance, subject to certain limitations on beneficial ownership.  The Series 1 and Series 2 warrants that accompany the pre-funded warrants have an additional provision, if certain beneficial ownership limitations are met, entitling the holder thereof to purchase a pre-funded warrant rather than a share of common stock at the warrant exercise price less the exercise price of the pre-funded warrant purchased. The price to the public in the offering was $6.25 per share of common stock and accompanying warrants, or in the case of pre-funded warrants, $6.249 per pre-funded warrant and accompanying warrants. The December 2020 Public Offering resulted in approximately $79.5 million of net proceeds to the Company after deducting the underwriting discount and offering expenses.

December 2019 Public Offering

On December 12, 2019, the Company completed a public offering (the “December 2019 Public Offering”) of its common stock and warrants pursuant to the Company's effective Shelf Registration.  The Company sold an aggregate of 3,888,888 shares of the Company’s common stock and warrants to purchase up to an aggregate of 3,888,888 shares of the Company’s common stock at a public offering price of $9.00 per share and accompanying warrant.  Net proceeds from the December 2019 Public Offering were approximately $32.5 million, after deducting the underwriting discount and offering expenses.  In addition, the Company granted to the underwriters an option to purchase up to 583,333 additional shares of common stock and/or warrants to purchase up to an aggregate of an additional 583,333 shares of common stock, in each case at the public offering price, less underwriting discounts and commissions. The underwriters exercised their option to purchase 583,333 warrants in December 2019.  The option to purchase up to 583,333 additional shares of common stock was not exercised by the underwriters and the option expired in January 2020.  

The warrants to purchase shares of common stock are immediately exercisable and expire on the earlier of (i) such date that is six months after the Company publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023, and have an exercise price of $11.0 per share. There is not expected to be any trading market for the warrants. Each warrant is exercisable immediately upon issuance, subject to certain limitations on beneficial ownership.  

March 2018 Public Offering

On March 8, 2018, the Company completed a public offering (the “March 2018 Public Offering”) of its common stock and warrants pursuant to the Company’s effective shelf registration.  The Company sold an aggregate of 1,775,150 shares of the Company’s common stock and warrants to purchase up to 2,130,180 shares of the Company’s common stock at a public offering price of $16.90 per share.  

Each purchaser received a warrant to purchase 0.75 of a share of common stock (the “March 2018 Series 1 warrants”) and 0.45 of a share of common stock (the “March 2018 Series 2 warrants”) for each share purchased in the March 2018 Public Offering.  The March 2018 Series 1 warrants to purchase in the aggregate up to 1,331,370 shares of common stock had a 53-week term and an exercise price of $18.5 per share, and the March 2018 Series 2 warrants to purchase in the aggregate up to 798,810 shares of common stock have a five-year term and an exercise price of $20.0 per share.  There is not expected to be any market for the warrants and each warrant is exercisable immediately upon issuance, subject to certain limitations on

68

 

beneficial ownership.  During the year ended December 31, 2019, there were 11,550 of the March 2018 Series 1 warrants exercised for total proceeds of $0.2 million and the March 2018 Series 1 warrants expired on March 14, 2019.

June 2016 Public Offering

On June 21, 2016, the Company completed a public offering (the “June 2016 Public Offering”) and sold 937,500 shares of its common stock and warrants to purchase up to 421,867 shares of the Company’s common stock.  Each purchaser received a warrant to purchase 0.45 of a share for each share purchased in the June 2016 Public Offering. There is not expected to be any trading market for the warrants. Each warrant was exercisable immediately upon issuance, will expire five years from the date of issuance, and has an exercise price of $30.0 per share.  

Warrant Liabilities

The June 2016, March 2018, December 2019, and December 2020 warrants contain a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, Distinguishing Liabilities from Equity, requires that these warrants be classified as liabilities. The fair values of these warrants have been determined using the Black-Scholes valuation model, and the changes in the fair value are recorded in the accompanying consolidated statements of operations.  The June 2016 and December 2020 Series 1 warrant liabilities are recorded as current liabilities in the accompanying consolidated balance sheet.  During the years ended December 31, 2020 and 2019, the Company recorded losses of $5.2 million and $4.5 million, respectively, due to the change in fair value of the warrant liabilities.  Issuance costs of $1.9 million and $1.0 million initially allocated to the December 2020 Public Offering and December 2019 Public Offering warrant liabilities, respectively, were written off upon settlement and were recognized in the loss on the fair value adjustment for the warrant liabilities for the years ended December 31, 2020 and 2019, respectively.  As of December 31, 2020, the fair value of the warrant liabilities was $51.2 million.

Common Stock Purchase Agreement

On April 10, 2020, the Company entered into the Common Stock Purchase Agreement with Aspire Capital pursuant to which the Company has the right to sell to Aspire Capital from time to time in its sole discretion up to $20.0 million in shares of the Company’s common stock over the next 30 months, subject to certain limitations and conditions set forth in the Common Stock Purchase Agreement.  The aggregate number of shares that we can sell to Aspire Capital under the Common Stock Purchase Agreement may in no case exceed 1,956,547 shares of the Company’s common stock (which is equal to approximately 19.99% of the common stock outstanding on the date of the Common Stock Purchase Agreement), including the 70,910 commitment shares (the Exchange Cap), unless either (a) shareholder approval is obtained to issue more, in which case the Exchange Cap will not apply, or (b) the average purchase price of all shares sold under the Common Stock Purchase Agreement exceeds $8.461; provided that at no time shall Aspire Capital (together with its affiliates) beneficially own more than 19.99% of the Company’s common stock.  During the year ended December 31, 2020, the Company sold 125,000 shares of its common stock under the Common Stock Purchase Agreement for gross proceeds of $0.6 million.

Under the Common Stock Purchase Agreement, on any trading day selected by the Company, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”), directing Aspire Capital (as principal) to purchase up to 25,000 shares of Common Stock per business day, up to $20.0 million of common stock in the aggregate at a per share price (the “Purchase Price”) equal to the lesser of:

 

•

the lowest sale price of Common Stock on the purchase date; or

 

•

the arithmetic average of the three (3) lowest closing sale prices for Common Stock during the ten (10) consecutive trading days ending on the trading day immediately preceding the purchase date.

The Company and Aspire Capital also may mutually agree to increase the number of shares that may be sold to as much as an additional 200,000 shares per business day.

In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital in an amount equal to at least 25,000 shares, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a “VWAP Purchase Notice”) directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of Common Stock traded on its principal market on the next trading day (the “VWAP Purchase Date”), subject to a maximum number of shares the Company may determine.  The purchase price per share pursuant to such VWAP Purchase Notice is generally the lessor of (i) the closing sale price on the VWAP Purchase Date, or (ii) 97% of the volume-weighted average price for common stock traded on its principal market on the VWAP Purchase Date.  

The Purchase Price will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the Purchase Price. The Company may deliver multiple Purchase Notices and VWAP Purchase Notices to Aspire Capital from time to time during the term of the Common Stock Purchase Agreement, so long as the most recent purchase has been completed.

69

 

The Common Stock Purchase Agreement provides that the Company and Aspire Capital shall not effect any sales under the Common Stock Purchase Agreement on any purchase date where the closing sale price of common stock is less than $0.25.  There are no trading volume requirements or restrictions under the Common Stock Purchase Agreement, and the Company will control the timing and amount of sales of common stock to Aspire Capital.  Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as directed by the Company in accordance with the Common Stock Purchase Agreement.  There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the Common Stock Purchase Agreement.  In consideration for entering into the Common Stock Purchase Agreement, concurrently with the execution of the Common Stock Purchase Agreement, the Company issued to Aspire Capital 70,910 shares of common stock (the “Commitment Shares”).  The fair value of the Commitment Shares of $0.6 million was recognized in other expense in the consolidated statements of operations for the year ended December 31, 2020.  The Common Stock Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of common stock during any time prior to the termination of the Common Stock Purchase Agreement. Any proceeds that the Company receives under the Common Stock Purchase Agreement are expected to be used for general corporate purposes, including working capital.

Warrant Associated with Solar Loan Agreement

Pursuant to a loan agreement, the Company issued to Solar a warrant to purchase an aggregate of up to 12,243 shares of the Company’s common stock at an exercise price of $36.754 per share. The warrant will expire five years from the date of the grant. The warrant was classified as equity and recorded at its relative fair value at issuance in the stockholders’ equity section of the balance sheet. 

10.

Income Taxes

The Company’s consolidated financial statements include a total tax benefit of $3.1 million and zero on loss before taxes of $58.3 million and $53.7 million for the years ended December 31, 2020 and 2019, respectively, and was generated entirely in the United States and Australia. Reconciliations of the differences between the benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (dollars in thousands):

 

 

 

2020

 

 

2019

 

 

 

Amount

 

 

Percent of Pretax Income

 

 

Amount

 

 

Percent of Pretax Income

 

Income taxes from continuing operations at statutory rate

 

$

(12,250

)

 

 

21.0

%

 

$

(11,279

)

 

 

21.0

%

State income taxes

 

 

(4,108

)

 

 

7.0

%

 

 

(3,778

)

 

 

7.0

%

State effect of permanent items

 

 

78

 

 

 

(0.1

)%

 

 

285

 

 

 

(0.5

)%

Stock-based compensation

 

 

96

 

 

 

(0.2

)%

 

 

100

 

 

 

(0.2

)%

Deferred rate change

 

 

—

 

 

 

—

 

 

 

(905

)

 

 

1.6

%

Warrants issuance

 

 

131

 

 

 

(0.2

)%

 

 

733

 

 

 

(1.4

)%

Other

 

 

206

 

 

 

(0.3

)%

 

 

883

 

 

 

(1.5

)%

NOL sale

 

 

301

 

 

 

(0.5

)%

 

 

—

 

 

 

—

 

R&D credit adjustment

 

 

2

 

 

 

—

 

 

 

(2,760

)

 

 

5.1

%

Increase in valuation allowance

 

 

12,396

 

 

 

(21.3

)%

 

 

16,721

 

 

 

(31.1

)%

Total income tax benefit

 

$

(3,148

)

 

 

5.4

%

 

$

—

 

 

 

—

%

 

The components of deferred tax assets and liabilities as of December 31, 2020 and 2019 are as follows (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Noncurrent deferred tax assets (liabilities)

 

 

 

 

 

 

 

 

Accrued expenses

 

$

148

 

 

$

107

 

Stock-based compensation

 

 

2,591

 

 

 

2,436

 

Lease liability

 

 

935

 

 

 

945

 

Other

 

 

(823

)

 

 

(856

)

Net operating loss carryforwards

 

 

70,936

 

 

 

58,073

 

Research and development credits

 

 

5,291

 

 

 

5,984

 

     Total deferred tax assets

 

 

79,078

 

 

 

66,689

 

Valuation allowances

 

 

(79,078

)

 

 

(66,689

)

Net deferred tax assets

 

$

—

 

 

$

—

 

70

 

 

 

As of December 31, 2020 and 2019, the Company had available federal net operating loss (“NOL”) carryforwards of approximately $294.4 million and $242.4 million, respectively, and state and net operating loss carryforwards of approximately $202.7 million and $178.2 million, respectively.  Approximately $169.6 million of the federal NOLs can be carried forward to future tax years and expire at various times through 2037. The federal NOLs generated in December 31, 2020 and 2019 of approximately $52.0 million and $47.5 million, respectively, are carried forward indefinitely and do not expire.  The Company’s state and net operating loss carryforwards began to expire in 2019.  As of December 31, 2020, the Company had available federal research and development credit carryforwards of $5.3 million which begin to expire in 2022.

The New Jersey Technology Business Tax Certificate Transfer (NOL) program, administered by the New Jersey Economic Development Authority, enables approved biotechnology companies to sell their unused net operating losses (“NOLs”) and research and development tax credits to unaffiliated, profitable corporate taxpayers in the State of New Jersey up to a maximum lifetime benefit of $20.0 million per business.   As of December 31, 2020, the Company has received approximately $9.9 million under the program.  In April 2020, the Company received a cash receipt of approximately $3.1 million, from the sale of its state NOLs and research and development credits and recognized an income tax benefit of $3.1 million  for the year ended December 31, 2020 in the statement of operations.  

On December 22, 2017, the “Tax Cuts and Jobs Act” was signed into law.  The tax reform has the following effects on the Company: (1) permanently reduces the maximum corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017, (2) allows temporary 100% expensing for certain business assets and property placed in service after September 27, 2018 and before January 1, 2023, (3) disallows NOL carrybacks but allows for the indefinite carryforward of those NOLs which applies to losses arising in tax years beginning after December 31, 2018 and, (4) limits NOL deductions for each year equal to the lesser of the available carryover or 80% of a taxpayer’s pre-NOL deduction taxable income. This applies to losses arising in tax years ending on or after December 31, 2017.  As of December 31, 2020 and 2019, the Company has concluded that it is more likely than not that the Company will not realize the benefit of its deferred tax assets due to its history of losses. Accordingly, the net deferred tax assets have been fully reserved.

 

In accordance with Section 382 of the Internal Revenue Code of 1986, as amended, a change in equity ownership of greater than 50% within a three-year period results in an annual limitation on the Company’s ability to utilize its NOL carryforwards created during the tax periods prior to the change in ownership. The Company has determined that ownership changes have occurred and as a result, a portion of the Company’s NOL carryforwards are limited.  Because the Company has incurred cumulative net operating losses since inception, all tax years remain open to examination by U.S. federal and state income tax authorities.

The Company applies ASC 740-10-25-5, Income Taxes, formerly FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes, as amended, on January 1, 2009. The difference between the tax benefit recognized in the financial statements and the tax benefit claimed in the tax return is referred to as an unrecognized tax benefit.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits as of December 31, 2020 and 2019 (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Unrecognized tax benefit—January 1

 

$

436

 

 

$

436

 

Additions for tax positions of current period

 

 

—

 

 

 

—

 

Additions for tax positions of prior periods

 

 

—

 

 

 

—

 

Deferred rate change

 

 

—

 

 

 

—

 

Unrecognized tax benefit—December 31

 

$

436

 

 

$

436

 

 

None of the unrecognized tax benefits would, if recognized, affect the effective tax rate because the Company has recorded a valuation allowance to fully offset federal and state deferred tax assets. The Company has no tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within the coming year. The Company has $0 provided for interest and penalties associated with uncertain tax positions.

11.

Stock-based Compensation

2009 Stock Option Plan

The Company had a share-based compensation plan (the “2009 Stock Option Plan”) under which the Company granted options to purchase shares of common stock to employees, directors, and consultants as either incentive stock options or nonqualified stock options. Incentive stock options could be granted with exercise prices not less than 100% to 110% of the fair

71

 

market value of the common stock. Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant.

2014 Equity Incentive Plan

In February 2014, the Company’s board of directors adopted the 2014 Equity Incentive Plan (“2014 Plan”), which was subsequently ratified by its stockholders and became effective on May 2, 2014 (the “Effective Date”). The 2014 Plan, as amended on June 18, 2014 and February 25, 2015, is the successor to and continuation of the 2009 Stock Option Plan. As of the Effective Date, no additional awards will be granted under the 2009 Stock Option Plan, but all stock awards granted under the 2009 Stock Option Plan prior to the Effective Date will remain subject to the terms of the 2009 Stock Option Plan. All awards granted on and after the Effective Date will be subject to the terms of the 2014 Plan. The 2014 Plan provides for the grant of the following awards: (i) incentive stock options, (ii) nonstatutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, and (vi) other stock awards. Employees, directors, and consultants are eligible to receive awards.  Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant.

Under the 2014 Plan, after giving effect to the increases to the share reserve approved by the Company’s stockholders in September 2014, and June 2015, but excluding the automatic increases discussed below, the aggregate number of shares of common stock that could be issued from and after the Effective Date (the “share reserve”) could not exceed the sum of (i) 112,273 new shares, (ii) the shares that represented the 2009 Stock Option Plan’s available reserve on the Effective Date, and (iii) any returning shares from the 2009 Stock Option Plan. Under the 2014 Plan, the share reserve will automatically increase on January 1st of each year, for a period of not more than 10 years, commencing on January 1, 2015, and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year. The board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur.

Pursuant to the terms of the 2014 Plan, on January 1, 2020 and 2019, the Company automatically added 389,650 and 191,887 shares to the total number shares of common stock available for future issuance under the 2014 Plan, respectively. As of December 31, 2020, there were 146,488 shares of common stock available for future issuance under the 2014 Plan.

2015 Inducement Plan

On March 26, 2015, the Company's board of directors adopted the 2015 Inducement Plan (“2015 Plan”). The 2015 Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to persons not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to the individuals’ entering into employment with the Company within the meaning of NASDAQ Listing Rule 5635I(4).  The 2015 Plan had an initial share reserve covering 45,000 shares of common stock.  On June 9, 2019, the Company’s board of directors amended the 2015 Plan, and the initial share reserve for the 2015 Plan was increased from 45,000 to 90,000 shares of common stock.  During the year ended December 31, 2020, there were 17,500 granted options of the Company’s common stock under the 2015 Plan. As of December 31, 2020, there were 14,050 shares of common stock available for future issuance under the 2015 Plan.  During the year ended December 31, 2019, there were 11,500 granted options of the Company’s common stock under the 2015 Plan.  As of December 31, 2019, there were 31,550 shares of common stock available for future issuance under the 2015 Plan.

Option Valuation Method

The fair value of a stock option is estimated using an option-pricing model that takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock, and the risk-free interest rate for the expected term of the option. The Company has used the simplified method in calculating the expected term of all option grants based on the vesting period. Compensation costs related to share-based payment transactions are recognized in the financial statements upon satisfaction of the requisite service or vesting requirements and forfeitures are recorded as incurred.

72

 

The Company has elected to use the Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable rather than for use in estimating the fair value of stock options subject to vesting and transferability restrictions. Using the Black-Scholes option-pricing model, the weighted-average fair value of options granted during 2020 and 2019 was $4.83 and $7.50 per option, respectively. The aggregate fair value of options granted during 2020 and 2019 was $1.7 million and $1.3 million, respectively. The assumptions used to estimate fair value and the resulting grant date fair values are as follows:

 

 

 

Employees

 

 

Non-employee Directors

 

 

 

Years Ended December 31,

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Weighted average expected volatility

 

 

64.67

%

 

 

66.47

%

 

 

66.55

%

 

 

65.36

%

Weighted average risk-free interest rate

 

 

1.18

%

 

 

2.47

%

 

 

0.36

%

 

 

2.11

%

Weighted average expected term (in years)

 

 

5.97

 

 

 

6.03

 

 

 

5.50

 

 

 

5.54

 

 

The activity for the 2009 Plan, 2014 Plan and 2015 Plan for the years ended December 31, 2020 is summarized as follows:

 

 

Number

of

Shares

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Life (in years)

 

 

Aggregate

Intrinsic

Value ($000)

 

Outstanding — December 31, 2019

 

 

526,070

 

 

$

30.55

 

 

 

7.62

 

 

$

60

 

Granted

 

 

349,437

 

 

$

8.17

 

 

 

 

 

 

 

 

 

Exercised

 

 

(166

)

 

$

8.60

 

 

 

 

 

 

 

 

 

Forfeited/expired

 

 

(44,998

)

 

$

23.50

 

 

 

 

 

 

 

 

 

Outstanding — December 31, 2020

 

 

830,343

 

 

$

21.52

 

 

 

7.71

 

 

$

96

 

Exercisable — December 31, 2020

 

 

447,802

 

 

$

31.47

 

 

 

6.74

 

 

$

22

 

Vested or expected to vest —December 31, 2020

 

 

830,343

 

 

$

21.52

 

 

 

7.71

 

 

$

96

 

The intrinsic values in the table above represent the total intrinsic value (the difference between the Company’s closing stock price as of December 31, 2020, and the exercise price multiplied by the number of options).

The total fair value of shares vested for both the years ended December 31, 2020 and 2019 was $1.3 million and $1.5 million, respectively.

As of December 31, 2020, there was approximately $2.0 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the plan. That cost is expected to be recognized over a weighted-average period of 2.4 years.

Restricted stock unit ("RSU") activity under the 2014 Plan and 2015 Plan for the years ended December 31, 2020, is summarized as follows:

 

 

Number of

Shares

 

 

Weighted

Average

Grant Date

Fair Value

Per Share

 

Non-vested at December 31, 2019

 

 

96,637

 

 

$

14.18

 

Granted

 

 

28,695

 

 

$

8.18

 

Vested

 

 

(78,859

)

 

$

14.05

 

Forfeited

 

 

(17,386

)

 

$

12.68

 

Non-vested at December 31, 2020

 

 

29,087

 

 

$

9.52

 

 

The fair value of RSUs is based on the market price of the Company's common stock on the date of grant.  RSUs generally vest 25% annually over a four year period from the date of grant. Upon vesting, the RSUs are net share settled to cover the required withholding tax with the remaining shares issued to the holder.  The Company recognizes compensation expense for such awards ratably over the corresponding vesting period.  As of December 31, 2020, there was approximately $0.2 million of total unrecognized compensation cost related to unvested RSU share-based compensation.  That cost is expected to be recognized over a weighted-average period of 2.8 years.

73

 

2014 Employee Stock Purchase Plan

In February 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (“2014 ESPP”), which was subsequently ratified by the Company’s stockholders and became effective on May 2, 2014. The purpose of the 2014 ESPP is to provide means by which eligible employees of the Company and of certain designated related corporations may be given an opportunity to purchase shares of the Company’s common stock, and to seek and retain services of new and existing employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. Common stock that may be issued under the 2014 ESPP will not exceed 4,779 shares, plus the number of shares of common stock that are automatically added on January 1st of each year for a period of ten years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 2,941 shares of common stock. Similar to the 2014 Plan, the board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. The 2014 ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code.

During the years ended December 31, 2020 and 2019, the Company issued 4,497 and 3,684 shares of common stock under the 2014 ESPP, respectively. During the years ended December 31, 2020 and 2019, the number of shares of common stock available for issuance under the ESPP was automatically increased by 2,941 shares.  As of December 31, 2020, there were 5,895 shares of common stock available for future issuance under the 2014 ESPP.

Compensation Cost

The compensation cost that has been charged against income for stock awards under the 2009 Stock Option Plan, the 2014 Plan, the 2015 Plan, and the 2014 ESPP was $2.2 million and $1.8 million for the years ended December 31, 2020 and 2019, respectively. The total income tax benefit recognized in the consolidated statements of operations for share-based compensation arrangements was $0 for the years ended December 31, 2020 and 2019, respectively. Cash received from options exercised was $2,000 and $12,000 for the years ended December 31, 2020 and 2019, respectively.

 

Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

Research and development

 

$

806

 

 

$

604

 

Selling, general and administrative

 

 

1,414

 

 

 

1,224

 

Total stock-based compensation expense

 

$

2,220

 

 

$

1,828

 

 

12.

Fair Value Measurements

The carrying amounts of certain financial instruments, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments.

74

 

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period, pursuant to the policy described in Note 2. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of December 31, 2020 and 2019 for financial instruments measured at fair value on a recurring basis (in thousands):

 

 

 

 

 

 

 

Fair Value Hierarchy Classification

 

 

 

Balance

 

 

Quoted Prices in Active

Markets for Identical Assets (Level 1)

 

 

Significant Other

Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

117

 

 

$

117

 

 

 

—

 

 

 

—

 

Restricted cash

 

 

273

 

 

 

273

 

 

 

—

 

 

 

—

 

Money market funds

 

 

92,924

 

 

 

92,924

 

 

 

—

 

 

 

—

 

Total assets

 

$

93,314

 

 

$

93,314

 

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liabilities

 

$

51,156

 

 

 

—

 

 

 

—

 

 

$

51,156

 

Derivative liabilities

 

 

5,954

 

 

 

—

 

 

 

—

 

 

 

5,954

 

Total liabilities

 

$

57,110

 

 

 

—

 

 

 

—

 

 

$

57,110

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

23

 

 

$

23

 

 

 

—

 

 

 

—

 

Restricted cash

 

 

273

 

 

 

273

 

 

 

—

 

 

 

—

 

Money market funds

 

 

41,897

 

 

 

41,897

 

 

 

—

 

 

 

—

 

Total assets

 

$

42,193

 

 

$

42,193

 

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liabilities

 

$

18,396

 

 

 

—

 

 

 

—

 

 

$

18,396

 

Derivative liability

 

 

3,192

 

 

 

 

 

 

 

 

 

 

 

3,192

 

Total liabilities

 

$

21,588

 

 

 

—

 

 

 

—

 

 

$

21,588

 

 

The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets.

 

Level 3 financial liabilities consist of the warrant liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as volatility.  The unobservable input for all of the Level 3 warrant liabilities includes volatility.  The historical volatility of the Company, using its closing common stock prices, is utilized to reflect future volatility over the expected term of the warrants.  At December 31, 2020, the range and weighted average of the Level 3 volatilities utilized in the Black-Scholes model to fair value the warrant liabilities were 71.8% to 86.6% and 78.0%, respectively.  Additionally, the expected term associated with the December 2019 Public Offering warrants is an unobservable input given that the expiration of the warrants is the earlier of (i) such date that is six months after the Company publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023.  The Company utilized a probability assessment to estimate the likelihood of occurrence for the two potential expiration dates and allocated the probability of occurrence percentage to the fair values calculated based on the two potential expected terms.  The weighted average expected term is 1.2 years as of December 31, 2020 for the December 2019 Public Offering warrants with a range of 0.9 to 2.5 years.   

 

The Company uses the binomial lattice valuation model to value the Level 3 derivative liabilities at inception and on subsequent valuation dates.  This model incorporates transaction details such as the Company’s stock price, contractual terms, dividend yield, risk-free rate, historical volatility, credit rating, market credit spread, and estimated effective yield.  The unobservable inputs associated with the Level 3 derivative liabilities are adjusted equity volatility, market credit spread, and estimated yield.  As of December 31, 2020, these inputs were 58.1%, 1,458 basis points, and 14.9%, respectively.  The range of volatilities were 56.5% to 60.1%.  The senior convertible notes are initially fair valued using the binomial lattice model and

75

 

with the straight debt fair value calculated using the discounted cash flow method.  The discount for lack of marketability, 7.0% as of December 31, 2020, is applied to the value of the March 2019 Notes.  The residual difference represents the fair value of the embedded derivative liabilities and the fair value of the embedded derivative liabilities are reassessed using the binomial lattice valuation model on a quarterly basis.  

 

A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):

 

 

 

 

Warrant Liabilities

 

Balance – January 1, 2020

 

 

$

18,396

 

December 2020 Public Offering

 

 

 

29,478

 

Loss adjustment to fair value

 

 

 

3,282

 

Balance – December 31, 2020

 

 

$

51,156

 

 

 

 

 

 

 

 

 

 

Derivative Liabilities

 

Balance – January 1, 2020

 

 

$

3,192

 

Bifurcated embedded conversion option associated with April 2020 Notes

 

 

 

8,110

 

Adjustment for partial conversion of April 2020 Notes

 

 

 

(2,690

)

Gain adjustment to fair value

 

 

 

(2,658

)

Balance – December 31, 2020

 

 

$

5,954

 

 

13.

Employee Benefit Plan

 

The Company has a 401(k) retirement plan, which covers all U.S. employees scheduled for and working more than 20 hours per week. The Company may provide a discretionary match with a maximum amount of 50% of the first 6% of eligible participant’s compensation, which vests ratably over four years. Contributions under the plan were approximately $0.1 million for the years ended December 31, 2020 and 2019.

14.

Subsequent Events

Pursuant to the terms of the 2014 Plan (see Note 11), on January 1, 2021, the Company automatically added 786,547 shares to the total number shares of common stock available for future issuance under the 2014 Plan.  Pursuant to the terms of the 2014 ESPP (see Note 11), on January 1, 2021, the Company automatically added 2,941 shares to the total number shares of common stock available for future issuance under the 2014 ESPP.  

 

In January 2021, Puissance converted the remaining $6.0 million of the April 2020 Notes for 959,080 shares of common stock.

 

In February 2021, the Company partnered with Amplity Inc. (“Amplity”) for the potential upcoming commercial launch of ibrexafungerp for the treatment of VVC.  Under the terms of the 5-year agreement, the Company will utilize the Amplity’s commercial execution expertise and resources for sales force, remote engagement, training, market access and select operations services.  The Company will maintain full ownership of ibrexafungerp and control of all strategic aspects of the launch. Amplity is deferring a portion of its direct service costs in the first two years (2021 and 2022), which the Company will repay over three years starting in 2023.  Amplity has the potential to earn a performance-based success fee in the 2023-2025 time frame by exceeding certain revenue targets.

 

On February 11, 2021, the Company entered into an Exclusive License and Collaboration Agreement with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, “Hansoh”), pursuant to which Hansoh obtains an exclusive license from the Company to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the agreement, Hansoh shall be responsible for the development, regulatory approval and commercialization of ibrexafungerp in Greater China. The Company received a $10 million upfront payment and will also be eligible to receive up to $112 million in development and commercial milestones, plus low double-digit royalties on net product sales. The obligation to pay royalties with respect to sales in a specified region will continue until the later of the date of expiration of all intellectual property and regulatory exclusivity for the product in the region and ten years from the first commercial sale, unless earlier terminated by Hansoh with advanced notice for convenience or under other specified circumstances.

 

76

 

 

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A.

CONTROLS AND PROCEDURES

Management’s Evaluation of our Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

As of December 31, 2020, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of December 31, 2020, our disclosure controls and procedures were effective at the reasonable assurance level.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control over financial reporting is designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements. A control system, no matter how well designed and operated, can only provide reasonable, not absolute, assurance that the objectives of the control system are met. Because of these inherent limitations, management does not expect that our internal controls over financial reporting will prevent all error and all fraud. Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework (2013 Framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Control—Integrated Framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2020.

Changes in Internal Control Over Financial Reporting

During the quarter ended December 31, 2020, there have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Securities Exchange Act of 1934, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B.

OTHER INFORMATION

None.

 

77

 

 

PART III

 

ITEM 10.

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this Item 10 is incorporated herein by reference from our Proxy Statement, which will be filed with the SEC within 120 days after the end of our 2020 fiscal year pursuant to Regulation 14A for our 2021 Annual Meeting of Stockholders (the “Proxy Statement”), under the captions “Executive Officers of the Company,” “Proposal 1 − Election of Directors,” “Information Regarding the Board and Its Committees,” “Nominating and Corporate Governance Committee,” “Delinquent Section Reports,” (if required) and “Code of Business Conduct and Ethics.”

A printed copy of the Proxy Statement will be sent, without charge, to any shareholder who requests it by writing to the Chief Financial Officer of SCYNEXIS, Inc., 1 Evertrust Plaza, 13th Floor, Jersey City, NJ  07302 - 6548.

ITEM 11.

EXECUTIVE COMPENSATION

The information required by this Item 11 is incorporated herein by reference from the Proxy Statement under the captions “Executive Compensation” and “Director Compensation.”

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this Item 12 is incorporated herein by reference from the Proxy Statement, under the captions “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information.”

ITEM 13.

The information required by this Item 13 is incorporated herein by reference from the Proxy Statement, under the captions “Transactions with Related Persons” and “Independence of the Board.”

ITEM 14.

PRINCIPAL ACCOUNTING FEES AND SERVICES

The information required by this Item 14 is incorporated herein by reference from the Proxy Statement, under the caption “Principal Accountant Fees and Services.”


78

 

 

PART IV

ITEM 15.

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Documents filed as part of this report:

 

1.

List of Financial Statements

The financial statements required by this item are listed in Item 8, “Consolidated Financial Statements and Supplementary Data” and incorporated by reference herein.

 

2.

List of Financial Statement Schedules

All schedules are omitted because they are not applicable, not required or the required information is shown in the consolidated financial statements or notes thereto.

 

3.

Exhibits

EXHIBIT INDEX

 

Exhibit

Number

 

Description of Document

 

 

3.1

 

Amended and Restated Certificate of Incorporation. (Filed with the SEC as Exhibit 3.1 to our Current Report on Form 8-K, filed with the SEC on May 12, 2014, SEC File No. 001-36365, and incorporated by reference here).

 

 

3.2

 

Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, In. (Filed with the SEC as Exhibit 3.2 to our Form 10-Q, filed with the SEC on August 7, 2019, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

3.3

 

Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, Inc. (Filed with the SEC as Exhibit 3.1 to our Form 8-K, filed with the SEC on July 16, 2020, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

3.4

 

Amended and Restated Bylaws, as amended and as currently in effect. (Filed with the SEC as Exhibit 3.4 to our Registration Statement on Form S-1, filed with the SEC on February 27, 2014, SEC File No. 333-194192, and incorporated by reference here).

 

 

4.1

 

Reference is made to Exhibits 3.1 through 3.4

 

 

 

4.2**

  

Description of Common Stock.

 

 

 

4.3

 

Registration Rights Agreement, dated April 10, 2020, between SCYNEXIS, Inc. and Aspire Capital Fund, LLC (Filed with the SEC as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on April 13, 2020, SEC File No. 001-36365, and incorporated by reference here).

 

 

10.1

 

Form of Indemnity Agreement between the Registrant and its directors and officers. (Filed with the SEC as Exhibit 10.1 to our Amendment No. 1 to Registration Statement on Form S-1, filed with the SEC on March 19, 2014, SEC File No. 333-194192, and incorporated by reference here).

 

 

10.2*

 

SCYNEXIS, Inc. Stock Option Plan, as amended and restated. (Filed with the SEC as Exhibit 10.1 to our Quarterly Report on Form 10-Q, filed with the SEC on August 10, 2020, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

10.3*

 

Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Stock Option Exercise under the SCYNEXIS, Inc. Stock Option Plan, as amended and restated. (Filed with the SEC as Annex B to our Proxy Statement on Schedule 14A, filed with the SEC on August 1, 2014, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

10.4*

 

SCYNEXIS, Inc. 2009 Stock Option Plan, as amended and restated. (Filed with the SEC as Exhibit 10.2 to our Quarterly Report on Form 10-Q, filed with the SEC on August 10, 2020, SEC File No. 333-194192, and incorporated by reference here).

 

 

 

10.5*

 

Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Stock Option Exercise under the SCYNEXIS, Inc. 2009 Stock Option Plan, as amended and restated. (Filed with the SEC as Exhibit 10.3 to our Amendment No. 1 to Registration Statement on Form S-1, filed with the SEC on March 19, 2014, SEC File No. 333-194192, and incorporated by reference here).

 

 

10.6*

 

SCYNEXIS, Inc. 2014 Equity Incentive Plan, as amended and restated, (Filed with the SEC as Exhibit 10.3 to our Quarterly Report on Form 10-Q, filed with the SEC on August 10, 2020, SEC File No. 001-36365, and incorporated by reference here).

79

 

 

 

10.7*

 

SCYNEXIS, Inc. 2014 Employee Stock Purchase Plan, as amended and restated. (Filed with the SEC as Exhibit 10.4 to our Quarterly Report on Form 10-Q, filed with the SEC on August 10, 2020, SEC File No. 333-196007, and incorporated by reference here).

 

 

 

10.8*

 

Form of Stock Option Agreement and Form of Stock Option Grant Notice under the SCYNEXIS, Inc. 2014 Equity Incentive Plan (Filed with the SEC as Exhibit 99.3 to our Registration Statement on Form S-8, filed with the SEC on May 16, 2014, SEC File No. 333-196007, and incorporated by reference here).

 

 

 

10.9#

 

Development, License and Supply Agreement, dated August 1, 2013, between SCYNEXIS, Inc. and R-Pharm, CJSC. (Filed with the SEC as Exhibit 10.10 to our Amendment No. 1 to Registration Statement on Form S-1, filed with the SEC on March 19, 2014, SEC File No. 333-194192, and incorporated by reference here).

 

 

 

10.10#

 

Termination and License Agreement, dated May 24, 2013, between SCYNEXIS. Inc. and Merck Sharp & Dohme Corp. (Filed with the SEC as Exhibit 10.12 to our Amendment No. 1 to Registration Statement on Form S-1, filed with the SEC on March 19, 2014, SEC File No. 333-194192, and incorporated by reference here).

 

 

 

10.11*

 

SCYNEXIS, Inc. Amended and Restated 2015 Inducement Award Plan, as amended and restated. (Filed with the SEC as Exhibit 10.5 to our Quarterly Report on Form 10-Q, filed with the SEC on August 10, 2020, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

10.12*

 

Form of Stock Option Grant Notice and Stock Option Agreement under the SCYNEXIS, Inc. 2015 Inducement Award Plan. (Filed with the SEC as Exhibit 10.34 to our Registration Statement on Form S-1, filed with the SEC on April 9, 2015, SEC File No. 333-203314, and incorporated by reference here).

 

 

 

10.13*

 

Employment Agreement, effective November 1, 2015, between SCYNEXIS, Inc. and Eric Francois. (Filed with the SEC as Exhibit 99.1 to our current report on Form 8-K, filed with the SEC on November 2, 2015, SEC File No. 001-36365, and incorporated by reference here, and incorporated by reference here).

 

 

 

10.14*

 

Employment Agreement, effective June 1, 2015, between SCYNEXIS, Inc. and David Angulo (Filed with the SEC as Exhibit 10.24 to our Annual Report on Form 10-K, filed with the SEC on March 7, 2016, SEC file No. 001-36365, and incorporated by reference here).

 

 

 

10.15*

 

Employment Agreement, dated February 5, 2015, between SCYNEXIS, Inc. and Dr. Marco Taglietti. (Filed with the SEC as Exhibit 10.27 to our Annual Report on Form 10-K, filed with the SEC on March 30, 2015, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

10.16

 

Patent Assignment, dated January 28, 2014, between SCYNEXIS, Inc. and Merck Sharpe & Dohme Corp. (Filed with the SEC as Exhibit 10.28 to our Registration Statement on Form S-1, filed with the SEC on February 27, 2014, SEC File No. 333-194192, and incorporated by reference here).

 

 

 

10.17#

 

Exclusive License Agreement, dated October 29, 2014, between SCYNEXIS, Inc. and Waterstone Pharmaceutical (HK Limited). (Filed with the SEC as Exhibit 10.32 to our Annual Report on Form 10-K, filed with the SEC on March 30 2015, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

10.18#

 

Amendment to Termination and License Agreement, dated December 11, 2014, between SCYNEXIS, Inc. and Merck Sharp & Dohme Corp. (Filed with the SEC as Exhibit 10.33 to our Annual Report on Form 10-K, filed with the SEC on March 30, 2015, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

10.19#

 

Second Amendment to License Agreement between SCYNEXIS, Inc. and Merck Sharp & Dohme Corp. dated December 21, 2016 (Filed with the SEC as Exhibit 10.30 to our Annual Report on Form 10-K, filed with the SEC on March 13, 2019, SEC file No. 001-36365, and incorporated by reference here).

 

 

 

10.20*

 

Amendment of Employment Agreement, effective April 18, 2016, between SCYNEXIS, Inc. and Marco Taglietti. (Filed with the SEC as Exhibit 10.2 to our Quarterly Report on Form 10-Q, filed with the SEC on May 9, 2016, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

10.21*

 

Amendment of Employment Agreement, effective April 18, 2016, between SCYNEXIS, Inc. and David Angulo. (Filed with the SEC as Exhibit 10.3 to our Quarterly Report on Form 10-Q, filed with the SEC on May 9, 2016, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

10.22

 

Amendment to the Development, License and Supply Agreement, dated August 1st, 2013, between SCYNEXIS, Inc. and R-Pharm, CJSC (Filed with the SEC as Exhibit 10.1 to our Quarterly Report on Form 10-Q, filed with the SEC on November 11, 2019, SEC file No. 001-36365, and incorporated by reference here).

 

 

 

10.23

 

Additional Agreement No. 2 to the Development, License and Supply Agreement, dated August 1st, 2013, between SCYNEXIS, Inc. and R-Pharm, CJSC (Filed with the SEC as Exhibit 10.2 to our Quarterly Report on Form 10-Q, filed with the SEC on November 11, 2019, SEC file No. 001-36365, and incorporated by reference here).

80

 

 

 

 

10.24

 

Additional Agreement No. 3 to the Development, License and Supply Agreement, dated August 1st, 2013, between SCYNEXIS, Inc. and R-Pharm, CJSC (Filed with the SEC as Exhibit 10.3 to our Quarterly Report on Form 10-Q, filed with the SEC on November 11, 2019, SEC file No. 001-36365, and incorporated by reference here).

 

 

 

10.25

 

Third Amendment to Termination and License Agreement between SCYNEXIS, Inc. and Merck Sharp & Dohme Corp. dated January 5, 2018 (Filed with the SEC as Exhibit 10.1 to our Quarterly Report on Form 10-Q, filed with the SEC on May 8, 2019, SEC file No. 001-36365, and incorporated by reference here).

 

 

 

10.26*

 

Non-Employee Director Compensation Arrangements (Filed with the SEC as Exhibit 10.24 to our Annual Report on Form 10-K/A, filed with the SEC on April 28, 2020, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

10.27

 

Senior Convertible Note Purchase Agreement, dated as of March 7, 2019, among SCYNEXIS, Inc., as Issuer, Puissance Capital Management, as the Investor (Filed with the SEC as Exhibit 10.1 to our current report on Form 8-K filed with the SEC on March 8, 2019, SEC File No 001-36365 and incorporated by reference here).

 

 

 

10.28

 

Common Stock Purchase Agreement, dated April 10, 2020, between SCYNEXIS, Inc. and Aspire Capital Fund, LLC (Filed with the SEC as Exhibit 10.1 to our Form 8-K, filed with the SEC on April 13, 2020, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

10.29

 

Senior Convertible Note Purchase Agreement, dated as of April 9, 2020, among SCYNEXIS, Inc., as Issuer, Puissance Life Science Opportunities Fund IV, as the Investor, (including the form of Note attached thereto as Exhibit A).  (Filed with the SEC as Exhibit 10.1 to our Form 8-K, filed with the SEC on April 9, 2020, SEC File No. 001-36365, and incorporated by reference here).

 

 

 

10.30

 

Fourth Amendment to Termination and License Agreement between SCYNEXIS, Inc. and Merck Sharp & Dohme Corp. dated December 2, 2020.

 

 

 

23.1**

 

Consent of Independent Registered Public Accounting Firm.

 

 

 

24.1

 

Power of Attorney (see Signature page).

 

 

 

31.1**

 

Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a)

 

 

 

31.2**

 

Certification of Chief Financial Officer pursuant to Rule 13(a)-14(a)/15d-14(a)

 

 

32.1***

 

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

101.INS

 

XBRL Instance Document

 

 

101.SCH

 

XBRL Taxonomy Schema Linkbase Document

 

 

101.CAL

 

XBRL Taxonomy Calculation Linkbase Document

 

 

101.DEF

 

XBRL Taxonomy Definition Linkbase Document

 

 

101.LAB

 

XBRL Taxonomy Labels Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Presentation Linkbase Document

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

# Portions of this exhibit have been omitted pursuant to a request for confidential treatment, which portions were omitted and filed separately with the Securities and Exchange Commission.

* Designates management contract or compensatory plan or arrangement.

** Filed herewith.

*** Furnished herewith.

 

ITEM 16.

FORM 10-K SUMMARY

None.

81

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

SCYNEXIS, INC.

 

 

By:

 

/s/ Marco Taglietti, M.D.

 

 

Marco Taglietti, M.D.

 

 

Chief Executive Officer

(Principal Executive Officer)

 

 

Date:

 

March 25, 2021

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Marco Taglietti and Eric Francois, as his true and lawful attorney-in-fact and agent, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, and any of them or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.  

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/ Marco Taglietti, M.D.

 

Chief Executive Officer

 

March 25, 2021

Marco Taglietti, M.D.

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/s/ Eric Francois

 

Chief Financial Officer

 

March 26, 2021

Eric Francois

 

(Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

/s/ Guy Macdonald

 

Director

 

March 24, 2021

Guy Macdonald

 

 

 

 

 

 

 

 

 

/s/ David Hastings

 

Director

 

March 25, 2021

David Hastings

 

 

 

 

 

 

 

 

 

/s/ Steven C. Gilman, Ph.D.

 

Director

 

March 24, 2021

Steven C. Gilman, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Ann F. Hanham, Ph.D.

 

Director

 

March 24, 2021

Ann F. Hanham, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Armando Anido

 

Director

 

March 24, 2021

Armando Anido

 

 

 

 

 

 

 

 

 

/s/ Brian Philippe Tinmouth

 

Director

 

March 24, 2021

Brian Philippe Tinmouth

 

 

 

 

 

 

82

 EX-4.2 2 scyx-ex42_139.htm EX-4.2 scyx-ex42_139.htm

Exhibit 4.2

 

 

SCYNEXIS, INC.

DESCRIPTION OF COMMON STOCK

SCYNEXIS, Inc. (“we,” “our,” “us,” or the “Company,”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock.

The following description of our common stock does not purport to be complete and is subject in all respects to applicable Delaware law and to the provisions of our amended and restated certificate of incorporation, and our amended and restated bylaws.

 General

Our amended and restated certificate of incorporation provides for common stock and authorized shares of undesignated preferred stock, the rights, preferences and privileges of which may be designated from time to time by our board of directors. Our authorized capital stock consists of 105,000,000 shares, all with a par value of $0.001 per share, of which 100,000,000 shares are designated as common stock and 5,000,000 shares are designated as preferred stock.

 Common Stock

Voting Rights. Each holder of our common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders, except as otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law. Cumulative voting for the election of directors is not provided for in our amended and restated certificate of incorporation, which means that the holders of a majority of our shares of common stock can elect all of the directors then standing for election.

Dividends and Distributions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its sole discretion, determines to issue dividends and only then at the times and in the amounts that our board of directors may determine.

Liquidation Rights. Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time after payment of liquidation preferences, if any, on any outstanding shares of preferred stock and payment of other claims of creditors. The rights, preferences, and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any series of preferred stock that we may designate and issue in the future.

Preemptive or Similar Rights. Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions.

Anti-Takeover Provisions

Certificate of Incorporation and Bylaws

Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the voting power of our shares of common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation and amended and restated bylaws provide that all stockholder actions must be effected at a duly called meeting of stockholders and not by consent in writing. A special meeting of stockholders may be called only by a majority of our whole board of directors, the chair of our board of directors, or our chief executive officer.

Our amended and restated certificate of incorporation further provides that the affirmative vote of holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of voting stock, voting as a single class, are required to amend certain provisions of our certificate of incorporation, including provisions relating to the size of the board, removal of directors, special meetings, actions by written consent and cumulative voting. The affirmative vote of holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting

 

 

power of all of the then outstanding shares of voting stock, voting as a single class, is required to amend or repeal our bylaws, although our bylaws may be amended by a simple majority vote of our board of directors.

The foregoing provisions will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of our company by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change the control of our company.

These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of our company. These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy rights. However, these provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in control of our company or our management. As a consequence, these provisions also may inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.

 

Section 203 of the Delaware General Corporation Law

We are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:

 

 

•

 

before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;

 

 

•

 

upon closing of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned by (1) persons who are directors and also officers and (2) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

 

 

•

 

on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.

In general, Section 203 defines business combination to include the following:

 

 

•

 

any merger or consolidation involving the corporation and the interested stockholder;

 

 

•

 

any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;

 

 

•

 

subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

 

 

•

 

any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or

 

 

•

 

the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.

In general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.

 

 

 EX-10.30 3 scyx-ex1030_12.htm EX-10.30 scyx-ex1030_12.htm

 

Exhibit 10.30

 

 

FOURTH AMENDMENT TO TERMINATION AND LICENSE AGREEMENT

 

 

THIS FOURTH AMENDMENT TO TERMINATION AND LICENSE AGREEMENT (the “Fourth Amendment”) is made and entered into as of December 2, 2020 by and between Merck Sharp & Dohme Corp., a New Jersey corporation with a place of business at One Merck Drive, Whitehouse Station, NJ 08889 (“Merck”) and SCYNEXIS, Inc., a Delaware corporation with a principal place of business at 1 Evertrust Plaza, 13th Floor, Jersey City, NJ 07302 (“Scynexis”).

 

RECITALS

 

WHEREAS, Scynexis and Merck are parties to a Termination and License Agreement dated as of May 24, 2013 (the “Original Agreement”), as amended by a letter agreement dated as of December 3, 2014 (the “First Amendment”), a Second Amendment to Termination and License Agreement dated as of December 21, 2016 (the “Second Amendment”) and a Third Amendment to Termination and License Agreement (the “Third Amendment”; the Original Agreement as amended by the First Amendment, the Second Amendment and the Third Amendment are collectively referred to herein as the “Agreement”); and

 

WHEREAS, the Parties desire to enter into this Fourth Amendment to amend the provisions of Article 5 concerning payment and creditability of certain milestone payments under the Agreement.

 

NOW, THEREFORE, Merck and Scynexis hereby agree as follows:

 

1.Definitions.  Unless otherwise defined herein, capitalized terms used in this Third Amendment have the meanings assigned thereto in the Agreement.

 

2.Milestone Payments and Creditability.

 

 

a.

Section 5.1 of the Agreement is amended to delete the milestone payments set forth in Sections 5.1(c) and 5.1(d).  The amounts that Scynexis would have paid to Merck as milestones will instead be paid as royalties, pursuant to the following paragraph.

 

 

b.

Section 5.1 of the Agreement is further amended as follows:

 

 

i.

The sentence:

 

“The foregoing milestone payments will be non-refundable, but will be creditable against future royalties payable.”

 

1

 

 

is deleted and replaced with the sentences:

 

“The foregoing milestone payments will be non-refundable, provided that certain milestones as set forth in this paragraph will be creditable against future royalties payable, but only to the extent set out below.  

 

 

(a)

Milestone payments set forth in Sections 5.1 (e) and (f), if and when paid, will be creditable against future royalties payable.

 

(b)

Milestone payments set forth in Sections 5.1(a) and 5.1(b) (which have been previously paid) shall not be credited against future royalties, and any prior credit will be forfeited and of no effect.  

 

(c)

As the milestone payments set forth in Sections 5.1(c) and 5.1(d) have been deleted, such milestones will accrue no credit against royalties.”

 

3.Notices.  Section 9.4 of the Agreement is amended to replace the notice address for Scynexis as follows:

 

If to Scynexis, to:SCYNEXIS, Inc.

1 Evertrust Plaza, 13th Floor

Jersey City, NJ 07302

Attn.: President and CEO

Fax: 201-884-5490

 

4.No Other Amendments.  Except as amended hereby, the Agreement shall remain in full force and effect.  Any references to the Agreement after the date of this Fourth Amendment shall be deemed to refer to the Agreement as amended by this Fourth Amendment.

 

5.Counterparts.  This Fourth Amendment may be signed in any number of counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.  Signatures to this Fourth Amendment may be provided by facsimile transmission or PDF file, which shall be deemed to be original signatures.

 

IN WITNESS WHEREOF, the Parties have executed this Fourth Amendment as of the date first above written.

 

MERCK SHARP & DOHME CORP.SCYNEXIS, INC.

 

 

 

By:/s/ Benjamin ThornerBy:/s/ Marco Taglietti

Name: Benjamin ThornerMarco Taglietti

Title: SVP & Head of BD&L, MRL President and CEO

2

 

 EX-23.1 4 scyx-ex231_7.htm EX-23.1 scyx-ex231_7.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm 

 

We consent to the incorporation by reference in Registration Statement Nos. 333-227167, 333-230449, 333-237952, 333-248751 and 333-251851 on Form S-3 and Registration Statement Nos. 333-196007, 333-201048, 333-202830, 333-204771, 333-204770, 333-209997, 333-216652, 333-223624, 333-230278, 333-233084, and 333-237077 on Form S-8 of our report dated March 29, 2021, relating to the financial statements of SCYNEXIS, Inc. appearing in this Annual Report on Form 10-K of SCYNEXIS, Inc., for the year ended December 31, 2020.

 

/s/ DELOITTE & TOUCHE LLP

 

Parsippany, New Jersey

March 29, 2021

 

 EX-31.1 5 scyx-ex311_8.htm EX-31.1 scyx-ex311_8.htm

Exhibit 31.1

CERTIFICATIONS

I, Marco Taglietti, certify that:

 

1.

I have reviewed this Form 10-K of SCYNEXIS, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

 a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

 b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 Date: March 25, 2021

/s/ Marco Taglietti, M.D.

Marco Taglietti, M.D.

Chief Executive Officer

Principal Executive Officer

 

 EX-31.2 6 scyx-ex312_6.htm EX-31.2 scyx-ex312_6.htm

Exhibit 31.2

CERTIFICATIONS

I, Eric Francois, certify that:

 

1.

I have reviewed this Form 10-K of SCYNEXIS, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

 d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

 b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: March 24, 2021

 

/s/ Eric Francois

Eric Francois

Chief Financial Officer

Principal Financial Officer

 

 

 

 EX-32.1 7 scyx-ex321_9.htm EX-32.1 scyx-ex321_9.htm

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Marco Taglietti, Chief Executive Officer of SCYNEXIS, Inc. (the “Company”), and Eric Francois, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

 

1.

The Company’s Annual Report on Form 10-K for the period ended December 31, 2020, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and

 

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In Witness Whereof, the undersigned have set their hands hereto as of March 26, 2021.

 

 

 

 

 

 

/s/ Marco Taglietti, M.D.

 

 

 

/s/ Eric Francois

Marco Taglietti, M.D.

Chief Executive Officer

Principal Executive Officer

 

 

 

Eric Francois

Chief Financial Officer

Principal Financial Officer

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of SCYNEXIS, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

 GRAPHIC 8 gssdxyiyyh5p000001.jpg GRAPHIC begin 644 gssdxyiyyh5p000001.jpg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end EX-101.SCH 9 scyx-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Description of Business and Basis of Preparation link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Short-term Investments link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Prepaid Expenses and Other Current Assets link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Property and Equipment link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Borrowings link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Stock-based Compensation link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Employee Benefit Plan link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Short-term Investments (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Property and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Stock-based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Description of Business and Basis of Preparation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Short-term Investments (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Short-term Investments - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Prepaid Expenses and Other Current Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Borrowings - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Condensed Consolidated Financial Statements for Lease (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Commitments and Contingencies - Presentation of Operating Lease Liability and Right-of-Use Asset (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Stock-based Compensation - 2009 Stock Option Plan (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Stock-based Compensation - 2014 Equity Incentive Plan (Details) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Stock-based Compensation - 2015 Inducement Plan (Details) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Stock-based Compensation - Option Valuation Method - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Stock-based Compensation - Option Valuation Method (Details) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Stock-based Compensation - Stock Option Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Stock-based Compensation - Stock Option Activity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units ("RSU") Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Stock-based Compensation - 2014 Employee Stock Purchase Plan (Details) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Stock-based Compensation - Compensation Cost (Details) link:calculationLink link:presentationLink link:definitionLink 100600 - Disclosure - Stock-based Compensation - Expense Related to Stock Options (Detail) link:calculationLink link:presentationLink link:definitionLink 100610 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100620 - Disclosure - Fair Value Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100630 - Disclosure - Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100640 - Disclosure - Employee Benefit Plan - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100650 - Disclosure - Subsequent Events - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 10 scyx-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 scyx-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 scyx-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Entity Registrant Name Entity Registrant Name Trading Symbol Trading Symbol Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Entity Emerging Growth Company Entity Emerging Growth Company Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status ICFR Auditor Attestation Flag Icfr Auditor Attestation Flag Entity Public Float Entity Public Float Entity Interactive Data Current Entity Interactive Data Current Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Document Transition Report Document Transition Report Title of Each Class Security12b Title Name of Each Exchange on Which Registered Security Exchange Name Document Annual Report Document Annual Report Warrant liability current. Convertible debt and derivative liability. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Held To Maturity Securities Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Other assets Other Assets Noncurrent Deferred offering costs Deferred Costs Restricted cash Restricted Cash Noncurrent Property and equipment, net Property Plant And Equipment Net Operating lease right-of-use asset (Note 8) Operating Lease Right Of Use Asset Total assets Assets Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Warrant liabilities Warrant Liabilities Current Operating lease liability, current portion (Note 8) Operating Lease Liability Current Total current liabilities Liabilities Current Warrant liabilities Warrants And Rights Outstanding Convertible debt and derivative liabilities (Note 7) Convertible Debt And Derivative Liability Operating lease liability (Note 8) Operating Lease Liability Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.001 par value, authorized 5,000,000 shares as of December 31, 2020 and December 31, 2019; 0 shares issued and outstanding as of December 31, 2020 and December 31, 2019 Preferred Stock Value Outstanding Common stock, $0.001 par value, 100,000,000 shares authorized as of December 31, 2020, and December 31, 2019; 19,663,698 and 9,741,372 shares issued and outstanding as of December 31, 2020, and December 31, 2019, respectively Common Stock Value Outstanding Additional paid-in capital Additional Paid In Capital Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value (in dollars per share) Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock Shares Outstanding Common stock, par value (in dollars per share) Common Stock Par Or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock Shares Authorized Common stock, shares issued (in shares) Common Stock Shares Issued Common stock, shares outstanding (in shares) Common Stock Shares Outstanding Income Statement [Abstract] Revenue Revenue From Contract With Customer Excluding Assessed Tax Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense Selling, general and administrative Selling General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other expense (income): Nonoperating Income Expense [Abstract] Loss on extinguishment of debt Gains Losses On Extinguishment Of Debt Amortization of debt issuance costs and discount Amortization Of Financing Costs And Discounts Interest income Interest Income Other Interest expense Interest Expense Other income Other Nonoperating Income Other expense Other Nonoperating Expense Warrant liabilities fair value adjustment Fair Value Adjustment Of Warrants Derivative liability fair value adjustment Gain Loss On Derivative Instruments Net Pretax Total other expense: Nonoperating Income Expense Loss before taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax benefit Income Tax Expense Benefit Net loss Net Income Loss Net loss per share – basic and diluted Income Loss From Continuing Operations Per Basic And Diluted Share Weighted average common shares outstanding – basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Common stock shares issued for commitment shares. Common stock value issued for commitment shares. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Beginning balance Beginning balance (in shares) Net loss Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Common stock issued through employee stock purchase and stock option plans Stock Issued During Period Value Employee Stock Purchase Plan Common stock issued through employee stock purchase plan and stock option plan (in shares) Stock Issued During Period Shares Employee Stock Purchase Plans Common stock issued, net of expenses Stock Issued During Period Value New Issues Common stock issued, net of expenses (in shares) Stock Issued During Period Shares New Issues Common stock issued for conversion Stock Issued During Period Value Conversion Of Convertible Securities Common stock issued for conversion of Notes (in shares) Stock Issued During Period Shares Conversion Of Convertible Securities Common stock issued for exercise of stock options Stock Issued During Period Value Stock Options Exercised Common stock issued for exercise of stock options (in shares) Stock Issued During Period Shares Stock Options Exercised Common stock issued for Commitment Shares Common Stock Value Issued For Commitment Shares Common stock issued for Commitment Shares (in shares) Common Stock Shares Issued For Commitment Shares Common stock issued for vested restricted stock units Stock Issued During Period Value Restricted Stock Award Gross Common stock issued for vested restricted stock units (in shares) Stock Issued During Period Shares Restricted Stock Award Gross Ending balance Ending balance (in shares) Noncash operating lease expense for right-of-use asset. Noncash consideration associated with common stock purchase agreement. Payments of offering costs and underwriting discounts and commissions. Deferred offering and issuance costs included in accounts payable. Deferred offering costs reclassified to additional paid in capital. Common stock issued for commitment shares. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation Depreciation Stock-based compensation expense Allocated Share Based Compensation Expense Accretion of investment discount Investment Income Net Amortization Of Discount And Premium Noncash operating lease expense for right-of-use asset Noncash Operating Lease Expense For Right Of Use Asset Noncash consideration associated with common stock purchase agreement Noncash Consideration Associated With Common Stock Purchase Agreement Changes in operating assets and liabilities: Increase Decrease In Other Operating Assets And Liabilities Net [Abstract] Prepaid expenses, other assets, and deferred costs Increase Decrease In Prepaid Expenses Other Accounts payable and accrued expenses Increase Decrease In Accounts Payable And Accrued Liabilities Deferred revenue Increase Decrease In Deferred Revenue Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Maturities of investments Proceeds From Sale Maturity And Collections Of Investments Purchases of property and equipment Payments To Acquire Property Plant And Equipment Purchase of investments Payments To Acquire Held To Maturity Securities Net cash provided by investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from common stock issued Proceeds From Issuance Of Common Stock Payments of offering costs and underwriting discounts and commissions Payments Of Offering Costs And Underwriting Discounts And Commissions Proceeds from employee stock purchase plan issuances Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Repurchase of shares to satisfy tax withholdings Payments Related To Tax Withholding For Share Based Compensation Proceeds from senior convertible notes Proceeds From Convertible Debt Payments of senior convertible notes issuance costs Payments Of Debt Issuance Costs Payment of loan payable expected to be refinanced Repayments Of Long Term Debt Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in cash, cash equivalents, and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Cash, cash equivalents, and restricted cash at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash, cash equivalents, and restricted cash at end of period Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Cash received for interest Proceeds From Interest Received Noncash financing and investing activities: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Operating lease liabilities arising from obtaining right-of-use assets Right Of Use Asset Obtained In Exchange For Operating Lease Liability Deferred offering and issuance costs included in accounts payable Deferred Offering And Issuance Costs Included In Accounts Payable Deferred offering costs reclassified to additional paid-in capital Deferred Offering Costs Reclassified To Additional Paid In Capital Common stock issued for settlement of senior convertible notes Stock Issued1 Common stock issued for Commitment Shares Common Stock Issued For Commitment Shares Documents Incorporated by Reference Documents Incorporated By Reference [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Description of Business and Basis of Preparation Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Basis Of Presentation And Significant Accounting Policies [Text Block] Investments Debt And Equity Securities [Abstract] Short-term Investments Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract] Prepaid Expenses and Other Current Assets Other Current Assets [Text Block] Property Plant And Equipment [Abstract] Property and Equipment Property Plant And Equipment Disclosure [Text Block] Payables And Accruals [Abstract] Accrued Expenses Accounts Payable And Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Borrowings Debt Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Equity [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Compensation And Retirement Disclosure [Abstract] Employee Benefit Plan Compensation And Employee Benefit Plans [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Concentration of Credit Risk Concentration Risk Credit Risk Cash and Cash Equivalents Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Short-Term Investments Marketable Securities Policy Warrant liabilities. Warrant Liabilities Warrant Liabilities Policy [Text Block] Convertible debt and derivative liability. Convertible Debt and Derivative Liabilities Convertible Debt And Derivative Liability Policy [Text Block] Research and Development Research And Development Expense Policy Patent expenditures. Patent Expenses Patent Expenditures Policy Policy [Text Block] Fair Value of Financial Instruments Fair Value Of Financial Instruments Policy Amortization of Debt Issuance Costs and Discount Deferred Charges Policy [Text Block] Income Taxes Income Tax Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Basic and Diluted Net Loss per Share of Common Stock Earnings Per Share Policy [Text Block] Segment and Geographic Information Segment Reporting Policy Policy [Text Block] Recently issued accounting pronouncements. Recently Issued Accounting Pronouncements Recently Issued Accounting Pronouncements Policy [Text Block] Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Held-to-maturity Securities Held To Maturity Securities [Text Block] Schedule of Prepaid Expenses and Other Current Assets Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block] Schedule of Property and Equipment Property Plant And Equipment [Text Block] Schedule of Accrued Expenses Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block] Summary of Quantitative Information Associated with Amounts Recognized in Condensed Consolidated Financial Statements for Lease Lease Cost Table [Text Block] Future Minimum Lease Payments Lessee Operating Lease Liability Maturity Table [Text Block] Operating lease liability and right-of-use asset. Presentation of Operating Lease Liability and Right-of-Use Asset Operating Lease Liability And Right Of Use Asset Table [Text Block] Common stock reserved for future issuances. Common Stock Reserved For Future Issuances Common Stock Reserved For Future Issuances Table Table [Text Block] Schedule of Effective Income Tax Rate Reconciliation Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Schedule of Deferred Tax Assets and Liabilities Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Schedule of Unrecognized Tax Benefits Roll Forward Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block] Assumptions Used To Estimate Fair Value of Options Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Schedule of Share-based Compensation, Stock Options, Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Schedule of Restricted Stock Units ("RSU") Activity Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Stock-Based Compensation Expense Related to Stock Options Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of Financial Instruments Measured on a Recurring Basis Fair Value Assets Measured On Recurring Basis [Text Block] Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Organization consolidation and presentation of financial statements disclosure. Organization consolidation and presentation of financial statements disclosure. Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] January 2021 Shelf Registration. January 2021 Shelf Registration January Twenty Thousand And Twenty One Shelf Registration [Member] October twenty thousand and twenty shelf registration. October 2020 Shelf Registration October Twenty Thousand And Twenty Shelf Registration [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Sales agreement prospectus. Sales Agreement Sales Agreement Prospectus [Member] Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Accumulated deficit Cash and cash equivalents Shelf registration maximum equity initial offering price. Shelf registration maximum equity initial offering price Shelf Registration Maximum Equity Initial Offering Price Shelf registration, maximum equity offering price. Shelf registration maximum equity offering price Shelf Registration Maximum Equity Offering Price Reverse stock split, ratio Stockholders Equity Note Stock Split Conversion Ratio1 Stock issued during period as result of reverse stock splits Stock Issued During Period Shares Reverse Stock Splits Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Six percent April two thousand and twenty and March two thousand and nineteen convertible senior notes. 6.0% April 2020 and March 2019 Convertible Senior Notes Six Percent April Two Thousand And Twenty And March Two Thousand And Nineteen Convertible Senior Notes [Member] Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Accounting Standards Update Type Of Adoption [Member] ASU 2018-13 Accounting Standards Update201813 [Member] Subsidiary, Sale of Stock [Line Items] Subsidiary Sale Of Stock [Line Items] Cash, cash equivalents, and restricted cash Interest rate Debt Instrument Interest Rate Stated Percentage Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Class of Warrant or Right Class Of Warrant Or Right [Axis] Class of Warrant or Right Class Of Warrant Or Right [Domain] Warrants associated with solar loan agreement. Warrants to purchase common stock associated with Solar loan agreement Warrants Associated With Solar Loan Agreement [Member] June 2016 public offering. Warrants to purchase common stock associated with June 2016 Public Offering June2016 Public Offering [Member] March 2018 public offering series 2. March 2018 Public Offering Series 2 [Member] March2018 Public Offering Series2 [Member] December 2020 public offering series 1. December 2020 Public Offering Series 1 December2020 Public Offering Series1 [Member] December 2020 public offering series 2. December 2020 Public Offering Series 2 December2020 Public Offering Series2 [Member] December two thousand and nineteen public offering. December 2019 Public Offering December Two Thousand And Nineteen Public Offering [Member] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Warrant liability Warrant [Member] Outstanding stock options Employee Stock Option [Member] Outstanding restricted stock units Restricted Stock Units R S U [Member] Option to purchase common stock. Option to purchase common stock Option To Purchase Common Stock [Member] Conversion of March 2019 notes. For possible future issuance for the conversion of the March 2019 Notes Conversion Of March2019 Notes [Member] Conversion of April 2020 notes. For possible future issuance for the conversion of the April 2020 Notes Conversion Of April2020 Notes [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Anti-dilutive securities (in shares) Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Operating segments (number) Number Of Operating Segments Change in Accounting Principle, Accounting Standards Update, Adopted Change In Accounting Principle Accounting Standards Update Adopted Change in Accounting Principle, Accounting Standards Update, Adoption Date Change In Accounting Principle Accounting Standards Update Adoption Date Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Change In Accounting Principle Accounting Standards Update Immaterial Effect Accounting Standards Update [Extensible List] Accounting Standards Update Extensible List Schedule Of Held To Maturity Securities [Table] Schedule Of Held To Maturity Securities [Table] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] U.S. government securities U S Government Agencies Debt Securities [Member] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Commercial paper Commercial Paper Not Included With Cash And Cash Equivalents [Member] Overnight repurchase agreements member. Overnight repurchase agreement Overnight Repurchase Agreements [Member] Schedule of Held-to-maturity Securities [Line Items] Schedule Of Held To Maturity Securities [Line Items] Amortized Cost Held To Maturity Securities Unrealized Gains Held To Maturity Securities Accumulated Unrecognized Holding Gain Unrealized Losses Held To Maturity Securities Accumulated Unrecognized Holding Loss Fair Value Held To Maturity Securities Fair Value Held-to-maturity investments Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount Prepaid research and development expenses, current. Prepaid research and development services Prepaid Researchand Development Expenses Current Prepaid insurance Prepaid Insurance Other prepaid expenses Other Prepaid Expense Current Other receivable Other Receivables Other current assets Other Assets Current Total prepaid expenses and other current assets Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Furniture and Fixtures Furniture And Fixtures [Member] Computer Equipment Computer Equipment [Member] Other Property Plant And Equipment Other Types [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment, gross Property Plant And Equipment Gross Less: accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Total property and equipment, net Accrued research and development expense, current. Accrued research and development expenses Accrued Researchand Development Expense Current Accrued employee bonus compensation Accrued Bonuses Current Other accrued expenses Other Accrued Liabilities Current Total accrued expenses Debt instrument purchase price as percentage of principal amount. Debt Instrument [Table] Debt Instrument [Table] April 2020 note purchase agreement. April 2020 Note Purchase Agreement April Two Thousand Twenty Note Purchase Agreement [Member] Senior convertible note purchase agreement. Senior Convertible Note Purchase Agreement Senior Convertible Note Purchase Agreement [Member] Term loan. Term Loan Term Loan [Member] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Secured Debt Secured Debt [Member] Variable Rate Variable Rate [Axis] Variable Rate Variable Rate [Domain] LIBOR London Interbank Offered Rate L I B O R [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Date of issuance and sale of notes Debt Instrument Offering Date1 Face amount Debt Instrument Face Amount Proceeds from debt, net of issuance costs Proceeds From Debt Net Of Issuance Costs Payment of debt issuance costs Purchase price as percentage of principal amount Debt Instrument Purchase Price As Percentage Of Principal Amount Payment terms Debt Instrument Payment Terms Notes maturity date Debt Instrument Maturity Date Notes maturity description Debt Instrument Maturity Date Description Senior convertible notes Convertible Debt Noncurrent Unamortized debt issuance cost Unamortized Debt Issuance Expense Bifurcated embedded conversion option derivative liability Embedded Derivative Fair Value Of Embedded Derivative Liability Derivative, fair value Derivative Fair Value Of Derivative Net Debt issuance costs Deferred Finance Costs Net Gain (loss) on fair value adjustment of derivative liability Embedded Derivative Gain Loss On Embedded Derivative Net Amortization of debt issuance costs and discount Conversion of convertible note, amount Debt Conversion Converted Instrument Amount1 Conversion of convertible note exchanged for shares Debt Conversion Converted Instrument Shares Issued1 Net carrying amount of convertible debt and derivative liability Fair value of the consideration issued Convertible Debt Fair Value Disclosures Convertible debt and derivative liability fair value disclosures. Fair value of convertible debt and derivative liability Convertible Debt And Derivative Liability Fair Value Disclosures Debt instrument principal amount denominator for conversion into common stock. Debt instrument convertible conversion ratio after adjustment to certain events. Conversion terms Debt Instrument Convertible Terms Of Conversion Feature Conversion rate, number of shares to be issued per $1000 of principal (in shares) Debt Instrument Convertible Conversion Ratio1 Principal amount of notes used as the denominator for conversion into notes Debt Instrument Principal Amount Denominator For Conversion Into Common Stock Initial conversion price of notes Debt Instrument Convertible Conversion Price1 Conversion rate, number of shares to be issued per $1000 of principal (in shares) after adjustment to certain events Debt Instrument Convertible Conversion Ratio After Adjustment To Certain Events Convertible notes, redemption start date Debt Instrument Redemption Period Start Date Convertible notes, threshold percentage of stock price trigger Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger Convertible notes, threshold trading days Debt Instrument Convertible Threshold Trading Days Convertible notes, threshold consecutive trading days Debt Instrument Convertible Threshold Consecutive Trading Days1 Redemption price as percentage of the principal amount Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed Debt instrument, redemption price, percentage of principal amount redeemed, subject to certain exceptions. Redemption price as percentage of the principal amount subject to certain exceptions Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed Subject To Certain Exceptions Reacquisition price of outstanding debt Debt Instrument Repurchase Amount Carrying value of debt obligation Debt Instrument Carrying Amount Debt instrument principal amount denominator for conversion into common stock after adjustment to certain events. Principal amount of notes used as the denominator for conversion into notes after adjustment of certain events Debt Instrument Principal Amount Denominator For Conversion Into Common Stock After Adjustment To Certain Events Loan agreement term Debt Instrument Term Basis spread on variable rate (as a percent) Debt Instrument Basis Spread On Variable Rate1 Lease agreement area of office space. Commitment and contingencies. Commitment and contingencies. Commitment And Contingencies [Table] Commitment And Contingencies [Table] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum Maximum [Member] Minimum Minimum [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Cypralis Limited. Cypralis Limited Cypralis Limited [Member] Waterstone Pharmaceutical HK Limited. Waterstone Pharmaceutical HK Limited Waterstone Pharmaceutical H K Limited [Member] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Asset purchase agreement. Asset Purchase Agreement Asset Purchase Agreement [Member] License agreement. License Agreement License Agreement [Member] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Long-term lease agreement, area of office space Lease Agreement Area Of Office Space Lease term Lessee Operating Lease Term Of Contract Total lease payments Operating Lease Payments Lessee, operating lease, existence of option to extend Lessee Operating Lease Existence Of Option To Extend Renewal term Lessee Operating Lease Renewal Term Renewal term, description Lessee Operating Lease Option To Extend Security deposit in the form of a standby letter of credit Security Deposit Decrease in security deposit Increase Decrease In Security Deposits Operating lease cost Operating Lease Cost Variable lease cost Variable Lease Cost Total operating lease expense Lease Cost Remaining Lease term (years) Operating Lease Weighted Average Remaining Lease Term1 Discount rate Operating Lease Weighted Average Discount Rate Percent 2021 Lessee Operating Lease Liability Payments Due Next Twelve Months 2022 Lessee Operating Lease Liability Payments Due Year Two 2023 Lessee Operating Lease Liability Payments Due Year Three 2024 Lessee Operating Lease Liability Payments Due Year Four 2025 Lessee Operating Lease Liability Payments Due Year Five Thereafter Lessee Operating Lease Liability Payments Due After Year Five Total Lessee Operating Lease Liability Payments Due Present value of future minimum lease payments Operating Lease Liability Operating lease liability, current portion Operating lease liability, long-term portion Total operating lease liability Difference between future minimum lease payments and discounted cash flows Lessee Operating Lease Liability Undiscounted Excess Amount Operating lease right-of-use asset Milestone payments. Milestone payments from the Company Milestone Payments Revenue recognized Contract With Customer Liability Revenue Recognized Schedule Of Capitalization Equity [Table] Schedule Of Capitalization Equity [Table] December 2020 public offering. December 2020 Public Offering December2020 Public Offering [Member] Prefunded warrants. Pre-funded Warrants Prefunded Warrants [Member] Series one warrant. Series 1 Warrant Series One Warrant [Member] Series two warrant. Series 2 Warrant Series Two Warrant [Member] Underwriters Over Allotment Option [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Option to Purchase Common Stock March 2018 public offering. March 2018 Public Offering March2018 Public Offering [Member] June 2016 Public Offering Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Aspire capital fund limited liability company. Aspire Capital Aspire Capital Fund Limited Liability Company [Member] Common stock purchase agreement. Common Stock Purchase Agreement Common Stock Purchase Agreement [Member] Commitment shares. Commitment Shares Commitment Shares [Member] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Other Expense Other Expense [Member] Warrant associated with solar loan agreement. Warrants to purchase common stock associated with Loan Agreement Warrant Associated With Solar Loan Agreements [Member] Schedule Of Capitalization Equity [Line Items] Schedule Of Capitalization Equity [Line Items] Common stock, reverse stock split Stockholders Equity Reverse Stock Split Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand and fourteen equity incentive plan. 2014 Equity Incentive Plan Two Thousand And Fourteen Equity Incentive Plan [Member] Two thousand and fourteen employee stock purchase plan. 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fifteen inducement award plan. 2015 Inducement Award Plan Two Thousand And Fifteen Inducement Award Plan [Member] Six percent convertible senior notes due two thousand and twenty five. March 2019 Notes Six Percent Convertible Senior Notes Due Two Thousand And Twenty Five [Member] Six point zero percentage senior convertible notes due two thousand and twenty six. April 2020 Notes Six Point Zero Percentage Senior Convertible Notes Due Two Thousand And Twenty Six [Member] Restricted Stock Units Option Indexed to Issuer's Equity Option Indexed To Issuers Equity Equity [Axis] Option Indexed to Issuer's Equity, Type Option Indexed To Issuers Equity Type [Domain] Stock options Class of Stock [Line Items] Class Of Stock [Line Items] Common shares reserved for future issuance Common Stock Capital Shares Reserved For Future Issuance Number of warrants issued to purchase common stock (in shares) Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exercise price of warrants (in dollars per share) Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Number of shares received per warrant (in shares) Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Warrant term. Warrant term Warrant Term Public offering price Sale Of Stock Price Per Share Option to purchase share of common stock. Class of warrants or right exercised. Class of warrants or right not exercised. Option expiration date. Share price (in dollars per share) Shares Issued Price Per Share Option to purchase shares of common stock Option To Purchase Share Of Common Stock Number of warrants exercised Class Of Warrants Or Right Exercised Number of options not exercised Class Of Warrants Or Right Not Exercised Options expiration date Option Expiration Date Warrants expiration date. Warrants, expiration date Warrants Expiration Date Proceeds from Warrant Exercises Proceeds From Warrant Exercises Warrants issued, expiration period. Warrant expiration period Warrants Issued Expiration Period Fair value of liabilities. Warrant liabilities Fair Value Of Liabilities Sale of common stock at sole discretion, amount. Number of purchase aggregate shares of common stock. Percentage of common stock outstanding. Number of shares committed. Average purchase price of shares sold. Common stock owned percentage. Sale of common stock at sole discretion Sale Of Common Stock At Sole Discretion Amount Number of purchase aggregate shares of common stock Number Of Purchase Aggregate Shares Of Common Stock Percentage of common stock outstanding Percentage Of Common Stock Outstanding Number of shares committed Number Of Shares Committed Average purchase price of shares sold Average Purchase Price Of Shares Sold Percentage of common stock owned Common Stock Owned Percentage Sale of common stock maximum number of share sold per business day. Stock purchase price average number of trading days lowest closing sales price out of consecutive trading days. Stock purchase price number of consecutive trading days. Sale of common stock maximum number of share sold per business day Sale Of Common Stock Maximum Number Of Share Sold Per Business Day Stock purchase price average number of trading days lowest closing sales price out of consecutive trading days Stock Purchase Price Average Number Of Trading Days Lowest Closing Sales Price Out Of Consecutive Trading Days Stock purchase price number of consecutive trading days Stock Purchase Price Number Of Consecutive Trading Days Increase in sale of common stock maximum number of share sold per business day. Increase in sale of common stock maximum number of share sold per business day Increase In Sale Of Common Stock Maximum Number Of Share Sold Per Business Day Stock purchase percentage on aggregate shares of common stock traded. Percentage of purchase price per share. Stock purchase percentage on aggregate shares of common stock traded Stock Purchase Percentage On Aggregate Shares Of Common Stock Traded Percentage of purchase price per share Percentage Of Purchase Price Per Share Sale of stock value of shares issued in transaction fair value. Common stock shares issued Sale Of Stock Number Of Shares Issued In Transaction Fair value of shares Sale Of Stock Value Of Shares Issued In Transaction Fair Value Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] Federal Domestic Country [Member] State State And Local Jurisdiction [Member] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] New Jersey NEW JERSEY Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Loss before taxes Income tax reconciliation state effect of permanent items. Effective income tax rate reconciliation issuance of warrants. Income tax reconciliation net operating loss sale. Effective income tax rate reconciliation state effect of permanent items. Effective income tax rate reconciliation issuance of warrants percent. Effective income tax rate reconciliation net operating loss sale. Amount Income Tax Expense Benefit Continuing Operations Income Tax Reconciliation [Abstract] Income taxes from continuing operations at statutory rate Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate State income taxes Income Tax Reconciliation State And Local Income Taxes State effect of permanent items Income Tax Reconciliation State Effect Of Permanent Items Stock-based compensation Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Deferred rate change Income Tax Reconciliation Change In Enacted Tax Rate Warrants issuance Effective Income Tax Rate Reconciliation Issuance Of Warrants Other Income Tax Reconciliation Other Adjustments NOL sale Income Tax Reconciliation Net Operating Loss Sale R&D credit adjustment Income Tax Reconciliation Tax Credits Research Increase in valuation allowance Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance Total income tax benefit Percent of Pretax Income Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract] Income taxes from continuing operations at statutory rate Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate State income taxes Effective Income Tax Rate Reconciliation State And Local Income Taxes State effect of permanent items Effective Income Tax Rate Reconciliation State Effect Of Permanent Items Stock-based compensation Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost Deferred rate change Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate Warrants issuance Effective Income Tax Rate Reconciliation Issuance Of Warrants Percent Other Effective Income Tax Rate Reconciliation Other Adjustments NOL sale Effective Income Tax Rate Reconciliation Net Operating Loss Sale R&D credit adjustment Effective Income Tax Rate Reconciliation Tax Credits Research Increase in valuation allowance Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Total income tax benefit Effective Income Tax Rate Continuing Operations Deferred tax assets tax deferred expense reserves and accruals accrued expenses noncurrent. Deferred tax assets tax deferred expense compensation and benefits share based compensation cost noncurrent. Deferred tax assets tax deferred expense lease liability. Deferred tax liabilities other noncurrent. Accrued expenses Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Expenses Noncurrent Stock-based compensation Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Noncurrent Lease liability Deferred Tax Assets Tax Deferred Expense Lease Liability Other Deferred Tax Liabilities Other Noncurrent Net operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards Research and development credits Deferred Tax Assets Tax Credit Carryforwards Research Total deferred tax assets Deferred Tax Assets Gross Valuation allowances Deferred Tax Assets Valuation Allowance Net deferred tax assets Deferred Tax Assets Liabilities Net Cash receipt from sale of net operating losses. Net operating loss carryforwards expiration year. Maximum selling value of unused net operating losses and research and development tax credit to profitable tax payers. Amount received from the New Jersey Technology Business Tax Certificate Transfer (NOL) Program. Net operating loss carryforward Operating Loss Carryforwards Tax credit carryforward Tax Credit Carryforward Amount NOLs subject to expiration Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration NOLs subject not to expiration Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration NOLs expiration date Operating Loss Carryforwards Expiration Date Net operating loss carryforwards expiration year Net Operating Loss Carryforwards Expiration Year Cash receipt from the sale of state NOLs Cash Receipt From Sale Of Net Operating Losses Maximum selling value of unused net operating losses and research and development tax credit to profitable tax payers. Maximum Selling Value Of Unused Net Operating Losses And Research And Development Tax Credit To Profitable Tax Payers Amount received from the program Amount Received From New Jersey Technology Business Tax Certificate Transfer N O L Program Tax Cuts and Jobs Act of 2017 temporary expense for certain business assets and property, percentage. Tax Cuts and Jobs Act of 2017 maximum percentage of pre-NOL deduction taxable income that can be be claimed each year as an NOL deduction. Corporate income tax rate Temporary expensing for certain business assets and property, percent Tax Cuts And Job Acts Of2017 Temporary Expense For Certain Business Assets And Property Percentage Maximum deduction percentage of pre-NOL taxable income Tax Cuts And Jobs Act Of2017 Maximum Percentage Of Pre Net Operating Loss Deduction Taxable Income Limit For Net Operating Loss Deduction Unrecognized tax benefits decreases resulting from deferred rate change. Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward Unrecognized tax benefits Unrecognized Tax Benefits Additions for tax positions of current period Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions Additions for tax positions of prior periods Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions Deferred rate change Unrecognized Tax Benefits Decreases Resulting From Deferred Rate Change Unrecognized tax benefits Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits That Would Impact Effective Tax Rate Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit Income tax examination, penalties and interest accrued Income Tax Examination Penalties And Interest Accrued Percentage of fair market value for which exercise price is designated on incentive and nonqualified stock option grants. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Two thousand and nine stock option plan. 2009 Stock Option Plan Two Thousand And Nine Stock Option Plan [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Percentage of exercise price Percentage Of Fair Market Value For Which Exercise Price Is Designated On Incentive And Nonqualified Stock Option Grants Vesting period of options Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Expiration period of options Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period The number of additional awards to be granted under the 2009 Equity Incentive Plan on or after the effective date of the 2014 equity incentive plan. Number of additional awards expected to be granted (in shares) Number Of Additional Awards To Be Granted Under Two Thousand Nine Equity Incentive Plan The base number of new shares of common stock that may be issued after the effective date of the 2014 equity incentive plan, adjusted by certain amounts as described in the plan agreement, to arrive at an aggregate number of new shares of common stock that may be issued under the plan. Common stock issuable period under equity incentive plan. Percentage of capital stock outstanding. Common stock capital shares reserved for future issuance, board of directors prerogative, increase during period. Base number of new shares available for future issuance under equity incentive plan (in shares) Base Number Of Additional Awards Authorized Under Two Thousand Fourteen Equity Incentive Plan Common stock issuable period Common Stock Issuable Period Under Equity Incentive Plan Common stock outstanding percentage Percentage Of Capital Stock Outstanding Number of shares of common stock for future issuance, board of directors prerogative, increase in period (in shares) Common Stock Capital Shares Reserved For Future Issuance Board Of Directors Prerogative Increase During Period Share-based compensation arrangement by share-based payment award, number of additional shares authorized Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized Possible future issuance under equity compensation plan (in shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Two thousand and fifteen inducement plan. 2015 Inducement Plan Two Thousand And Fifteen Inducement Plan [Member] Shares authorized under the plan (in shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Granted (shares) Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Weighted average value of options granted in period (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Aggregate fair value of options granted Stock Granted During Period Value Sharebased Compensation Share-based Goods and Nonemployee Services Transaction, Valuation Method, Forfeiture Rate Expected dividend yield, non-employees directors Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate Weighted average expected volatility, employees Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate Weighted average expected volatility, non-employees directors Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate Weighted average risk-free interest rate, employees Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Weighted average risk-free interest rate, non-employees directors Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate Weighted average expected term (in years), employees Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Weighted average expected term (in years), non-employees directors Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 Forfeiture rate, non-employees directors Sharebased Goodsand Nonemployee Services Transaction Valuation Method Forfeiture Rate Number of Shares Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Beginning balance - Outstanding (shares) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Exercised (shares) Forfeited/expired (shares) Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Ending balance - Outstanding (shares) Exercisable (shares) Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number Vested or expected to vest (shares) Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Weighted- Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Beginning balance - Outstanding (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Granted (in dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Exercised (in dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Forfeited/expired (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Ending balance - Outstanding (in dollars per share) Exercisable (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price Vested or expected to vest (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract] Balance - Outstanding Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Exercisable Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 Vested or expected to vest Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Aggregate Intrinsic Value ($000) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value Roll Forward Balance - Outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value Vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value Total fair value of shares vested during the year Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 Total unrecognized compensation cost related to unvested share-based compensation arrangements Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Total unrecognized compensation cost related to unvested share-based compensation arrangements, recognition period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Number of Shares Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Roll Forward Beginning balance - Outstanding (shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Options granted in period (shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Vested (shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Forfeited (shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Ending balance - Outstanding (shares) Weighted Average Grant Date Fair Value Per Share Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward Beginning balance - Outstanding (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Granted (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Vested (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Ending balance - Outstanding (in dollars per share) Vesting percentage Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage Total unrecognized compensation cost related to unvested RSU share-based compensation Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options Common stock issuable period under employee stock purchase plan. Employee stock purchase plan, number of shares that can be added to common stock outstanding on conditional basis. For possible future issuance under employee stock purchase plan (in shares) Common stock issuable period Common Stock Issuable Period Under Employee Stock Purchase Plan Employee stock purchase plan, number of shares, which might be added to common stock outstanding (in shares) Employee Stock Purchase Plan Number Of Shares Which Might Be Added To Common Stock Outstanding Common stock issued through employee stock purchase plan (in shares) Tax benefit from compensation expense Employee Service Share Based Compensation Tax Benefit From Compensation Expense Cash received from option exercised Proceeds From Stock Options Exercised Research and development, net Research And Development Expense [Member] Selling, general and administrative Selling General And Administrative Expenses [Member] Stock-based compensation expense related to stock options Fair Value By Balance Sheet Grouping [Table] Fair Value By Balance Sheet Grouping [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value Measurements Recurring [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value Inputs Level1 [Member] Significant Other Observable Inputs (Level 2) Fair Value Inputs Level2 [Member] Significant Unobservable Inputs (Level 3) Fair Value Inputs Level3 [Member] Cash and Cash Equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Cash Cash [Member] Restricted cash. Restricted cash Restricted Cash [Member] Money market funds Money Market Funds [Member] Warrant liabilities Derivative liabilities Derivative [Member] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair value of financial assets Assets Fair Value Disclosure Fair value of financial liabilities Liabilities Fair Value Disclosure Measurement Input Type Measurement Input Type [Axis] Measurement Input Type Measurement Input Type [Domain] Stock Price Volatility Measurement Input Price Volatility [Member] Weighted Average Expected Term Measurement Input Expected Term [Member] Weighted Average Weighted Average [Member] Market Credit Spread Measurement Input Credit Spread [Member] Estimated Yield Measurement Input Expected Dividend Rate [Member] Discounts for Lack of Marketability Measurement Input Discount For Lack Of Marketability [Member] Warrant liabilities, stock price volatility rate Warrants And Rights Outstanding Measurement Input Warrant liabilities, expected term Warrants And Rights Outstanding Term Warrant liabilities, maturity date Warrants And Rights Outstanding Maturity Date Derivative liabilities, unobservable inputs rate Derivative Liability Measurement Input Senior convertible notes, unobservable inputs rate Long Term Debt Measurement Input Derivative fair value gain (loss) from mark to market adjustment. Fair value measurement with unobservable inputs reconciliation recurring basis liability adjustment for conversion of notes. Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation Calculation Roll Forward Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Beginning balance Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Bifurcated embedded conversion option associated with Notes Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity December 2020 Public Offering Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues Adjustment for partial conversion of April 2020 Notes Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Adjustment For Conversion Of Notes Gain (loss) adjustment to fair value Derivative Fair Value Gain Loss From Mark To Market Adjustment Ending balance Defined contribution plan, minimum required work hours per week. Defined contribution plan, employers matching contribution, vesting period. Work hours per week Defined Contribution Plan Required Work Hours Per Week Employer matching percent Defined Contribution Plan Employer Matching Contribution Percent Of Match Maximum percentage of contributions per employee Defined Contribution Plan Maximum Annual Contributions Per Employee Percent Vesting period Defined Contribution Plan Employers Matching Contribution Vesting Period Contribution amount Defined Contribution Plan Employer Discretionary Contribution Amount Subsequent Event [Table] Subsequent Event [Table] Amplity Inc. Amplity Inc. Amplity Inc [Member] Exclusive license and collaboration agreement. Exclusive License and Collaboration Agreement Exclusive License And Collaboration Agreement [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Term of agreement. Term of agreement Term Of Agreement Upfront payment received. Development and commercial milestones received. Upfront payment received Upfront Payment Received Development and commercial milestones received Development And Commercial Milestones Received EX-101.PRE 13 scyx-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 14 scyx-10k_20201231_htm.xml IDEA: XBRL DOCUMENT 0001178253 2020-01-01 2020-12-31 0001178253 2021-03-01 0001178253 2020-06-30 0001178253 2020-12-31 0001178253 2019-12-31 0001178253 2019-01-01 2019-12-31 0001178253 us-gaap:CommonStockMember 2018-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001178253 us-gaap:RetainedEarningsMember 2018-12-31 0001178253 2018-12-31 0001178253 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001178253 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001178253 us-gaap:CommonStockMember 2019-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001178253 us-gaap:RetainedEarningsMember 2019-12-31 0001178253 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001178253 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001178253 us-gaap:CommonStockMember 2020-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001178253 us-gaap:RetainedEarningsMember 2020-12-31 0001178253 scyx:JanuaryTwentyThousandAndTwentyOneShelfRegistrationMember us-gaap:SubsequentEventMember 2021-01-06 2021-01-08 0001178253 scyx:OctoberTwentyThousandAndTwentyShelfRegistrationMember 2020-09-29 2020-10-01 0001178253 scyx:OctoberTwentyThousandAndTwentyShelfRegistrationMember us-gaap:CommonStockMember scyx:SalesAgreementProspectusMember 2020-09-29 2020-10-01 0001178253 2020-07-14 2020-07-16 0001178253 2020-07-16 0001178253 2020-07-17 0001178253 2020-07-15 2020-07-17 0001178253 scyx:SixPercentAprilTwoThousandAndTwentyAndMarchTwoThousandAndNineteenConvertibleSeniorNotesMember 2020-12-31 0001178253 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001178253 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001178253 us-gaap:WarrantMember scyx:June2016PublicOfferingMember 2020-01-01 2020-12-31 0001178253 us-gaap:WarrantMember scyx:June2016PublicOfferingMember 2019-01-01 2019-12-31 0001178253 us-gaap:WarrantMember scyx:March2018PublicOfferingSeries2Member 2020-01-01 2020-12-31 0001178253 us-gaap:WarrantMember scyx:March2018PublicOfferingSeries2Member 2019-01-01 2019-12-31 0001178253 us-gaap:WarrantMember scyx:DecemberTwoThousandAndNineteenPublicOfferingMember 2020-01-01 2020-12-31 0001178253 us-gaap:WarrantMember scyx:DecemberTwoThousandAndNineteenPublicOfferingMember 2019-01-01 2019-12-31 0001178253 scyx:OptionToPurchaseCommonStockMember scyx:DecemberTwoThousandAndNineteenPublicOfferingMember 2020-01-01 2020-12-31 0001178253 scyx:OptionToPurchaseCommonStockMember scyx:DecemberTwoThousandAndNineteenPublicOfferingMember 2019-01-01 2019-12-31 0001178253 us-gaap:WarrantMember scyx:December2020PublicOfferingSeries1Member 2020-01-01 2020-12-31 0001178253 us-gaap:WarrantMember scyx:December2020PublicOfferingSeries1Member 2019-01-01 2019-12-31 0001178253 us-gaap:WarrantMember scyx:December2020PublicOfferingSeries2Member 2020-01-01 2020-12-31 0001178253 us-gaap:WarrantMember scyx:December2020PublicOfferingSeries2Member 2019-01-01 2019-12-31 0001178253 scyx:ConversionOfMarch2019NotesMember 2020-01-01 2020-12-31 0001178253 scyx:ConversionOfMarch2019NotesMember 2019-01-01 2019-12-31 0001178253 scyx:ConversionOfApril2020NotesMember 2020-01-01 2020-12-31 0001178253 scyx:ConversionOfApril2020NotesMember 2019-01-01 2019-12-31 0001178253 us-gaap:WarrantMember scyx:WarrantsAssociatedWithSolarLoanAgreementMember 2020-01-01 2020-12-31 0001178253 us-gaap:WarrantMember scyx:WarrantsAssociatedWithSolarLoanAgreementMember 2019-01-01 2019-12-31 0001178253 us-gaap:AccountingStandardsUpdate201813Member 2020-12-31 0001178253 us-gaap:AccountingStandardsUpdate201813Member 2020-01-01 2020-12-31 0001178253 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001178253 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0001178253 scyx:OvernightRepurchaseAgreementsMember 2019-12-31 0001178253 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001178253 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001178253 us-gaap:ComputerEquipmentMember 2020-12-31 0001178253 us-gaap:ComputerEquipmentMember 2019-12-31 0001178253 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2020-12-31 0001178253 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2019-12-31 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-03-10 2020-04-09 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-04-09 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-01-01 2020-12-31 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-12-31 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-06-01 2020-06-30 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-12-01 2020-12-31 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember us-gaap:SubsequentEventMember 2021-01-02 2021-01-31 0001178253 scyx:AprilTwoThousandTwentyNotePurchaseAgreementMember 2020-06-30 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-03-07 2019-03-07 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-03-07 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-01-01 2019-12-31 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-12-31 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2020-12-31 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2020-01-01 2020-12-31 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-04-01 2019-04-30 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-04-30 0001178253 scyx:TermLoanMember us-gaap:SecuredDebtMember 2016-09-29 2016-09-30 0001178253 scyx:TermLoanMember us-gaap:SecuredDebtMember 2016-09-30 0001178253 scyx:TermLoanMember us-gaap:SecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-09-29 2016-09-30 0001178253 2018-03-01 0001178253 2018-02-28 2018-03-01 0001178253 srt:MaximumMember 2020-01-01 2020-12-31 0001178253 scyx:CypralisLimitedMember scyx:AssetPurchaseAgreementMember 2020-01-01 2020-12-31 0001178253 scyx:CypralisLimitedMember scyx:AssetPurchaseAgreementMember 2019-01-01 2019-12-31 0001178253 scyx:WaterstonePharmaceuticalHKLimitedMember scyx:LicenseAgreementMember 2020-01-01 2020-12-31 0001178253 scyx:WaterstonePharmaceuticalHKLimitedMember scyx:LicenseAgreementMember 2019-01-01 2019-12-31 0001178253 2019-06-17 0001178253 2019-06-18 0001178253 us-gaap:EmployeeStockOptionMember 2020-12-31 0001178253 us-gaap:EmployeeStockOptionMember 2019-12-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001178253 scyx:June2016PublicOfferingMember us-gaap:WarrantMember 2020-12-31 0001178253 scyx:June2016PublicOfferingMember us-gaap:WarrantMember 2019-12-31 0001178253 scyx:March2018PublicOfferingMember scyx:SeriesTwoWarrantMember 2020-12-31 0001178253 scyx:March2018PublicOfferingMember scyx:SeriesTwoWarrantMember 2019-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember us-gaap:WarrantMember 2020-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember us-gaap:WarrantMember 2019-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember scyx:OptionToPurchaseCommonStockMember 2020-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember scyx:OptionToPurchaseCommonStockMember 2019-12-31 0001178253 scyx:December2020PublicOfferingSeries1Member us-gaap:WarrantMember 2020-12-31 0001178253 scyx:December2020PublicOfferingSeries1Member us-gaap:WarrantMember 2019-12-31 0001178253 scyx:December2020PublicOfferingSeries2Member us-gaap:WarrantMember 2020-12-31 0001178253 scyx:December2020PublicOfferingSeries2Member us-gaap:WarrantMember 2019-12-31 0001178253 scyx:December2020PublicOfferingMember 2020-12-31 0001178253 scyx:December2020PublicOfferingMember 2019-12-31 0001178253 scyx:WarrantsAssociatedWithSolarLoanAgreementMember us-gaap:WarrantMember 2020-12-31 0001178253 scyx:WarrantsAssociatedWithSolarLoanAgreementMember us-gaap:WarrantMember 2019-12-31 0001178253 scyx:SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember 2020-12-31 0001178253 scyx:SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember 2019-12-31 0001178253 scyx:SixPointZeroPercentageSeniorConvertibleNotesDueTwoThousandAndTwentySixMember 2020-12-31 0001178253 scyx:SixPointZeroPercentageSeniorConvertibleNotesDueTwoThousandAndTwentySixMember 2019-12-31 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2019-12-31 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2019-12-31 0001178253 scyx:TwoThousandAndFifteenInducementAwardPlanMember 2020-12-31 0001178253 scyx:TwoThousandAndFifteenInducementAwardPlanMember 2019-12-31 0001178253 2014-05-07 0001178253 scyx:December2020PublicOfferingMember 2020-12-17 2020-12-17 0001178253 scyx:December2020PublicOfferingMember 2020-12-17 0001178253 scyx:PrefundedWarrantsMember scyx:December2020PublicOfferingMember 2020-12-17 0001178253 srt:MaximumMember scyx:SeriesOneWarrantMember scyx:December2020PublicOfferingMember 2020-12-17 0001178253 srt:MinimumMember scyx:SeriesTwoWarrantMember scyx:December2020PublicOfferingMember 2020-12-17 0001178253 scyx:SeriesOneWarrantMember scyx:December2020PublicOfferingMember 2020-12-17 2020-12-17 0001178253 scyx:SeriesOneWarrantMember scyx:December2020PublicOfferingMember 2020-12-17 0001178253 scyx:SeriesTwoWarrantMember scyx:December2020PublicOfferingMember 2020-12-17 2020-12-17 0001178253 scyx:SeriesTwoWarrantMember scyx:December2020PublicOfferingMember 2020-12-17 0001178253 us-gaap:CommonStockMember scyx:December2020PublicOfferingMember 2020-12-17 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember 2019-12-12 2019-12-12 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember 2019-12-12 0001178253 srt:MaximumMember us-gaap:OverAllotmentOptionMember 2019-12-12 2019-12-12 0001178253 us-gaap:WarrantMember us-gaap:OverAllotmentOptionMember 2019-12-12 0001178253 srt:MaximumMember scyx:OptionToPurchaseCommonStockMember 2019-12-12 0001178253 scyx:OptionToPurchaseCommonStockMember 2019-12-12 2019-12-12 0001178253 2018-03-07 2018-03-08 0001178253 srt:MaximumMember us-gaap:WarrantMember scyx:March2018PublicOfferingMember 2018-03-08 0001178253 scyx:March2018PublicOfferingMember 2018-03-08 0001178253 scyx:SeriesOneWarrantMember scyx:March2018PublicOfferingMember 2018-03-08 0001178253 scyx:SeriesTwoWarrantMember scyx:March2018PublicOfferingMember 2018-03-08 0001178253 srt:MaximumMember scyx:SeriesOneWarrantMember scyx:March2018PublicOfferingMember 2018-03-08 0001178253 scyx:SeriesOneWarrantMember scyx:March2018PublicOfferingMember 2018-03-07 2018-03-08 0001178253 srt:MaximumMember scyx:SeriesTwoWarrantMember scyx:March2018PublicOfferingMember 2018-03-08 0001178253 scyx:SeriesTwoWarrantMember scyx:March2018PublicOfferingMember 2018-03-07 2018-03-08 0001178253 scyx:SeriesOneWarrantMember 2018-12-31 0001178253 scyx:SeriesOneWarrantMember 2018-01-01 2018-12-31 0001178253 scyx:SeriesOneWarrantMember 2018-03-07 2018-03-08 0001178253 2016-06-21 2016-06-21 0001178253 srt:MaximumMember us-gaap:WarrantMember scyx:June2016PublicOfferingMember 2016-06-21 0001178253 scyx:June2016PublicOfferingMember 2016-06-21 0001178253 scyx:June2016PublicOfferingMember 2016-06-21 2016-06-21 0001178253 scyx:December2020PublicOfferingMember 2020-01-01 2020-12-31 0001178253 scyx:DecemberTwoThousandAndNineteenPublicOfferingMember 2020-01-01 2020-12-31 0001178253 srt:MaximumMember scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommonStockPurchaseAgreementMember 2020-04-10 2020-04-10 0001178253 scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommonStockPurchaseAgreementMember 2020-04-10 2020-04-10 0001178253 scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommonStockPurchaseAgreementMember 2020-04-10 0001178253 scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommonStockPurchaseAgreementMember 2020-01-01 2020-12-31 0001178253 srt:MaximumMember scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommonStockPurchaseAgreementMember 2020-04-10 0001178253 scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommitmentSharesMember scyx:CommonStockPurchaseAgreementMember 2020-04-10 2020-04-10 0001178253 us-gaap:OtherExpenseMember scyx:AspireCapitalFundLimitedLiabilityCompanyMember scyx:CommitmentSharesMember scyx:CommonStockPurchaseAgreementMember 2020-01-01 2020-12-31 0001178253 scyx:WarrantAssociatedWithSolarLoanAgreementsMember 2016-09-30 0001178253 scyx:WarrantAssociatedWithSolarLoanAgreementsMember 2016-09-29 2016-09-30 0001178253 us-gaap:DomesticCountryMember 2020-12-31 0001178253 us-gaap:DomesticCountryMember 2019-12-31 0001178253 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001178253 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001178253 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001178253 stpr:NJ us-gaap:StateAndLocalJurisdictionMember 2020-04-01 2020-04-30 0001178253 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001178253 stpr:NJ us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001178253 srt:MaximumMember 2017-01-01 2017-12-31 0001178253 srt:MinimumMember scyx:TwoThousandAndNineStockOptionPlanMember 2020-01-01 2020-12-31 0001178253 srt:MaximumMember scyx:TwoThousandAndNineStockOptionPlanMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndNineStockOptionPlanMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2014-05-02 0001178253 srt:MinimumMember scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001178253 srt:MaximumMember scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001178253 srt:MaximumMember scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2014-05-01 2014-05-02 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2014-05-01 2014-05-02 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2019-01-01 2019-12-31 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2015-03-26 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2019-06-08 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2019-06-09 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2020-12-31 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2019-01-01 2019-12-31 0001178253 scyx:TwoThousandAndFifteenInducementPlanMember 2019-12-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2014-05-02 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2014-05-01 2014-05-02 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001178253 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001178253 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001178253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001178253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001178253 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2020-12-31 0001178253 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeMember 2020-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001178253 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2019-12-31 0001178253 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeMember 2019-12-31 0001178253 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001178253 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001178253 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001178253 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001178253 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputCreditSpreadMember 2020-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001178253 scyx:SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember 2020-12-31 0001178253 us-gaap:WarrantMember 2019-12-31 0001178253 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001178253 us-gaap:WarrantMember 2020-12-31 0001178253 us-gaap:DerivativeMember 2019-12-31 0001178253 us-gaap:DerivativeMember 2020-01-01 2020-12-31 0001178253 us-gaap:DerivativeMember 2020-12-31 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember us-gaap:SubsequentEventMember 2020-12-02 2021-01-01 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember us-gaap:SubsequentEventMember 2020-12-02 2021-01-01 0001178253 us-gaap:SubsequentEventMember scyx:AmplityIncMember 2021-02-01 2021-02-28 0001178253 us-gaap:SubsequentEventMember scyx:ExclusiveLicenseAndCollaborationAgreementMember 2021-02-11 2021-02-11 0001178253 srt:MaximumMember us-gaap:SubsequentEventMember scyx:ExclusiveLicenseAndCollaborationAgreementMember 2021-02-11 2021-02-11 shares iso4217:USD iso4217:USD shares pure scyx:Segment utr:D utr:sqft scyx:hour 0001178253 --12-31 FY false 0.1 true true us-gaap:AccountingStandardsUpdate201813Member true 0.1 2037-12-31 0.21 0.1 P5Y P1Y P3Y6M P371D P5Y P2Y6M P10M24D P8Y7M2D P9Y7M2D P5Y11M19D P6Y10D P5Y6M P5Y6M14D P7Y7M13D P7Y8M15D P6Y8M26D P7Y8M15D 0 0 10-K true 2020-12-31 2020 false 001-36365 SCYNEXIS, Inc. DE 56-2181648 1 Evertrust Plaza 13th Floor Jersey City NJ 07302 - 6548 201 884-5485 Common Stock, par value $0.001 per share SCYX NASDAQ No No Yes Yes Non-accelerated Filer true false false false 77935551 20622778 <p style="text-align:center;Background-color:#auto;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Documents Incorporated by Reference</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant’s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s 2021 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant’s fiscal year ended December 31, 2020.</p> 93041000 41920000 6494000 5165000 3988000 98206000 52402000 573000 812000 187000 70000 273000 273000 298000 405000 2999000 3191000 102536000 57153000 4639000 7177000 4141000 3801000 17564000 52000 36000 26396000 11014000 33592000 18396000 16516000 11522000 3274000 3326000 79778000 44258000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 0.001 0.001 100000000 100000000 19663698 19663698 9741372 9741372 20000 10000 349351000 284313000 -326613000 -271428000 22758000 12895000 102536000 57153000 0 121000 36522000 38394000 14627000 10648000 51149000 49042000 -51149000 -48921000 -1766000 -1045000 1201000 1171000 189000 805000 1181000 986000 334000 538000 602000 0 5214000 4497000 2257000 1567000 -7184000 -4789000 -58333000 -53710000 -3148000 0 -55185000 -53710000 -5.15 -9.58 10720211 5608138 4797198 5000 248938000 -217718000 31225000 -53710000 -53710000 1828000 1828000 3684 37000 37000 4773692 5000 30525000 30530000 162600 2984000 2984000 2252 12000 12000 1946 -11000 -11000 9741372 10000 284313000 -271428000 12895000 -55185000 -55185000 2220000 2220000 4652 28000 28000 9156304 9000 57175000 57184000 638809 1000 5221000 5222000 70910 602000 602000 51651 -208000 -208000 19663698 20000 349351000 -326613000 22758000 -55185000 -53710000 111000 111000 2220000 1828000 0 16000 1201000 1171000 5214000 4497000 2257000 1567000 192000 174000 -1766000 -1045000 602000 0 922000 -3254000 -2296000 5215000 0 -121000 -49354000 -38119000 20713000 65740000 4000 0 14235000 39500000 6474000 26240000 90554000 46337000 5879000 2855000 28000 49000 208000 0 10000000 16000000 494000 1253000 0 15973000 94001000 42305000 51121000 30426000 42193000 11767000 93314000 42193000 1088000 850000 186000 898000 0 3365000 62000 0 153000 36000 5221000 2984000 602000 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.49%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.91%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. </span></p></td> <td valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description of Business and Basis of Preparation</p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Organization</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections.  The Company is developing its lead product candidate, ibrexafungerp, as the first representative of a novel oral and intravenous triterpenoid antifungal family for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred significant losses and negative cash flows from operations since its initial public offering in May 2014 and expects to continue to incur losses and negative cash flows for the foreseeable future. As a result, the Company had an accumulated deficit of $326.6 million at December 31, 2020 and limited capital resources to fund ongoing operations.   These capital resources primarily comprised cash and cash equivalents of $93.0 million at December 31, 2020. While the Company believes its capital resources are sufficient to fund the Company’s on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying consolidated financial statements, the Company's liquidity could be materially affected over this period by, among other things: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding; (2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events or unanticipated costs related to its development of ibrexafungerp; (4) its ability to potentially commercialize ibrexafungerp for the treatment of vaginal yeast infections and; (5) any other unanticipated material negative events or costs.  One or more of these events or costs could materially affect the Company’s liquidity.  If the Company is unable to meet its obligations when they become due, the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to its operating plan.  The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.  Intercompany balances and transactions are eliminated in consolidation. </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shelf Registration Filings</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On December 31, 2020 and September 11, 2020, the Company filed shelf registration statements on Form S-3 (File No. 333-251851 and File No. 333-248751, respectively) with the Securities and Exchange Commission (“SEC”), which were declared effective on January 8, 2021 and October 1, 2020, respectively (the “January 2021 Shelf Registration” and “October 2020 Shelf Registration”).  Both shelf registrations contain </span><span style="color:#000000;">a </span><span style="Background-color:#FFFFFF;">base prospectus which covers the offering, issuance and sale of such indeterminate number of shares of common stock and preferred stock, such indeterminate principal amount of debt securities, and such indeterminate number of warrants to purchase common stock, preferred stock and/or debt securities, which together shall have an aggregate initial offering price not to exceed $200.0 million.  </span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A <span style="Background-color:#FFFFFF;color:#000000;">prospectus is included in the October 2020 Shelf Registration covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $50.0 million of the Company’s common stock that may be issued and sold under a Controlled Equity Offering</span><span style="color:#000000;font-size:7pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">SM</sup></span><span style="Background-color:#FFFFFF;color:#000000;"> Sales Agreement with Cantor Fitzgerald &amp; Co. (“Cantor”) and/or Controlled Equity Offering</span><span style="color:#000000;font-size:7pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">SM</sup></span><span style="Background-color:#FFFFFF;color:#000000;"> Sales Agreement with Ladenburg Thalmann &amp; Co. Inc. (such agreements, the “Sales Agreements”).  These Sales Agreements were cancelled in December 2020.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2020, approximately $437.0 million of the securities registered under the Company’s effective shelf registrations, which include the January 2021 Shelf Registration, October 2020 Shelf Registration, and the Form S-3 shelf registration filed by the Company in August 2018 (effective September 14, 2018), are available to be offered, issued and sold by the Company.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Reverse Stock Split</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”), which became effective on Friday, July 17, 2020, (a) implementing a <span style="-sec-ix-hidden:F_000319">1-for-10 </span>reverse stock split of the Company’s common stock and (b) decreasing the number of authorized shares of the Company’s common stock from 250,000,000 shares to 100,000,000 shares.  <span style="Background-color:#FFFFFF;">On the effective date of July 17, 2020, the number of the Company’s issued and outstanding shares of common stock was decreased from 105,083,291 to 10,508,302 and the par value per common share remained unchanged.  No fractional shares were issued as a result of the reverse stock split.  </span>Stockholders who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof.  All share and per share amounts<span style="Background-color:#FFFFFF;"> presented in these consolidated financial statements have been retroactively adjusted for the reverse stock split and certain items in the prior period financial statements have been revised to conform to the current presentation.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of outstanding convertible notes or upon the exercise of stock options or warrants outstanding.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Use of Estimates</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates</span><span style="color:#000000;"> and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </span>Significant estimates include: determination of the fair value of stock-based compensation grants; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimates and assumptions utilized in measuring the fair values of the warrant and derivative liabilities each reporting period.</p> -326600000 93000000.0 200000000.0 200000000.0 50000000.0 437000000.0 250000000 100000000 105083291 105083291 10508302 10508302 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td> <td valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;margin-left:4.79%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents.  The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any significant losses in the account.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents.  <span style="color:#000000;">The Company reported cash, cash equivalents, and restricted cash of $93.3 million and $42.2 million as of December 31, 2020 and 2019, respectively.  See Note 8 for further details on the nature of the restricted cash.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Short-Term Investments</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's held-to-maturity investments in U.S. government securities, commercial paper, and its overnight repurchase agreement are carried at amortized cost and any premiums or discounts are amortized or accreted through the maturity date of the investment.  Any impairment that is not deemed to be temporary is recognized in the period identified.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warrant Liabilities</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for the outstanding warrants associated with the June 2016 public offering, March 2018 Public Offering, December 2019 Public Offering and December 2020 Public Offering as liabilities measured at fair value. The fair values of these warrants have been determined using the Black-Scholes valuation model ("Black-Scholes"). The warrants are subject to remeasurement at each balance sheet date, using Black-Scholes, with any changes in the fair value of the outstanding warrants recognized in the accompanying consolidated statements of operations. <span style="color:#000000;">See Notes 9 and 12 for further details.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Debt and Derivative Liabilities</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company’s issuance of its April 2020 and March 2019 6.0% Convertible Senior Notes (the “April 2020 Notes” and the “March 2019 Notes”), the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as long-term derivative liabilities in the Company’s balance sheet in accordance with <span style="color:#000000;">FASB Accounting Standards Codification (“</span>ASC”) 815, <span style="font-style:italic;">Derivatives and Hedging</span>.  The convertible debt and the derivative liabilities associated with the April 2020 Notes and March 2019 Notes are presented in total on the consolidated balance sheet as the convertible debt and derivative liabilities.  The convertible debt is carried at amortized cost.  The derivative liabilities will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the consolidated statements of operations in other expense (income).  See Notes 7 and 12 for further details.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting ibrexafungerp clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its consolidated </p> <p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Patent Expenses</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">• </span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">• </span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">• </span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.</span></p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amortization of Debt Issuance Costs and Discount</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s convertible debt is recorded net of debt issuance costs which comprised issuance costs and an advisory fee.  The portion of the debt issuance costs allocated to the convertible debt, based on the amount of proceeds allocated between the convertible debt and the derivative liability, is being amortized over the term of the convertible debt using the effective interest method in addition to the discount initially recognized for the fair value of the bifurcated derivative liability from the convertible debt.  Debt issuance costs allocated to the derivative liabilities were included in other expense as a component of the fair value adjustment for the year ended December 31, 2020.  The Company’s previous term loan with Solar Capital Ltd. (“Solar”), which was paid in full in March 2019 (see Note 7), was recorded net of debt discount which comprised issuance costs, customary closing and final fees, and the fair value of the warrants issued in conjunction with the term loan. The resulting debt discount was being amortized over the term of the term loan using the straight-line method, which approximated the effective interest method.  The amortization of debt issuance costs and discount is included in other expense within the accompanying consolidated statements of operations.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date.  The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Basic and Diluted Net Loss per Share of Common Stock</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates net loss per common share in accordance with <span style="color:#000000;">ASC</span> 260, <span style="font-style:italic;">Earnings Per Share</span>. Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">830,343</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">526,070</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding restricted stock units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,087</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,637</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with June 2016 Public Offering</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,867</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,867</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with March 2018 Public Offering - Series 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2019 Public Offering</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,472,205</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,472,205</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option to purchase common stock associated with December 2019 Public Offering</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">583,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2020 Public Offering - Series 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2020 Public Offering - Series 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance for the conversion of the March 2019 Notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance for the conversion of the April 2020 Notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,299,790</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with Solar loan agreement</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,243</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,243</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">          Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,602,545</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,049,365</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Segment and Geographic Information</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. The material assets of the Company were held in the United States for the years ended December 31, 2020 and 2019.  <span style="color:#000000;">In July 2019, the Company incorporated SCYNEXIS Pacific Pty Ltd, a wholly-owned subsidiary, in Sydney, Australia, for the initial purpose of conducting certain clinical trials and other research and development activities.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although all operations are primarily based in the United States, the Company generated a portion of its revenue from R-Pharm outside of the United States for the year ended December 31, 2019.  All of the Company's revenue in 2019 was generated from a non-refundable upfront payment received under a licensing and collaboration arrangement with a partner located in Russia.  All sales, including sales outside of the United States, are denominated in United States dollars.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span> (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, <span style="font-style:italic;">Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) </span>(“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted.  As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its consolidated financial statements.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <span style="font-style:italic;">Income Taxes: Simplifying the Accounting for Income Taxes</span> (“ASU 2019-12”). ASU 2019-12<span style="Background-color:#FFFFFF;"> simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, </span><span style="font-style:italic;Background-color:#FFFFFF;">Income Taxes</span><span style="Background-color:#FFFFFF;">, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company is currently evaluating the impact ASU 2019-12 will have on its consolidated financial statements.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU No. 2020-06, <span style="font-style:italic;">Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity</span> (“ASU 2020-06”). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share.  The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years.  As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its consolidated financial statements.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13, <span style="font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement</span> (“ASU 2018-13”). ASU 2018-13 removes, modifies and adds certain disclosure requirements in ASU 2018-13, Fair Value Measurement. ASU 2018-13 eliminates certain disclosures related to transfers and the valuation process, modifies disclosures for investments that are valued based on net asset value, clarifies the measurement uncertainty disclosure, and requires additional disclosures for Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The Company adopted ASU 2018-13 during the year ended December 31, 2020 and as a result, included the required additional disclosures for its Level 3 fair value measurements in its consolidated financial statements (see Note 12).  The Company did not identify any other material impacts of ASU 2018-13 on its consolidated financial statements.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:6pt;margin-top:6pt;margin-left:4.79%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents.  The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any significant losses in the account.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents.  <span style="color:#000000;">The Company reported cash, cash equivalents, and restricted cash of $93.3 million and $42.2 million as of December 31, 2020 and 2019, respectively.  See Note 8 for further details on the nature of the restricted cash.</span></p> 93300000 42200000 <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Short-Term Investments</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's held-to-maturity investments in U.S. government securities, commercial paper, and its overnight repurchase agreement are carried at amortized cost and any premiums or discounts are amortized or accreted through the maturity date of the investment.  Any impairment that is not deemed to be temporary is recognized in the period identified.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warrant Liabilities</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for the outstanding warrants associated with the June 2016 public offering, March 2018 Public Offering, December 2019 Public Offering and December 2020 Public Offering as liabilities measured at fair value. The fair values of these warrants have been determined using the Black-Scholes valuation model ("Black-Scholes"). The warrants are subject to remeasurement at each balance sheet date, using Black-Scholes, with any changes in the fair value of the outstanding warrants recognized in the accompanying consolidated statements of operations. <span style="color:#000000;">See Notes 9 and 12 for further details.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Convertible Debt and Derivative Liabilities</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company’s issuance of its April 2020 and March 2019 6.0% Convertible Senior Notes (the “April 2020 Notes” and the “March 2019 Notes”), the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as long-term derivative liabilities in the Company’s balance sheet in accordance with <span style="color:#000000;">FASB Accounting Standards Codification (“</span>ASC”) 815, <span style="font-style:italic;">Derivatives and Hedging</span>.  The convertible debt and the derivative liabilities associated with the April 2020 Notes and March 2019 Notes are presented in total on the consolidated balance sheet as the convertible debt and derivative liabilities.  The convertible debt is carried at amortized cost.  The derivative liabilities will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the consolidated statements of operations in other expense (income).  See Notes 7 and 12 for further details.</p> 0.060 <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting ibrexafungerp clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its consolidated </p> <p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Patent Expenses</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">• </span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">• </span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">• </span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.</span></p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amortization of Debt Issuance Costs and Discount</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s convertible debt is recorded net of debt issuance costs which comprised issuance costs and an advisory fee.  The portion of the debt issuance costs allocated to the convertible debt, based on the amount of proceeds allocated between the convertible debt and the derivative liability, is being amortized over the term of the convertible debt using the effective interest method in addition to the discount initially recognized for the fair value of the bifurcated derivative liability from the convertible debt.  Debt issuance costs allocated to the derivative liabilities were included in other expense as a component of the fair value adjustment for the year ended December 31, 2020.  The Company’s previous term loan with Solar Capital Ltd. (“Solar”), which was paid in full in March 2019 (see Note 7), was recorded net of debt discount which comprised issuance costs, customary closing and final fees, and the fair value of the warrants issued in conjunction with the term loan. The resulting debt discount was being amortized over the term of the term loan using the straight-line method, which approximated the effective interest method.  The amortization of debt issuance costs and discount is included in other expense within the accompanying consolidated statements of operations.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date.  The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Basic and Diluted Net Loss per Share of Common Stock</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates net loss per common share in accordance with <span style="color:#000000;">ASC</span> 260, <span style="font-style:italic;">Earnings Per Share</span>. Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">830,343</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">526,070</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding restricted stock units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,087</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,637</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with June 2016 Public Offering</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,867</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,867</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with March 2018 Public Offering - Series 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2019 Public Offering</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,472,205</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,472,205</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option to purchase common stock associated with December 2019 Public Offering</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">583,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2020 Public Offering - Series 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2020 Public Offering - Series 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance for the conversion of the March 2019 Notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance for the conversion of the April 2020 Notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,299,790</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with Solar loan agreement</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,243</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,243</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">          Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,602,545</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,049,365</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">830,343</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">526,070</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding restricted stock units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,087</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,637</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with June 2016 Public Offering</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,867</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,867</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with March 2018 Public Offering - Series 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2019 Public Offering</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,472,205</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,472,205</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option to purchase common stock associated with December 2019 Public Offering</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">583,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2020 Public Offering - Series 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2020 Public Offering - Series 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance for the conversion of the March 2019 Notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance for the conversion of the April 2020 Notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,299,790</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with Solar loan agreement</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,243</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,243</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">          Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,602,545</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,049,365</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 830343 526070 29087 96637 421867 421867 798810 798810 4472205 4472205 0 583333 6800000 0 6800000 0 1138200 1138200 1299790 0 12243 12243 22602545 8049365 <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Segment and Geographic Information</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. The material assets of the Company were held in the United States for the years ended December 31, 2020 and 2019.  <span style="color:#000000;">In July 2019, the Company incorporated SCYNEXIS Pacific Pty Ltd, a wholly-owned subsidiary, in Sydney, Australia, for the initial purpose of conducting certain clinical trials and other research and development activities.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although all operations are primarily based in the United States, the Company generated a portion of its revenue from R-Pharm outside of the United States for the year ended December 31, 2019.  All of the Company's revenue in 2019 was generated from a non-refundable upfront payment received under a licensing and collaboration arrangement with a partner located in Russia.  All sales, including sales outside of the United States, are denominated in United States dollars.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> 1 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span> (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, <span style="font-style:italic;">Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) </span>(“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted.  As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its consolidated financial statements.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <span style="font-style:italic;">Income Taxes: Simplifying the Accounting for Income Taxes</span> (“ASU 2019-12”). ASU 2019-12<span style="Background-color:#FFFFFF;"> simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, </span><span style="font-style:italic;Background-color:#FFFFFF;">Income Taxes</span><span style="Background-color:#FFFFFF;">, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company is currently evaluating the impact ASU 2019-12 will have on its consolidated financial statements.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU No. 2020-06, <span style="font-style:italic;">Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity</span> (“ASU 2020-06”). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share.  The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years.  As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its consolidated financial statements.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13, <span style="font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement</span> (“ASU 2018-13”). ASU 2018-13 removes, modifies and adds certain disclosure requirements in ASU 2018-13, Fair Value Measurement. ASU 2018-13 eliminates certain disclosures related to transfers and the valuation process, modifies disclosures for investments that are valued based on net asset value, clarifies the measurement uncertainty disclosure, and requires additional disclosures for Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The Company adopted ASU 2018-13 during the year ended December 31, 2020 and as a result, included the required additional disclosures for its Level 3 fair value measurements in its consolidated financial statements (see Note 12).  The Company did not identify any other material impacts of ASU 2018-13 on its consolidated financial statements.</p> 2020-12-31 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td> <td valign="top"> <p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Short-term Investments</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the held-to-maturity securities held at December 31, 2019 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,997</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">998</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">998</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Overnight repurchase agreement</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.3%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,494</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,495</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, the Company had $6.5 million of held-to-maturity investments which all matured as of December 31, 2020.  <span style="color:#000000;">The gross unrealized gains and losses for the Company's commercial paper and overnight repurchase agreement are not significant</span>.  The Company carries short-term investments at amortized cost. The fair value of the short-term investments is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the held-to-maturity securities held at December 31, 2019 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,997</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">998</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">998</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Overnight repurchase agreement</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.3%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,494</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,495</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 1996000 15000 14000 1997000 998000 0 0 998000 3500000 0 0 3500000 6494000 15000 14000 6495000 6500000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td> <td valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Prepaid Expenses and Other Current Assets</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.79%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research and development services</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,535</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,043</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other prepaid expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other receivable</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,876</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,165</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,988</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.79%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research and development services</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,535</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,043</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other prepaid expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other receivable</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,876</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,165</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,988</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 1535000 3043000 362000 252000 19000 19000 2876000 0 373000 674000 5165000 3988000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. </span></p></td> <td valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property and Equipment</p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following (in thousands): </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">580</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(282</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(172</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">298</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following (in thousands): </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">580</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(282</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(172</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">298</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 406000 406000 76000 73000 98000 98000 580000 577000 282000 172000 298000 405000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accrued Expenses</p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">991</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,296</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued employee bonus compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,190</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,798</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">960</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">707</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,141</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,801</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">991</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,296</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued employee bonus compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,190</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,798</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">960</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">707</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,141</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,801</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 991000 1296000 2190000 1798000 960000 707000 4141000 3801000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td> <td valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> Borrowings</p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">April 2020 Note Purchase Agreement</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 9, 2020, the Company entered into a <span style="Background-color:#FFFFFF;">Senior Convertible Note Purchase Agreement (the “April 2020 Note Purchase Agreement”) </span>and issued and sold to Puissance Life Science Opportunities Fund VI (“Puissance”) $10.0 million aggregate principal amount of its April 2020 Notes, resulting in net proceeds of approximately $9.5 million after deducting $0.5 million for an <span style="Background-color:#FFFFFF;">advisory fee and other issuance costs</span>  The April 2020 Notes were issued and sold for cash at a purchase price equal to 100% of their principal amount, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), due to the April 2020 Notes being issued to one financially sophisticated investor.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The April 2020 Notes will bear interest at a rate of 6.0% per annum, payable semiannually in arrears on April 15 and October 15 of each year, beginning October 15, 2020. The April 2020 Notes will mature on April 15, 2026, unless earlier converted, redeemed or repurchased.  The April 2020 Notes constitute general, senior unsecured obligations of the Company.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2020, the Company’s April 2020 Notes consists of the convertible debt balance of $1.2 million, presented net of the unamortized debt issuance costs allocated to the convertible debt of $0.1 million, and the bifurcated embedded conversion option derivative liability of $3.3 million.  In connection with the Company’s issuance of its April 2020 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, </span><span style="font-style:italic;Background-color:#FFFFFF;">Derivatives and Hedging</span><span style="Background-color:#FFFFFF;">, at its initial fair value of $8.1 million as the interest make-whole provision is settled in shares of common stock.  Debt issuance costs of $0.4 million initially allocated to the derivative liability were written off upon issuance of the April 2020 Notes and were recognized in the gain on the fair value adjustment for the derivative liability for the year ended December 31, 2020.  For the year ended December 31, 2020, the Company recognized a gain of $1.7 million on the fair value adjustment for the derivative liability and recognized $0.2 million in amortization of debt issuance costs and discount for the year ended December 31, 2020, related to the April 2020 Notes.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In June 2020, Puissance converted $2.0 million of the April 2020 Notes for 316,461 shares of common stock.  Upon conversion of the $2.0 million of the April 2020 Notes, the Company recognized a $0.8 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $2.0 million and the fair value of the consideration issued of $2.8 million.  In December 2020 and January 2021, Puissance converted the remaining $2.0 million and $6.0 million of the April 2020 Notes for 322,348 and 959,080 shares of common stock, respectively.</span><span style="font-weight:bold;color:#000000;">  </span><span style="color:#000000;">Upon conversion of the $2.0 million of the April 2020 Notes in December 2020, the Company recognized a $1.0 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $1.4 million and the fair value of the consideration issued of $2.4 million.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company estimated the fair value of the convertible debt and derivative liability for the April 2020 Notes using a binomial lattice valuation model and Level 3 inputs. At December 31, 2020, the fair value of the April 2020 Notes is $7.4 million.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The holders of the April 2020 Notes may convert their April 2020 Notes at their option at any time prior to the close of business on the business day immediately preceding April 15, 2026 into shares of the Company’s common stock. The initial conversion rate is 111.1108 shares of common stock per $1,000 principal amount of the April 2020 Notes, which is equivalent to an initial conversion price of approximately $9.00 per share, and is subject to adjustment in certain events described in the April 2020 Note Purchase Agreement. Holders who convert may also be entitled to receive, under certain circumstances, an “interest make-whole payment” (as defined in the April 2020 Note Purchase Agreement) payable in shares of common stock. In addition, following certain corporate events that occur prior to the maturity date, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its April 2020 Notes in connection with such a corporate event. Unless the Company seeks and receives stockholder approval, the number of shares that the Company may deliver in connection with a conversion of the April 2020 Notes, including those delivered in connection with an “interest make-whole payment” or a “make-whole fundamental change” (each as defined in the April 2020 Note Purchase Agreement), will not exceed a cap of 1,938,600 shares of common stock</span>.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On or after April 15, 2023, the Company has the right, at its election, to redeem all or any portion of the April 2020 Notes not previously converted if the last reported sale price per share of common stock exceeds 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. The redemption price will be 100% of the principal amount of the April 2020 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">If a “fundamental change” (as defined in the April 2020 Note Purchase Agreement) occurs, then, subject to certain exceptions, the Company must offer to repurchase the April 2020 Notes for cash at a repurchase price of 100% of the principal amount of the April 2020 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date.</span>  </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">March 2019 Note Purchase Agreement</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March 7, 2019, the Company entered into a Senior Convertible Note Purchase Agreement (the “March 2019 Note Purchase Agreement”) with Puissance.  Pursuant to the March 2019 Note Purchase Agreement, on March 7, 2019, the Company issued and sold to Puissance $16.0 million aggregate principal amount of its March 2019 Notes, resulting in $14.7 million in net proceeds after deducting $1.3 million for an advisory fee and other issuance costs.  The Company used the net proceeds to pay the remaining outstanding Solar term loan in full and recorded a loss on debt extinguishment of $0.8 million during the year ended December 31, 2019.  The loss on debt extinguishment of $0.8 million for the year ended December 31, 2019 was recognized as the difference between the reacquisition price of the outstanding Solar debt of $15.9 million and the $15.1 million net carrying value of the Solar debt obligation prior to repayment.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2020 and 2019, the Company’s March 2019 Notes consists of the convertible debt balance of $9.4 million and $8.3 million, presented net of the unamortized debt issuance costs allocated to the convertible debt of $0.4 million and $0.5 million, and the bifurcated embedded conversion option derivative liability of $2.7 million and $3.2 million, respectively.  In connection with the Company’s issuance of its March 2019 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, </span><span style="font-style:italic;Background-color:#FFFFFF;">Derivatives and Hedging</span><span style="Background-color:#FFFFFF;">, at its initial fair value of $7.0 million as the interest make-whole provision is settled in shares of common stock.  Debt issuance costs of $0.6 million initially allocated to the derivative liability were written off upon issuance of the March 2019 Notes and were recognized in the gain on the fair value adjustment for the derivative liability for the year ended December 31, 2019.  For the years ended December 31, 2020 and 2019, the Company recognized gains of $0.5 million and $1.6 million, respectively, on the fair value adjustment for the derivative liability.   For the years ended December 31, 2020 and 2019, the Company recognized $1.0 million and $1.1 million, respectively, in amortization of debt issuance costs and discount, related to the March 2019 Notes.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In April 2019, Puissance converted $2.0 million of the March 2019 Notes for 162,600 shares of common stock.  Upon conversion of the $2.0 million of the March 2019 Notes, the Company recognized a $0.2 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $2.8 million and the fair value of the consideration issued of $3.0 million</span>.  </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company estimated the fair value of the convertible debt and derivative liability for the March 2019 Notes using a binomial lattice valuation model and Level 3 inputs. At December 31, 2020 and 2019, the fair value of the convertible debt and derivative liability for the March 2019 Notes is $12.9 million and $11.7 million, respectively.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The March 2019 Notes were issued and sold for cash at a purchase price equal to 100% of their principal amount, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), due to the March 2019 Notes being issued to one financially sophisticated investor. The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased. The March 2019 Notes constitute general, senior unsecured obligations of the Company.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The holder of the March 2019 Notes may convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company’s common stock. The initial conversion rate is 73.9096 shares of common stock per $1,000 principal amount of March 2019 Notes, which is equivalent to an initial conversion price of approximately $13.53 and is subject to adjustment in certain events described in the March 2019 Note Purchase Agreement. The Holder upon conversion may also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of common stock. In addition, following certain corporate events that occur prior to the maturity date, the Company will, in certain circumstances, increase the conversion rate if the holder elects to convert its March 2019 Notes in connection with such a corporate event. Subject to adjustment in the conversion rate, the number of shares that the Company may deliver in connection with a conversion of the March 2019 Notes, including those delivered in connection with an interest make-whole payment, will not exceed a cap of 81 shares of common stock per $1,000 principal amount of the March 2019 Notes.  </span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On or after March 15, 2022, the Company has the right, at its election, to redeem all or any portion of the March 2019 Notes not previously converted if the last reported sale price per share of common stock exceeds 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. The redemption price will be 100% of the principal amount of the March 2019 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.  If a “fundamental change” (as defined in the March 2019 Note Purchase Agreement) occurs, then, subject to certain exceptions, the Company must offer to repurchase the March 2019 Notes for cash at a repurchase price of 100% of the principal amount of the March 2019 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Solar Loan Agreement</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On September 30, 2016, the Company entered into a loan agreement with Solar Capital Ltd. (“Solar”), in its capacity as administrative and collateral agent and as lender. Pursuant to the loan agreement, Solar was providing the Company with a 48-month secured term loan in the amount of $15.0 million.  The term loan bore interest at a floating rate equal to the LIBOR rate in effect plus 8.49%.  The Solar term loan was paid in full in March 2019</span>.</p> 2020-04-09 10000000.0 9500000 500000 1 The April 2020 Notes will bear interest at a rate of 6.0% per annum, payable semiannually in arrears on April 15 and October 15 of each year, beginning October 15, 2020. The April 2020 Notes will mature on April 15, 2026, unless earlier converted, redeemed or repurchased.   0.060 The April 2020 Notes will mature on April 15, 2026, unless earlier converted, redeemed or repurchased 2026-04-15 1200000 100000 3300000 8100000 400000 1700000 200000 2000000.0 316461 2000000.0 -800000 2000000.0 2800000 2000000.0 6000000.0 322348 959080 2000000.0 -1000000.0 1400000 2400000 7400000 holders of the April 2020 Notes may convert their April 2020 Notes at their option at any time prior to the close of business on the business day immediately preceding April 15, 2026 into shares of the Company’s common stock. 111.1108 1000 9.00 1938600 2023-04-15 1.30 20 30 1 1 2019-03-07 16000000.0 14700000 1300000 -800000 -800000 15900000 15100000 9400000 8300000 400000 500000 2700000 3200000 7000000.0 600000 500000 1600000 1000000.0 1100000 2000000.0 162600 2000000.0 -200000 2800000 3000000.0 12900000 11700000 1 The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased.  0.060 The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased 2025-03-15 holder of the March 2019 Notes may convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company’s common stock. 73.9096 1000 13.53 81 1000 2022-03-15 1.30 20 30 1 1 P48M 15000000.0 0.0849 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March 1, 2018, the Company entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey, that the Company identified as an operating lease under ASC 842 (the “Lease”). The lease term is eleven years from August 1, 2018, the commencement date, with total lease payments of $7.3 million over the lease term. The Company has the option to renew for two consecutive <span style="-sec-ix-hidden:F_000502">five-year</span> periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which will be reduced by fifty-five thousand dollars every two years for ten years after the commencement of the lease.  The security deposit is classified as restricted cash </span>in the accompanying consolidated balance sheets<span style="Background-color:#FFFFFF;">.</span>  </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The consideration in the Lease allocated to the single lease component includes the fixed payments for the right to use the office space as well as common area maintenance.  The Lease also contains costs associated with certain expense escalation, property taxes, insurance, parking, and utilities which are all considered variable payments and are excluded from the operating lease liability.  The incremental borrowing rate utilized approximated the prevailing market interest rate the Company would incur to borrow a similar amount equal to the total Lease payments on a collateralized basis over the term of the Lease.  </span>The following table summarizes certain quantitative information associated with the amounts recognized in the accompanying consolidated financial statements for the Lease (dollars in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">664</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">664</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">705</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of operating lease liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">507</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remaining Lease term (years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000514">8.59</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000515">9.59</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Future minimum lease payments for all operating leases as of December 31, 2020 are as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">527</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">730</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">744</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,789</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The presentation of the operating lease liability and right-of-use asset as of December 31, 2020 are as follows (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of future minimum lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,326</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, long-term portion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,274</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,326</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Difference between future minimum lease payments and discounted cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,696</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use asset</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License Arrangements with Potential Future Expenditures</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had a license arrangement with Merck Sharp &amp; Dohme Corp., or Merck, as amended, that involves potential future expenditures. Under the license arrangement, executed in May 2013, the Company exclusively licensed from Merck its rights to ibrexafungerp in the field of human health.  In January 2014, Merck assigned the patents related to ibrexafungerp that it had exclusively licensed to the Company.  Ibrexafungerp is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck was originally eligible to receive milestone payments from the Company that could total $19.0 million upon occurrence of specific events, including initiation of a Phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets, and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of ibrexafungerp. The aggregate royalties are mid- to high-single digits. </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first Phase 2 clinical trial of a product containing the ibrexafungerp compound (the “Deferred Milestone”). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the ibrexafungerp compound.  In December 2016 and January 2018, the Company entered into second and third amendments to the license agreement with Merck which clarified what would constitute the initiation of a Phase 3 clinical trial for the purpose of milestone payment.  In January 2019, a milestone payment became due to Merck as a result of the initiation of the VANISH Phase 3 VVC program and was paid in March 2019. The milestone payment was recognized in the consolidated statement of operations in research and development expense for the year ended December 31, 2019 and is included in cash used in operating activities on the consolidated statement of cash flows.  <span style="Background-color:#FFFFFF;">On December 2, 2020, the Company entered into a fourth amendment to the license agreement with Merck.  The amendment eliminates two cash milestone payments that the Company would have paid to Merck upon the first filing of a NDA, triggered by the FDA acceptance for filing of its NDA for ibrexafungerp for the treatment of VVC, and first marketing approval in the U.S., anticipated in June 2021 for the Company’s NDA for ibrexafungerp for the treatment of VVC.  Such cash milestone payments would have been creditable against future royalties owed to Merck on net sales of ibrexafungerp. With the amendment, these milestones will not be paid in cash and, accordingly, credits will not accrue. Pursuant to the amendment, the Company will also forfeit the credits against future royalties that it had accrued from a prior milestone payment already paid to Merck.  All other key terms of the license agreement are unchanged.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Development Arrangements</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into, and expects to continue to enter into, contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other License Arrangements</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2016, the Company entered into an asset purchase agreement with UK-based Cypralis Limited (or "Cypralis"), a life sciences company, for the sale of its cyclophilin inhibitor assets. Cypralis also acquired all patents, patent applications and know-how related to the acquired portfolio. In connection with the asset purchase agreement, the Company is eligible to receive milestone payments upon the successful progression of Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. The Company retains the right to repurchase the portfolio assets from Cypralis if abandoned or deprioritized.  For the years ended December 31, 2020 and 2019, there was no revenue recognized associated with this agreement given the variable consideration associated with the sale of intellectual property to Cypralis was fully constrained.  Additionally, in October 2014 the Company entered into a license agreement with Waterstone Pharmaceutical HK Limited (or “Waterstone”) and granted Waterstone an exclusive, worldwide license to develop and commercialize certain non-strategic compounds.  The Company is entitled to receive potential milestones and royalties from Waterstone and for the years ended December 31, 2020 and 2019, there was no revenue recognized by the Company associated with this agreement given the variable consideration was fully constrained.</p> 19275 P11Y 7300000 The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which will be reduced by fifty-five thousand dollars every two years for ten years after the commencement of the lease 300000 55000 The following table summarizes certain quantitative information associated with the amounts recognized in the accompanying consolidated financial statements for the Lease (dollars in thousands): <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">664</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">664</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">705</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of operating lease liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">507</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remaining Lease term (years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000514">8.59</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000515">9.59</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 664000 664000 51000 41000 715000 705000 507000 497000 0.15 0.15 Future minimum lease payments for all operating leases as of December 31, 2020 are as follows (in thousands): <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">527</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">730</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">744</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,789</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 517000 527000 715000 730000 744000 2789000 6022000 <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The presentation of the operating lease liability and right-of-use asset as of December 31, 2020 are as follows (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of future minimum lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,326</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, long-term portion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,274</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,326</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Difference between future minimum lease payments and discounted cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,696</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.48%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use asset</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 3326000 52000 3274000 3326000 2696000 2999000 19000000.0 0 0 0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders’ Equity</p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Authorized, Issued, and Outstanding Common Shares</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s authorized common stock has a par value of $0.001 per share and consists of 100,000,000 shares as of December 31, 2020 and 2019; 19,663,698 and 9,741,372 shares were issued and outstanding at December 31, 2020, and December 31, 2019, respectively.  On June 18, 2019, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 125,000,000 to 250,000,000.  On July 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, which became effective on Friday, July 17, 2020, (a) implementing a 1-for-10 reverse stock split of the Company’s common stock and (b) decreasing the number of authorized shares of the Company’s common stock from 250,000,000 shares to 100,000,000 shares.  </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.39%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of outstanding convertible notes or upon the exercise of stock options or warrants outstanding. No fractional shares were issued as a result of the reverse stock split.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shares Reserved for Future Issuance</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved shares of common stock for future issuance as follows:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">830,343</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">526,070</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding restricted stock units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,087</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,637</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with June 2016 Public Offering</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,867</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,867</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with March 2018 Public Offering - Series 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2019 Public Offering</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,472,205</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,472,205</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option to purchase common stock associated with December 2019 Public Offering</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">583,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2020 Public Offering - Series 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2020 Public Offering - Series 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prefunded warrants to purchase common stock associated with December 2020 Public Offering</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,260,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with Solar loan agreement</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,243</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,243</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance for the conversion of the March 2019 Notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance for the conversion of the April 2020 Notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,299,790</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance under 2014 Equity Incentive Plan  (Note 11)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,488</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,478</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance under Employee Stock Purchase Plan (Note 11)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,895</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,423</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance under 2015 Inducement Award Plan (Note 11)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,050</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,550</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total common shares reserved for future issuance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,028,978</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,143,816</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Liquidation Rights</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any liquidation or dissolution of the Company, the holders of the common stock are entitled to the remaining assets of the Company legally available for distribution.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dividends and Voting Rights</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the common stock are entitled to receive dividends if and when declared by the Company.  </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preferred Stock</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 7, 2014, the Company amended and restated its articles of incorporation relating to its approved capital structure. The Company’s board of directors has authorized the Company, subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of preferred stock with a par value of $0.001 per share in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions. The Company’s board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series </p> <p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">then outstanding, without any further vote or action by the stockholders. The Company</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">’</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. There were </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of preferred stock issued and outstanding as of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">December 2020 Public Offering</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On December 17, 2020, the Company completed a public offering (the “December 2020 Public Offering”) of its common stock and warrants pursuant to the Company’s effective shelf registration.  The Company sold an aggregate of (a) 8,340,000 shares of the Company’s common stock, par value $0.001 per share, (b) pre-funded warrants, in lieu of common stock, to purchase 5,260,000 shares of the Company’s common stock, par value $0.001 per share, and (c) two series of warrants, which will accompany the common stock or pre-funded warrants, to purchase up to an aggregate of 13,600,000 shares of the Company’s common stock.  The pre-funded warrants entitle the holders to purchase up to 5,260,000 shares of common stock and have an unlimited term and an exercise price of $0.001 per share. Each of the two series of warrants entitle the holders to purchase up to an aggregate of 6,800,000 shares of common stock. </span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The prefunded warrants are classified as equity in accordance with ASC 815, <span style="font-style:italic;">Derivatives and Hedging</span> given the prefunded warrants are indexed to the Company’s own shares of common stock and meet the requirements to be classified in equity.  The prefunded warrants were recorded at their relative fair value at issuance in the stockholders’ equity section of the balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per share calculation for the year ended December 31, 2020 given their nominal exercise price. </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Series 1 warrants have a <span style="-sec-ix-hidden:F_000598">one-year</span> term and an exercise price of $7.33 per share, and Series 2 warrants have a <span style="-sec-ix-hidden:F_000600">three-and-a-half-year</span> term and an exercise price of $8.25 per share.  There is not expected to be any trading market for the pre-funded warrants, the Series 1 warrants or the Series 2 warrants issued in the offering. Each warrant is exercisable immediately upon issuance, subject to certain limitations on beneficial ownership.  The Series 1 and Series 2 warrants that accompany the pre-funded warrants have an additional provision, if certain beneficial ownership limitations are met, entitling the holder thereof to purchase a pre-funded warrant rather than a share of common stock at the warrant exercise price less the exercise price of the pre-funded warrant purchased. The price to the public in the offering was $6.25 per share of common stock and accompanying warrants, or in the case of pre-funded warrants, $6.249 per pre-funded warrant and accompanying warrants. The December 2020 Public Offering resulted in approximately $79.5 million of net proceeds to the Company after deducting the underwriting discount and offering expenses. </span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">December 2019 Public Offering</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On December 12, 2019, </span>the Company completed a public offering (the “December 2019 Public Offering”) of its common stock and warrants pursuant to the Company's effective Shelf Registration.  The Company sold an aggregate of <span style="Background-color:#FFFFFF;">3,888,888</span> shares of the Company’s common stock and warrants to purchase up to an aggregate of 3,888,888 shares of the Company’s common stock at a public offering price of $9.00 per share and accompanying warrant.  Net proceeds from the December 2019 Public Offering were approximately $32.5 million, after deducting the underwriting discount and offering expenses.  In addition, the Company granted to the underwriters an option to purchase up to 583,333 additional shares of common stock and/or warrants to purchase up to an aggregate of an additional 583,333 shares of common stock, in each case at the public offering price, less underwriting discounts and commissions. The underwriters exercised their option to purchase 583,333 warrants in December 2019.  The option to purchase up to 583,333 additional shares of common stock was not exercised by the underwriters and the option expired in January 2020.  </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The warrants to purchase shares of common stock are immediately exercisable and expire on the earlier of (i) such date that is six months after the Company publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023, and have an exercise price of $11.0 per share. There is not expected to be any trading market for the warrants. Each warrant is exercisable immediately upon issuance, subject to certain limitations on beneficial ownership.  </span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">March 2018 Public Offering</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March 8, 2018, </span>the Company completed a public offering (the “March 2018 Public Offering”) of its common stock and warrants pursuant to the Company’s effective shelf registration.  The Company sold an aggregate of <span style="Background-color:#FFFFFF;">1,775,150</span> shares of the Company’s common stock and warrants to purchase up to 2,130,180 shares of the Company’s common stock at a public offering price of $16.90 per share.  </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"> Each purchaser received a warrant to purchase 0.75 of a share of common stock (the “March 2018 Series 1 warrants”) and 0.45 of a share of common stock (the “March 2018 Series 2 warrants”) for each share purchased in the March 2018 Public Offering.  The March 2018 Series 1 warrants to purchase in the aggregate up to 1,331,370 shares of common stock had a <span style="-sec-ix-hidden:F_000622">53-week</span> term and an exercise price of $18.5 per share, and the March 2018 Series 2 warrants to purchase in the aggregate up to 798,810 shares of common stock have a <span style="-sec-ix-hidden:F_000625">five-year</span> term and an exercise price of $20.0 per share.  There is not expected to be any market for the warrants and each warrant is exercisable immediately upon issuance, subject to certain limitations on </span></p> <p style="margin-bottom:6pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">beneficial ownership.  During the year ended December 31, 2019, there were </span>11,550<span style="Background-color:#FFFFFF;"> of the </span><span style="Background-color:#FFFFFF;">March 2018 </span><span style="Background-color:#FFFFFF;">Series 1 warrants exercised for total proceeds of $</span><span style="Background-color:#FFFFFF;">0.2</span><span style="Background-color:#FFFFFF;"> million and the </span><span style="Background-color:#FFFFFF;">March 2018 </span><span style="Background-color:#FFFFFF;">Series 1 warrants expired on </span><span style="Background-color:#FFFFFF;">March 14, 2019</span><span style="Background-color:#FFFFFF;">.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">June 2016 Public Offering</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 21, 2016, the Company completed a public offering (the “June 2016 Public Offering”) and sold 937,500 shares of its common stock and warrants to purchase up to 421,867 shares of the Company’s common stock.  Each purchaser received a warrant to purchase 0.45 of a share for each share purchased in the June 2016 Public Offering. There is not expected to be any trading market for the warrants. Each warrant was exercisable immediately upon issuance, will expire five years from the date of issuance, and has an exercise price of $30.0 per share.  </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Warrant Liabilities</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The June 2016, March 2018, December 2019, and December 2020 warrants contain a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, <span style="font-style:italic;">Distinguishing Liabilities from Equity</span>, requires that these warrants be classified as liabilities. The fair values of these warrants have been determined using the Black-Scholes valuation model, and the changes in the fair value are recorded in the accompanying consolidated statements of operations.  The June 2016 and December 2020 Series 1 warrant liabilities are recorded as current liabilities in the accompanying consolidated balance sheet.  During the years ended December 31, 2020 and 2019, the Company recorded losses of $5.2 million and $4.5 million, respectively, due to the change in fair value of the warrant liabilities.  I<span style="color:#000000;">ssuance costs of $1.9 million and $1.0 million initially allocated to the December 2020 Public Offering and December 2019 Public Offering warrant liabilities, respectively, were written off upon settlement and were recognized in the loss on the fair value adjustment for the warrant liabilities for the years ended December 31, 2020 and 2019, respectively.</span>  As of December 31, 2020, the fair value of the warrant liabilities was $51.2 million.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Common Stock Purchase Agreement</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On April 10, 2020, the Company entered into the Common Stock Purchase Agreement with Aspire Capital pursuant to which the Company has the right to sell to Aspire Capital from time to time in its sole discretion up to $20.0 million in shares of the Company’s common stock over the next 30 months, subject to certain limitations and conditions set forth in the Common Stock Purchase Agreement.  The aggregate number of shares that we can sell to Aspire Capital under the Common Stock Purchase Agreement may in no case exceed 1,956,547 shares of the Company’s common stock (which is equal to approximately 19.99% of the common stock outstanding on the date of the Common Stock Purchase Agreement), including the 70,910 commitment shares (the Exchange Cap), unless either (a) shareholder approval is obtained to issue more, in which case the Exchange Cap will not apply, or (b) the average purchase price of all shares sold under the Common Stock Purchase Agreement exceeds $8.461; provided that at no time shall Aspire Capital (together with its affiliates) beneficially own more than 19.99% of the Company’s common stock.  During the year ended December 31, 2020, the Company sold 125,000 shares of its common stock under the Common Stock Purchase Agreement for gross proceeds of $0.6 million.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Under the Common Stock Purchase Agreement, on any trading day selected by the Company, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”), directing Aspire Capital (as principal) to purchase up to 25,000 shares of Common Stock per business day, up to $20.0 million of common stock in the aggregate at a per share price (the “Purchase Price”) equal to the lesser of:</span></p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:1.41%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">• </span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">the lowest sale price of Common Stock on the purchase date; or</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:1.41%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">• </span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">the arithmetic average of the three (3) lowest closing sale prices for Common Stock during the ten (10) consecutive trading days ending on the trading day immediately preceding the purchase date.</span></p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company and Aspire Capital also may mutually agree to increase the number of shares that may be sold to as much as an additional 200,000 shares per business day.</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital in an amount equal to at least 25,000 shares, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a “VWAP Purchase Notice”) directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of Common Stock traded on its principal market on the next trading day (the “VWAP Purchase Date”), subject to a maximum number of shares the Company may determine.  The purchase price per share pursuant to such VWAP Purchase Notice is generally the lessor of (i) the closing sale price on the VWAP Purchase Date, or (ii) 97% of the volume-weighted average price for common stock traded on its principal market on the VWAP Purchase Date.  </span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Purchase Price will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the Purchase Price. The Company may deliver multiple Purchase Notices and VWAP Purchase Notices to Aspire Capital from time to time during the term of the Common Stock Purchase Agreement, so long as the most recent purchase has been completed.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Common Stock Purchase Agreement provides that the Company and Aspire Capital shall not effect any sales under the Common Stock Purchase Agreement on any purchase date where the closing sale price of common stock is less than</span> <span style="Background-color:#FFFFFF;">$0.25.  There are no trading volume requirements or restrictions under the Common Stock Purchase Agreement, and the Company will control the timing and amount of sales of common stock to Aspire Capital.  Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as directed by the Company in accordance with the Common Stock Purchase Agreement.  There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the Common Stock Purchase Agreement.  In consideration for entering into the Common Stock Purchase Agreement, concurrently with the execution of the Common Stock Purchase Agreement, the Company issued to Aspire Capital 70,910 shares of common stock (the “Commitment Shares”).  The fair value of the Commitment Shares of $0.6 million was recognized in other expense in the consolidated statements of operations for the year ended December 31, 2020.  The Common Stock Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of common stock during any time prior to the termination of the Common Stock Purchase Agreement. Any proceeds that the Company receives under the Common Stock Purchase Agreement are expected to be used for general corporate purposes, including working capital.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warrant Associated with Solar Loan Agreement</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to a loan agreement, the Company issued to Solar a warrant to purchase an aggregate of up to 12,243 shares of the Company’s common stock at an exercise price of $36.754 per share. The warrant will expire five years from the date of the grant. The warrant was classified as equity and recorded at its relative fair value at issuance in the stockholders’ equity section of the balance sheet. </p> 0.001 0.001 100000000 100000000 19663698 19663698 9741372 9741372 125000000 250000000 1-for-10 250000000 100000000 0 0 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved shares of common stock for future issuance as follows:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">830,343</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">526,070</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding restricted stock units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,087</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,637</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with June 2016 Public Offering</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,867</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,867</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with March 2018 Public Offering - Series 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2019 Public Offering</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,472,205</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,472,205</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option to purchase common stock associated with December 2019 Public Offering</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">583,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2020 Public Offering - Series 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with December 2020 Public Offering - Series 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prefunded warrants to purchase common stock associated with December 2020 Public Offering</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,260,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock associated with Solar loan agreement</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,243</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,243</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance for the conversion of the March 2019 Notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance for the conversion of the April 2020 Notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,299,790</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance under 2014 Equity Incentive Plan  (Note 11)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,488</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,478</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance under Employee Stock Purchase Plan (Note 11)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,895</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,423</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For possible future issuance under 2015 Inducement Award Plan (Note 11)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,050</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,550</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total common shares reserved for future issuance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,028,978</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,143,816</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 830343 526070 29087 96637 421867 421867 798810 798810 4472205 4472205 0 583333 6800000 0 6800000 0 5260000 0 12243 12243 1138200 1138200 1299790 0 146488 55478 5895 7423 14050 31550 28028978 8143816 5000000 0.001 0 0 0 0 8340000 0.001 5260000 0.001 13600000 5260000 0.001 6800000 7.33 8.25 6.25 6.249 79500000 3888888 3888888 9.00 32500000 583333 583333 583333 583333 2020-01 2023-06-12 11.0 1775150 2130180 16.90 0.75 0.45 1331370 18.5 798810 20.0 11550 200000 2019-03-14 937500 421867 0.45 P5Y 30.0 5200000 4500000 1900000 1000000.0 51200000 20000000.0 1956547 0.1999 70910 8.461 0.1999 125000 600000 25000 20000000.0 3 10 200000 25000 0.30 0.97 0.25 70910 600000 12243 36.754 P5Y <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s consolidated financial statements include a total tax benefit of $3.1 million and zero on loss before taxes of $58.3 million and $53.7 million for the years ended December 31, 2020 and 2019, respectively, and was generated entirely in the United States and Australia. Reconciliations of the differences between the benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (dollars in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent of Pretax Income</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent of Pretax Income</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes from continuing operations at statutory rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,250</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,279</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,108</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,778</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State effect of permanent items</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rate change</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(905</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants issuance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">733</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">883</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOL sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D credit adjustment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,760</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,396</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,721</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income tax benefit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,148</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of deferred tax assets and liabilities as of December 31, 2020 and 2019 are as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax assets (liabilities)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,591</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,436</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">935</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">945</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(823</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(856</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,936</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,073</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,291</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,984</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Total deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,078</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,689</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowances</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,078</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,689</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:0pt;margin-bottom:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company had available federal net operating loss (“NOL”) carryforwards of approximately $294.4 million and $242.4 million, respectively, and state and net operating loss carryforwards of approximately $202.7 million and $178.2 million, respectively.  Approximately $169.6 million of the federal NOLs can be carried forward to future tax years and expire at various times through 2037. The federal NOLs generated in December 31, 2020 and 2019 of approximately $52.0 million and $47.5 million, respectively, are carried forward indefinitely and do not expire.  The Company’s state and net operating loss carryforwards began to expire in 2019.  As of December 31, 2020, the Company had available federal research and development credit carryforwards of $5.3 million which begin to expire in 2022.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The New Jersey Technology Business Tax Certificate Transfer (NOL) program, administered by the New Jersey Economic Development Authority, enables approved biotechnology companies to sell their unused net operating losses (“NOLs”) and research and development tax credits to unaffiliated, profitable corporate taxpayers in the State of New Jersey up to a maximum lifetime benefit of $20.0 million per business.   As of December 31, 2020, the Company has received approximately $9.9 million under the program.  In April 2020, the Company received a cash receipt of approximately $3.1 million, from the sale of its state NOLs and research and development credits and recognized an income tax benefit of $3.1 million<span style="font-size:12pt;"> </span> for the year ended December 31, 2020 in the statement of operations.  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 22, 2017, the “Tax Cuts and Jobs Act” was signed into law.  The tax reform has the following effects on the Company: (1) permanently reduces the maximum corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017, (2) allows temporary 100% expensing for certain business assets and property placed in service after September 27, 2018 and before January 1, 2023, (3) disallows NOL carrybacks but allows for the indefinite carryforward of those NOLs which applies to losses arising in tax years beginning after December 31, 2018 and, (4) limits NOL deductions for each year equal to the lesser of the available carryover or 80% of a taxpayer’s pre-NOL deduction taxable income. This applies to losses arising in tax years ending on or after December 31, 2017.  As of December 31, 2020 and 2019, the Company has concluded that it is more likely than not that the Company will not realize the benefit of its deferred tax assets due to its history of losses. Accordingly, the net deferred tax assets have been fully reserved.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Section 382 of the Internal Revenue Code of 1986, as amended, a change in equity ownership of greater than 50% within a three-year period results in an annual limitation on the Company’s ability to utilize its NOL carryforwards created during the tax periods prior to the change in ownership. The Company has determined that ownership changes have occurred and as a result, a portion of the Company’s NOL carryforwards are limited.  Because the Company has incurred cumulative net operating losses since inception, all tax years remain open to examination by U.S. federal and state income tax authorities.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies ASC 740-10-25-5, <span style="font-style:italic;">Income Taxes</span>, formerly FASB Interpretation No. 48, <span style="font-style:italic;">Accounting for Uncertainty in Income Taxes</span>, as amended, on January 1, 2009. The difference between the tax benefit recognized in the financial statements and the tax benefit claimed in the tax return is referred to as an unrecognized tax benefit.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits as of December 31, 2020 and 2019 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefit—January 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions of current period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions of prior periods</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rate change</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefit—December 31</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of the unrecognized tax benefits would, if recognized, affect the effective tax rate because the Company has recorded a valuation allowance to fully offset federal and state deferred tax assets. The Company has no tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within the coming year. The Company has $0 provided for interest and penalties associated with uncertain tax positions.</p> -3100000 0 -58300000 -53700000 Reconciliations of the differences between the benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (dollars in thousands): <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent of Pretax Income</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent of Pretax Income</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes from continuing operations at statutory rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,250</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,279</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,108</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,778</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State effect of permanent items</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rate change</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(905</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants issuance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">733</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">883</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOL sale</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D credit adjustment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,760</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,396</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,721</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income tax benefit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,148</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> -12250000 0.210 -11279000 0.210 -4108000 0.070 -3778000 0.070 78000 -0.001 285000 -0.005 96000 -0.002 100000 -0.002 0 -905000 0.016 131000 -0.002 733000 -0.014 206000 -0.003 883000 -0.015 301000 -0.005 0 -2000 0 2760000 0.051 12396000 -0.213 16721000 -0.311 -3148000 0.054 0 0 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of deferred tax assets and liabilities as of December 31, 2020 and 2019 are as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax assets (liabilities)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,591</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,436</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">935</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">945</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(823</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(856</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,936</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,073</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,291</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,984</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Total deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,078</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,689</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowances</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,078</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,689</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 148000 107000 2591000 2436000 935000 945000 823000 856000 70936000 58073000 5291000 5984000 79078000 66689000 79078000 66689000 0 0 294400000 242400000 202700000 178200000 169600000 52000000.0 47500000 2019 5300000 2022 20000000.0 9900000 3100000 -3100000 0.35 0.21 1 0.80 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits as of December 31, 2020 and 2019 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefit—January 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions of current period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions of prior periods</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rate change</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefit—December 31</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 436000 436000 0 0 0 0 0 0 436000 436000 0 0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock-based Compensation</p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2009 Stock Option Plan</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a share-based compensation plan (the “2009 Stock Option Plan”) under which the Company granted options to purchase shares of common stock to employees, directors, and consultants as either incentive stock options or nonqualified stock options. Incentive stock options could be granted with exercise prices not less than 100% to 110% of the fair </p> <p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">market value of the common stock. Options granted under the plan generally vest over </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">three to four years</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and expire in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 years</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from the date of grant.</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2014 Equity Incentive Plan</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2014, the Company’s board of directors adopted the 2014 Equity Incentive Plan (“2014 Plan”), which was subsequently ratified by its stockholders and became effective on May 2, 2014 (the “Effective Date”). The 2014 Plan, as amended on June 18, 2014 and February 25, 2015, is the successor to and continuation of the 2009 Stock Option Plan. As of the Effective Date, no additional awards will be granted under the 2009 Stock Option Plan, but all stock awards granted under the 2009 Stock Option Plan prior to the Effective Date will remain subject to the terms of the 2009 Stock Option Plan. All awards granted on and after the Effective Date will be subject to the terms of the 2014 Plan. The 2014 Plan provides for the grant of the following awards: (i) incentive stock options, (ii) nonstatutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, and (vi) other stock awards. Employees, directors, and consultants are eligible to receive awards.  Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2014 Plan, after giving effect to the increases to the share reserve approved by the Company’s stockholders in September 2014, and June 2015, but excluding the automatic increases discussed below, the aggregate number of shares of common stock that could be issued from and after the Effective Date (the “share reserve”) could not exceed the sum of (i) 112,273 new shares, (ii) the shares that represented the 2009 Stock Option Plan’s available reserve on the Effective Date, and (iii) any returning shares from the 2009 Stock Option Plan. Under the 2014 Plan, the share reserve will automatically increase on January 1st of each year, for a period of not more than 10 years, commencing on January 1, 2015, and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year. The board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the 2014 Plan, on January 1, 2020 and 2019, the Company automatically added 389,650 and 191,887 shares to the total number shares of common stock available for future issuance under the 2014 Plan, respectively. As of December 31, 2020, there were 146,488 shares of common stock available for future issuance under the 2014 Plan.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2015 Inducement Plan</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 26, 2015, the Company's board of directors adopted the 2015 Inducement Plan (“2015 Plan”). The 2015 Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to persons not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to the individuals’ entering into employment with the Company within the meaning of NASDAQ Listing Rule 5635I(4).  The 2015 Plan had an initial share reserve covering 45,000 shares of common stock.  <span style="color:#000000;">On June 9, 2019, the Company’s board of directors amended the 2015 Plan, and the initial share reserve for the 2015 Plan was increased from 45,000 to 90,000 shares of common stock.</span>  During the year ended December 31, 2020, there were 17,500 granted options of the Company’s common stock under the 2015 Plan. <span style="color:#000000;">As of December 31, 2020, there were 14,050 shares of common stock available for future issuance under the 2015 Plan.  During the year ended December 31, 2019, there were 11,500 granted options of the Company’s common stock under the 2015 Plan.  </span>As of December 31, 2019, there were 31,550 shares of common stock available for future issuance under the 2015 Plan.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Option Valuation Method</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of a stock option is estimated using an option-pricing model that takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock, and the risk-free interest rate for the expected term of the option. The Company has used the simplified method in calculating the expected term of all option grants based on the vesting period. Compensation costs related to share-based payment transactions are recognized in the financial statements upon satisfaction of the requisite service or vesting requirements and forfeitures are recorded as incurred.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected to use the Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable rather than for use in estimating the fair value of stock options subject to vesting and transferability restrictions. Using the Black-Scholes option-pricing model, the weighted-average fair value of options granted during 2020 and 2019 was $4.83 and $7.50 per option, respectively. The aggregate fair value of options granted during 2020 and 2019 was $1.7 million and $1.3 million, respectively. The assumptions used to estimate fair value and the resulting grant date fair values are as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-employee Directors</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64.67</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.47</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.55</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65.36</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.47</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.11</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000790">5.97</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000791">6.03</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000796">5.50</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000797">5.54</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The activity for the 2009 Plan, 2014 Plan and 2015 Plan for the years ended December 31, 2020 is summarized as follows:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value ($000)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding — December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">526,070</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.55</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000812">7.62</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">349,437</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(166</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.60</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/expired</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,998</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.50</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding — December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">830,343</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.52</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000813">7.71</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable — December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,802</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.47</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000814">6.74</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested or expected to vest —December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">830,343</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.52</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000815">7.71</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intrinsic values in the table above represent the total intrinsic value (the difference between the Company’s closing stock price as of December 31, 2020, and the exercise price multiplied by the number of options). </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total fair value of shares vested for both the years ended December 31, 2020 and 2019 was $1.3 million and $1.5 million, respectively.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, there was approximately $2.0 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the plan. That cost is expected to be recognized over a weighted-average period of 2.4 years.</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock unit ("RSU") activity under the 2014 Plan and 2015 Plan for the years ended December 31, 2020, is summarized as follows:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,637</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.18</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,695</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.18</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78,859</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.05</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,386</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.68</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,087</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.52</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of RSUs is based on the market price of the Company's common stock on the date of grant.  RSUs generally vest 25% annually over a four year period from the date of grant. Upon vesting, the RSUs are net share settled to cover the required withholding tax with the remaining shares issued to the holder.  The Company recognizes compensation expense for such awards ratably over the corresponding vesting period.  As of December 31, 2020, there was approximately $0.2 million of total unrecognized compensation cost related to unvested RSU share-based compensation.  That cost is expected to be recognized over a weighted-average period of 2.8 years.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2014 Employee Stock Purchase Plan</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (“2014 ESPP”), which was subsequently ratified by the Company’s stockholders and became effective on May 2, 2014. The purpose of the 2014 ESPP is to provide means by which eligible employees of the Company and of certain designated related corporations may be given an opportunity to purchase shares of the Company’s common stock, and to seek and retain services of new and existing employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. Common stock that may be issued under the 2014 ESPP will not exceed 4,779 shares, plus the number of shares of common stock that are automatically added on January 1st of each year for a period of ten years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 2,941 shares of common stock. Similar to the 2014 Plan, the board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. The 2014 ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, the Company issued 4,497 and 3,684 shares of common stock under the 2014 ESPP, respectively. During the years ended December 31, 2020 and 2019, the number of shares of common stock available for issuance under the ESPP was automatically increased by 2,941 shares.  As of December 31, 2020, there were 5,895 shares of common stock available for future issuance under the 2014 ESPP. </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Compensation Cost</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The compensation cost that has been charged against income for stock awards under the 2009 Stock Option Plan, the 2014 Plan, the 2015 Plan, and the 2014 ESPP was $2.2 million and $1.8 million for the years ended December 31, 2020 and 2019, respectively. The total income tax benefit recognized in the consolidated statements of operations for share-based compensation arrangements was $0 for the years ended December 31, 2020 and 2019, respectively. Cash received from options exercised was $2,000 and $12,000 for the years ended December 31, 2020 and 2019, respectively.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,414</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,224</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,220</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,828</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1 1.10 P3Y P4Y P10Y 0 P3Y P4Y P10Y 112273 P10Y 0.040 0 389650 191887 146488 45000 45000 90000 17500 14050 11500 31550 4.83 7.50 1700000 1300000 The assumptions used to estimate fair value and the resulting grant date fair values are as follows: <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-employee Directors</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64.67</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.47</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.55</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65.36</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.47</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.11</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000790">5.97</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000791">6.03</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000796">5.50</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000797">5.54</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0.6467 0.6647 0.6655 0.6536 0.0118 0.0247 0.0036 0.0211 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The activity for the 2009 Plan, 2014 Plan and 2015 Plan for the years ended December 31, 2020 is summarized as follows:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value ($000)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding — December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">526,070</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.55</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000812">7.62</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">349,437</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.17</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(166</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.60</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/expired</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,998</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.50</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding — December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">830,343</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.52</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000813">7.71</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable — December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,802</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.47</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000814">6.74</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested or expected to vest —December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">830,343</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.52</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000815">7.71</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 526070 30.55 60000 349437 8.17 166 8.60 44998 23.50 830343 21.52 96000 447802 31.47 22000 830343 21.52 96000 1300000 1500000 2000000.0 P2Y4M24D <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock unit ("RSU") activity under the 2014 Plan and 2015 Plan for the years ended December 31, 2020, is summarized as follows:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,637</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.18</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,695</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.18</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78,859</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.05</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,386</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.68</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,087</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.52</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> 96637 14.18 28695 8.18 78859 14.05 17386 12.68 29087 9.52 0.25 P4Y 200000 P2Y9M18D 4779 P10Y 0.008 2941 0 4497 3684 2941 2941 5895 2200000 1800000 0 0 2000 12000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,414</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,224</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,220</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,828</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 806000 604000 1414000 1224000 2220000 1828000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value Measurements</p></td></tr></table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of certain financial instruments, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period, pursuant to the policy described in Note 2. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of December 31, 2020 and 2019 for financial instruments measured at fair value on a recurring basis (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.54%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Hierarchy Classification</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in Active</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for Identical Assets (Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable Inputs (Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs (Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,924</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,924</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,156</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,156</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,954</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,954</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,110</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,110</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,193</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,193</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,396</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,396</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000909"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000910"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,588</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,588</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Level 3 financial liabilities consist of the warrant liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as volatility.  The unobservable input for all of the Level 3 warrant liabilities includes volatility.  The historical volatility of the Company, using its closing common stock prices, is utilized to reflect future volatility over the expected term of the warrants.  At December 31, 2020, the range and weighted average of the Level 3 volatilities utilized in the Black-Scholes model to fair value the warrant liabilities were 71.8% to 86.6% and 78.0%, respectively.  Additionally, the expected term associated with the December 2019 Public Offering warrants is an unobservable input given that the expiration of the warrants is the earlier of (i) such date that is six months after the Company publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023.  The Company utilized a probability assessment to estimate the likelihood of occurrence for the two potential expiration dates and allocated the probability of occurrence percentage to the fair values calculated based on the two potential expected terms.  The weighted average expected term is 1.2 years as of December 31, 2020 for the December 2019 Public Offering warrants with a range of <span style="-sec-ix-hidden:F_000921">0.9 to 2.5 years</span>.  </span> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company uses the binomial lattice valuation model to value the Level 3 derivative liabilities at inception and on subsequent valuation dates.  This model incorporates transaction details such as the Company’s stock price, contractual terms, dividend yield, risk-free rate, historical volatility, credit rating, market credit spread, and estimated effective yield.  The unobservable inputs associated with the Level 3 derivative liabilities are adjusted equity volatility, market credit spread, and estimated yield.  As of December 31, 2020, these inputs were 58.1%, 1,458 basis points, and 14.9%, respectively.  The range of volatilities were 56.5% to 60.1%.  The senior convertible notes are initially fair valued using the binomial lattice model and </span></p> <p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">with the straight debt fair value calculated using the discounted cash flow method.  The discount for lack of marketability, </span><span style="Background-color:#FFFFFF;">7.0</span><span style="Background-color:#FFFFFF;">% as of </span><span style="Background-color:#FFFFFF;">December 31, 2020</span><span style="Background-color:#FFFFFF;">, is applied to the value of the March 2019 Notes.  The residual difference represents the fair value of the embedded derivative liabilities and the fair value of the embedded derivative liabilities are reassessed using the binomial lattice valuation model on a quarterly basis.  </span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrant Liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance – January 1, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,396</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 2020 Public Offering</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,478</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss adjustment to fair value</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,282</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance – December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,156</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative Liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance – January 1, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bifurcated embedded conversion option associated with April 2020 Notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,110</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment for partial conversion of April 2020 Notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,690</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain adjustment to fair value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,658</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance – December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,954</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> The following table summarizes the conclusions reached as of December 31, 2020 and 2019 for financial instruments measured at fair value on a recurring basis (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.54%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Hierarchy Classification</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in Active</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for Identical Assets (Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable Inputs (Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs (Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,924</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,924</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,156</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,156</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,954</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,954</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,110</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,110</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,193</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,193</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,396</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,396</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000909"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000910"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,588</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,588</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 117000 117000 0 0 273000 273000 0 0 92924000 92924000 0 0 93314000 93314000 0 0 51156000 0 0 51156000 5954000 0 0 5954000 57110000 0 0 57110000 23000 23000 0 0 273000 273000 0 0 41897000 41897000 0 0 42193000 42193000 0 0 18396000 0 0 18396000 3192000 3192000 21588000 0 0 21588000 71.8 86.6 78.0 2023-06-12 P1Y2M12D 58.1 1458 14.9 56.5 60.1 7.0 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrant Liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance – January 1, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,396</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 2020 Public Offering</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,478</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss adjustment to fair value</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,282</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance – December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,156</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative Liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance – January 1, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bifurcated embedded conversion option associated with April 2020 Notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,110</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment for partial conversion of April 2020 Notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,690</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain adjustment to fair value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,658</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance – December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,954</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 18396000 29478000 -3282000 51156000 3192000 8110000 -2690000 2658000 5954000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Employee Benefit Plan</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a 401(k) retirement plan, which covers all U.S. employees scheduled for and working more than 20 hours per week. The Company may provide a discretionary match with a maximum amount of 50% of the first 6% of eligible participant’s compensation, which vests ratably over four years. Contributions under the plan were approximately $0.1 million for the years ended December 31, 2020 and 2019.</p> 20 0.50 0.06 P4Y 100000 100000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.79%;white-space:nowrap" valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.</span></p></td> <td valign="top"> <p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subsequent Events</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the 2014 Plan (see Note 11), on January 1, 2021, the Company automatically added 786,547 shares to the total number shares of common stock available for future issuance under the 2014 Plan.  Pursuant to the terms of the 2014 ESPP (see Note 11), on January 1, 2021, the Company automatically added 2,941 shares to the total number shares of common stock available for future issuance under the 2014 ESPP.  </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, Puissance converted the remaining $6.0 million of the April 2020 Notes for 959,080 shares of common stock.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In February 2021, the Company partnered with Amplity Inc. (“Amplity”) for the potential upcoming commercial launch of ibrexafungerp for the treatment of VVC.  Under the terms of the 5-year agreement, the Company will utilize the Amplity’s commercial execution expertise and resources for sales force, remote engagement, training, market access and select operations services.  The Company will maintain full ownership of ibrexafungerp and control of all strategic aspects of the launch. Amplity is deferring a portion of its direct service costs in the first two years (2021 and 2022), which the Company will repay over three years starting in 2023.  Amplity has the potential to earn a performance-based success fee in the 2023-2025 time frame by exceeding certain revenue targets.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 11, 2021, the Company entered into an Exclusive License and Collaboration Agreement with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited<span style="font-weight:bold;"> </span>(collectively, “Hansoh”), pursuant to which Hansoh obtains an exclusive license from the Company to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the agreement, Hansoh shall be responsible for the development, regulatory approval and commercialization of ibrexafungerp in Greater China. The Company received a $10 million upfront payment and will also be eligible to receive up to $112 million in development and commercial milestones, plus low double-digit royalties on net product sales. The obligation to pay royalties with respect to sales in a specified region will continue until the later of the date of expiration of all intellectual property and regulatory exclusivity for the product in the region and ten years from the first commercial sale, unless earlier terminated by Hansoh with advanced notice for convenience or under other specified circumstances.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 786547 2941 6000000.0 959080 P5Y 10000000 112000000 XML 15 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2020
Mar. 01, 2021
Jun. 30, 2020
Cover [Abstract]      
Entity Registrant Name SCYNEXIS, Inc.    
Trading Symbol SCYX    
Entity Central Index Key 0001178253    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Shell Company false    
Entity Emerging Growth Company false    
Document Type 10-K    
Document Period End Date Dec. 31, 2020    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Amendment Flag false    
Entity Common Stock, Shares Outstanding   20,622,778  
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
ICFR Auditor Attestation Flag false    
Entity Public Float     $ 77,935,551
Entity Interactive Data Current Yes    
Entity File Number 001-36365    
Entity Tax Identification Number 56-2181648    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 1 Evertrust Plaza    
Entity Address, Address Line Two 13th Floor    
Entity Address, City or Town Jersey City    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07302 - 6548    
City Area Code 201    
Local Phone Number 884-5485    
Document Transition Report false    
Title of Each Class Common Stock, par value $0.001 per share    
Name of Each Exchange on Which Registered NASDAQ    
Document Annual Report true    
Documents Incorporated by Reference

Documents Incorporated by Reference

Portions of the registrant’s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant’s 2021 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant’s fiscal year ended December 31, 2020.

    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 93,041 $ 41,920
Short-term investments   6,494
Prepaid expenses and other current assets 5,165 3,988
Total current assets 98,206 52,402
Other assets 573 812
Deferred offering costs 187 70
Restricted cash 273 273
Property and equipment, net 298 405
Operating lease right-of-use asset (Note 8) 2,999 3,191
Total assets 102,536 57,153
Current liabilities:    
Accounts payable 4,639 7,177
Accrued expenses 4,141 3,801
Warrant liabilities 17,564  
Operating lease liability, current portion (Note 8) 52 36
Total current liabilities 26,396 11,014
Warrant liabilities 33,592 18,396
Convertible debt and derivative liabilities (Note 7) 16,516 11,522
Operating lease liability (Note 8) 3,274 3,326
Total liabilities 79,778 44,258
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value, authorized 5,000,000 shares as of December 31, 2020 and December 31, 2019; 0 shares issued and outstanding as of December 31, 2020 and December 31, 2019 0 0
Common stock, $0.001 par value, 100,000,000 shares authorized as of December 31, 2020, and December 31, 2019; 19,663,698 and 9,741,372 shares issued and outstanding as of December 31, 2020, and December 31, 2019, respectively 20 10
Additional paid-in capital 349,351 284,313
Accumulated deficit (326,613) (271,428)
Total stockholders’ equity 22,758 12,895
Total liabilities and stockholders’ equity $ 102,536 $ 57,153
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2020
Jul. 17, 2020
Jul. 16, 2020
Dec. 31, 2019
Jun. 18, 2019
Jun. 17, 2019
May 07, 2014
Statement Of Financial Position [Abstract]              
Preferred stock, par value (in dollars per share) $ 0.001     $ 0.001     $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000     5,000,000     5,000,000
Preferred stock, shares issued (in shares) 0     0      
Preferred stock, shares outstanding (in shares) 0     0      
Common stock, par value (in dollars per share) $ 0.001     $ 0.001      
Common stock, shares authorized (in shares) 100,000,000 100,000,000 250,000,000 100,000,000 250,000,000 125,000,000  
Common stock, shares issued (in shares) 19,663,698 10,508,302 105,083,291 9,741,372      
Common stock, shares outstanding (in shares) 19,663,698 10,508,302 105,083,291 9,741,372      
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]    
Revenue $ 0 $ 121
Operating expenses:    
Research and development 36,522 38,394
Selling, general and administrative 14,627 10,648
Total operating expenses 51,149 49,042
Loss from operations (51,149) (48,921)
Other expense (income):    
Loss on extinguishment of debt 1,766 1,045
Amortization of debt issuance costs and discount 1,201 1,171
Interest income (189) (805)
Interest expense 1,181 986
Other income (334) (538)
Other expense 602 0
Warrant liabilities fair value adjustment 5,214 4,497
Derivative liability fair value adjustment (2,257) (1,567)
Total other expense: 7,184 4,789
Loss before taxes (58,333) (53,710)
Income tax benefit 3,148 0
Net loss $ (55,185) $ (53,710)
Net loss per share – basic and diluted $ (5.15) $ (9.58)
Weighted average common shares outstanding – basic and diluted 10,720,211 5,608,138
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance at Dec. 31, 2018 $ 31,225 $ 5 $ 248,938 $ (217,718)
Beginning balance (in shares) at Dec. 31, 2018   4,797,198    
Net loss (53,710)     (53,710)
Stock-based compensation expense 1,828   1,828  
Common stock issued through employee stock purchase and stock option plans 37   37  
Common stock issued through employee stock purchase plan and stock option plan (in shares)   3,684    
Common stock issued, net of expenses 30,530 $ 5 30,525  
Common stock issued, net of expenses (in shares)   4,773,692    
Common stock issued for conversion 2,984   2,984  
Common stock issued for conversion of Notes (in shares)   162,600    
Common stock issued for exercise of stock options 12   12  
Common stock issued for exercise of stock options (in shares)   2,252    
Common stock issued for vested restricted stock units (11)   (11)  
Common stock issued for vested restricted stock units (in shares)   1,946    
Ending balance at Dec. 31, 2019 $ 12,895 $ 10 284,313 (271,428)
Ending balance (in shares) at Dec. 31, 2019 9,741,372 9,741,372    
Net loss $ (55,185)     (55,185)
Stock-based compensation expense 2,220   2,220  
Common stock issued through employee stock purchase and stock option plans 28   28  
Common stock issued through employee stock purchase plan and stock option plan (in shares)   4,652    
Common stock issued, net of expenses 57,184 $ 9 57,175  
Common stock issued, net of expenses (in shares)   9,156,304    
Common stock issued for conversion $ 5,222 $ 1 5,221  
Common stock issued for conversion of Notes (in shares)   638,809    
Common stock issued for exercise of stock options (in shares) 166      
Common stock issued for Commitment Shares $ 602   602  
Common stock issued for Commitment Shares (in shares)   70,910    
Common stock issued for vested restricted stock units (208)   (208)  
Common stock issued for vested restricted stock units (in shares)   51,651    
Ending balance at Dec. 31, 2020 $ 22,758 $ 20 $ 349,351 $ (326,613)
Ending balance (in shares) at Dec. 31, 2020 19,663,698 19,663,698    
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:    
Net loss $ (55,185) $ (53,710)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 111 111
Stock-based compensation expense 2,220 1,828
Accretion of investment discount 0 (16)
Amortization of debt issuance costs and discount 1,201 1,171
Warrant liabilities fair value adjustment 5,214 4,497
Derivative liability fair value adjustment (2,257) (1,567)
Noncash operating lease expense for right-of-use asset 192 174
Loss on extinguishment of debt 1,766 1,045
Noncash consideration associated with common stock purchase agreement 602 0
Changes in operating assets and liabilities:    
Prepaid expenses, other assets, and deferred costs (922) 3,254
Accounts payable and accrued expenses (2,296) 5,215
Deferred revenue 0 (121)
Net cash used in operating activities (49,354) (38,119)
Cash flows from investing activities:    
Maturities of investments 20,713 65,740
Purchases of property and equipment (4) 0
Purchase of investments (14,235) (39,500)
Net cash provided by investing activities 6,474 26,240
Cash flows from financing activities:    
Proceeds from common stock issued 90,554 46,337
Payments of offering costs and underwriting discounts and commissions (5,879) (2,855)
Proceeds from employee stock purchase plan issuances 28 49
Repurchase of shares to satisfy tax withholdings (208) 0
Proceeds from senior convertible notes 10,000 16,000
Payments of senior convertible notes issuance costs (494) (1,253)
Payment of loan payable expected to be refinanced 0 (15,973)
Net cash provided by financing activities 94,001 42,305
Net increase in cash, cash equivalents, and restricted cash 51,121 30,426
Cash, cash equivalents, and restricted cash at beginning of period 42,193 11,767
Cash, cash equivalents, and restricted cash at end of period 93,314 42,193
Supplemental cash flow information:    
Cash paid for interest 1,088 850
Cash received for interest 186 898
Noncash financing and investing activities:    
Operating lease liabilities arising from obtaining right-of-use assets 0 3,365
Deferred offering and issuance costs included in accounts payable 62 0
Deferred offering costs reclassified to additional paid-in capital 153 36
Common stock issued for settlement of senior convertible notes 5,221 2,984
Common stock issued for Commitment Shares $ 602 $ 0
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Description of Business and Basis of Preparation
 12 Months Ended
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Description of Business and Basis of Preparation

 

1.

Description of Business and Basis of Preparation

Organization

SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections.  The Company is developing its lead product candidate, ibrexafungerp, as the first representative of a novel oral and intravenous triterpenoid antifungal family for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.

The Company has incurred significant losses and negative cash flows from operations since its initial public offering in May 2014 and expects to continue to incur losses and negative cash flows for the foreseeable future. As a result, the Company had an accumulated deficit of $326.6 million at December 31, 2020 and limited capital resources to fund ongoing operations.   These capital resources primarily comprised cash and cash equivalents of $93.0 million at December 31, 2020. While the Company believes its capital resources are sufficient to fund the Company’s on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying consolidated financial statements, the Company's liquidity could be materially affected over this period by, among other things: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding; (2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events or unanticipated costs related to its development of ibrexafungerp; (4) its ability to potentially commercialize ibrexafungerp for the treatment of vaginal yeast infections and; (5) any other unanticipated material negative events or costs.  One or more of these events or costs could materially affect the Company’s liquidity.  If the Company is unable to meet its obligations when they become due, the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to its operating plan.  The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary.  Intercompany balances and transactions are eliminated in consolidation.

Shelf Registration Filings

On December 31, 2020 and September 11, 2020, the Company filed shelf registration statements on Form S-3 (File No. 333-251851 and File No. 333-248751, respectively) with the Securities and Exchange Commission (“SEC”), which were declared effective on January 8, 2021 and October 1, 2020, respectively (the “January 2021 Shelf Registration” and “October 2020 Shelf Registration”).  Both shelf registrations contain a base prospectus which covers the offering, issuance and sale of such indeterminate number of shares of common stock and preferred stock, such indeterminate principal amount of debt securities, and such indeterminate number of warrants to purchase common stock, preferred stock and/or debt securities, which together shall have an aggregate initial offering price not to exceed $200.0 million.  

A prospectus is included in the October 2020 Shelf Registration covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $50.0 million of the Company’s common stock that may be issued and sold under a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. (“Cantor”) and/or Controlled Equity OfferingSM Sales Agreement with Ladenburg Thalmann & Co. Inc. (such agreements, the “Sales Agreements”).  These Sales Agreements were cancelled in December 2020.

As of December 31, 2020, approximately $437.0 million of the securities registered under the Company’s effective shelf registrations, which include the January 2021 Shelf Registration, October 2020 Shelf Registration, and the Form S-3 shelf registration filed by the Company in August 2018 (effective September 14, 2018), are available to be offered, issued and sold by the Company.

Reverse Stock Split

On July 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”), which became effective on Friday, July 17, 2020, (a) implementing a 1-for-10 reverse stock split of the Company’s common stock and (b) decreasing the number of authorized shares of the Company’s common stock from 250,000,000 shares to 100,000,000 shares.  On the effective date of July 17, 2020, the number of the Company’s issued and outstanding shares of common stock was decreased from 105,083,291 to 10,508,302 and the par value per common share remained unchanged.  No fractional shares were issued as a result of the reverse stock split.  Stockholders who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof.  All share and per share amounts presented in these consolidated financial statements have been retroactively adjusted for the reverse stock split and certain items in the prior period financial statements have been revised to conform to the current presentation.

The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of outstanding convertible notes or upon the exercise of stock options or warrants outstanding.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: determination of the fair value of stock-based compensation grants; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimates and assumptions utilized in measuring the fair values of the warrant and derivative liabilities each reporting period.
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2.

Summary of Significant Accounting Policies

Concentration of Credit Risk

Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents.  The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any significant losses in the account.

Cash and Cash Equivalents

The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents.  The Company reported cash, cash equivalents, and restricted cash of $93.3 million and $42.2 million as of December 31, 2020 and 2019, respectively.  See Note 8 for further details on the nature of the restricted cash.

Short-Term Investments

The Company's held-to-maturity investments in U.S. government securities, commercial paper, and its overnight repurchase agreement are carried at amortized cost and any premiums or discounts are amortized or accreted through the maturity date of the investment.  Any impairment that is not deemed to be temporary is recognized in the period identified.

Warrant Liabilities

The Company accounts for the outstanding warrants associated with the June 2016 public offering, March 2018 Public Offering, December 2019 Public Offering and December 2020 Public Offering as liabilities measured at fair value. The fair values of these warrants have been determined using the Black-Scholes valuation model ("Black-Scholes"). The warrants are subject to remeasurement at each balance sheet date, using Black-Scholes, with any changes in the fair value of the outstanding warrants recognized in the accompanying consolidated statements of operations. See Notes 9 and 12 for further details.

Convertible Debt and Derivative Liabilities

In connection with the Company’s issuance of its April 2020 and March 2019 6.0% Convertible Senior Notes (the “April 2020 Notes” and the “March 2019 Notes”), the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as long-term derivative liabilities in the Company’s balance sheet in accordance with FASB Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging.  The convertible debt and the derivative liabilities associated with the April 2020 Notes and March 2019 Notes are presented in total on the consolidated balance sheet as the convertible debt and derivative liabilities.  The convertible debt is carried at amortized cost.  The derivative liabilities will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the consolidated statements of operations in other expense (income).  See Notes 7 and 12 for further details.

Research and Development

Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance.

The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting ibrexafungerp clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its consolidated

financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel.  

Patent Expenses

Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows:

 

•

Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

 

•

Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

 

•

Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.

Amortization of Debt Issuance Costs and Discount

The Company’s convertible debt is recorded net of debt issuance costs which comprised issuance costs and an advisory fee.  The portion of the debt issuance costs allocated to the convertible debt, based on the amount of proceeds allocated between the convertible debt and the derivative liability, is being amortized over the term of the convertible debt using the effective interest method in addition to the discount initially recognized for the fair value of the bifurcated derivative liability from the convertible debt.  Debt issuance costs allocated to the derivative liabilities were included in other expense as a component of the fair value adjustment for the year ended December 31, 2020.  The Company’s previous term loan with Solar Capital Ltd. (“Solar”), which was paid in full in March 2019 (see Note 7), was recorded net of debt discount which comprised issuance costs, customary closing and final fees, and the fair value of the warrants issued in conjunction with the term loan. The resulting debt discount was being amortized over the term of the term loan using the straight-line method, which approximated the effective interest method.  The amortization of debt issuance costs and discount is included in other expense within the accompanying consolidated statements of operations.

Income Taxes

The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions.

Stock-Based Compensation

The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date.  The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods.

Basic and Diluted Net Loss per Share of Common Stock

The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period.

The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive:

 

 

December 31,

 

 

 

2020

 

 

2019

 

Outstanding stock options

 

 

830,343

 

 

 

526,070

 

Outstanding restricted stock units

 

 

29,087

 

 

 

96,637

 

Warrants to purchase common stock associated with June 2016 Public Offering

 

 

421,867

 

 

 

421,867

 

Warrants to purchase common stock associated with March 2018 Public Offering - Series 2

 

 

798,810

 

 

 

798,810

 

Warrants to purchase common stock associated with December 2019 Public Offering

 

 

4,472,205

 

 

 

4,472,205

 

Option to purchase common stock associated with December 2019 Public Offering

 

 

—

 

 

 

583,333

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 1

 

 

6,800,000

 

 

 

—

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 2

 

 

6,800,000

 

 

 

—

 

For possible future issuance for the conversion of the March 2019 Notes

 

 

1,138,200

 

 

 

1,138,200

 

For possible future issuance for the conversion of the April 2020 Notes

 

 

1,299,790

 

 

 

—

 

Warrants to purchase common stock associated with Solar loan agreement

 

 

12,243

 

 

 

12,243

 

          Total

 

 

22,602,545

 

 

 

8,049,365

 

Segment and Geographic Information

Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. The material assets of the Company were held in the United States for the years ended December 31, 2020 and 2019.  In July 2019, the Company incorporated SCYNEXIS Pacific Pty Ltd, a wholly-owned subsidiary, in Sydney, Australia, for the initial purpose of conducting certain clinical trials and other research and development activities.

Although all operations are primarily based in the United States, the Company generated a portion of its revenue from R-Pharm outside of the United States for the year ended December 31, 2019.  All of the Company's revenue in 2019 was generated from a non-refundable upfront payment received under a licensing and collaboration arrangement with a partner located in Russia.  All sales, including sales outside of the United States, are denominated in United States dollars.

 

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) (“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted.  As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its consolidated financial statements.

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company is currently evaluating the impact ASU 2019-12 will have on its consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity (“ASU 2020-06”). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share.  The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years.  As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its consolidated financial statements.

 

Recently Adopted Accounting Pronouncements

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). ASU 2018-13 removes, modifies and adds certain disclosure requirements in ASU 2018-13, Fair Value Measurement. ASU 2018-13 eliminates certain disclosures related to transfers and the valuation process, modifies disclosures for investments that are valued based on net asset value, clarifies the measurement uncertainty disclosure, and requires additional disclosures for Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The Company adopted ASU 2018-13 during the year ended December 31, 2020 and as a result, included the required additional disclosures for its Level 3 fair value measurements in its consolidated financial statements (see Note 12).  The Company did not identify any other material impacts of ASU 2018-13 on its consolidated financial statements.

 
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Short-term Investments
 12 Months Ended
Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]  
Short-term Investments

3.

Short-term Investments

The following table summarizes the held-to-maturity securities held at December 31, 2019 (in thousands):

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair Value

 

As of December 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government securities

 

$

1,996

 

 

$

15

 

 

$

(14

)

 

$

1,997

 

Commercial paper

 

 

998

 

 

 

—

 

 

 

—

 

 

 

998

 

Overnight repurchase agreement

 

 

3,500

 

 

 

—

 

 

 

—

 

 

 

3,500

 

Total short-term investments

 

$

6,494

 

 

$

15

 

 

$

(14

)

 

$

6,495

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2019, the Company had $6.5 million of held-to-maturity investments which all matured as of December 31, 2020.  The gross unrealized gains and losses for the Company's commercial paper and overnight repurchase agreement are not significant.  The Company carries short-term investments at amortized cost. The fair value of the short-term investments is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Prepaid Expenses and Other Current Assets
 12 Months Ended
Dec. 31, 2020
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]  
Prepaid Expenses and Other Current Assets

4.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

December 31,

 

 

 

2020

 

 

2019

 

Prepaid research and development services

 

$

1,535

 

 

$

3,043

 

Prepaid insurance

 

 

362

 

 

 

252

 

Other prepaid expenses

 

 

19

 

 

 

19

 

Other receivable

 

 

2,876

 

 

 

—

 

Other current assets

 

 

373

 

 

 

674

 

Total prepaid expenses and other current assets

 

$

5,165

 

 

$

3,988

 

 
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment
 12 Months Ended
Dec. 31, 2020
Property Plant And Equipment [Abstract]  
Property and Equipment

5.

Property and Equipment

Property and equipment consisted of the following (in thousands):

 

 

December 31,

 

 

 

2020

 

 

2019

 

Furniture and fixtures

 

$

406

 

 

$

406

 

Computer equipment

 

 

76

 

 

 

73

 

Other

 

 

98

 

 

 

98

 

 

 

 

580

 

 

 

577

 

Less: accumulated depreciation and amortization

 

 

(282

)

 

 

(172

)

Total property and equipment, net

 

$

298

 

 

$

405

 

 

 
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses
 12 Months Ended
Dec. 31, 2020
Payables And Accruals [Abstract]  
Accrued Expenses

6.

Accrued Expenses

Accrued expenses consisted of the following (in thousands):

 

 

December 31,

 

 

 

2020

 

 

2019

 

Accrued research and development expenses

 

$

991

 

 

$

1,296

 

Accrued employee bonus compensation

 

 

2,190

 

 

 

1,798

 

Other accrued expenses

 

 

960

 

 

 

707

 

Total accrued expenses

 

$

4,141

 

 

$

3,801

 

 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Borrowings
 12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
Borrowings

7.

Borrowings

April 2020 Note Purchase Agreement

On April 9, 2020, the Company entered into a Senior Convertible Note Purchase Agreement (the “April 2020 Note Purchase Agreement”) and issued and sold to Puissance Life Science Opportunities Fund VI (“Puissance”) $10.0 million aggregate principal amount of its April 2020 Notes, resulting in net proceeds of approximately $9.5 million after deducting $0.5 million for an advisory fee and other issuance costs  The April 2020 Notes were issued and sold for cash at a purchase price equal to 100% of their principal amount, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), due to the April 2020 Notes being issued to one financially sophisticated investor.

The April 2020 Notes will bear interest at a rate of 6.0% per annum, payable semiannually in arrears on April 15 and October 15 of each year, beginning October 15, 2020. The April 2020 Notes will mature on April 15, 2026, unless earlier converted, redeemed or repurchased.  The April 2020 Notes constitute general, senior unsecured obligations of the Company.

As of December 31, 2020, the Company’s April 2020 Notes consists of the convertible debt balance of $1.2 million, presented net of the unamortized debt issuance costs allocated to the convertible debt of $0.1 million, and the bifurcated embedded conversion option derivative liability of $3.3 million.  In connection with the Company’s issuance of its April 2020 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, Derivatives and Hedging, at its initial fair value of $8.1 million as the interest make-whole provision is settled in shares of common stock.  Debt issuance costs of $0.4 million initially allocated to the derivative liability were written off upon issuance of the April 2020 Notes and were recognized in the gain on the fair value adjustment for the derivative liability for the year ended December 31, 2020.  For the year ended December 31, 2020, the Company recognized a gain of $1.7 million on the fair value adjustment for the derivative liability and recognized $0.2 million in amortization of debt issuance costs and discount for the year ended December 31, 2020, related to the April 2020 Notes.

In June 2020, Puissance converted $2.0 million of the April 2020 Notes for 316,461 shares of common stock.  Upon conversion of the $2.0 million of the April 2020 Notes, the Company recognized a $0.8 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $2.0 million and the fair value of the consideration issued of $2.8 million.  In December 2020 and January 2021, Puissance converted the remaining $2.0 million and $6.0 million of the April 2020 Notes for 322,348 and 959,080 shares of common stock, respectively.  Upon conversion of the $2.0 million of the April 2020 Notes in December 2020, the Company recognized a $1.0 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $1.4 million and the fair value of the consideration issued of $2.4 million.

The Company estimated the fair value of the convertible debt and derivative liability for the April 2020 Notes using a binomial lattice valuation model and Level 3 inputs. At December 31, 2020, the fair value of the April 2020 Notes is $7.4 million.

The holders of the April 2020 Notes may convert their April 2020 Notes at their option at any time prior to the close of business on the business day immediately preceding April 15, 2026 into shares of the Company’s common stock. The initial conversion rate is 111.1108 shares of common stock per $1,000 principal amount of the April 2020 Notes, which is equivalent to an initial conversion price of approximately $9.00 per share, and is subject to adjustment in certain events described in the April 2020 Note Purchase Agreement. Holders who convert may also be entitled to receive, under certain circumstances, an “interest make-whole payment” (as defined in the April 2020 Note Purchase Agreement) payable in shares of common stock. In addition, following certain corporate events that occur prior to the maturity date, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its April 2020 Notes in connection with such a corporate event. Unless the Company seeks and receives stockholder approval, the number of shares that the Company may deliver in connection with a conversion of the April 2020 Notes, including those delivered in connection with an “interest make-whole payment” or a “make-whole fundamental change” (each as defined in the April 2020 Note Purchase Agreement), will not exceed a cap of 1,938,600 shares of common stock.

On or after April 15, 2023, the Company has the right, at its election, to redeem all or any portion of the April 2020 Notes not previously converted if the last reported sale price per share of common stock exceeds 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. The redemption price will be 100% of the principal amount of the April 2020 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

If a “fundamental change” (as defined in the April 2020 Note Purchase Agreement) occurs, then, subject to certain exceptions, the Company must offer to repurchase the April 2020 Notes for cash at a repurchase price of 100% of the principal amount of the April 2020 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date.  

March 2019 Note Purchase Agreement

On March 7, 2019, the Company entered into a Senior Convertible Note Purchase Agreement (the “March 2019 Note Purchase Agreement”) with Puissance.  Pursuant to the March 2019 Note Purchase Agreement, on March 7, 2019, the Company issued and sold to Puissance $16.0 million aggregate principal amount of its March 2019 Notes, resulting in $14.7 million in net proceeds after deducting $1.3 million for an advisory fee and other issuance costs.  The Company used the net proceeds to pay the remaining outstanding Solar term loan in full and recorded a loss on debt extinguishment of $0.8 million during the year ended December 31, 2019.  The loss on debt extinguishment of $0.8 million for the year ended December 31, 2019 was recognized as the difference between the reacquisition price of the outstanding Solar debt of $15.9 million and the $15.1 million net carrying value of the Solar debt obligation prior to repayment.

As of December 31, 2020 and 2019, the Company’s March 2019 Notes consists of the convertible debt balance of $9.4 million and $8.3 million, presented net of the unamortized debt issuance costs allocated to the convertible debt of $0.4 million and $0.5 million, and the bifurcated embedded conversion option derivative liability of $2.7 million and $3.2 million, respectively.  In connection with the Company’s issuance of its March 2019 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, Derivatives and Hedging, at its initial fair value of $7.0 million as the interest make-whole provision is settled in shares of common stock.  Debt issuance costs of $0.6 million initially allocated to the derivative liability were written off upon issuance of the March 2019 Notes and were recognized in the gain on the fair value adjustment for the derivative liability for the year ended December 31, 2019.  For the years ended December 31, 2020 and 2019, the Company recognized gains of $0.5 million and $1.6 million, respectively, on the fair value adjustment for the derivative liability.   For the years ended December 31, 2020 and 2019, the Company recognized $1.0 million and $1.1 million, respectively, in amortization of debt issuance costs and discount, related to the March 2019 Notes.

In April 2019, Puissance converted $2.0 million of the March 2019 Notes for 162,600 shares of common stock.  Upon conversion of the $2.0 million of the March 2019 Notes, the Company recognized a $0.2 million extinguishment loss which represents the difference between the total net carrying amount of the convertible debt and derivative liability of $2.8 million and the fair value of the consideration issued of $3.0 million.  

The Company estimated the fair value of the convertible debt and derivative liability for the March 2019 Notes using a binomial lattice valuation model and Level 3 inputs. At December 31, 2020 and 2019, the fair value of the convertible debt and derivative liability for the March 2019 Notes is $12.9 million and $11.7 million, respectively.

The March 2019 Notes were issued and sold for cash at a purchase price equal to 100% of their principal amount, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), due to the March 2019 Notes being issued to one financially sophisticated investor. The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased. The March 2019 Notes constitute general, senior unsecured obligations of the Company.

The holder of the March 2019 Notes may convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company’s common stock. The initial conversion rate is 73.9096 shares of common stock per $1,000 principal amount of March 2019 Notes, which is equivalent to an initial conversion price of approximately $13.53 and is subject to adjustment in certain events described in the March 2019 Note Purchase Agreement. The Holder upon conversion may also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of common stock. In addition, following certain corporate events that occur prior to the maturity date, the Company will, in certain circumstances, increase the conversion rate if the holder elects to convert its March 2019 Notes in connection with such a corporate event. Subject to adjustment in the conversion rate, the number of shares that the Company may deliver in connection with a conversion of the March 2019 Notes, including those delivered in connection with an interest make-whole payment, will not exceed a cap of 81 shares of common stock per $1,000 principal amount of the March 2019 Notes.  

On or after March 15, 2022, the Company has the right, at its election, to redeem all or any portion of the March 2019 Notes not previously converted if the last reported sale price per share of common stock exceeds 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. The redemption price will be 100% of the principal amount of the March 2019 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.  If a “fundamental change” (as defined in the March 2019 Note Purchase Agreement) occurs, then, subject to certain exceptions, the Company must offer to repurchase the March 2019 Notes for cash at a repurchase price of 100% of the principal amount of the March 2019 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date.

Solar Loan Agreement

On September 30, 2016, the Company entered into a loan agreement with Solar Capital Ltd. (“Solar”), in its capacity as administrative and collateral agent and as lender. Pursuant to the loan agreement, Solar was providing the Company with a 48-month secured term loan in the amount of $15.0 million.  The term loan bore interest at a floating rate equal to the LIBOR rate in effect plus 8.49%.  The Solar term loan was paid in full in March 2019.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

8.

Commitments and Contingencies

Leases

On March 1, 2018, the Company entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey, that the Company identified as an operating lease under ASC 842 (the “Lease”). The lease term is eleven years from August 1, 2018, the commencement date, with total lease payments of $7.3 million over the lease term. The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which will be reduced by fifty-five thousand dollars every two years for ten years after the commencement of the lease.  The security deposit is classified as restricted cash in the accompanying consolidated balance sheets.  

The consideration in the Lease allocated to the single lease component includes the fixed payments for the right to use the office space as well as common area maintenance.  The Lease also contains costs associated with certain expense escalation, property taxes, insurance, parking, and utilities which are all considered variable payments and are excluded from the operating lease liability.  The incremental borrowing rate utilized approximated the prevailing market interest rate the Company would incur to borrow a similar amount equal to the total Lease payments on a collateralized basis over the term of the Lease.  The following table summarizes certain quantitative information associated with the amounts recognized in the accompanying consolidated financial statements for the Lease (dollars in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

Operating lease cost

 

$

664

 

 

$

664

 

Variable lease cost

 

 

51

 

 

 

41

 

Total operating lease expense

 

$

715

 

 

$

705

 

 

 

 

 

 

 

 

 

 

Cash paid for amounts included in the measurement of operating lease liability

 

$

507

 

 

$

497

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2020

 

 

December 31, 2019

 

Remaining Lease term (years)

 

 

8.59

 

 

 

9.59

 

Discount rate

 

 

15

%

 

 

15

%

 

Future minimum lease payments for all operating leases as of December 31, 2020 are as follows (in thousands):

 

 

 

December 31, 2020

 

2021

 

$

517

 

2022

 

 

527

 

2023

 

 

715

 

2024

 

 

730

 

2025

 

 

744

 

Thereafter

 

 

2,789

 

Total

 

$

6,022

 

 

The presentation of the operating lease liability and right-of-use asset as of December 31, 2020 are as follows (in thousands):

 

 

December 31, 2020

 

Present value of future minimum lease payments

 

$

3,326

 

 

 

 

 

 

Operating lease liability, current portion

 

$

52

 

Operating lease liability, long-term portion

 

 

3,274

 

Total operating lease liability

 

$

3,326

 

 

 

 

 

 

Difference between future minimum lease payments and discounted cash flows

 

$

2,696

 

 

 

 

 

 

Operating lease right-of-use asset

 

$

2,999

 

License Arrangements with Potential Future Expenditures

As of December 31, 2020, the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, as amended, that involves potential future expenditures. Under the license arrangement, executed in May 2013, the Company exclusively licensed from Merck its rights to ibrexafungerp in the field of human health.  In January 2014, Merck assigned the patents related to ibrexafungerp that it had exclusively licensed to the Company.  Ibrexafungerp is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck was originally eligible to receive milestone payments from the Company that could total $19.0 million upon occurrence of specific events, including initiation of a Phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets, and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of ibrexafungerp. The aggregate royalties are mid- to high-single digits.

In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first Phase 2 clinical trial of a product containing the ibrexafungerp compound (the “Deferred Milestone”). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the ibrexafungerp compound.  In December 2016 and January 2018, the Company entered into second and third amendments to the license agreement with Merck which clarified what would constitute the initiation of a Phase 3 clinical trial for the purpose of milestone payment.  In January 2019, a milestone payment became due to Merck as a result of the initiation of the VANISH Phase 3 VVC program and was paid in March 2019. The milestone payment was recognized in the consolidated statement of operations in research and development expense for the year ended December 31, 2019 and is included in cash used in operating activities on the consolidated statement of cash flows.  On December 2, 2020, the Company entered into a fourth amendment to the license agreement with Merck.  The amendment eliminates two cash milestone payments that the Company would have paid to Merck upon the first filing of a NDA, triggered by the FDA acceptance for filing of its NDA for ibrexafungerp for the treatment of VVC, and first marketing approval in the U.S., anticipated in June 2021 for the Company’s NDA for ibrexafungerp for the treatment of VVC.  Such cash milestone payments would have been creditable against future royalties owed to Merck on net sales of ibrexafungerp. With the amendment, these milestones will not be paid in cash and, accordingly, credits will not accrue. Pursuant to the amendment, the Company will also forfeit the credits against future royalties that it had accrued from a prior milestone payment already paid to Merck.  All other key terms of the license agreement are unchanged.

Clinical Development Arrangements

The Company has entered into, and expects to continue to enter into, contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.

Other License Arrangements

In July 2016, the Company entered into an asset purchase agreement with UK-based Cypralis Limited (or "Cypralis"), a life sciences company, for the sale of its cyclophilin inhibitor assets. Cypralis also acquired all patents, patent applications and know-how related to the acquired portfolio. In connection with the asset purchase agreement, the Company is eligible to receive milestone payments upon the successful progression of Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. The Company retains the right to repurchase the portfolio assets from Cypralis if abandoned or deprioritized.  For the years ended December 31, 2020 and 2019, there was no revenue recognized associated with this agreement given the variable consideration associated with the sale of intellectual property to Cypralis was fully constrained.  Additionally, in October 2014 the Company entered into a license agreement with Waterstone Pharmaceutical HK Limited (or “Waterstone”) and granted Waterstone an exclusive, worldwide license to develop and commercialize certain non-strategic compounds.  The Company is entitled to receive potential milestones and royalties from Waterstone and for the years ended December 31, 2020 and 2019, there was no revenue recognized by the Company associated with this agreement given the variable consideration was fully constrained.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity
 12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Stockholders' Equity

9.

Stockholders’ Equity

Authorized, Issued, and Outstanding Common Shares

The Company’s authorized common stock has a par value of $0.001 per share and consists of 100,000,000 shares as of December 31, 2020 and 2019; 19,663,698 and 9,741,372 shares were issued and outstanding at December 31, 2020, and December 31, 2019, respectively.  On June 18, 2019, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 125,000,000 to 250,000,000.  On July 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, which became effective on Friday, July 17, 2020, (a) implementing a 1-for-10 reverse stock split of the Company’s common stock and (b) decreasing the number of authorized shares of the Company’s common stock from 250,000,000 shares to 100,000,000 shares.  

The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of outstanding convertible notes or upon the exercise of stock options or warrants outstanding. No fractional shares were issued as a result of the reverse stock split.

Shares Reserved for Future Issuance

The Company had reserved shares of common stock for future issuance as follows:

 

 

December 31,

 

 

 

2020

 

 

2019

 

Outstanding stock options

 

 

830,343

 

 

 

526,070

 

Outstanding restricted stock units

 

 

29,087

 

 

 

96,637

 

Warrants to purchase common stock associated with June 2016 Public Offering

 

 

421,867

 

 

 

421,867

 

Warrants to purchase common stock associated with March 2018 Public Offering - Series 2

 

 

798,810

 

 

 

798,810

 

Warrants to purchase common stock associated with December 2019 Public Offering

 

 

4,472,205

 

 

 

4,472,205

 

Option to purchase common stock associated with December 2019 Public Offering

 

 

—

 

 

 

583,333

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 1

 

 

6,800,000

 

 

 

—

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 2

 

 

6,800,000

 

 

 

—

 

Prefunded warrants to purchase common stock associated with December 2020 Public Offering

 

 

5,260,000

 

 

 

—

 

Warrants to purchase common stock associated with Solar loan agreement

 

 

12,243

 

 

 

12,243

 

For possible future issuance for the conversion of the March 2019 Notes

 

 

1,138,200

 

 

 

1,138,200

 

For possible future issuance for the conversion of the April 2020 Notes

 

 

1,299,790

 

 

 

—

 

For possible future issuance under 2014 Equity Incentive Plan  (Note 11)

 

 

146,488

 

 

 

55,478

 

For possible future issuance under Employee Stock Purchase Plan (Note 11)

 

 

5,895

 

 

 

7,423

 

For possible future issuance under 2015 Inducement Award Plan (Note 11)

 

 

14,050

 

 

 

31,550

 

Total common shares reserved for future issuance

 

 

28,028,978

 

 

 

8,143,816

 

 

Liquidation Rights

In the event of any liquidation or dissolution of the Company, the holders of the common stock are entitled to the remaining assets of the Company legally available for distribution.

Dividends and Voting Rights

The holders of the common stock are entitled to receive dividends if and when declared by the Company.  

Preferred Stock

On May 7, 2014, the Company amended and restated its articles of incorporation relating to its approved capital structure. The Company’s board of directors has authorized the Company, subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of preferred stock with a par value of $0.001 per share in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions. The Company’s board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series

then outstanding, without any further vote or action by the stockholders. The Company’s board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. There were no shares of preferred stock issued and outstanding as of December 31, 2020 and 2019.

December 2020 Public Offering

On December 17, 2020, the Company completed a public offering (the “December 2020 Public Offering”) of its common stock and warrants pursuant to the Company’s effective shelf registration.  The Company sold an aggregate of (a) 8,340,000 shares of the Company’s common stock, par value $0.001 per share, (b) pre-funded warrants, in lieu of common stock, to purchase 5,260,000 shares of the Company’s common stock, par value $0.001 per share, and (c) two series of warrants, which will accompany the common stock or pre-funded warrants, to purchase up to an aggregate of 13,600,000 shares of the Company’s common stock.  The pre-funded warrants entitle the holders to purchase up to 5,260,000 shares of common stock and have an unlimited term and an exercise price of $0.001 per share. Each of the two series of warrants entitle the holders to purchase up to an aggregate of 6,800,000 shares of common stock.

The prefunded warrants are classified as equity in accordance with ASC 815, Derivatives and Hedging given the prefunded warrants are indexed to the Company’s own shares of common stock and meet the requirements to be classified in equity.  The prefunded warrants were recorded at their relative fair value at issuance in the stockholders’ equity section of the balance sheet and the prefunded warrants are considered outstanding shares in the basic earnings per share calculation for the year ended December 31, 2020 given their nominal exercise price. 

The Series 1 warrants have a one-year term and an exercise price of $7.33 per share, and Series 2 warrants have a three-and-a-half-year term and an exercise price of $8.25 per share.  There is not expected to be any trading market for the pre-funded warrants, the Series 1 warrants or the Series 2 warrants issued in the offering. Each warrant is exercisable immediately upon issuance, subject to certain limitations on beneficial ownership.  The Series 1 and Series 2 warrants that accompany the pre-funded warrants have an additional provision, if certain beneficial ownership limitations are met, entitling the holder thereof to purchase a pre-funded warrant rather than a share of common stock at the warrant exercise price less the exercise price of the pre-funded warrant purchased. The price to the public in the offering was $6.25 per share of common stock and accompanying warrants, or in the case of pre-funded warrants, $6.249 per pre-funded warrant and accompanying warrants. The December 2020 Public Offering resulted in approximately $79.5 million of net proceeds to the Company after deducting the underwriting discount and offering expenses.

December 2019 Public Offering

On December 12, 2019, the Company completed a public offering (the “December 2019 Public Offering”) of its common stock and warrants pursuant to the Company's effective Shelf Registration.  The Company sold an aggregate of 3,888,888 shares of the Company’s common stock and warrants to purchase up to an aggregate of 3,888,888 shares of the Company’s common stock at a public offering price of $9.00 per share and accompanying warrant.  Net proceeds from the December 2019 Public Offering were approximately $32.5 million, after deducting the underwriting discount and offering expenses.  In addition, the Company granted to the underwriters an option to purchase up to 583,333 additional shares of common stock and/or warrants to purchase up to an aggregate of an additional 583,333 shares of common stock, in each case at the public offering price, less underwriting discounts and commissions. The underwriters exercised their option to purchase 583,333 warrants in December 2019.  The option to purchase up to 583,333 additional shares of common stock was not exercised by the underwriters and the option expired in January 2020.  

The warrants to purchase shares of common stock are immediately exercisable and expire on the earlier of (i) such date that is six months after the Company publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023, and have an exercise price of $11.0 per share. There is not expected to be any trading market for the warrants. Each warrant is exercisable immediately upon issuance, subject to certain limitations on beneficial ownership.  

March 2018 Public Offering

On March 8, 2018, the Company completed a public offering (the “March 2018 Public Offering”) of its common stock and warrants pursuant to the Company’s effective shelf registration.  The Company sold an aggregate of 1,775,150 shares of the Company’s common stock and warrants to purchase up to 2,130,180 shares of the Company’s common stock at a public offering price of $16.90 per share.  

Each purchaser received a warrant to purchase 0.75 of a share of common stock (the “March 2018 Series 1 warrants”) and 0.45 of a share of common stock (the “March 2018 Series 2 warrants”) for each share purchased in the March 2018 Public Offering.  The March 2018 Series 1 warrants to purchase in the aggregate up to 1,331,370 shares of common stock had a 53-week term and an exercise price of $18.5 per share, and the March 2018 Series 2 warrants to purchase in the aggregate up to 798,810 shares of common stock have a five-year term and an exercise price of $20.0 per share.  There is not expected to be any market for the warrants and each warrant is exercisable immediately upon issuance, subject to certain limitations on

beneficial ownership.  During the year ended December 31, 2019, there were 11,550 of the March 2018 Series 1 warrants exercised for total proceeds of $0.2 million and the March 2018 Series 1 warrants expired on March 14, 2019.

June 2016 Public Offering

On June 21, 2016, the Company completed a public offering (the “June 2016 Public Offering”) and sold 937,500 shares of its common stock and warrants to purchase up to 421,867 shares of the Company’s common stock.  Each purchaser received a warrant to purchase 0.45 of a share for each share purchased in the June 2016 Public Offering. There is not expected to be any trading market for the warrants. Each warrant was exercisable immediately upon issuance, will expire five years from the date of issuance, and has an exercise price of $30.0 per share.  

Warrant Liabilities

The June 2016, March 2018, December 2019, and December 2020 warrants contain a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, Distinguishing Liabilities from Equity, requires that these warrants be classified as liabilities. The fair values of these warrants have been determined using the Black-Scholes valuation model, and the changes in the fair value are recorded in the accompanying consolidated statements of operations.  The June 2016 and December 2020 Series 1 warrant liabilities are recorded as current liabilities in the accompanying consolidated balance sheet.  During the years ended December 31, 2020 and 2019, the Company recorded losses of $5.2 million and $4.5 million, respectively, due to the change in fair value of the warrant liabilities.  Issuance costs of $1.9 million and $1.0 million initially allocated to the December 2020 Public Offering and December 2019 Public Offering warrant liabilities, respectively, were written off upon settlement and were recognized in the loss on the fair value adjustment for the warrant liabilities for the years ended December 31, 2020 and 2019, respectively.  As of December 31, 2020, the fair value of the warrant liabilities was $51.2 million.

Common Stock Purchase Agreement

On April 10, 2020, the Company entered into the Common Stock Purchase Agreement with Aspire Capital pursuant to which the Company has the right to sell to Aspire Capital from time to time in its sole discretion up to $20.0 million in shares of the Company’s common stock over the next 30 months, subject to certain limitations and conditions set forth in the Common Stock Purchase Agreement.  The aggregate number of shares that we can sell to Aspire Capital under the Common Stock Purchase Agreement may in no case exceed 1,956,547 shares of the Company’s common stock (which is equal to approximately 19.99% of the common stock outstanding on the date of the Common Stock Purchase Agreement), including the 70,910 commitment shares (the Exchange Cap), unless either (a) shareholder approval is obtained to issue more, in which case the Exchange Cap will not apply, or (b) the average purchase price of all shares sold under the Common Stock Purchase Agreement exceeds $8.461; provided that at no time shall Aspire Capital (together with its affiliates) beneficially own more than 19.99% of the Company’s common stock.  During the year ended December 31, 2020, the Company sold 125,000 shares of its common stock under the Common Stock Purchase Agreement for gross proceeds of $0.6 million.

Under the Common Stock Purchase Agreement, on any trading day selected by the Company, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”), directing Aspire Capital (as principal) to purchase up to 25,000 shares of Common Stock per business day, up to $20.0 million of common stock in the aggregate at a per share price (the “Purchase Price”) equal to the lesser of:

 

•

the lowest sale price of Common Stock on the purchase date; or

 

•

the arithmetic average of the three (3) lowest closing sale prices for Common Stock during the ten (10) consecutive trading days ending on the trading day immediately preceding the purchase date.

The Company and Aspire Capital also may mutually agree to increase the number of shares that may be sold to as much as an additional 200,000 shares per business day.

In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital in an amount equal to at least 25,000 shares, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a “VWAP Purchase Notice”) directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of Common Stock traded on its principal market on the next trading day (the “VWAP Purchase Date”), subject to a maximum number of shares the Company may determine.  The purchase price per share pursuant to such VWAP Purchase Notice is generally the lessor of (i) the closing sale price on the VWAP Purchase Date, or (ii) 97% of the volume-weighted average price for common stock traded on its principal market on the VWAP Purchase Date.  

The Purchase Price will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the Purchase Price. The Company may deliver multiple Purchase Notices and VWAP Purchase Notices to Aspire Capital from time to time during the term of the Common Stock Purchase Agreement, so long as the most recent purchase has been completed.

The Common Stock Purchase Agreement provides that the Company and Aspire Capital shall not effect any sales under the Common Stock Purchase Agreement on any purchase date where the closing sale price of common stock is less than $0.25.  There are no trading volume requirements or restrictions under the Common Stock Purchase Agreement, and the Company will control the timing and amount of sales of common stock to Aspire Capital.  Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as directed by the Company in accordance with the Common Stock Purchase Agreement.  There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the Common Stock Purchase Agreement.  In consideration for entering into the Common Stock Purchase Agreement, concurrently with the execution of the Common Stock Purchase Agreement, the Company issued to Aspire Capital 70,910 shares of common stock (the “Commitment Shares”).  The fair value of the Commitment Shares of $0.6 million was recognized in other expense in the consolidated statements of operations for the year ended December 31, 2020.  The Common Stock Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of common stock during any time prior to the termination of the Common Stock Purchase Agreement. Any proceeds that the Company receives under the Common Stock Purchase Agreement are expected to be used for general corporate purposes, including working capital.

Warrant Associated with Solar Loan Agreement

Pursuant to a loan agreement, the Company issued to Solar a warrant to purchase an aggregate of up to 12,243 shares of the Company’s common stock at an exercise price of $36.754 per share. The warrant will expire five years from the date of the grant. The warrant was classified as equity and recorded at its relative fair value at issuance in the stockholders’ equity section of the balance sheet. 
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Income Taxes

10.

Income Taxes

The Company’s consolidated financial statements include a total tax benefit of $3.1 million and zero on loss before taxes of $58.3 million and $53.7 million for the years ended December 31, 2020 and 2019, respectively, and was generated entirely in the United States and Australia. Reconciliations of the differences between the benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (dollars in thousands):

 

 

 

2020

 

 

2019

 

 

 

Amount

 

 

Percent of Pretax Income

 

 

Amount

 

 

Percent of Pretax Income

 

Income taxes from continuing operations at statutory rate

 

$

(12,250

)

 

 

21.0

%

 

$

(11,279

)

 

 

21.0

%

State income taxes

 

 

(4,108

)

 

 

7.0

%

 

 

(3,778

)

 

 

7.0

%

State effect of permanent items

 

 

78

 

 

 

(0.1

)%

 

 

285

 

 

 

(0.5

)%

Stock-based compensation

 

 

96

 

 

 

(0.2

)%

 

 

100

 

 

 

(0.2

)%

Deferred rate change

 

 

—

 

 

 

—

 

 

 

(905

)

 

 

1.6

%

Warrants issuance

 

 

131

 

 

 

(0.2

)%

 

 

733

 

 

 

(1.4

)%

Other

 

 

206

 

 

 

(0.3

)%

 

 

883

 

 

 

(1.5

)%

NOL sale

 

 

301

 

 

 

(0.5

)%

 

 

—

 

 

 

—

 

R&D credit adjustment

 

 

2

 

 

 

—

 

 

 

(2,760

)

 

 

5.1

%

Increase in valuation allowance

 

 

12,396

 

 

 

(21.3

)%

 

 

16,721

 

 

 

(31.1

)%

Total income tax benefit

 

$

(3,148

)

 

 

5.4

%

 

$

—

 

 

 

—

%

 

The components of deferred tax assets and liabilities as of December 31, 2020 and 2019 are as follows (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Noncurrent deferred tax assets (liabilities)

 

 

 

 

 

 

 

 

Accrued expenses

 

$

148

 

 

$

107

 

Stock-based compensation

 

 

2,591

 

 

 

2,436

 

Lease liability

 

 

935

 

 

 

945

 

Other

 

 

(823

)

 

 

(856

)

Net operating loss carryforwards

 

 

70,936

 

 

 

58,073

 

Research and development credits

 

 

5,291

 

 

 

5,984

 

     Total deferred tax assets

 

 

79,078

 

 

 

66,689

 

Valuation allowances

 

 

(79,078

)

 

 

(66,689

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 

 

As of December 31, 2020 and 2019, the Company had available federal net operating loss (“NOL”) carryforwards of approximately $294.4 million and $242.4 million, respectively, and state and net operating loss carryforwards of approximately $202.7 million and $178.2 million, respectively.  Approximately $169.6 million of the federal NOLs can be carried forward to future tax years and expire at various times through 2037. The federal NOLs generated in December 31, 2020 and 2019 of approximately $52.0 million and $47.5 million, respectively, are carried forward indefinitely and do not expire.  The Company’s state and net operating loss carryforwards began to expire in 2019.  As of December 31, 2020, the Company had available federal research and development credit carryforwards of $5.3 million which begin to expire in 2022.

The New Jersey Technology Business Tax Certificate Transfer (NOL) program, administered by the New Jersey Economic Development Authority, enables approved biotechnology companies to sell their unused net operating losses (“NOLs”) and research and development tax credits to unaffiliated, profitable corporate taxpayers in the State of New Jersey up to a maximum lifetime benefit of $20.0 million per business.   As of December 31, 2020, the Company has received approximately $9.9 million under the program.  In April 2020, the Company received a cash receipt of approximately $3.1 million, from the sale of its state NOLs and research and development credits and recognized an income tax benefit of $3.1 million  for the year ended December 31, 2020 in the statement of operations.  

On December 22, 2017, the “Tax Cuts and Jobs Act” was signed into law.  The tax reform has the following effects on the Company: (1) permanently reduces the maximum corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017, (2) allows temporary 100% expensing for certain business assets and property placed in service after September 27, 2018 and before January 1, 2023, (3) disallows NOL carrybacks but allows for the indefinite carryforward of those NOLs which applies to losses arising in tax years beginning after December 31, 2018 and, (4) limits NOL deductions for each year equal to the lesser of the available carryover or 80% of a taxpayer’s pre-NOL deduction taxable income. This applies to losses arising in tax years ending on or after December 31, 2017.  As of December 31, 2020 and 2019, the Company has concluded that it is more likely than not that the Company will not realize the benefit of its deferred tax assets due to its history of losses. Accordingly, the net deferred tax assets have been fully reserved.

 

In accordance with Section 382 of the Internal Revenue Code of 1986, as amended, a change in equity ownership of greater than 50% within a three-year period results in an annual limitation on the Company’s ability to utilize its NOL carryforwards created during the tax periods prior to the change in ownership. The Company has determined that ownership changes have occurred and as a result, a portion of the Company’s NOL carryforwards are limited.  Because the Company has incurred cumulative net operating losses since inception, all tax years remain open to examination by U.S. federal and state income tax authorities.

The Company applies ASC 740-10-25-5, Income Taxes, formerly FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes, as amended, on January 1, 2009. The difference between the tax benefit recognized in the financial statements and the tax benefit claimed in the tax return is referred to as an unrecognized tax benefit.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits as of December 31, 2020 and 2019 (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Unrecognized tax benefit—January 1

 

$

436

 

 

$

436

 

Additions for tax positions of current period

 

 

—

 

 

 

—

 

Additions for tax positions of prior periods

 

 

—

 

 

 

—

 

Deferred rate change

 

 

—

 

 

 

—

 

Unrecognized tax benefit—December 31

 

$

436

 

 

$

436

 

 

None of the unrecognized tax benefits would, if recognized, affect the effective tax rate because the Company has recorded a valuation allowance to fully offset federal and state deferred tax assets. The Company has no tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within the coming year. The Company has $0 provided for interest and penalties associated with uncertain tax positions.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation
 12 Months Ended
Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock-based Compensation

11.

Stock-based Compensation

2009 Stock Option Plan

The Company had a share-based compensation plan (the “2009 Stock Option Plan”) under which the Company granted options to purchase shares of common stock to employees, directors, and consultants as either incentive stock options or nonqualified stock options. Incentive stock options could be granted with exercise prices not less than 100% to 110% of the fair

market value of the common stock. Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant.

2014 Equity Incentive Plan

In February 2014, the Company’s board of directors adopted the 2014 Equity Incentive Plan (“2014 Plan”), which was subsequently ratified by its stockholders and became effective on May 2, 2014 (the “Effective Date”). The 2014 Plan, as amended on June 18, 2014 and February 25, 2015, is the successor to and continuation of the 2009 Stock Option Plan. As of the Effective Date, no additional awards will be granted under the 2009 Stock Option Plan, but all stock awards granted under the 2009 Stock Option Plan prior to the Effective Date will remain subject to the terms of the 2009 Stock Option Plan. All awards granted on and after the Effective Date will be subject to the terms of the 2014 Plan. The 2014 Plan provides for the grant of the following awards: (i) incentive stock options, (ii) nonstatutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, and (vi) other stock awards. Employees, directors, and consultants are eligible to receive awards.  Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant.

Under the 2014 Plan, after giving effect to the increases to the share reserve approved by the Company’s stockholders in September 2014, and June 2015, but excluding the automatic increases discussed below, the aggregate number of shares of common stock that could be issued from and after the Effective Date (the “share reserve”) could not exceed the sum of (i) 112,273 new shares, (ii) the shares that represented the 2009 Stock Option Plan’s available reserve on the Effective Date, and (iii) any returning shares from the 2009 Stock Option Plan. Under the 2014 Plan, the share reserve will automatically increase on January 1st of each year, for a period of not more than 10 years, commencing on January 1, 2015, and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year. The board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur.

Pursuant to the terms of the 2014 Plan, on January 1, 2020 and 2019, the Company automatically added 389,650 and 191,887 shares to the total number shares of common stock available for future issuance under the 2014 Plan, respectively. As of December 31, 2020, there were 146,488 shares of common stock available for future issuance under the 2014 Plan.

2015 Inducement Plan

On March 26, 2015, the Company's board of directors adopted the 2015 Inducement Plan (“2015 Plan”). The 2015 Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to persons not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to the individuals’ entering into employment with the Company within the meaning of NASDAQ Listing Rule 5635I(4).  The 2015 Plan had an initial share reserve covering 45,000 shares of common stock.  On June 9, 2019, the Company’s board of directors amended the 2015 Plan, and the initial share reserve for the 2015 Plan was increased from 45,000 to 90,000 shares of common stock.  During the year ended December 31, 2020, there were 17,500 granted options of the Company’s common stock under the 2015 Plan. As of December 31, 2020, there were 14,050 shares of common stock available for future issuance under the 2015 Plan.  During the year ended December 31, 2019, there were 11,500 granted options of the Company’s common stock under the 2015 Plan.  As of December 31, 2019, there were 31,550 shares of common stock available for future issuance under the 2015 Plan.

Option Valuation Method

The fair value of a stock option is estimated using an option-pricing model that takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock, and the risk-free interest rate for the expected term of the option. The Company has used the simplified method in calculating the expected term of all option grants based on the vesting period. Compensation costs related to share-based payment transactions are recognized in the financial statements upon satisfaction of the requisite service or vesting requirements and forfeitures are recorded as incurred.

The Company has elected to use the Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable rather than for use in estimating the fair value of stock options subject to vesting and transferability restrictions. Using the Black-Scholes option-pricing model, the weighted-average fair value of options granted during 2020 and 2019 was $4.83 and $7.50 per option, respectively. The aggregate fair value of options granted during 2020 and 2019 was $1.7 million and $1.3 million, respectively. The assumptions used to estimate fair value and the resulting grant date fair values are as follows:

 

 

 

Employees

 

 

Non-employee Directors

 

 

 

Years Ended December 31,

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Weighted average expected volatility

 

 

64.67

%

 

 

66.47

%

 

 

66.55

%

 

 

65.36

%

Weighted average risk-free interest rate

 

 

1.18

%

 

 

2.47

%

 

 

0.36

%

 

 

2.11

%

Weighted average expected term (in years)

 

 

5.97

 

 

 

6.03

 

 

 

5.50

 

 

 

5.54

 

 

The activity for the 2009 Plan, 2014 Plan and 2015 Plan for the years ended December 31, 2020 is summarized as follows:

 

 

Number

of

Shares

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Life (in years)

 

 

Aggregate

Intrinsic

Value ($000)

 

Outstanding — December 31, 2019

 

 

526,070

 

 

$

30.55

 

 

 

7.62

 

 

$

60

 

Granted

 

 

349,437

 

 

$

8.17

 

 

 

 

 

 

 

 

 

Exercised

 

 

(166

)

 

$

8.60

 

 

 

 

 

 

 

 

 

Forfeited/expired

 

 

(44,998

)

 

$

23.50

 

 

 

 

 

 

 

 

 

Outstanding — December 31, 2020

 

 

830,343

 

 

$

21.52

 

 

 

7.71

 

 

$

96

 

Exercisable — December 31, 2020

 

 

447,802

 

 

$

31.47

 

 

 

6.74

 

 

$

22

 

Vested or expected to vest —December 31, 2020

 

 

830,343

 

 

$

21.52

 

 

 

7.71

 

 

$

96

 

The intrinsic values in the table above represent the total intrinsic value (the difference between the Company’s closing stock price as of December 31, 2020, and the exercise price multiplied by the number of options).

The total fair value of shares vested for both the years ended December 31, 2020 and 2019 was $1.3 million and $1.5 million, respectively.

As of December 31, 2020, there was approximately $2.0 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the plan. That cost is expected to be recognized over a weighted-average period of 2.4 years.

Restricted stock unit ("RSU") activity under the 2014 Plan and 2015 Plan for the years ended December 31, 2020, is summarized as follows:

 

 

Number of

Shares

 

 

Weighted

Average

Grant Date

Fair Value

Per Share

 

Non-vested at December 31, 2019

 

 

96,637

 

 

$

14.18

 

Granted

 

 

28,695

 

 

$

8.18

 

Vested

 

 

(78,859

)

 

$

14.05

 

Forfeited

 

 

(17,386

)

 

$

12.68

 

Non-vested at December 31, 2020

 

 

29,087

 

 

$

9.52

 

 

The fair value of RSUs is based on the market price of the Company's common stock on the date of grant.  RSUs generally vest 25% annually over a four year period from the date of grant. Upon vesting, the RSUs are net share settled to cover the required withholding tax with the remaining shares issued to the holder.  The Company recognizes compensation expense for such awards ratably over the corresponding vesting period.  As of December 31, 2020, there was approximately $0.2 million of total unrecognized compensation cost related to unvested RSU share-based compensation.  That cost is expected to be recognized over a weighted-average period of 2.8 years.

2014 Employee Stock Purchase Plan

In February 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (“2014 ESPP”), which was subsequently ratified by the Company’s stockholders and became effective on May 2, 2014. The purpose of the 2014 ESPP is to provide means by which eligible employees of the Company and of certain designated related corporations may be given an opportunity to purchase shares of the Company’s common stock, and to seek and retain services of new and existing employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. Common stock that may be issued under the 2014 ESPP will not exceed 4,779 shares, plus the number of shares of common stock that are automatically added on January 1st of each year for a period of ten years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 2,941 shares of common stock. Similar to the 2014 Plan, the board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. The 2014 ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code.

During the years ended December 31, 2020 and 2019, the Company issued 4,497 and 3,684 shares of common stock under the 2014 ESPP, respectively. During the years ended December 31, 2020 and 2019, the number of shares of common stock available for issuance under the ESPP was automatically increased by 2,941 shares.  As of December 31, 2020, there were 5,895 shares of common stock available for future issuance under the 2014 ESPP.

Compensation Cost

The compensation cost that has been charged against income for stock awards under the 2009 Stock Option Plan, the 2014 Plan, the 2015 Plan, and the 2014 ESPP was $2.2 million and $1.8 million for the years ended December 31, 2020 and 2019, respectively. The total income tax benefit recognized in the consolidated statements of operations for share-based compensation arrangements was $0 for the years ended December 31, 2020 and 2019, respectively. Cash received from options exercised was $2,000 and $12,000 for the years ended December 31, 2020 and 2019, respectively.

 

Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

Research and development

 

$

806

 

 

$

604

 

Selling, general and administrative

 

 

1,414

 

 

 

1,224

 

Total stock-based compensation expense

 

$

2,220

 

 

$

1,828

 
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurements

12.

Fair Value Measurements

The carrying amounts of certain financial instruments, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period, pursuant to the policy described in Note 2. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of December 31, 2020 and 2019 for financial instruments measured at fair value on a recurring basis (in thousands):

 

 

 

 

 

 

 

Fair Value Hierarchy Classification

 

 

 

Balance

 

 

Quoted Prices in Active

Markets for Identical Assets (Level 1)

 

 

Significant Other

Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

117

 

 

$

117

 

 

 

—

 

 

 

—

 

Restricted cash

 

 

273

 

 

 

273

 

 

 

—

 

 

 

—

 

Money market funds

 

 

92,924

 

 

 

92,924

 

 

 

—

 

 

 

—

 

Total assets

 

$

93,314

 

 

$

93,314

 

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liabilities

 

$

51,156

 

 

 

—

 

 

 

—

 

 

$

51,156

 

Derivative liabilities

 

 

5,954

 

 

 

—

 

 

 

—

 

 

 

5,954

 

Total liabilities

 

$

57,110

 

 

 

—

 

 

 

—

 

 

$

57,110

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

23

 

 

$

23

 

 

 

—

 

 

 

—

 

Restricted cash

 

 

273

 

 

 

273

 

 

 

—

 

 

 

—

 

Money market funds

 

 

41,897

 

 

 

41,897

 

 

 

—

 

 

 

—

 

Total assets

 

$

42,193

 

 

$

42,193

 

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liabilities

 

$

18,396

 

 

 

—

 

 

 

—

 

 

$

18,396

 

Derivative liability

 

 

3,192

 

 

 

 

 

 

 

 

 

 

 

3,192

 

Total liabilities

 

$

21,588

 

 

 

—

 

 

 

—

 

 

$

21,588

 

 

The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets.

 

Level 3 financial liabilities consist of the warrant liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as volatility.  The unobservable input for all of the Level 3 warrant liabilities includes volatility.  The historical volatility of the Company, using its closing common stock prices, is utilized to reflect future volatility over the expected term of the warrants.  At December 31, 2020, the range and weighted average of the Level 3 volatilities utilized in the Black-Scholes model to fair value the warrant liabilities were 71.8% to 86.6% and 78.0%, respectively.  Additionally, the expected term associated with the December 2019 Public Offering warrants is an unobservable input given that the expiration of the warrants is the earlier of (i) such date that is six months after the Company publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023.  The Company utilized a probability assessment to estimate the likelihood of occurrence for the two potential expiration dates and allocated the probability of occurrence percentage to the fair values calculated based on the two potential expected terms.  The weighted average expected term is 1.2 years as of December 31, 2020 for the December 2019 Public Offering warrants with a range of 0.9 to 2.5 years.   

 

The Company uses the binomial lattice valuation model to value the Level 3 derivative liabilities at inception and on subsequent valuation dates.  This model incorporates transaction details such as the Company’s stock price, contractual terms, dividend yield, risk-free rate, historical volatility, credit rating, market credit spread, and estimated effective yield.  The unobservable inputs associated with the Level 3 derivative liabilities are adjusted equity volatility, market credit spread, and estimated yield.  As of December 31, 2020, these inputs were 58.1%, 1,458 basis points, and 14.9%, respectively.  The range of volatilities were 56.5% to 60.1%.  The senior convertible notes are initially fair valued using the binomial lattice model and

with the straight debt fair value calculated using the discounted cash flow method.  The discount for lack of marketability, 7.0% as of December 31, 2020, is applied to the value of the March 2019 Notes.  The residual difference represents the fair value of the embedded derivative liabilities and the fair value of the embedded derivative liabilities are reassessed using the binomial lattice valuation model on a quarterly basis.  

 

A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):

 

 

 

 

Warrant Liabilities

 

Balance – January 1, 2020

 

 

$

18,396

 

December 2020 Public Offering

 

 

 

29,478

 

Loss adjustment to fair value

 

 

 

3,282

 

Balance – December 31, 2020

 

 

$

51,156

 

 

 

 

 

 

 

 

 

 

Derivative Liabilities

 

Balance – January 1, 2020

 

 

$

3,192

 

Bifurcated embedded conversion option associated with April 2020 Notes

 

 

 

8,110

 

Adjustment for partial conversion of April 2020 Notes

 

 

 

(2,690

)

Gain adjustment to fair value

 

 

 

(2,658

)

Balance – December 31, 2020

 

 

$

5,954

 

 
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Employee Benefit Plan
 12 Months Ended
Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]  
Employee Benefit Plan

13.

Employee Benefit Plan

 

The Company has a 401(k) retirement plan, which covers all U.S. employees scheduled for and working more than 20 hours per week. The Company may provide a discretionary match with a maximum amount of 50% of the first 6% of eligible participant’s compensation, which vests ratably over four years. Contributions under the plan were approximately $0.1 million for the years ended December 31, 2020 and 2019.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events
 12 Months Ended
Dec. 31, 2020
Subsequent Events [Abstract]  
Subsequent Events

14.

Subsequent Events

Pursuant to the terms of the 2014 Plan (see Note 11), on January 1, 2021, the Company automatically added 786,547 shares to the total number shares of common stock available for future issuance under the 2014 Plan.  Pursuant to the terms of the 2014 ESPP (see Note 11), on January 1, 2021, the Company automatically added 2,941 shares to the total number shares of common stock available for future issuance under the 2014 ESPP.  

 

In January 2021, Puissance converted the remaining $6.0 million of the April 2020 Notes for 959,080 shares of common stock.

 

In February 2021, the Company partnered with Amplity Inc. (“Amplity”) for the potential upcoming commercial launch of ibrexafungerp for the treatment of VVC.  Under the terms of the 5-year agreement, the Company will utilize the Amplity’s commercial execution expertise and resources for sales force, remote engagement, training, market access and select operations services.  The Company will maintain full ownership of ibrexafungerp and control of all strategic aspects of the launch. Amplity is deferring a portion of its direct service costs in the first two years (2021 and 2022), which the Company will repay over three years starting in 2023.  Amplity has the potential to earn a performance-based success fee in the 2023-2025 time frame by exceeding certain revenue targets.

 

On February 11, 2021, the Company entered into an Exclusive License and Collaboration Agreement with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, “Hansoh”), pursuant to which Hansoh obtains an exclusive license from the Company to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan. Under the terms of the agreement, Hansoh shall be responsible for the development, regulatory approval and commercialization of ibrexafungerp in Greater China. The Company received a $10 million upfront payment and will also be eligible to receive up to $112 million in development and commercial milestones, plus low double-digit royalties on net product sales. The obligation to pay royalties with respect to sales in a specified region will continue until the later of the date of expiration of all intellectual property and regulatory exclusivity for the product in the region and ten years from the first commercial sale, unless earlier terminated by Hansoh with advanced notice for convenience or under other specified circumstances.

 

 
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents.  The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any significant losses in the account.
Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents.  The Company reported cash, cash equivalents, and restricted cash of $93.3 million and $42.2 million as of December 31, 2020 and 2019, respectively.  See Note 8 for further details on the nature of the restricted cash.
Short-Term Investments

Short-Term Investments

The Company's held-to-maturity investments in U.S. government securities, commercial paper, and its overnight repurchase agreement are carried at amortized cost and any premiums or discounts are amortized or accreted through the maturity date of the investment.  Any impairment that is not deemed to be temporary is recognized in the period identified.
Warrant Liabilities

Warrant Liabilities

The Company accounts for the outstanding warrants associated with the June 2016 public offering, March 2018 Public Offering, December 2019 Public Offering and December 2020 Public Offering as liabilities measured at fair value. The fair values of these warrants have been determined using the Black-Scholes valuation model ("Black-Scholes"). The warrants are subject to remeasurement at each balance sheet date, using Black-Scholes, with any changes in the fair value of the outstanding warrants recognized in the accompanying consolidated statements of operations. See Notes 9 and 12 for further details.
Convertible Debt and Derivative Liabilities

Convertible Debt and Derivative Liabilities

In connection with the Company’s issuance of its April 2020 and March 2019 6.0% Convertible Senior Notes (the “April 2020 Notes” and the “March 2019 Notes”), the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as long-term derivative liabilities in the Company’s balance sheet in accordance with FASB Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging.  The convertible debt and the derivative liabilities associated with the April 2020 Notes and March 2019 Notes are presented in total on the consolidated balance sheet as the convertible debt and derivative liabilities.  The convertible debt is carried at amortized cost.  The derivative liabilities will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the consolidated statements of operations in other expense (income).  See Notes 7 and 12 for further details.
Research and Development

Research and Development

Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance.

The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting ibrexafungerp clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its consolidated

financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel.  
Patent Expenses

Patent Expenses

Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows:

 

•

Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

 

•

Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

 

•

Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.
Amortization of Debt Issuance Costs and Discount

Amortization of Debt Issuance Costs and Discount

The Company’s convertible debt is recorded net of debt issuance costs which comprised issuance costs and an advisory fee.  The portion of the debt issuance costs allocated to the convertible debt, based on the amount of proceeds allocated between the convertible debt and the derivative liability, is being amortized over the term of the convertible debt using the effective interest method in addition to the discount initially recognized for the fair value of the bifurcated derivative liability from the convertible debt.  Debt issuance costs allocated to the derivative liabilities were included in other expense as a component of the fair value adjustment for the year ended December 31, 2020.  The Company’s previous term loan with Solar Capital Ltd. (“Solar”), which was paid in full in March 2019 (see Note 7), was recorded net of debt discount which comprised issuance costs, customary closing and final fees, and the fair value of the warrants issued in conjunction with the term loan. The resulting debt discount was being amortized over the term of the term loan using the straight-line method, which approximated the effective interest method.  The amortization of debt issuance costs and discount is included in other expense within the accompanying consolidated statements of operations.
Income Taxes

Income Taxes

The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions.
Stock-Based Compensation

Stock-Based Compensation

The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date.  The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods.
Basic and Diluted Net Loss per Share of Common Stock

Basic and Diluted Net Loss per Share of Common Stock

The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period.

The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive:

 

 

December 31,

 

 

 

2020

 

 

2019

 

Outstanding stock options

 

 

830,343

 

 

 

526,070

 

Outstanding restricted stock units

 

 

29,087

 

 

 

96,637

 

Warrants to purchase common stock associated with June 2016 Public Offering

 

 

421,867

 

 

 

421,867

 

Warrants to purchase common stock associated with March 2018 Public Offering - Series 2

 

 

798,810

 

 

 

798,810

 

Warrants to purchase common stock associated with December 2019 Public Offering

 

 

4,472,205

 

 

 

4,472,205

 

Option to purchase common stock associated with December 2019 Public Offering

 

 

—

 

 

 

583,333

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 1

 

 

6,800,000

 

 

 

—

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 2

 

 

6,800,000

 

 

 

—

 

For possible future issuance for the conversion of the March 2019 Notes

 

 

1,138,200

 

 

 

1,138,200

 

For possible future issuance for the conversion of the April 2020 Notes

 

 

1,299,790

 

 

 

—

 

Warrants to purchase common stock associated with Solar loan agreement

 

 

12,243

 

 

 

12,243

 

          Total

 

 

22,602,545

 

 

 

8,049,365

 
Segment and Geographic Information

Segment and Geographic Information

Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. The material assets of the Company were held in the United States for the years ended December 31, 2020 and 2019.  In July 2019, the Company incorporated SCYNEXIS Pacific Pty Ltd, a wholly-owned subsidiary, in Sydney, Australia, for the initial purpose of conducting certain clinical trials and other research and development activities.

Although all operations are primarily based in the United States, the Company generated a portion of its revenue from R-Pharm outside of the United States for the year ended December 31, 2019.  All of the Company's revenue in 2019 was generated from a non-refundable upfront payment received under a licensing and collaboration arrangement with a partner located in Russia.  All sales, including sales outside of the United States, are denominated in United States dollars.

 
Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) (“ASU 2019-10”), which revised the effective dates for ASU 2016-13 for public business entities that meet the SEC definition of a smaller reporting company to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022, with early adoption permitted.  As a smaller reporting company, the Company is currently evaluating the impact ASU 2016-13 will have on its consolidated financial statements.

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company is currently evaluating the impact ASU 2019-12 will have on its consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity’s Own Equity: Accounting for Convertible Instruments and Contracts in and Entity’s Own Equity (“ASU 2020-06”). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share.  The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years.  As a smaller reporting company, the Company is currently evaluating the impact ASU 2020-06 will have on its consolidated financial statements.

 

Recently Adopted Accounting Pronouncements

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). ASU 2018-13 removes, modifies and adds certain disclosure requirements in ASU 2018-13, Fair Value Measurement. ASU 2018-13 eliminates certain disclosures related to transfers and the valuation process, modifies disclosures for investments that are valued based on net asset value, clarifies the measurement uncertainty disclosure, and requires additional disclosures for Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.  The Company adopted ASU 2018-13 during the year ended December 31, 2020 and as a result, included the required additional disclosures for its Level 3 fair value measurements in its consolidated financial statements (see Note 12).  The Company did not identify any other material impacts of ASU 2018-13 on its consolidated financial statements.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding

The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive:

 

 

December 31,

 

 

 

2020

 

 

2019

 

Outstanding stock options

 

 

830,343

 

 

 

526,070

 

Outstanding restricted stock units

 

 

29,087

 

 

 

96,637

 

Warrants to purchase common stock associated with June 2016 Public Offering

 

 

421,867

 

 

 

421,867

 

Warrants to purchase common stock associated with March 2018 Public Offering - Series 2

 

 

798,810

 

 

 

798,810

 

Warrants to purchase common stock associated with December 2019 Public Offering

 

 

4,472,205

 

 

 

4,472,205

 

Option to purchase common stock associated with December 2019 Public Offering

 

 

—

 

 

 

583,333

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 1

 

 

6,800,000

 

 

 

—

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 2

 

 

6,800,000

 

 

 

—

 

For possible future issuance for the conversion of the March 2019 Notes

 

 

1,138,200

 

 

 

1,138,200

 

For possible future issuance for the conversion of the April 2020 Notes

 

 

1,299,790

 

 

 

—

 

Warrants to purchase common stock associated with Solar loan agreement

 

 

12,243

 

 

 

12,243

 

          Total

 

 

22,602,545

 

 

 

8,049,365

 
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Short-term Investments (Tables)
 12 Months Ended
Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]  
Held-to-maturity Securities

The following table summarizes the held-to-maturity securities held at December 31, 2019 (in thousands):

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair Value

 

As of December 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government securities

 

$

1,996

 

 

$

15

 

 

$

(14

)

 

$

1,997

 

Commercial paper

 

 

998

 

 

 

—

 

 

 

—

 

 

 

998

 

Overnight repurchase agreement

 

 

3,500

 

 

 

—

 

 

 

—

 

 

 

3,500

 

Total short-term investments

 

$

6,494

 

 

$

15

 

 

$

(14

)

 

$

6,495

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Prepaid Expenses and Other Current Assets (Tables)
 12 Months Ended
Dec. 31, 2020
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

December 31,

 

 

 

2020

 

 

2019

 

Prepaid research and development services

 

$

1,535

 

 

$

3,043

 

Prepaid insurance

 

 

362

 

 

 

252

 

Other prepaid expenses

 

 

19

 

 

 

19

 

Other receivable

 

 

2,876

 

 

 

—

 

Other current assets

 

 

373

 

 

 

674

 

Total prepaid expenses and other current assets

 

$

5,165

 

 

$

3,988

 

 
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2020
Property Plant And Equipment [Abstract]  
Schedule of Property and Equipment

Property and equipment consisted of the following (in thousands):

 

 

December 31,

 

 

 

2020

 

 

2019

 

Furniture and fixtures

 

$

406

 

 

$

406

 

Computer equipment

 

 

76

 

 

 

73

 

Other

 

 

98

 

 

 

98

 

 

 

 

580

 

 

 

577

 

Less: accumulated depreciation and amortization

 

 

(282

)

 

 

(172

)

Total property and equipment, net

 

$

298

 

 

$

405

 

 

 
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2020
Payables And Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consisted of the following (in thousands):

 

 

December 31,

 

 

 

2020

 

 

2019

 

Accrued research and development expenses

 

$

991

 

 

$

1,296

 

Accrued employee bonus compensation

 

 

2,190

 

 

 

1,798

 

Other accrued expenses

 

 

960

 

 

 

707

 

Total accrued expenses

 

$

4,141

 

 

$

3,801

 

 
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]  
Summary of Quantitative Information Associated with Amounts Recognized in Condensed Consolidated Financial Statements for Lease The following table summarizes certain quantitative information associated with the amounts recognized in the accompanying consolidated financial statements for the Lease (dollars in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

Operating lease cost

 

$

664

 

 

$

664

 

Variable lease cost

 

 

51

 

 

 

41

 

Total operating lease expense

 

$

715

 

 

$

705

 

 

 

 

 

 

 

 

 

 

Cash paid for amounts included in the measurement of operating lease liability

 

$

507

 

 

$

497

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2020

 

 

December 31, 2019

 

Remaining Lease term (years)

 

 

8.59

 

 

 

9.59

 

Discount rate

 

 

15

%

 

 

15

%

 
Future Minimum Lease Payments Future minimum lease payments for all operating leases as of December 31, 2020 are as follows (in thousands):

 

 

 

December 31, 2020

 

2021

 

$

517

 

2022

 

 

527

 

2023

 

 

715

 

2024

 

 

730

 

2025

 

 

744

 

Thereafter

 

 

2,789

 

Total

 

$

6,022

 
Presentation of Operating Lease Liability and Right-of-Use Asset

The presentation of the operating lease liability and right-of-use asset as of December 31, 2020 are as follows (in thousands):

 

 

December 31, 2020

 

Present value of future minimum lease payments

 

$

3,326

 

 

 

 

 

 

Operating lease liability, current portion

 

$

52

 

Operating lease liability, long-term portion

 

 

3,274

 

Total operating lease liability

 

$

3,326

 

 

 

 

 

 

Difference between future minimum lease payments and discounted cash flows

 

$

2,696

 

 

 

 

 

 

Operating lease right-of-use asset

 

$

2,999

 
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Common Stock Reserved For Future Issuances

The Company had reserved shares of common stock for future issuance as follows:

 

 

December 31,

 

 

 

2020

 

 

2019

 

Outstanding stock options

 

 

830,343

 

 

 

526,070

 

Outstanding restricted stock units

 

 

29,087

 

 

 

96,637

 

Warrants to purchase common stock associated with June 2016 Public Offering

 

 

421,867

 

 

 

421,867

 

Warrants to purchase common stock associated with March 2018 Public Offering - Series 2

 

 

798,810

 

 

 

798,810

 

Warrants to purchase common stock associated with December 2019 Public Offering

 

 

4,472,205

 

 

 

4,472,205

 

Option to purchase common stock associated with December 2019 Public Offering

 

 

—

 

 

 

583,333

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 1

 

 

6,800,000

 

 

 

—

 

Warrants to purchase common stock associated with December 2020 Public Offering - Series 2

 

 

6,800,000

 

 

 

—

 

Prefunded warrants to purchase common stock associated with December 2020 Public Offering

 

 

5,260,000

 

 

 

—

 

Warrants to purchase common stock associated with Solar loan agreement

 

 

12,243

 

 

 

12,243

 

For possible future issuance for the conversion of the March 2019 Notes

 

 

1,138,200

 

 

 

1,138,200

 

For possible future issuance for the conversion of the April 2020 Notes

 

 

1,299,790

 

 

 

—

 

For possible future issuance under 2014 Equity Incentive Plan  (Note 11)

 

 

146,488

 

 

 

55,478

 

For possible future issuance under Employee Stock Purchase Plan (Note 11)

 

 

5,895

 

 

 

7,423

 

For possible future issuance under 2015 Inducement Award Plan (Note 11)

 

 

14,050

 

 

 

31,550

 

Total common shares reserved for future issuance

 

 

28,028,978

 

 

 

8,143,816

 

 
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate Reconciliation Reconciliations of the differences between the benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (dollars in thousands):

 

 

 

2020

 

 

2019

 

 

 

Amount

 

 

Percent of Pretax Income

 

 

Amount

 

 

Percent of Pretax Income

 

Income taxes from continuing operations at statutory rate

 

$

(12,250

)

 

 

21.0

%

 

$

(11,279

)

 

 

21.0

%

State income taxes

 

 

(4,108

)

 

 

7.0

%

 

 

(3,778

)

 

 

7.0

%

State effect of permanent items

 

 

78

 

 

 

(0.1

)%

 

 

285

 

 

 

(0.5

)%

Stock-based compensation

 

 

96

 

 

 

(0.2

)%

 

 

100

 

 

 

(0.2

)%

Deferred rate change

 

 

—

 

 

 

—

 

 

 

(905

)

 

 

1.6

%

Warrants issuance

 

 

131

 

 

 

(0.2

)%

 

 

733

 

 

 

(1.4

)%

Other

 

 

206

 

 

 

(0.3

)%

 

 

883

 

 

 

(1.5

)%

NOL sale

 

 

301

 

 

 

(0.5

)%

 

 

—

 

 

 

—

 

R&D credit adjustment

 

 

2

 

 

 

—

 

 

 

(2,760

)

 

 

5.1

%

Increase in valuation allowance

 

 

12,396

 

 

 

(21.3

)%

 

 

16,721

 

 

 

(31.1

)%

Total income tax benefit

 

$

(3,148

)

 

 

5.4

%

 

$

—

 

 

 

—

%
Schedule of Deferred Tax Assets and Liabilities

 

The components of deferred tax assets and liabilities as of December 31, 2020 and 2019 are as follows (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Noncurrent deferred tax assets (liabilities)

 

 

 

 

 

 

 

 

Accrued expenses

 

$

148

 

 

$

107

 

Stock-based compensation

 

 

2,591

 

 

 

2,436

 

Lease liability

 

 

935

 

 

 

945

 

Other

 

 

(823

)

 

 

(856

)

Net operating loss carryforwards

 

 

70,936

 

 

 

58,073

 

Research and development credits

 

 

5,291

 

 

 

5,984

 

     Total deferred tax assets

 

 

79,078

 

 

 

66,689

 

Valuation allowances

 

 

(79,078

)

 

 

(66,689

)

Net deferred tax assets

 

$

—

 

 

$

—

 
Schedule of Unrecognized Tax Benefits Roll Forward

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits as of December 31, 2020 and 2019 (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Unrecognized tax benefit—January 1

 

$

436

 

 

$

436

 

Additions for tax positions of current period

 

 

—

 

 

 

—

 

Additions for tax positions of prior periods

 

 

—

 

 

 

—

 

Deferred rate change

 

 

—

 

 

 

—

 

Unrecognized tax benefit—December 31

 

$

436

 

 

$

436

 
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Assumptions Used To Estimate Fair Value of Options The assumptions used to estimate fair value and the resulting grant date fair values are as follows:

 

 

 

Employees

 

 

Non-employee Directors

 

 

 

Years Ended December 31,

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Weighted average expected volatility

 

 

64.67

%

 

 

66.47

%

 

 

66.55

%

 

 

65.36

%

Weighted average risk-free interest rate

 

 

1.18

%

 

 

2.47

%

 

 

0.36

%

 

 

2.11

%

Weighted average expected term (in years)

 

 

5.97

 

 

 

6.03

 

 

 

5.50

 

 

 

5.54

 
Schedule of Share-based Compensation, Stock Options, Activity

The activity for the 2009 Plan, 2014 Plan and 2015 Plan for the years ended December 31, 2020 is summarized as follows:

 

 

Number

of

Shares

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Life (in years)

 

 

Aggregate

Intrinsic

Value ($000)

 

Outstanding — December 31, 2019

 

 

526,070

 

 

$

30.55

 

 

 

7.62

 

 

$

60

 

Granted

 

 

349,437

 

 

$

8.17

 

 

 

 

 

 

 

 

 

Exercised

 

 

(166

)

 

$

8.60

 

 

 

 

 

 

 

 

 

Forfeited/expired

 

 

(44,998

)

 

$

23.50

 

 

 

 

 

 

 

 

 

Outstanding — December 31, 2020

 

 

830,343

 

 

$

21.52

 

 

 

7.71

 

 

$

96

 

Exercisable — December 31, 2020

 

 

447,802

 

 

$

31.47

 

 

 

6.74

 

 

$

22

 

Vested or expected to vest —December 31, 2020

 

 

830,343

 

 

$

21.52

 

 

 

7.71

 

 

$

96

 
Schedule of Restricted Stock Units ("RSU") Activity

Restricted stock unit ("RSU") activity under the 2014 Plan and 2015 Plan for the years ended December 31, 2020, is summarized as follows:

 

 

Number of

Shares

 

 

Weighted

Average

Grant Date

Fair Value

Per Share

 

Non-vested at December 31, 2019

 

 

96,637

 

 

$

14.18

 

Granted

 

 

28,695

 

 

$

8.18

 

Vested

 

 

(78,859

)

 

$

14.05

 

Forfeited

 

 

(17,386

)

 

$

12.68

 

Non-vested at December 31, 2020

 

 

29,087

 

 

$

9.52

 

 
Stock-Based Compensation Expense Related to Stock Options

Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

Research and development

 

$

806

 

 

$

604

 

Selling, general and administrative

 

 

1,414

 

 

 

1,224

 

Total stock-based compensation expense

 

$

2,220

 

 

$

1,828

 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Summary of Financial Instruments Measured on a Recurring Basis The following table summarizes the conclusions reached as of December 31, 2020 and 2019 for financial instruments measured at fair value on a recurring basis (in thousands):

 

 

 

 

 

 

Fair Value Hierarchy Classification

 

 

 

Balance

 

 

Quoted Prices in Active

Markets for Identical Assets (Level 1)

 

 

Significant Other

Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

117

 

 

$

117

 

 

 

—

 

 

 

—

 

Restricted cash

 

 

273

 

 

 

273

 

 

 

—

 

 

 

—

 

Money market funds

 

 

92,924

 

 

 

92,924

 

 

 

—

 

 

 

—

 

Total assets

 

$

93,314

 

 

$

93,314

 

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liabilities

 

$

51,156

 

 

 

—

 

 

 

—

 

 

$

51,156

 

Derivative liabilities

 

 

5,954

 

 

 

—

 

 

 

—

 

 

 

5,954

 

Total liabilities

 

$

57,110

 

 

 

—

 

 

 

—

 

 

$

57,110

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

23

 

 

$

23

 

 

 

—

 

 

 

—

 

Restricted cash

 

 

273

 

 

 

273

 

 

 

—

 

 

 

—

 

Money market funds

 

 

41,897

 

 

 

41,897

 

 

 

—

 

 

 

—

 

Total assets

 

$

42,193

 

 

$

42,193

 

 

 

—

 

 

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liabilities

 

$

18,396

 

 

 

—

 

 

 

—

 

 

$

18,396

 

Derivative liability

 

 

3,192

 

 

 

 

 

 

 

 

 

 

 

3,192

 

Total liabilities

 

$

21,588

 

 

 

—

 

 

 

—

 

 

$

21,588

 
Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis

 

A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):

 

 

 

 

Warrant Liabilities

 

Balance – January 1, 2020

 

 

$

18,396

 

December 2020 Public Offering

 

 

 

29,478

 

Loss adjustment to fair value

 

 

 

3,282

 

Balance – December 31, 2020

 

 

$

51,156

 

 

 

 

 

 

 

 

 

 

Derivative Liabilities

 

Balance – January 1, 2020

 

 

$

3,192

 

Bifurcated embedded conversion option associated with April 2020 Notes

 

 

 

8,110

 

Adjustment for partial conversion of April 2020 Notes

 

 

 

(2,690

)

Gain adjustment to fair value

 

 

 

(2,658

)

Balance – December 31, 2020

 

 

$

5,954

 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Description of Business and Basis of Preparation - Additional Information (Detail)
 12 Months Ended
Jan. 08, 2021
USD ($)
Oct. 01, 2020
USD ($)
Jul. 17, 2020
shares
Jul. 16, 2020
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
Jun. 18, 2019
shares
Jun. 17, 2019
shares
Dec. 31, 2018
shares
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Accumulated deficit         $ (326,613,000) $ (271,428,000)      
Cash and cash equivalents         93,041,000 $ 41,920,000      
Shelf registration maximum equity offering price         $ 437,000,000.0        
Reverse stock split, ratio       0.1          
Common stock, shares authorized (in shares) | shares     100,000,000 250,000,000 100,000,000 100,000,000 250,000,000 125,000,000  
Common stock, shares issued (in shares) | shares     10,508,302 105,083,291 19,663,698 9,741,372      
Common stock, shares outstanding (in shares) | shares     10,508,302 105,083,291 19,663,698 9,741,372      
Stock issued during period as result of reverse stock splits | shares     0 0          
Common Stock                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Common stock, shares outstanding (in shares) | shares         19,663,698 9,741,372     4,797,198
October 2020 Shelf Registration                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Shelf registration maximum equity initial offering price   $ 200,000,000.0              
October 2020 Shelf Registration | Sales Agreement | Common Stock                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Shelf registration maximum equity offering price   $ 50,000,000.0              
Subsequent Event | January 2021 Shelf Registration                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Shelf registration maximum equity initial offering price $ 200,000,000.0                
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Additional Information (Detail)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Segment
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Subsidiary, Sale of Stock [Line Items]      
Cash, cash equivalents, and restricted cash | $ $ 93,314 $ 42,193 $ 11,767
Operating segments (number) | Segment 1    
ASU 2018-13      
Subsidiary, Sale of Stock [Line Items]      
Change in Accounting Principle, Accounting Standards Update, Adopted true    
Change in Accounting Principle, Accounting Standards Update, Adoption Date Dec. 31, 2020    
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] true    
Accounting Standards Update [Extensible List] ASU 2018-13    
6.0% April 2020 and March 2019 Convertible Senior Notes      
Subsidiary, Sale of Stock [Line Items]      
Interest rate 6.00%    
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Details) - shares
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities (in shares) 22,602,545 8,049,365
Outstanding stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities (in shares) 830,343 526,070
Outstanding restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities (in shares) 29,087 96,637
For possible future issuance for the conversion of the March 2019 Notes    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities (in shares) 1,138,200 1,138,200
For possible future issuance for the conversion of the April 2020 Notes    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities (in shares) 1,299,790 0
Warrants to purchase common stock associated with Solar loan agreement | Warrant liability    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities (in shares) 12,243 12,243
Warrants to purchase common stock associated with June 2016 Public Offering | Warrant liability    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities (in shares) 421,867 421,867
March 2018 Public Offering Series 2 [Member] | Warrant liability    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities (in shares) 798,810 798,810
December 2020 Public Offering Series 1 | Warrant liability    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities (in shares) 6,800,000 0
December 2020 Public Offering Series 2 | Warrant liability    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities (in shares) 6,800,000 0
December 2019 Public Offering | Warrant liability    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities (in shares) 4,472,205 4,472,205
December 2019 Public Offering | Option to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities (in shares) 0 583,333
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Short-term Investments (Details)
$ in Thousands
Dec. 31, 2019
USD ($)
Schedule of Held-to-maturity Securities [Line Items]  
Amortized Cost $ 6,494
Unrealized Gains 15
Unrealized Losses (14)
Fair Value 6,495
Commercial paper  
Schedule of Held-to-maturity Securities [Line Items]  
Amortized Cost 998
Unrealized Gains 0
Unrealized Losses 0
Fair Value 998
Overnight repurchase agreement  
Schedule of Held-to-maturity Securities [Line Items]  
Amortized Cost 3,500
Unrealized Gains 0
Unrealized Losses 0
Fair Value 3,500
U.S. government securities  
Schedule of Held-to-maturity Securities [Line Items]  
Amortized Cost 1,996
Unrealized Gains 15
Unrealized Losses (14)
Fair Value $ 1,997
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Short-term Investments - Additional Information (Details)
$ in Millions
Dec. 31, 2019
USD ($)
Investments Debt And Equity Securities [Abstract]  
Held-to-maturity investments $ 6.5
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Prepaid Expenses and Other Current Assets (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]    
Prepaid research and development services $ 1,535 $ 3,043
Prepaid insurance 362 252
Other prepaid expenses 19 19
Other receivable 2,876 0
Other current assets 373 674
Total prepaid expenses and other current assets $ 5,165 $ 3,988
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 580 $ 577
Less: accumulated depreciation and amortization (282) (172)
Total property and equipment, net 298 405
Furniture and Fixtures    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 406 406
Computer Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 76 73
Other    
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 98 $ 98
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Payables And Accruals [Abstract]    
Accrued research and development expenses $ 991 $ 1,296
Accrued employee bonus compensation 2,190 1,798
Other accrued expenses 960 707
Total accrued expenses $ 4,141 $ 3,801
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Borrowings - Additional Information (Details)
 1 Months Ended 12 Months Ended
Mar. 07, 2019
USD ($)
d
$ / shares
Sep. 30, 2016
USD ($)
Jan. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Jun. 30, 2020
USD ($)
shares
Apr. 09, 2020
USD ($)
d
$ / shares
Apr. 30, 2019
USD ($)
shares
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]                  
Payment of debt issuance costs               $ 494,000 $ 1,253,000
Amortization of debt issuance costs and discount               1,201,000 1,171,000
Loss on extinguishment of debt               1,766,000 1,045,000
Net carrying amount of convertible debt and derivative liability       $ 16,516,000       $ 16,516,000 11,522,000
April 2020 Note Purchase Agreement                  
Debt Instrument [Line Items]                  
Date of issuance and sale of notes           Apr. 09, 2020      
Face amount           $ 10,000,000.0      
Proceeds from debt, net of issuance costs           9,500,000      
Payment of debt issuance costs           $ 500,000      
Purchase price as percentage of principal amount           100.00%      
Interest rate           6.00%      
Payment terms               The April 2020 Notes will bear interest at a rate of 6.0% per annum, payable semiannually in arrears on April 15 and October 15 of each year, beginning October 15, 2020. The April 2020 Notes will mature on April 15, 2026, unless earlier converted, redeemed or repurchased.    
Notes maturity date           Apr. 15, 2026      
Notes maturity description               The April 2020 Notes will mature on April 15, 2026, unless earlier converted, redeemed or repurchased  
Senior convertible notes       1,200,000       $ 1,200,000  
Unamortized debt issuance cost       100,000       100,000  
Bifurcated embedded conversion option derivative liability       3,300,000       3,300,000  
Derivative, fair value       8,100,000       8,100,000  
Debt issuance costs       400,000       400,000  
Gain (loss) on fair value adjustment of derivative liability               1,700,000  
Amortization of debt issuance costs and discount               200,000  
Conversion of convertible note, amount       $ 2,000,000.0 $ 2,000,000.0        
Conversion of convertible note exchanged for shares | shares       322,348 316,461        
Loss on extinguishment of debt       $ 1,000,000.0 $ 800,000        
Net carrying amount of convertible debt and derivative liability       1,400,000 2,000,000.0     1,400,000  
Fair value of the consideration issued       2,400,000 $ 2,800,000     2,400,000  
Fair value of convertible debt and derivative liability       7,400,000       $ 7,400,000  
Conversion terms               holders of the April 2020 Notes may convert their April 2020 Notes at their option at any time prior to the close of business on the business day immediately preceding April 15, 2026 into shares of the Company’s common stock.  
Conversion rate, number of shares to be issued per $1000 of principal (in shares)           111.1108      
Principal amount of notes used as the denominator for conversion into notes           $ 1,000      
Initial conversion price of notes | $ / shares           $ 9.00      
Conversion rate, number of shares to be issued per $1000 of principal (in shares) after adjustment to certain events           1,938,600      
Convertible notes, redemption start date           Apr. 15, 2023      
Convertible notes, threshold percentage of stock price trigger           130.00%      
Convertible notes, threshold trading days | d           20      
Convertible notes, threshold consecutive trading days | d           30      
Redemption price as percentage of the principal amount           100.00%      
Redemption price as percentage of the principal amount subject to certain exceptions           100.00%      
April 2020 Note Purchase Agreement | Subsequent Event                  
Debt Instrument [Line Items]                  
Conversion of convertible note, amount     $ 6,000,000.0            
Conversion of convertible note exchanged for shares | shares     959,080            
Senior Convertible Note Purchase Agreement                  
Debt Instrument [Line Items]                  
Date of issuance and sale of notes Mar. 07, 2019                
Face amount $ 16,000,000.0                
Proceeds from debt, net of issuance costs 14,700,000                
Payment of debt issuance costs $ 1,300,000                
Purchase price as percentage of principal amount 100.00%                
Interest rate 6.00%                
Payment terms               The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased.   
Notes maturity date Mar. 15, 2025                
Notes maturity description               The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased  
Senior convertible notes       9,400,000       $ 9,400,000 8,300,000
Unamortized debt issuance cost       400,000       400,000 500,000
Bifurcated embedded conversion option derivative liability       2,700,000       2,700,000 3,200,000
Derivative, fair value       7,000,000.0       7,000,000.0  
Debt issuance costs       600,000       600,000  
Gain (loss) on fair value adjustment of derivative liability               500,000 1,600,000
Amortization of debt issuance costs and discount               1,000,000.0 1,100,000
Conversion of convertible note, amount             $ 2,000,000.0    
Conversion of convertible note exchanged for shares | shares             162,600    
Loss on extinguishment of debt             $ 200,000   800,000
Net carrying amount of convertible debt and derivative liability             2,800,000    
Fair value of the consideration issued             $ 3,000,000.0    
Fair value of convertible debt and derivative liability       $ 12,900,000       $ 12,900,000 11,700,000
Conversion terms               holder of the March 2019 Notes may convert their March 2019 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 into shares of the Company’s common stock.  
Conversion rate, number of shares to be issued per $1000 of principal (in shares) 73.9096                
Principal amount of notes used as the denominator for conversion into notes $ 1,000                
Initial conversion price of notes | $ / shares $ 13.53                
Conversion rate, number of shares to be issued per $1000 of principal (in shares) after adjustment to certain events 81                
Convertible notes, redemption start date Mar. 15, 2022                
Convertible notes, threshold percentage of stock price trigger 130.00%                
Convertible notes, threshold trading days | d 20                
Convertible notes, threshold consecutive trading days | d 30                
Redemption price as percentage of the principal amount 100.00%                
Redemption price as percentage of the principal amount subject to certain exceptions 100.00%                
Reacquisition price of outstanding debt                 15,900,000
Carrying value of debt obligation                 $ 15,100,000
Principal amount of notes used as the denominator for conversion into notes after adjustment of certain events $ 1,000                
Term Loan | Secured Debt                  
Debt Instrument [Line Items]                  
Face amount   $ 15,000,000.0              
Loan agreement term   48 months              
Term Loan | Secured Debt | LIBOR                  
Debt Instrument [Line Items]                  
Basis spread on variable rate (as a percent)   8.49%              
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies - Additional Information (Detail)
 12 Months Ended
Mar. 01, 2018
USD ($)
ft²
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Commitment And Contingencies [Line Items]      
Long-term lease agreement, area of office space | ft² 19,275    
Lease term 11 years    
Total lease payments $ 7,300,000 $ 507,000 $ 497,000
Lessee, operating lease, existence of option to extend true    
Renewal term 5 years    
Renewal term, description The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which will be reduced by fifty-five thousand dollars every two years for ten years after the commencement of the lease    
Security deposit in the form of a standby letter of credit $ 300,000    
Decrease in security deposit $ 55,000    
Cypralis Limited | Asset Purchase Agreement      
Commitment And Contingencies [Line Items]      
Revenue recognized   0 0
Waterstone Pharmaceutical HK Limited | License Agreement      
Commitment And Contingencies [Line Items]      
Revenue recognized   0 $ 0
Maximum      
Commitment And Contingencies [Line Items]      
Milestone payments from the Company   $ 19,000,000.0  
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Condensed Consolidated Financial Statements for Lease (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Mar. 01, 2018
Dec. 31, 2020
Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]      
Operating lease cost   $ 664 $ 664
Variable lease cost   51 41
Total operating lease expense   715 705
Total lease payments $ 7,300 $ 507 $ 497
Remaining Lease term (years)   8 years 7 months 2 days 9 years 7 months 2 days
Discount rate   15.00% 15.00%
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies - Future Minimum Lease Payments (Detail)
$ in Thousands
Dec. 31, 2020
USD ($)
Commitments And Contingencies Disclosure [Abstract]  
2021 $ 517
2022 527
2023 715
2024 730
2025 744
Thereafter 2,789
Total $ 6,022
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies - Presentation of Operating Lease Liability and Right-of-Use Asset (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]    
Present value of future minimum lease payments $ 3,326  
Operating lease liability, current portion 52 $ 36
Operating lease liability, long-term portion 3,274 3,326
Total operating lease liability 3,326  
Difference between future minimum lease payments and discounted cash flows 2,696  
Operating lease right-of-use asset $ 2,999 $ 3,191
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity - Additional Information (Detail)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 17, 2020
USD ($)
$ / shares
shares
Jul. 17, 2020
shares
Jul. 16, 2020
shares
Apr. 10, 2020
USD ($)
d
$ / shares
shares
Dec. 12, 2019
USD ($)
$ / shares
shares
Mar. 08, 2018
$ / shares
shares
Sep. 30, 2016
$ / shares
shares
Jun. 21, 2016
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
$ / shares
shares
Dec. 31, 2018
USD ($)
shares
Jun. 18, 2019
shares
Jun. 17, 2019
shares
May 07, 2014
$ / shares
shares
Schedule Of Capitalization Equity [Line Items]                            
Common stock, par value (in dollars per share) | $ / shares                 $ 0.001 $ 0.001        
Common stock, shares authorized (in shares)   100,000,000 250,000,000           100,000,000 100,000,000   250,000,000 125,000,000  
Common stock, shares issued (in shares)   10,508,302 105,083,291           19,663,698 9,741,372        
Common stock, shares outstanding (in shares)   10,508,302 105,083,291           19,663,698 9,741,372        
Common stock, reverse stock split                 1-for-10          
Reverse stock split, ratio     0.1                      
Stock issued during period as result of reverse stock splits   0 0                      
Preferred stock, shares authorized (in shares)                 5,000,000 5,000,000       5,000,000
Preferred stock, par value (in dollars per share) | $ / shares                 $ 0.001 $ 0.001       $ 0.001
Preferred stock, shares issued (in shares)                 0 0        
Preferred stock, shares outstanding (in shares)                 0 0        
Common stock issued, net of expenses (in shares)           1,775,150   937,500            
Proceeds from common stock issued | $                 $ 90,554 $ 46,337        
Common stock issued, net of expenses | $                 57,184 30,530        
Warrant liabilities fair value adjustment | $                 5,214 $ 4,497        
Warrant liabilities | $                 $ 51,200          
Warrants to purchase common stock associated with Loan Agreement                            
Schedule Of Capitalization Equity [Line Items]                            
Number of warrants issued to purchase common stock (in shares)             12,243              
Exercise price of warrants (in dollars per share) | $ / shares             $ 36.754              
Warrant expiration period             5 years              
Aspire Capital | Common Stock Purchase Agreement                            
Schedule Of Capitalization Equity [Line Items]                            
Common stock issued, net of expenses (in shares)                 125,000          
Proceeds from common stock issued | $                 $ 600          
Number of purchase aggregate shares of common stock       1,956,547                    
Percentage of common stock outstanding       19.99%                    
Number of shares committed       70,910                    
Average purchase price of shares sold | $ / shares       $ 8.461                    
Percentage of common stock owned       19.99%                    
Sale of common stock maximum number of share sold per business day       25,000                    
Stock purchase price average number of trading days lowest closing sales price out of consecutive trading days | d       3                    
Stock purchase price number of consecutive trading days | d       10                    
Increase in sale of common stock maximum number of share sold per business day       200,000                    
Percentage of purchase price per share       97.00%                    
Option to Purchase Common Stock                            
Schedule Of Capitalization Equity [Line Items]                            
Options expiration date         2020-01                  
Maximum | Aspire Capital | Common Stock Purchase Agreement                            
Schedule Of Capitalization Equity [Line Items]                            
Public offering price | $ / shares       $ 0.25                    
Sale of common stock at sole discretion | $       $ 20,000                    
Stock purchase percentage on aggregate shares of common stock traded       30.00%                    
Maximum | Option to Purchase Common Stock                            
Schedule Of Capitalization Equity [Line Items]                            
Number of options not exercised         583,333                  
Series 1 Warrant                            
Schedule Of Capitalization Equity [Line Items]                            
Number of warrants issued to purchase common stock (in shares)                     11,550      
Warrants, expiration date           Mar. 14, 2019                
Proceeds from Warrant Exercises | $                     $ 200      
Common Stock                            
Schedule Of Capitalization Equity [Line Items]                            
Common stock, shares outstanding (in shares)                 19,663,698 9,741,372 4,797,198      
Common stock issued, net of expenses (in shares)                 9,156,304 4,773,692        
Common stock issued, net of expenses | $                 $ 9 $ 5        
Commitment Shares | Aspire Capital | Common Stock Purchase Agreement                            
Schedule Of Capitalization Equity [Line Items]                            
Common stock shares issued       70,910                    
Commitment Shares | Aspire Capital | Common Stock Purchase Agreement | Other Expense                            
Schedule Of Capitalization Equity [Line Items]                            
Fair value of shares | $                 600          
December 2020 Public Offering                            
Schedule Of Capitalization Equity [Line Items]                            
Common stock, par value (in dollars per share) | $ / shares $ 0.001                          
Common stock issued, net of expenses (in shares) 8,340,000                          
Exercise price of warrants (in dollars per share) | $ / shares $ 0.001                          
Number of shares received per warrant (in shares) 6,800,000                          
Proceeds from common stock issued | $ $ 79,500                          
Warrant liabilities fair value adjustment | $                 1,900          
December 2020 Public Offering | Pre-funded Warrants                            
Schedule Of Capitalization Equity [Line Items]                            
Common stock, par value (in dollars per share) | $ / shares $ 0.001                          
Number of warrants issued to purchase common stock (in shares) 5,260,000                          
Public offering price | $ / shares $ 6.249                          
December 2020 Public Offering | Series 1 Warrant                            
Schedule Of Capitalization Equity [Line Items]                            
Exercise price of warrants (in dollars per share) | $ / shares $ 7.33                          
Warrant term 1 year                          
December 2020 Public Offering | Series 1 Warrant | Maximum                            
Schedule Of Capitalization Equity [Line Items]                            
Number of warrants issued to purchase common stock (in shares) 13,600,000                          
December 2020 Public Offering | Series 2 Warrant                            
Schedule Of Capitalization Equity [Line Items]                            
Exercise price of warrants (in dollars per share) | $ / shares $ 8.25                          
Warrant term 3 years 6 months                          
December 2020 Public Offering | Series 2 Warrant | Minimum                            
Schedule Of Capitalization Equity [Line Items]                            
Number of warrants issued to purchase common stock (in shares) 5,260,000                          
December 2020 Public Offering | Common Stock                            
Schedule Of Capitalization Equity [Line Items]                            
Public offering price | $ / shares $ 6.25                          
December 2019 Public Offering                            
Schedule Of Capitalization Equity [Line Items]                            
Common stock issued, net of expenses (in shares)         3,888,888                  
Number of warrants issued to purchase common stock (in shares)         3,888,888                  
Exercise price of warrants (in dollars per share) | $ / shares         $ 11.0                  
Share price (in dollars per share) | $ / shares         $ 9.00                  
Common stock issued, net of expenses | $         $ 32,500                  
Warrants, expiration date         Jun. 12, 2023                  
Warrant liabilities fair value adjustment | $                 $ 1,000          
Underwriters | Maximum                            
Schedule Of Capitalization Equity [Line Items]                            
Option to purchase shares of common stock         583,333                  
Underwriters | Warrant liability                            
Schedule Of Capitalization Equity [Line Items]                            
Number of warrants issued to purchase common stock (in shares)         583,333                  
Number of warrants exercised         583,333                  
March 2018 Public Offering                            
Schedule Of Capitalization Equity [Line Items]                            
Public offering price | $ / shares           $ 16.90                
March 2018 Public Offering | Series 1 Warrant                            
Schedule Of Capitalization Equity [Line Items]                            
Exercise price of warrants (in dollars per share) | $ / shares           $ 18.5                
Number of shares received per warrant (in shares)           0.75                
Warrant term           371 days                
March 2018 Public Offering | Series 1 Warrant | Maximum                            
Schedule Of Capitalization Equity [Line Items]                            
Number of warrants issued to purchase common stock (in shares)           1,331,370                
March 2018 Public Offering | Series 2 Warrant                            
Schedule Of Capitalization Equity [Line Items]                            
Exercise price of warrants (in dollars per share) | $ / shares           $ 20.0                
Number of shares received per warrant (in shares)           0.45                
Warrant term           5 years                
March 2018 Public Offering | Series 2 Warrant | Maximum                            
Schedule Of Capitalization Equity [Line Items]                            
Number of warrants issued to purchase common stock (in shares)           798,810                
March 2018 Public Offering | Warrant liability | Maximum                            
Schedule Of Capitalization Equity [Line Items]                            
Number of warrants issued to purchase common stock (in shares)           2,130,180                
June 2016 Public Offering                            
Schedule Of Capitalization Equity [Line Items]                            
Exercise price of warrants (in dollars per share) | $ / shares               $ 30.0            
Number of shares received per warrant (in shares)               0.45            
Warrant expiration period               5 years            
June 2016 Public Offering | Warrant liability | Maximum                            
Schedule Of Capitalization Equity [Line Items]                            
Number of warrants issued to purchase common stock (in shares)               421,867            
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) - shares
Dec. 31, 2020
Dec. 31, 2019
Class of Stock [Line Items]    
Common shares reserved for future issuance 28,028,978 8,143,816
Stock options    
Class of Stock [Line Items]    
Common shares reserved for future issuance 830,343 526,070
Restricted Stock Units    
Class of Stock [Line Items]    
Common shares reserved for future issuance 29,087 96,637
December 2020 Public Offering    
Class of Stock [Line Items]    
Common shares reserved for future issuance 5,260,000 0
Warrant liability | June 2016 Public Offering    
Class of Stock [Line Items]    
Common shares reserved for future issuance 421,867 421,867
Warrant liability | December 2020 Public Offering Series 1    
Class of Stock [Line Items]    
Common shares reserved for future issuance 6,800,000 0
Warrant liability | December 2019 Public Offering    
Class of Stock [Line Items]    
Common shares reserved for future issuance 4,472,205 4,472,205
Warrant liability | Warrants to purchase common stock associated with Solar loan agreement    
Class of Stock [Line Items]    
Common shares reserved for future issuance 12,243 12,243
Warrant liability | December 2020 Public Offering Series 2    
Class of Stock [Line Items]    
Common shares reserved for future issuance 6,800,000 0
Series 2 Warrant | March 2018 Public Offering    
Class of Stock [Line Items]    
Common shares reserved for future issuance 798,810 798,810
Option to Purchase Common Stock | December 2019 Public Offering    
Class of Stock [Line Items]    
Common shares reserved for future issuance 0 583,333
March 2019 Notes    
Class of Stock [Line Items]    
Common shares reserved for future issuance 1,138,200 1,138,200
April 2020 Notes    
Class of Stock [Line Items]    
Common shares reserved for future issuance 1,299,790 0
2014 Equity Incentive Plan    
Class of Stock [Line Items]    
Common shares reserved for future issuance 146,488 55,478
2014 Employee Stock Purchase Plan    
Class of Stock [Line Items]    
Common shares reserved for future issuance 5,895 7,423
2015 Inducement Award Plan    
Class of Stock [Line Items]    
Common shares reserved for future issuance 14,050 31,550
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Apr. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2017
Operating Loss Carryforwards [Line Items]        
Income tax benefit   $ 3,148,000 $ 0  
Loss before taxes   $ 58,333,000 $ 53,710,000  
Corporate income tax rate   21.00% 21.00%  
Temporary expensing for certain business assets and property, percent   100.00%    
Maximum deduction percentage of pre-NOL taxable income   80.00%    
Unrecognized tax benefits that would impact effective tax rate   $ 0    
Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit   0    
Income tax examination, penalties and interest accrued   $ 0    
Maximum        
Operating Loss Carryforwards [Line Items]        
Corporate income tax rate   21.00%   35.00%
Federal        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforward   $ 294,400,000 $ 242,400,000  
Tax credit carryforward   5,300,000    
NOLs subject to expiration   169,600,000    
NOLs subject not to expiration   $ 52,000,000.0 47,500,000  
NOLs expiration date   Dec. 31, 2037    
Net operating loss carryforwards expiration year   2022    
State        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforward   $ 202,700,000 $ 178,200,000  
Net operating loss carryforwards expiration year   2019    
State | New Jersey        
Operating Loss Carryforwards [Line Items]        
Cash receipt from the sale of state NOLs $ 3,100,000      
Maximum selling value of unused net operating losses and research and development tax credit to profitable tax payers.   $ 20,000,000.0    
Amount received from the program   $ 9,900,000    
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Amount    
Income taxes from continuing operations at statutory rate $ (12,250) $ (11,279)
State income taxes (4,108) (3,778)
State effect of permanent items 78 285
Stock-based compensation 96 100
Deferred rate change   (905)
Warrants issuance 131 733
Other 206 883
NOL sale 301  
R&D credit adjustment 2 (2,760)
Increase in valuation allowance 12,396 16,721
Total income tax benefit $ (3,148) $ 0
Percent of Pretax Income    
Income taxes from continuing operations at statutory rate 21.00% 21.00%
State income taxes 7.00% 7.00%
State effect of permanent items (0.10%) (0.50%)
Stock-based compensation (0.20%) (0.20%)
Deferred rate change 0.00% 1.60%
Warrants issuance (0.20%) (1.40%)
Other (0.30%) (1.50%)
NOL sale (0.50%) 0.00%
R&D credit adjustment 0.00% 5.10%
Increase in valuation allowance (21.30%) (31.10%)
Total income tax benefit 5.40% 0.00%
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]    
Accrued expenses $ 148 $ 107
Stock-based compensation 2,591 2,436
Lease liability 935 945
Other (823) (856)
Net operating loss carryforwards 70,936 58,073
Research and development credits 5,291 5,984
Total deferred tax assets 79,078 66,689
Valuation allowances (79,078) (66,689)
Net deferred tax assets $ 0 $ 0
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]    
Unrecognized tax benefits $ 436 $ 436
Additions for tax positions of current period 0 0
Additions for tax positions of prior periods 0 0
Deferred rate change 0 0
Unrecognized tax benefits $ 436 $ 436
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - 2009 Stock Option Plan (Details) - 2009 Stock Option Plan
 12 Months Ended
Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Expiration period of options 10 years
Minimum  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Percentage of exercise price 100.00%
Vesting period of options 3 years
Maximum  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Percentage of exercise price 110.00%
Vesting period of options 4 years
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - 2014 Equity Incentive Plan (Details) - 2014 Equity Incentive Plan - shares
 12 Months Ended
May 02, 2014
Dec. 31, 2020
Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Number of additional awards expected to be granted (in shares) 0    
Expiration period of options   10 years  
Common stock outstanding percentage 4.00%    
Number of shares of common stock for future issuance, board of directors prerogative, increase in period (in shares) 0    
Share-based compensation arrangement by share-based payment award, number of additional shares authorized   389,650 191,887
Possible future issuance under equity compensation plan (in shares)   146,488  
Minimum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Vesting period of options   3 years  
Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Vesting period of options   4 years  
Base number of new shares available for future issuance under equity incentive plan (in shares) 112,273    
Common stock issuable period 10 years    
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - 2015 Inducement Plan (Details) - shares
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Jun. 09, 2019
Jun. 08, 2019
Mar. 26, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]          
Granted (shares) 349,437        
2015 Inducement Plan          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]          
Shares authorized under the plan (in shares)     90,000 45,000 45,000
Granted (shares) 17,500 11,500      
Possible future issuance under equity compensation plan (in shares) 14,050 31,550      
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Option Valuation Method - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]    
Weighted average value of options granted in period (in dollars per share) $ 4.83 $ 7.50
Aggregate fair value of options granted $ 1.7 $ 1.3
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Option Valuation Method (Details)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]    
Weighted average expected volatility, employees 64.67% 66.47%
Weighted average expected volatility, non-employees directors 66.55% 65.36%
Weighted average risk-free interest rate, employees 1.18% 2.47%
Weighted average risk-free interest rate, non-employees directors 0.36% 2.11%
Weighted average expected term (in years), employees 5 years 11 months 19 days 6 years 10 days
Weighted average expected term (in years), non-employees directors 5 years 6 months 5 years 6 months 14 days
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Number of Shares    
Beginning balance - Outstanding (shares) 526,070  
Granted (shares) 349,437  
Exercised (shares) (166)  
Forfeited/expired (shares) (44,998)  
Ending balance - Outstanding (shares) 830,343 526,070
Exercisable (shares) 447,802  
Vested or expected to vest (shares) 830,343  
Weighted- Average Exercise Price    
Beginning balance - Outstanding (in dollars per share) $ 30.55  
Granted (in dollars per share) 8.17  
Exercised (in dollars per share) 8.60  
Forfeited/expired (in dollars per share) 23.50  
Ending balance - Outstanding (in dollars per share) 21.52 $ 30.55
Exercisable (in dollars per share) 31.47  
Vested or expected to vest (in dollars per share) $ 21.52  
Weighted- Average Remaining Contractual Life (in years)    
Balance - Outstanding 7 years 8 months 15 days 7 years 7 months 13 days
Exercisable 6 years 8 months 26 days  
Vested or expected to vest 7 years 8 months 15 days  
Aggregate Intrinsic Value ($000)    
Balance - Outstanding $ 96 $ 60
Exercisable 22  
Vested and expected to vest $ 96  
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Stock Option Activity - Additional Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]    
Total fair value of shares vested during the year $ 1.3 $ 1.5
Total unrecognized compensation cost related to unvested share-based compensation arrangements $ 2.0  
Total unrecognized compensation cost related to unvested share-based compensation arrangements, recognition period 2 years 4 months 24 days  
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Schedule of Restricted Stock Units ("RSU") Activity (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2020
USD ($)
$ / shares
shares
Weighted Average Grant Date Fair Value Per Share  
Total unrecognized compensation cost related to unvested share-based compensation arrangements, recognition period 2 years 4 months 24 days
Restricted Stock Units  
Number of Shares  
Beginning balance - Outstanding (shares) | shares 96,637
Options granted in period (shares) | shares 28,695
Vested (shares) | shares (78,859)
Forfeited (shares) | shares (17,386)
Ending balance - Outstanding (shares) | shares 29,087
Weighted Average Grant Date Fair Value Per Share  
Beginning balance - Outstanding (in dollars per share) | $ / shares $ 14.18
Granted (in dollars per share) | $ / shares 8.18
Vested (in dollars per share) | $ / shares 14.05
Forfeited (in dollars per share) | $ / shares 12.68
Ending balance - Outstanding (in dollars per share) | $ / shares $ 9.52
Vesting percentage 25.00%
Vesting period of options 4 years
Total unrecognized compensation cost related to unvested RSU share-based compensation | $ $ 0.2
Total unrecognized compensation cost related to unvested share-based compensation arrangements, recognition period 2 years 9 months 18 days
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - 2014 Employee Stock Purchase Plan (Details) - 2014 Employee Stock Purchase Plan - shares
 12 Months Ended
May 02, 2014
Dec. 31, 2020
Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
For possible future issuance under employee stock purchase plan (in shares) 4,779    
Common stock issuable period 10 years    
Common stock outstanding percentage 0.80%    
Employee stock purchase plan, number of shares, which might be added to common stock outstanding (in shares) 2,941    
Number of shares of common stock for future issuance, board of directors prerogative, increase in period (in shares) 0    
Common stock issued through employee stock purchase plan (in shares)   4,497 3,684
Share-based compensation arrangement by share-based payment award, number of additional shares authorized   2,941 2,941
Possible future issuance under equity compensation plan (in shares)   5,895  
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Compensation Cost (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]    
Stock-based compensation expense $ 2,220,000 $ 1,828,000
Tax benefit from compensation expense 0 0
Cash received from option exercised $ 2,000 $ 12,000
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Expense Related to Stock Options (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Stock-based compensation expense related to stock options $ 2,220 $ 1,828
Research and development, net    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Stock-based compensation expense related to stock options 806 604
Selling, general and administrative    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Stock-based compensation expense related to stock options $ 1,414 $ 1,224
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets $ 93,314 $ 42,193
Fair value of financial liabilities 57,110 21,588
Warrant liabilities    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial liabilities 51,156 18,396
Derivative liabilities    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial liabilities 5,954 3,192
Cash    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 117 23
Restricted cash    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 273 273
Money market funds    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 92,924 41,897
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 93,314 42,193
Fair value of financial liabilities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liabilities    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial liabilities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Derivative liabilities    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial liabilities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 117 23
Quoted Prices in Active Markets for Identical Assets (Level 1) | Restricted cash    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 273 273
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 92,924 41,897
Significant Other Observable Inputs (Level 2)    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 0 0
Fair value of financial liabilities 0 0
Significant Other Observable Inputs (Level 2) | Warrant liabilities    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial liabilities 0 0
Significant Other Observable Inputs (Level 2) | Derivative liabilities    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial liabilities 0 0
Significant Other Observable Inputs (Level 2) | Cash    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 0 0
Significant Other Observable Inputs (Level 2) | Restricted cash    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 0 0
Significant Other Observable Inputs (Level 2) | Money market funds    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 0 0
Significant Unobservable Inputs (Level 3)    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 0 0
Fair value of financial liabilities 57,110 21,588
Significant Unobservable Inputs (Level 3) | Warrant liabilities    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial liabilities 51,156 18,396
Significant Unobservable Inputs (Level 3) | Derivative liabilities    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial liabilities 5,954 3,192
Significant Unobservable Inputs (Level 3) | Cash    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 0 0
Significant Unobservable Inputs (Level 3) | Restricted cash    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets 0 0
Significant Unobservable Inputs (Level 3) | Money market funds    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of financial assets $ 0 $ 0
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Additional Information (Details) - Significant Unobservable Inputs (Level 3)
Dec. 31, 2020
Dec. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Warrant liabilities, maturity date Jun. 12, 2023  
Stock Price Volatility    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Derivative liabilities, unobservable inputs rate 58.1  
Stock Price Volatility | Minimum    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Warrant liabilities, stock price volatility rate 71.8  
Derivative liabilities, unobservable inputs rate 56.5  
Stock Price Volatility | Maximum    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Warrant liabilities, stock price volatility rate 86.6  
Derivative liabilities, unobservable inputs rate 60.1  
Stock Price Volatility | Weighted Average    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Warrant liabilities, stock price volatility rate 78.0  
Weighted Average Expected Term    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Warrant liabilities, expected term 1 year 2 months 12 days  
Weighted Average Expected Term | Minimum    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Warrant liabilities, expected term   10 months 24 days
Weighted Average Expected Term | Maximum    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Warrant liabilities, expected term   2 years 6 months
Market Credit Spread    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Derivative liabilities, unobservable inputs rate 1,458  
Estimated Yield    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Derivative liabilities, unobservable inputs rate 14.9  
Discounts for Lack of Marketability | March 2019 Notes    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Senior convertible notes, unobservable inputs rate 7.0  
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Warrant liabilities  
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]  
Beginning balance $ 18,396
December 2020 Public Offering 29,478
Gain (loss) adjustment to fair value 3,282
Ending balance 51,156
Derivative liabilities  
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]  
Beginning balance 3,192
Bifurcated embedded conversion option associated with Notes 8,110
Adjustment for partial conversion of April 2020 Notes (2,690)
Gain (loss) adjustment to fair value (2,658)
Ending balance $ 5,954
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Employee Benefit Plan - Additional Information (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2020
USD ($)
hour
Dec. 31, 2019
USD ($)
Compensation And Retirement Disclosure [Abstract]    
Work hours per week | hour 20  
Employer matching percent 50.00%  
Maximum percentage of contributions per employee 6.00%  
Vesting period 4 years  
Contribution amount | $ $ 0.1 $ 0.1
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Feb. 11, 2021
Feb. 28, 2021
Jan. 31, 2021
Jan. 01, 2021
Dec. 31, 2020
Jun. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
April 2020 Note Purchase Agreement                
Subsequent Event [Line Items]                
Conversion of convertible note, amount         $ 2,000,000.0 $ 2,000,000.0    
Conversion of convertible note exchanged for shares         322,348 316,461    
2014 Equity Incentive Plan                
Subsequent Event [Line Items]                
Share-based compensation arrangement by share-based payment award, number of additional shares authorized             389,650 191,887
2014 Employee Stock Purchase Plan                
Subsequent Event [Line Items]                
Share-based compensation arrangement by share-based payment award, number of additional shares authorized             2,941 2,941
Subsequent Event | Amplity Inc.                
Subsequent Event [Line Items]                
Term of agreement   5 years            
Subsequent Event | Exclusive License and Collaboration Agreement                
Subsequent Event [Line Items]                
Upfront payment received $ 10,000,000              
Subsequent Event | Exclusive License and Collaboration Agreement | Maximum                
Subsequent Event [Line Items]                
Development and commercial milestones received $ 112,000,000              
Subsequent Event | April 2020 Note Purchase Agreement                
Subsequent Event [Line Items]                
Conversion of convertible note, amount     $ 6,000,000.0          
Conversion of convertible note exchanged for shares     959,080          
Subsequent Event | 2014 Equity Incentive Plan                
Subsequent Event [Line Items]                
Share-based compensation arrangement by share-based payment award, number of additional shares authorized       786,547        
Subsequent Event | 2014 Employee Stock Purchase Plan                
Subsequent Event [Line Items]                
Share-based compensation arrangement by share-based payment award, number of additional shares authorized       2,941        
EXCEL 81 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 82 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 83 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 84 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 270 473 1 false 88 0 false 8 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations Sheet http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Cash Flows Sheet http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - Description of Business and Basis of Preparation Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparation Description of Business and Basis of Preparation Notes 7 false false R8.htm 100070 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 100080 - Disclosure - Short-term Investments Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestments Short-term Investments Notes 9 false false R10.htm 100090 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 10 false false R11.htm 100100 - Disclosure - Property and Equipment Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 100110 - Disclosure - Accrued Expenses Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses Notes 12 false false R13.htm 100120 - Disclosure - Borrowings Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowings Borrowings Notes 13 false false R14.htm 100130 - Disclosure - Commitments and Contingencies Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 100140 - Disclosure - Stockholders' Equity Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 100150 - Disclosure - Income Taxes Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 16 false false R17.htm 100160 - Disclosure - Stock-based Compensation Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation Stock-based Compensation Notes 17 false false R18.htm 100170 - Disclosure - Fair Value Measurements Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 18 false false R19.htm 100180 - Disclosure - Employee Benefit Plan Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan Employee Benefit Plan Notes 19 false false R20.htm 100190 - Disclosure - Subsequent Events Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 20 false false R21.htm 100200 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 100210 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 100220 - Disclosure - Short-term Investments (Tables) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables Short-term Investments (Tables) Tables http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestments 23 false false R24.htm 100230 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 24 false false R25.htm 100240 - Disclosure - Property and Equipment (Tables) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment 25 false false R26.htm 100250 - Disclosure - Accrued Expenses (Tables) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpenses 26 false false R27.htm 100260 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies 27 false false R28.htm 100270 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquity 28 false false R29.htm 100280 - Disclosure - Income Taxes (Tables) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxes 29 false false R30.htm 100290 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation 30 false false R31.htm 100300 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurements 31 false false R32.htm 100310 - Disclosure - Description of Business and Basis of Preparation - Additional Information (Detail) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail Description of Business and Basis of Preparation - Additional Information (Detail) Details 32 false false R33.htm 100320 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 33 false false R34.htm 100330 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Details) Details 34 false false R35.htm 100340 - Disclosure - Short-term Investments (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails Short-term Investments (Details) Details http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables 35 false false R36.htm 100350 - Disclosure - Short-term Investments - Additional Information (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails Short-term Investments - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Prepaid Expenses and Other Current Assets (Detail) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail Prepaid Expenses and Other Current Assets (Detail) Details http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 37 false false R38.htm 100370 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 38 false false R39.htm 100380 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails Accrued Expenses - Schedule of Accrued Expenses (Details) Details 39 false false R40.htm 100390 - Disclosure - Borrowings - Additional Information (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails Borrowings - Additional Information (Details) Details 40 false false R41.htm 100400 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 41 false false R42.htm 100410 - Disclosure - Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Condensed Consolidated Financial Statements for Lease (Detail) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInCondensedConsolidatedFinancialStatementsForLeaseDetail Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Condensed Consolidated Financial Statements for Lease (Detail) Details 42 false false R43.htm 100420 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Detail) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail Commitments and Contingencies - Future Minimum Lease Payments (Detail) Details 43 false false R44.htm 100430 - Disclosure - Commitments and Contingencies - Presentation of Operating Lease Liability and Right-of-Use Asset (Detail) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityAndRightOfUseAssetDetail Commitments and Contingencies - Presentation of Operating Lease Liability and Right-of-Use Asset (Detail) Details 44 false false R45.htm 100440 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 45 false false R46.htm 100450 - Disclosure - Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) Details 46 false false R47.htm 100460 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 47 false false R48.htm 100470 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Details 48 false false R49.htm 100480 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) Details 49 false false R50.htm 100490 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) Details 50 false false R51.htm 100500 - Disclosure - Stock-based Compensation - 2009 Stock Option Plan (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails Stock-based Compensation - 2009 Stock Option Plan (Details) Details 51 false false R52.htm 100510 - Disclosure - Stock-based Compensation - 2014 Equity Incentive Plan (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails Stock-based Compensation - 2014 Equity Incentive Plan (Details) Details 52 false false R53.htm 100520 - Disclosure - Stock-based Compensation - 2015 Inducement Plan (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2015InducementPlanDetails Stock-based Compensation - 2015 Inducement Plan (Details) Details 53 false false R54.htm 100530 - Disclosure - Stock-based Compensation - Option Valuation Method - Additional Information (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodAdditionalInformationDetails Stock-based Compensation - Option Valuation Method - Additional Information (Details) Details 54 false false R55.htm 100540 - Disclosure - Stock-based Compensation - Option Valuation Method (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodDetails Stock-based Compensation - Option Valuation Method (Details) Details 55 false false R56.htm 100550 - Disclosure - Stock-based Compensation - Stock Option Activity (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails Stock-based Compensation - Stock Option Activity (Details) Details 56 false false R57.htm 100560 - Disclosure - Stock-based Compensation - Stock Option Activity - Additional Information (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityAdditionalInformationDetails Stock-based Compensation - Stock Option Activity - Additional Information (Details) Details 57 false false R58.htm 100570 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units ("RSU") Activity (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails Stock-based Compensation - Schedule of Restricted Stock Units ("RSU") Activity (Details) Details 58 false false R59.htm 100580 - Disclosure - Stock-based Compensation - 2014 Employee Stock Purchase Plan (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails Stock-based Compensation - 2014 Employee Stock Purchase Plan (Details) Details 59 false false R60.htm 100590 - Disclosure - Stock-based Compensation - Compensation Cost (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCompensationCostDetails Stock-based Compensation - Compensation Cost (Details) Details 60 false false R61.htm 100600 - Disclosure - Stock-based Compensation - Expense Related to Stock Options (Detail) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseRelatedToStockOptionsDetail Stock-based Compensation - Expense Related to Stock Options (Detail) Details 61 false false R62.htm 100610 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Details) Details 62 false false R63.htm 100620 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 63 false false R64.htm 100630 - Disclosure - Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Details) Details 64 false false R65.htm 100640 - Disclosure - Employee Benefit Plan - Additional Information (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails Employee Benefit Plan - Additional Information (Details) Details 65 false false R66.htm 100650 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 66 false false All Reports Book All Reports scyx-10k_20201231.htm scyx-20201231.xsd scyx-20201231_cal.xml scyx-20201231_def.xml scyx-20201231_lab.xml scyx-20201231_pre.xml scyx-ex1030_12.htm scyx-ex231_7.htm scyx-ex311_8.htm scyx-ex312_6.htm scyx-ex321_9.htm scyx-ex42_139.htm gssdxyiyyh5p000001.jpg http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 true true JSON 87 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "scyx-10k_20201231.htm": { "axisCustom": 0, "axisStandard": 27, "contextCount": 270, "dts": { "calculationLink": { "local": [ "scyx-20201231_cal.xml" ] }, "definitionLink": { "local": [ "scyx-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "scyx-10k_20201231.htm" ] }, "labelLink": { "local": [ "scyx-20201231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "scyx-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "scyx-20201231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 618, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 26, "http://www.scynexis.com/20201231": 4, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 34 }, "keyCustom": 81, "keyStandard": 392, "memberCustom": 40, "memberStandard": 37, "nsprefix": "scyx", "nsuri": "http://www.scynexis.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Prepaid Expenses and Other Current Assets", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Property and Equipment", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Accrued Expenses", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Borrowings", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowings", "shortName": "Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Commitments and Contingencies", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Stockholders' Equity", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Income Taxes", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Stock-based Compensation", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Fair Value Measurements", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Employee Benefit Plan", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan", "shortName": "Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20191231", "decimals": "-3", "lang": null, "name": "us-gaap:HeldToMaturitySecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Subsequent Events", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCreditRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCreditRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Short-term Investments (Tables)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables", "shortName": "Short-term Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Property and Equipment (Tables)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "scyx:CommonStockReservedForFutureIssuancesTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "scyx:CommonStockReservedForFutureIssuancesTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Income Taxes (Tables)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Stock-based Compensation (Tables)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Description of Business and Basis of Preparation - Additional Information (Detail)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "shortName": "Description of Business and Basis of Preparation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-5", "lang": null, "name": "scyx:ShelfRegistrationMaximumEquityOfferingPrice", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_scyxSegment", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails", "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:HeldToMaturitySecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Short-term Investments (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails", "shortName": "Short-term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:HeldToMaturitySecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Short-term Investments - Additional Information (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails", "shortName": "Short-term Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "scyx:PrepaidResearchandDevelopmentExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Prepaid Expenses and Other Current Assets (Detail)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail", "shortName": "Prepaid Expenses and Other Current Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "scyx:PrepaidResearchandDevelopmentExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails", "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "scyx:AccruedResearchandDevelopmentExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails", "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "scyx:AccruedResearchandDevelopmentExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Statements of Operations", "role": "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfDebtIssuanceCosts", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Borrowings - Additional Information (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "shortName": "Borrowings - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapDebtInstrumentAxis_scyxAprilTwoThousandTwentyNotePurchaseAgreementMember_20200310_20200409", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentOfferingDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20180301", "decimals": "INF", "first": true, "lang": null, "name": "scyx:LeaseAgreementAreaOfOfficeSpace", "reportCount": 1, "unique": true, "unitRef": "U_utrsqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20180301", "decimals": "INF", "first": true, "lang": null, "name": "scyx:LeaseAgreementAreaOfOfficeSpace", "reportCount": 1, "unique": true, "unitRef": "U_utrsqft", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Condensed Consolidated Financial Statements for Lease (Detail)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInCondensedConsolidatedFinancialStatementsForLeaseDetail", "shortName": "Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Condensed Consolidated Financial Statements for Lease (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Detail)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail", "shortName": "Commitments and Contingencies - Future Minimum Lease Payments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "scyx:OperatingLeaseLiabilityAndRightOfUseAssetTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Commitments and Contingencies - Presentation of Operating Lease Liability and Right-of-Use Asset (Detail)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityAndRightOfUseAssetDetail", "shortName": "Commitments and Contingencies - Presentation of Operating Lease Liability and Right-of-Use Asset (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "scyx:OperatingLeaseLiabilityAndRightOfUseAssetTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Stockholders' Equity - Additional Information (Detail)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "shortName": "Stockholders' Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "scyx:CommonStockReservedForFutureIssuancesTableTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "shortName": "Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "scyx:CommonStockReservedForFutureIssuancesTableTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "INF", "lang": null, "name": "scyx:TaxCutsAndJobActsOf2017TemporaryExpenseForCertainBusinessAssetsAndPropertyPercentage", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "scyx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedExpensesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20201231", "decimals": "-3", "first": true, "lang": null, "name": "scyx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedExpensesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "role": "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails", "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20181231", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapPlanNameAxis_scyxTwoThousandAndNineStockOptionPlanMember_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Stock-based Compensation - 2009 Stock Option Plan (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails", "shortName": "Stock-based Compensation - 2009 Stock Option Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapPlanNameAxis_scyxTwoThousandAndNineStockOptionPlanMember_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapPlanNameAxis_scyxTwoThousandAndFourteenEquityIncentivePlanMember_20140502", "decimals": "INF", "first": true, "lang": null, "name": "scyx:NumberOfAdditionalAwardsToBeGrantedUnderTwoThousandNineEquityIncentivePlan", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Stock-based Compensation - 2014 Equity Incentive Plan (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "shortName": "Stock-based Compensation - 2014 Equity Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapPlanNameAxis_scyxTwoThousandAndFourteenEquityIncentivePlanMember_20140502", "decimals": "INF", "first": true, "lang": null, "name": "scyx:NumberOfAdditionalAwardsToBeGrantedUnderTwoThousandNineEquityIncentivePlan", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Stock-based Compensation - 2015 Inducement Plan (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2015InducementPlanDetails", "shortName": "Stock-based Compensation - 2015 Inducement Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapPlanNameAxis_scyxTwoThousandAndFifteenInducementPlanMember_20190609", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Stock-based Compensation - Option Valuation Method - Additional Information (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodAdditionalInformationDetails", "shortName": "Stock-based Compensation - Option Valuation Method - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Stock-based Compensation - Option Valuation Method (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodDetails", "shortName": "Stock-based Compensation - Option Valuation Method (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "shortName": "Stock-based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Stock-based Compensation - Stock Option Activity - Additional Information (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityAdditionalInformationDetails", "shortName": "Stock-based Compensation - Stock Option Activity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units (\"RSU\") Activity (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails", "shortName": "Stock-based Compensation - Schedule of Restricted Stock Units (\"RSU\") Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapPlanNameAxis_scyxTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140502", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Stock-based Compensation - 2014 Employee Stock Purchase Plan (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails", "shortName": "Stock-based Compensation - 2014 Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapPlanNameAxis_scyxTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140502", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Stock-based Compensation - Compensation Cost (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCompensationCostDetails", "shortName": "Stock-based Compensation - Compensation Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Stock-based Compensation - Expense Related to Stock Options (Detail)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseRelatedToStockOptionsDetail", "shortName": "Stock-based Compensation - Expense Related to Stock Options (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "scyx:DefinedContributionPlanRequiredWorkHoursPerWeek", "reportCount": 1, "unique": true, "unitRef": "U_scyxhour", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Employee Benefit Plan - Additional Information (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails", "shortName": "Employee Benefit Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "scyx:DefinedContributionPlanRequiredWorkHoursPerWeek", "reportCount": 1, "unique": true, "unitRef": "U_scyxhour", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapDebtInstrumentAxis_scyxAprilTwoThousandTwentyNotePurchaseAgreementMember_20201201_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Subsequent Events - Additional Information (Details)", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_scyxAmplityIncMember_20210201_20210228", "decimals": null, "lang": "en-US", "name": "scyx:TermOfAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Description of Business and Basis of Preparation", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparation", "shortName": "Description of Business and Basis of Preparation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Short-term Investments", "role": "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestments", "shortName": "Short-term Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scyx-10k_20201231.htm", "contextRef": "C_0001178253_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 88, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r537", "r538", "r539" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "verboseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r537", "r538", "r539" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of Each Class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of Each Exchange on Which Registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "verboseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "scyx_AccruedResearchandDevelopmentExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development expense, current.", "label": "Accrued Researchand Development Expense Current", "terseLabel": "Accrued research and development expenses" } } }, "localname": "AccruedResearchandDevelopmentExpenseCurrent", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "scyx_AmountReceivedFromNewJerseyTechnologyBusinessTaxCertificateTransferNOLProgram": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount received from the New Jersey Technology Business Tax Certificate Transfer (NOL) Program.", "label": "Amount Received From New Jersey Technology Business Tax Certificate Transfer N O L Program", "terseLabel": "Amount received from the program" } } }, "localname": "AmountReceivedFromNewJerseyTechnologyBusinessTaxCertificateTransferNOLProgram", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "scyx_AmplityIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amplity Inc.", "label": "Amplity Inc [Member]", "terseLabel": "Amplity Inc." } } }, "localname": "AmplityIncMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "scyx_AprilTwoThousandTwentyNotePurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "April 2020 note purchase agreement.", "label": "April Two Thousand Twenty Note Purchase Agreement [Member]", "terseLabel": "April 2020 Note Purchase Agreement" } } }, "localname": "AprilTwoThousandTwentyNotePurchaseAgreementMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "scyx_AspireCapitalFundLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aspire capital fund limited liability company.", "label": "Aspire Capital Fund Limited Liability Company [Member]", "terseLabel": "Aspire Capital" } } }, "localname": "AspireCapitalFundLimitedLiabilityCompanyMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_AssetPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset purchase agreement.", "label": "Asset Purchase Agreement [Member]", "terseLabel": "Asset Purchase Agreement" } } }, "localname": "AssetPurchaseAgreementMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_AveragePurchasePriceOfSharesSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average purchase price of shares sold.", "label": "Average Purchase Price Of Shares Sold", "terseLabel": "Average purchase price of shares sold" } } }, "localname": "AveragePurchasePriceOfSharesSold", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "scyx_BaseNumberOfAdditionalAwardsAuthorizedUnderTwoThousandFourteenEquityIncentivePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The base number of new shares of common stock that may be issued after the effective date of the 2014 equity incentive plan, adjusted by certain amounts as described in the plan agreement, to arrive at an aggregate number of new shares of common stock that may be issued under the plan.", "label": "Base Number Of Additional Awards Authorized Under Two Thousand Fourteen Equity Incentive Plan", "terseLabel": "Base number of new shares available for future issuance under equity incentive plan (in shares)" } } }, "localname": "BaseNumberOfAdditionalAwardsAuthorizedUnderTwoThousandFourteenEquityIncentivePlan", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "scyx_CashReceiptFromSaleOfNetOperatingLosses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash receipt from sale of net operating losses.", "label": "Cash Receipt From Sale Of Net Operating Losses", "terseLabel": "Cash receipt from the sale of state NOLs" } } }, "localname": "CashReceiptFromSaleOfNetOperatingLosses", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "scyx_ClassOfWarrantsOrRightExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants or right exercised.", "label": "Class Of Warrants Or Right Exercised", "terseLabel": "Number of warrants exercised" } } }, "localname": "ClassOfWarrantsOrRightExercised", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "scyx_ClassOfWarrantsOrRightNotExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants or right not exercised.", "label": "Class Of Warrants Or Right Not Exercised", "terseLabel": "Number of options not exercised" } } }, "localname": "ClassOfWarrantsOrRightNotExercised", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "scyx_CommitmentAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment and contingencies.", "label": "Commitment And Contingencies [Line Items]", "terseLabel": "Commitment And Contingencies [Line Items]" } } }, "localname": "CommitmentAndContingenciesLineItems", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "scyx_CommitmentAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment and contingencies.", "label": "Commitment And Contingencies [Table]", "terseLabel": "Commitment And Contingencies [Table]" } } }, "localname": "CommitmentAndContingenciesTable", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "scyx_CommitmentSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment shares.", "label": "Commitment Shares [Member]", "terseLabel": "Commitment Shares" } } }, "localname": "CommitmentSharesMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_CommonStockCapitalSharesReservedForFutureIssuanceBoardOfDirectorsPrerogativeIncreaseDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock capital shares reserved for future issuance, board of directors prerogative, increase during period.", "label": "Common Stock Capital Shares Reserved For Future Issuance Board Of Directors Prerogative Increase During Period", "terseLabel": "Number of shares of common stock for future issuance, board of directors prerogative, increase in period (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuanceBoardOfDirectorsPrerogativeIncreaseDuringPeriod", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "scyx_CommonStockIssuablePeriodUnderEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issuable period under employee stock purchase plan.", "label": "Common Stock Issuable Period Under Employee Stock Purchase Plan", "terseLabel": "Common stock issuable period" } } }, "localname": "CommonStockIssuablePeriodUnderEmployeeStockPurchasePlan", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails" ], "xbrltype": "durationItemType" }, "scyx_CommonStockIssuablePeriodUnderEquityIncentivePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issuable period under equity incentive plan.", "label": "Common Stock Issuable Period Under Equity Incentive Plan", "terseLabel": "Common stock issuable period" } } }, "localname": "CommonStockIssuablePeriodUnderEquityIncentivePlan", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails" ], "xbrltype": "durationItemType" }, "scyx_CommonStockIssuedForCommitmentShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for commitment shares.", "label": "Common Stock Issued For Commitment Shares", "terseLabel": "Common stock issued for Commitment Shares" } } }, "localname": "CommonStockIssuedForCommitmentShares", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scyx_CommonStockOwnedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock owned percentage.", "label": "Common Stock Owned Percentage", "terseLabel": "Percentage of common stock owned" } } }, "localname": "CommonStockOwnedPercentage", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "scyx_CommonStockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock purchase agreement.", "label": "Common Stock Purchase Agreement [Member]", "terseLabel": "Common Stock Purchase Agreement" } } }, "localname": "CommonStockPurchaseAgreementMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_CommonStockReservedForFutureIssuancesTableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock reserved for future issuances.", "label": "Common Stock Reserved For Future Issuances Table Table [Text Block]", "terseLabel": "Common Stock Reserved For Future Issuances" } } }, "localname": "CommonStockReservedForFutureIssuancesTableTableTextBlock", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "scyx_CommonStockSharesIssuedForCommitmentShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares issued for commitment shares.", "label": "Common Stock Shares Issued For Commitment Shares", "terseLabel": "Common stock issued for Commitment Shares (in shares)" } } }, "localname": "CommonStockSharesIssuedForCommitmentShares", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "scyx_CommonStockValueIssuedForCommitmentShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock value issued for commitment shares.", "label": "Common Stock Value Issued For Commitment Shares", "terseLabel": "Common stock issued for Commitment Shares" } } }, "localname": "CommonStockValueIssuedForCommitmentShares", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "scyx_ConversionOfApril2020NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of April 2020 notes.", "label": "Conversion Of April2020 Notes [Member]", "terseLabel": "For possible future issuance for the conversion of the April 2020 Notes" } } }, "localname": "ConversionOfApril2020NotesMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "scyx_ConversionOfMarch2019NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of March 2019 notes.", "label": "Conversion Of March2019 Notes [Member]", "terseLabel": "For possible future issuance for the conversion of the March 2019 Notes" } } }, "localname": "ConversionOfMarch2019NotesMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "scyx_ConvertibleDebtAndDerivativeLiability": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible debt and derivative liability.", "label": "Convertible Debt And Derivative Liability", "terseLabel": "Convertible debt and derivative liabilities (Note 7)", "verboseLabel": "Net carrying amount of convertible debt and derivative liability" } } }, "localname": "ConvertibleDebtAndDerivativeLiability", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "scyx_ConvertibleDebtAndDerivativeLiabilityFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible debt and derivative liability fair value disclosures.", "label": "Convertible Debt And Derivative Liability Fair Value Disclosures", "terseLabel": "Fair value of convertible debt and derivative liability" } } }, "localname": "ConvertibleDebtAndDerivativeLiabilityFairValueDisclosures", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "scyx_ConvertibleDebtAndDerivativeLiabilityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible debt and derivative liability.", "label": "Convertible Debt And Derivative Liability Policy [Text Block]", "terseLabel": "Convertible Debt and Derivative Liabilities" } } }, "localname": "ConvertibleDebtAndDerivativeLiabilityPolicyTextBlock", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "scyx_CypralisLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cypralis Limited.", "label": "Cypralis Limited [Member]", "terseLabel": "Cypralis Limited" } } }, "localname": "CypralisLimitedMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_DebtInstrumentConvertibleConversionRatioAfterAdjustmentToCertainEvents": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument convertible conversion ratio after adjustment to certain events.", "label": "Debt Instrument Convertible Conversion Ratio After Adjustment To Certain Events", "terseLabel": "Conversion rate, number of shares to be issued per $1000 of principal (in shares) after adjustment to certain events" } } }, "localname": "DebtInstrumentConvertibleConversionRatioAfterAdjustmentToCertainEvents", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "scyx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument principal amount denominator for conversion into common stock.", "label": "Debt Instrument Principal Amount Denominator For Conversion Into Common Stock", "terseLabel": "Principal amount of notes used as the denominator for conversion into notes" } } }, "localname": "DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStock", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "scyx_DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStockAfterAdjustmentToCertainEvents": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument principal amount denominator for conversion into common stock after adjustment to certain events.", "label": "Debt Instrument Principal Amount Denominator For Conversion Into Common Stock After Adjustment To Certain Events", "terseLabel": "Principal amount of notes used as the denominator for conversion into notes after adjustment of certain events" } } }, "localname": "DebtInstrumentPrincipalAmountDenominatorForConversionIntoCommonStockAfterAdjustmentToCertainEvents", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "scyx_DebtInstrumentPurchasePriceAsPercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument purchase price as percentage of principal amount.", "label": "Debt Instrument Purchase Price As Percentage Of Principal Amount", "terseLabel": "Purchase price as percentage of principal amount" } } }, "localname": "DebtInstrumentPurchasePriceAsPercentageOfPrincipalAmount", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "scyx_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemedSubjectToCertainExceptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, redemption price, percentage of principal amount redeemed, subject to certain exceptions.", "label": "Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed Subject To Certain Exceptions", "terseLabel": "Redemption price as percentage of the principal amount subject to certain exceptions" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemedSubjectToCertainExceptions", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "scyx_December2020PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2020 public offering.", "label": "December2020 Public Offering [Member]", "terseLabel": "December 2020 Public Offering" } } }, "localname": "December2020PublicOfferingMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "scyx_December2020PublicOfferingSeries1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2020 public offering series 1.", "label": "December2020 Public Offering Series1 [Member]", "terseLabel": "December 2020 Public Offering Series 1" } } }, "localname": "December2020PublicOfferingSeries1Member", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "scyx_December2020PublicOfferingSeries2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2020 public offering series 2.", "label": "December2020 Public Offering Series2 [Member]", "terseLabel": "December 2020 Public Offering Series 2" } } }, "localname": "December2020PublicOfferingSeries2Member", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "scyx_DecemberTwoThousandAndNineteenPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December two thousand and nineteen public offering.", "label": "December Two Thousand And Nineteen Public Offering [Member]", "terseLabel": "December 2019 Public Offering" } } }, "localname": "DecemberTwoThousandAndNineteenPublicOfferingMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "scyx_DeferredOfferingAndIssuanceCostsIncludedInAccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred offering and issuance costs included in accounts payable.", "label": "Deferred Offering And Issuance Costs Included In Accounts Payable", "terseLabel": "Deferred offering and issuance costs included in accounts payable" } } }, "localname": "DeferredOfferingAndIssuanceCostsIncludedInAccountsPayable", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scyx_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs reclassified to additional paid in capital.", "label": "Deferred Offering Costs Reclassified To Additional Paid In Capital", "terseLabel": "Deferred offering costs reclassified to additional paid-in capital" } } }, "localname": "DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scyx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCostNoncurrent": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax deferred expense compensation and benefits share based compensation cost noncurrent.", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Noncurrent", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCostNoncurrent", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "scyx_DeferredTaxAssetsTaxDeferredExpenseLeaseLiability": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10050.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax deferred expense lease liability.", "label": "Deferred Tax Assets Tax Deferred Expense Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseLeaseLiability", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "scyx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedExpensesNoncurrent": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax deferred expense reserves and accruals accrued expenses noncurrent.", "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Expenses Noncurrent", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedExpensesNoncurrent", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "scyx_DeferredTaxLiabilitiesOtherNoncurrent": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10060.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities other noncurrent.", "label": "Deferred Tax Liabilities Other Noncurrent", "negatedLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOtherNoncurrent", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "scyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined contribution plan, employers matching contribution, vesting period.", "label": "Defined Contribution Plan Employers Matching Contribution Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionVestingPeriod", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "scyx_DefinedContributionPlanRequiredWorkHoursPerWeek": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined contribution plan, minimum required work hours per week.", "label": "Defined Contribution Plan Required Work Hours Per Week", "terseLabel": "Work hours per week" } } }, "localname": "DefinedContributionPlanRequiredWorkHoursPerWeek", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "scyx_DerivativeFairValueGainLossFromMarkToMarketAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative fair value gain (loss) from mark to market adjustment.", "label": "Derivative Fair Value Gain Loss From Mark To Market Adjustment", "negatedLabel": "Gain (loss) adjustment to fair value" } } }, "localname": "DerivativeFairValueGainLossFromMarkToMarketAdjustment", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "scyx_DevelopmentAndCommercialMilestonesReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Development and commercial milestones received.", "label": "Development And Commercial Milestones Received", "terseLabel": "Development and commercial milestones received" } } }, "localname": "DevelopmentAndCommercialMilestonesReceived", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "scyx_EffectiveIncomeTaxRateReconciliationIssuanceOfWarrants": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10160.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation issuance of warrants.", "label": "Effective Income Tax Rate Reconciliation Issuance Of Warrants", "terseLabel": "Warrants issuance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationIssuanceOfWarrants", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "scyx_EffectiveIncomeTaxRateReconciliationIssuanceOfWarrantsPercent": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10060.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation issuance of warrants percent.", "label": "Effective Income Tax Rate Reconciliation Issuance Of Warrants Percent", "terseLabel": "Warrants issuance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationIssuanceOfWarrantsPercent", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "scyx_EffectiveIncomeTaxRateReconciliationNetOperatingLossSale": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10080.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation net operating loss sale.", "label": "Effective Income Tax Rate Reconciliation Net Operating Loss Sale", "terseLabel": "NOL sale" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossSale", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "scyx_EffectiveIncomeTaxRateReconciliationStateEffectOfPermanentItems": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10030.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation state effect of permanent items.", "label": "Effective Income Tax Rate Reconciliation State Effect Of Permanent Items", "terseLabel": "State effect of permanent items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateEffectOfPermanentItems", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "scyx_EmployeeStockPurchasePlanNumberOfSharesWhichMightBeAddedToCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan, number of shares that can be added to common stock outstanding on conditional basis.", "label": "Employee Stock Purchase Plan Number Of Shares Which Might Be Added To Common Stock Outstanding", "terseLabel": "Employee stock purchase plan, number of shares, which might be added to common stock outstanding (in shares)" } } }, "localname": "EmployeeStockPurchasePlanNumberOfSharesWhichMightBeAddedToCommonStockOutstanding", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "scyx_ExclusiveLicenseAndCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive license and collaboration agreement.", "label": "Exclusive License And Collaboration Agreement [Member]", "terseLabel": "Exclusive License and Collaboration Agreement" } } }, "localname": "ExclusiveLicenseAndCollaborationAgreementMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "scyx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustmentForConversionOfNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability adjustment for conversion of notes.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Adjustment For Conversion Of Notes", "terseLabel": "Adjustment for partial conversion of April 2020 Notes" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustmentForConversionOfNotes", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "scyx_FairValueOfLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of liabilities.", "label": "Fair Value Of Liabilities", "terseLabel": "Warrant liabilities" } } }, "localname": "FairValueOfLiabilities", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "scyx_IncomeTaxReconciliationNetOperatingLossSale": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10180.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation net operating loss sale.", "label": "Income Tax Reconciliation Net Operating Loss Sale", "terseLabel": "NOL sale" } } }, "localname": "IncomeTaxReconciliationNetOperatingLossSale", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "scyx_IncomeTaxReconciliationStateEffectOfPermanentItems": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10130.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation state effect of permanent items.", "label": "Income Tax Reconciliation State Effect Of Permanent Items", "terseLabel": "State effect of permanent items" } } }, "localname": "IncomeTaxReconciliationStateEffectOfPermanentItems", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "scyx_IncreaseInSaleOfCommonStockMaximumNumberOfShareSoldPerBusinessDay": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in sale of common stock maximum number of share sold per business day.", "label": "Increase In Sale Of Common Stock Maximum Number Of Share Sold Per Business Day", "terseLabel": "Increase in sale of common stock maximum number of share sold per business day" } } }, "localname": "IncreaseInSaleOfCommonStockMaximumNumberOfShareSoldPerBusinessDay", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "scyx_JanuaryTwentyThousandAndTwentyOneShelfRegistrationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "January 2021 Shelf Registration.", "label": "January Twenty Thousand And Twenty One Shelf Registration [Member]", "terseLabel": "January 2021 Shelf Registration" } } }, "localname": "JanuaryTwentyThousandAndTwentyOneShelfRegistrationMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_June2016PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "June 2016 public offering.", "label": "June2016 Public Offering [Member]", "terseLabel": "June 2016 Public Offering", "verboseLabel": "Warrants to purchase common stock associated with June 2016 Public Offering" } } }, "localname": "June2016PublicOfferingMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "scyx_LeaseAgreementAreaOfOfficeSpace": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease agreement area of office space.", "label": "Lease Agreement Area Of Office Space", "verboseLabel": "Long-term lease agreement, area of office space" } } }, "localname": "LeaseAgreementAreaOfOfficeSpace", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "scyx_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement [Member]", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_March2018PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2018 public offering.", "label": "March2018 Public Offering [Member]", "terseLabel": "March 2018 Public Offering" } } }, "localname": "March2018PublicOfferingMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "scyx_March2018PublicOfferingSeries2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2018 public offering series 2.", "label": "March2018 Public Offering Series2 [Member]", "terseLabel": "March 2018 Public Offering Series 2 [Member]" } } }, "localname": "March2018PublicOfferingSeries2Member", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "scyx_MaximumSellingValueOfUnusedNetOperatingLossesAndResearchAndDevelopmentTaxCreditToProfitableTaxPayers": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum selling value of unused net operating losses and research and development tax credit to profitable tax payers.", "label": "Maximum Selling Value Of Unused Net Operating Losses And Research And Development Tax Credit To Profitable Tax Payers", "terseLabel": "Maximum selling value of unused net operating losses and research and development tax credit to profitable tax payers." } } }, "localname": "MaximumSellingValueOfUnusedNetOperatingLossesAndResearchAndDevelopmentTaxCreditToProfitableTaxPayers", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "scyx_MilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestone payments from the Company" } } }, "localname": "MilestonePayments", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "scyx_NetOperatingLossCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss carryforwards expiration year.", "label": "Net Operating Loss Carryforwards Expiration Year", "terseLabel": "Net operating loss carryforwards expiration year" } } }, "localname": "NetOperatingLossCarryforwardsExpirationYear", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "scyx_NoncashConsiderationAssociatedWithCommonStockPurchaseAgreement": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash consideration associated with common stock purchase agreement.", "label": "Noncash Consideration Associated With Common Stock Purchase Agreement", "terseLabel": "Noncash consideration associated with common stock purchase agreement" } } }, "localname": "NoncashConsiderationAssociatedWithCommonStockPurchaseAgreement", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scyx_NoncashOperatingLeaseExpenseForRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash operating lease expense for right-of-use asset.", "label": "Noncash Operating Lease Expense For Right Of Use Asset", "terseLabel": "Noncash operating lease expense for right-of-use asset" } } }, "localname": "NoncashOperatingLeaseExpenseForRightOfUseAsset", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scyx_NumberOfAdditionalAwardsToBeGrantedUnderTwoThousandNineEquityIncentivePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of additional awards to be granted under the 2009 Equity Incentive Plan on or after the effective date of the 2014 equity incentive plan.", "label": "Number Of Additional Awards To Be Granted Under Two Thousand Nine Equity Incentive Plan", "terseLabel": "Number of additional awards expected to be granted (in shares)" } } }, "localname": "NumberOfAdditionalAwardsToBeGrantedUnderTwoThousandNineEquityIncentivePlan", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "scyx_NumberOfPurchaseAggregateSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of purchase aggregate shares of common stock.", "label": "Number Of Purchase Aggregate Shares Of Common Stock", "terseLabel": "Number of purchase aggregate shares of common stock" } } }, "localname": "NumberOfPurchaseAggregateSharesOfCommonStock", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "scyx_NumberOfSharesCommitted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares committed.", "label": "Number Of Shares Committed", "terseLabel": "Number of shares committed" } } }, "localname": "NumberOfSharesCommitted", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "scyx_OctoberTwentyThousandAndTwentyShelfRegistrationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October twenty thousand and twenty shelf registration.", "label": "October Twenty Thousand And Twenty Shelf Registration [Member]", "terseLabel": "October 2020 Shelf Registration" } } }, "localname": "OctoberTwentyThousandAndTwentyShelfRegistrationMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_OperatingLeaseLiabilityAndRightOfUseAssetTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease liability and right-of-use asset.", "label": "Operating Lease Liability And Right Of Use Asset Table [Text Block]", "terseLabel": "Presentation of Operating Lease Liability and Right-of-Use Asset" } } }, "localname": "OperatingLeaseLiabilityAndRightOfUseAssetTableTextBlock", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "scyx_OptionExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option expiration date.", "label": "Option Expiration Date", "terseLabel": "Options expiration date" } } }, "localname": "OptionExpirationDate", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "scyx_OptionToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option to purchase common stock.", "label": "Option To Purchase Common Stock [Member]", "terseLabel": "Option to Purchase Common Stock", "verboseLabel": "Option to purchase common stock" } } }, "localname": "OptionToPurchaseCommonStockMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "scyx_OptionToPurchaseShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option to purchase share of common stock.", "label": "Option To Purchase Share Of Common Stock", "terseLabel": "Option to purchase shares of common stock" } } }, "localname": "OptionToPurchaseShareOfCommonStock", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "scyx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "scyx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "scyx_OvernightRepurchaseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Overnight repurchase agreements member.", "label": "Overnight Repurchase Agreements [Member]", "terseLabel": "Overnight repurchase agreement" } } }, "localname": "OvernightRepurchaseAgreementsMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "scyx_PatentExpendituresPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patent expenditures.", "label": "Patent Expenditures Policy Policy [Text Block]", "terseLabel": "Patent Expenses" } } }, "localname": "PatentExpendituresPolicyPolicyTextBlock", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "scyx_PaymentsOfOfferingCostsAndUnderwritingDiscountsAndCommissions": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments of offering costs and underwriting discounts and commissions.", "label": "Payments Of Offering Costs And Underwriting Discounts And Commissions", "negatedLabel": "Payments of offering costs and underwriting discounts and commissions" } } }, "localname": "PaymentsOfOfferingCostsAndUnderwritingDiscountsAndCommissions", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scyx_PercentageOfCapitalStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of capital stock outstanding.", "label": "Percentage Of Capital Stock Outstanding", "terseLabel": "Common stock outstanding percentage" } } }, "localname": "PercentageOfCapitalStockOutstanding", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails" ], "xbrltype": "percentItemType" }, "scyx_PercentageOfCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of common stock outstanding.", "label": "Percentage Of Common Stock Outstanding", "terseLabel": "Percentage of common stock outstanding" } } }, "localname": "PercentageOfCommonStockOutstanding", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "scyx_PercentageOfFairMarketValueForWhichExercisePriceIsDesignatedOnIncentiveAndNonqualifiedStockOptionGrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of fair market value for which exercise price is designated on incentive and nonqualified stock option grants.", "label": "Percentage Of Fair Market Value For Which Exercise Price Is Designated On Incentive And Nonqualified Stock Option Grants", "terseLabel": "Percentage of exercise price" } } }, "localname": "PercentageOfFairMarketValueForWhichExercisePriceIsDesignatedOnIncentiveAndNonqualifiedStockOptionGrants", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails" ], "xbrltype": "percentItemType" }, "scyx_PercentageOfPurchasePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of purchase price per share.", "label": "Percentage Of Purchase Price Per Share", "terseLabel": "Percentage of purchase price per share" } } }, "localname": "PercentageOfPurchasePricePerShare", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "scyx_PrefundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prefunded warrants.", "label": "Prefunded Warrants [Member]", "terseLabel": "Pre-funded Warrants" } } }, "localname": "PrefundedWarrantsMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_PrepaidResearchandDevelopmentExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10010.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid research and development expenses, current.", "label": "Prepaid Researchand Development Expenses Current", "terseLabel": "Prepaid research and development services" } } }, "localname": "PrepaidResearchandDevelopmentExpensesCurrent", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "scyx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recently issued accounting pronouncements.", "label": "Recently Issued Accounting Pronouncements Policy [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "scyx_RestrictedCashMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted cash.", "label": "Restricted Cash [Member]", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "scyx_SaleOfCommonStockAtSoleDiscretionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale of common stock at sole discretion, amount.", "label": "Sale Of Common Stock At Sole Discretion Amount", "terseLabel": "Sale of common stock at sole discretion" } } }, "localname": "SaleOfCommonStockAtSoleDiscretionAmount", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "scyx_SaleOfCommonStockMaximumNumberOfShareSoldPerBusinessDay": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of common stock maximum number of share sold per business day.", "label": "Sale Of Common Stock Maximum Number Of Share Sold Per Business Day", "terseLabel": "Sale of common stock maximum number of share sold per business day" } } }, "localname": "SaleOfCommonStockMaximumNumberOfShareSoldPerBusinessDay", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "scyx_SaleOfStockValueOfSharesIssuedInTransactionFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale of stock value of shares issued in transaction fair value.", "label": "Sale Of Stock Value Of Shares Issued In Transaction Fair Value", "terseLabel": "Fair value of shares" } } }, "localname": "SaleOfStockValueOfSharesIssuedInTransactionFairValue", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "scyx_SalesAgreementProspectusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales agreement prospectus.", "label": "Sales Agreement Prospectus [Member]", "terseLabel": "Sales Agreement" } } }, "localname": "SalesAgreementProspectusMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_SeniorConvertibleNotePurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior convertible note purchase agreement.", "label": "Senior Convertible Note Purchase Agreement [Member]", "terseLabel": "Senior Convertible Note Purchase Agreement" } } }, "localname": "SeniorConvertibleNotePurchaseAgreementMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "scyx_SeriesOneWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series one warrant.", "label": "Series One Warrant [Member]", "terseLabel": "Series 1 Warrant" } } }, "localname": "SeriesOneWarrantMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_SeriesTwoWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series two warrant.", "label": "Series Two Warrant [Member]", "terseLabel": "Series 2 Warrant" } } }, "localname": "SeriesTwoWarrantMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "scyx_SharebasedGoodsandNonemployeeServicesTransactionValuationMethodForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Forfeiture Rate", "label": "Sharebased Goodsand Nonemployee Services Transaction Valuation Method Forfeiture Rate", "terseLabel": "Forfeiture rate, non-employees directors" } } }, "localname": "SharebasedGoodsandNonemployeeServicesTransactionValuationMethodForfeitureRate", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodDetails" ], "xbrltype": "percentItemType" }, "scyx_ShelfRegistrationMaximumEquityInitialOfferingPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shelf registration maximum equity initial offering price.", "label": "Shelf Registration Maximum Equity Initial Offering Price", "terseLabel": "Shelf registration maximum equity initial offering price" } } }, "localname": "ShelfRegistrationMaximumEquityInitialOfferingPrice", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "scyx_ShelfRegistrationMaximumEquityOfferingPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shelf registration, maximum equity offering price.", "label": "Shelf Registration Maximum Equity Offering Price", "terseLabel": "Shelf registration maximum equity offering price" } } }, "localname": "ShelfRegistrationMaximumEquityOfferingPrice", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "scyx_SixPercentAprilTwoThousandAndTwentyAndMarchTwoThousandAndNineteenConvertibleSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Six percent April two thousand and twenty and March two thousand and nineteen convertible senior notes.", "label": "Six Percent April Two Thousand And Twenty And March Two Thousand And Nineteen Convertible Senior Notes [Member]", "terseLabel": "6.0% April 2020 and March 2019 Convertible Senior Notes" } } }, "localname": "SixPercentAprilTwoThousandAndTwentyAndMarchTwoThousandAndNineteenConvertibleSeniorNotesMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Six percent convertible senior notes due two thousand and twenty five.", "label": "Six Percent Convertible Senior Notes Due Two Thousand And Twenty Five [Member]", "terseLabel": "March 2019 Notes" } } }, "localname": "SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "scyx_SixPointZeroPercentageSeniorConvertibleNotesDueTwoThousandAndTwentySixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Six point zero percentage senior convertible notes due two thousand and twenty six.", "label": "Six Point Zero Percentage Senior Convertible Notes Due Two Thousand And Twenty Six [Member]", "terseLabel": "April 2020 Notes" } } }, "localname": "SixPointZeroPercentageSeniorConvertibleNotesDueTwoThousandAndTwentySixMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "scyx_StockPurchasePercentageOnAggregateSharesOfCommonStockTraded": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock purchase percentage on aggregate shares of common stock traded.", "label": "Stock Purchase Percentage On Aggregate Shares Of Common Stock Traded", "terseLabel": "Stock purchase percentage on aggregate shares of common stock traded" } } }, "localname": "StockPurchasePercentageOnAggregateSharesOfCommonStockTraded", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "scyx_StockPurchasePriceAverageNumberOfTradingDaysLowestClosingSalesPriceOutOfConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock purchase price average number of trading days lowest closing sales price out of consecutive trading days.", "label": "Stock Purchase Price Average Number Of Trading Days Lowest Closing Sales Price Out Of Consecutive Trading Days", "terseLabel": "Stock purchase price average number of trading days lowest closing sales price out of consecutive trading days" } } }, "localname": "StockPurchasePriceAverageNumberOfTradingDaysLowestClosingSalesPriceOutOfConsecutiveTradingDays", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "scyx_StockPurchasePriceNumberOfConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock purchase price number of consecutive trading days.", "label": "Stock Purchase Price Number Of Consecutive Trading Days", "terseLabel": "Stock purchase price number of consecutive trading days" } } }, "localname": "StockPurchasePriceNumberOfConsecutiveTradingDays", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "scyx_TaxCutsAndJobActsOf2017TemporaryExpenseForCertainBusinessAssetsAndPropertyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017 temporary expense for certain business assets and property, percentage.", "label": "Tax Cuts And Job Acts Of2017 Temporary Expense For Certain Business Assets And Property Percentage", "terseLabel": "Temporary expensing for certain business assets and property, percent" } } }, "localname": "TaxCutsAndJobActsOf2017TemporaryExpenseForCertainBusinessAssetsAndPropertyPercentage", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "scyx_TaxCutsAndJobsActOf2017MaximumPercentageOfPreNetOperatingLossDeductionTaxableIncomeLimitForNetOperatingLossDeduction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017 maximum percentage of pre-NOL deduction taxable income that can be be claimed each year as an NOL deduction.", "label": "Tax Cuts And Jobs Act Of2017 Maximum Percentage Of Pre Net Operating Loss Deduction Taxable Income Limit For Net Operating Loss Deduction", "terseLabel": "Maximum deduction percentage of pre-NOL taxable income" } } }, "localname": "TaxCutsAndJobsActOf2017MaximumPercentageOfPreNetOperatingLossDeductionTaxableIncomeLimitForNetOperatingLossDeduction", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "scyx_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan.", "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "localname": "TermLoanMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "scyx_TermOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of agreement.", "label": "Term Of Agreement", "terseLabel": "Term of agreement" } } }, "localname": "TermOfAgreement", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "scyx_TwoThousandAndFifteenInducementAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and fifteen inducement award plan.", "label": "Two Thousand And Fifteen Inducement Award Plan [Member]", "terseLabel": "2015 Inducement Award Plan" } } }, "localname": "TwoThousandAndFifteenInducementAwardPlanMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "scyx_TwoThousandAndFifteenInducementPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and fifteen inducement plan.", "label": "Two Thousand And Fifteen Inducement Plan [Member]", "terseLabel": "2015 Inducement Plan" } } }, "localname": "TwoThousandAndFifteenInducementPlanMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2015InducementPlanDetails" ], "xbrltype": "domainItemType" }, "scyx_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and fourteen employee stock purchase plan.", "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]", "terseLabel": "2014 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "scyx_TwoThousandAndFourteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and fourteen equity incentive plan.", "label": "Two Thousand And Fourteen Equity Incentive Plan [Member]", "terseLabel": "2014 Equity Incentive Plan" } } }, "localname": "TwoThousandAndFourteenEquityIncentivePlanMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "scyx_TwoThousandAndNineStockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and nine stock option plan.", "label": "Two Thousand And Nine Stock Option Plan [Member]", "terseLabel": "2009 Stock Option Plan" } } }, "localname": "TwoThousandAndNineStockOptionPlanMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "scyx_UnrecognizedTaxBenefitsDecreasesResultingFromDeferredRateChange": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized tax benefits decreases resulting from deferred rate change.", "label": "Unrecognized Tax Benefits Decreases Resulting From Deferred Rate Change", "negatedLabel": "Deferred rate change" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromDeferredRateChange", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "scyx_UpfrontPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront payment received.", "label": "Upfront Payment Received", "terseLabel": "Upfront payment received" } } }, "localname": "UpfrontPaymentReceived", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "scyx_WarrantAssociatedWithSolarLoanAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant associated with solar loan agreement.", "label": "Warrant Associated With Solar Loan Agreements [Member]", "terseLabel": "Warrants to purchase common stock associated with Loan Agreement" } } }, "localname": "WarrantAssociatedWithSolarLoanAgreementsMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "scyx_WarrantLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability current.", "label": "Warrant Liabilities Current", "terseLabel": "Warrant liabilities" } } }, "localname": "WarrantLiabilitiesCurrent", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "scyx_WarrantLiabilitiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant liabilities.", "label": "Warrant Liabilities Policy [Text Block]", "terseLabel": "Warrant Liabilities" } } }, "localname": "WarrantLiabilitiesPolicyTextBlock", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "scyx_WarrantTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant term.", "label": "Warrant Term", "terseLabel": "Warrant term" } } }, "localname": "WarrantTerm", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "scyx_WarrantsAssociatedWithSolarLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants associated with solar loan agreement.", "label": "Warrants Associated With Solar Loan Agreement [Member]", "terseLabel": "Warrants to purchase common stock associated with Solar loan agreement" } } }, "localname": "WarrantsAssociatedWithSolarLoanAgreementMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "scyx_WarrantsExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants expiration date.", "label": "Warrants Expiration Date", "terseLabel": "Warrants, expiration date" } } }, "localname": "WarrantsExpirationDate", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "scyx_WarrantsIssuedExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants issued, expiration period.", "label": "Warrants Issued Expiration Period", "verboseLabel": "Warrant expiration period" } } }, "localname": "WarrantsIssuedExpirationPeriod", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "scyx_WaterstonePharmaceuticalHKLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Waterstone Pharmaceutical HK Limited.", "label": "Waterstone Pharmaceutical H K Limited [Member]", "terseLabel": "Waterstone Pharmaceutical HK Limited" } } }, "localname": "WaterstonePharmaceuticalHKLimitedMember", "nsuri": "http://www.scynexis.com/20201231", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r51", "r92" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r239", "r240", "r414", "r415", "r416", "r417", "r418", "r419", "r438", "r487", "r489" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r239", "r240", "r414", "r415", "r416", "r417", "r418", "r419", "r438", "r487", "r489" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r229", "r239", "r240", "r414", "r415", "r416", "r417", "r418", "r419", "r438", "r487", "r489" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r229", "r239", "r240", "r414", "r415", "r416", "r417", "r418", "r419", "r438", "r487", "r489" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r147", "r148", "r224", "r226", "r488", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r147", "r148", "r224", "r226", "r488", "r518", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r414", "r416", "r419" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "stpr_NJ": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW JERSEY", "terseLabel": "New Jersey" } } }, "localname": "NJ", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201813Member": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.", "label": "Accounting Standards Update201813 [Member]", "terseLabel": "ASU 2018-13" } } }, "localname": "AccountingStandardsUpdate201813Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r99", "r100", "r101", "r102", "r170", "r171", "r172", "r173", "r175", "r176", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r324", "r325", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update Extensible List", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r9", "r10", "r36" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses Current", "terseLabel": "Accrued employee bonus compensation" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r31", "r190" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r22", "r286" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid In Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r95", "r96", "r97", "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r99", "r100", "r101", "r102", "r170", "r171", "r172", "r173", "r175", "r176", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r322", "r323", "r324", "r325", "r440", "r441", "r442", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments For New Accounting Pronouncements [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r243", "r245", "r289", "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r245", "r275", "r288" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation expense related to stock options" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCompensationCostDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseRelatedToStockOptionsDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r78", "r386" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10060.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization Of Financing Costs And Discounts", "terseLabel": "Amortization of debt issuance costs and discount", "verboseLabel": "Amortization of debt issuance costs and discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Anti-dilutive securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r90", "r129", "r138", "r144", "r166", "r337", "r341", "r373", "r459", "r479" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r50", "r90", "r166", "r337", "r341", "r373" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Fair value of financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r246", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r29", "r80" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash And Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r12", "r81", "r87", "r457" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r74", "r80", "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "terseLabel": "Cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r74", "r375" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Noncash financing and investing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r98", "r167", "r168", "r169", "r170", "r171", "r279", "r280", "r281", "r322", "r352", "r374", "r388", "r440", "r441", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change In Accounting Principle Accounting Standards Update Adopted", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r105", "r167", "r168", "r169", "r170", "r171", "r279", "r280", "r281", "r322", "r352", "r374", "r388", "r440", "r441", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in CCYY-MM-DD format.", "label": "Change In Accounting Principle Accounting Standards Update Adoption Date", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r99", "r110", "r174", "r286", "r326" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r88", "r90", "r111", "r112", "r113", "r115", "r116", "r120", "r121", "r122", "r166", "r373" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r221", "r244" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class Of Warrant Or Right [Axis]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class Of Warrant Or Right [Domain]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "terseLabel": "Exercise price of warrants (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right", "terseLabel": "Number of shares received per warrant (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights", "terseLabel": "Number of warrants issued to purchase common stock (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r230", "r364" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper Not Included With Cash And Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r43", "r197", "r464", "r483" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r194", "r195", "r196", "r198" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r210" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r21" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock Value Outstanding", "terseLabel": "Common stock, $0.001 par value, 100,000,000 shares authorized as of December 31, 2020, and December 31, 2019; 19,663,698 and 9,741,372 shares issued and outstanding as of December 31, 2020, and December 31, 2019, respectively" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r227", "r228", "r241", "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation And Employee Benefit Plans [Text Block]", "terseLabel": "Employee Benefit Plan" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation And Retirement Disclosure [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r123", "r476" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract With Customer Liability Revenue Recognized", "terseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt Fair Value Disclosures", "terseLabel": "Fair value of the consideration issued" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt Noncurrent", "terseLabel": "Senior convertible notes" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r83", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion Converted Instrument Amount1", "terseLabel": "Conversion of convertible note, amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r83", "r85" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion Converted Instrument Shares Issued1", "terseLabel": "Conversion of convertible note exchanged for shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Borrowings" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r17", "r18", "r460", "r461", "r477" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Basis spread on variable rate (as a percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r18", "r200", "r461", "r477" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument Carrying Amount", "terseLabel": "Carrying value of debt obligation" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument Convertible Conversion Price1", "terseLabel": "Initial conversion price of notes" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r41", "r211", "r214", "r216" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument Convertible Conversion Ratio1", "terseLabel": "Conversion rate, number of shares to be issued per $1000 of principal (in shares)" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "auth_ref": [ "r41", "r211", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.", "label": "Debt Instrument Convertible Terms Of Conversion Feature", "terseLabel": "Conversion terms" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument Convertible Threshold Consecutive Trading Days1", "terseLabel": "Convertible notes, threshold consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger", "terseLabel": "Convertible notes, threshold percentage of stock price trigger" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument Convertible Threshold Trading Days", "terseLabel": "Convertible notes, threshold trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r385", "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument Face Amount", "terseLabel": "Face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r39", "r361" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument Maturity Date", "terseLabel": "Notes maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument Maturity Date Description", "terseLabel": "Notes maturity description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentOfferingDate1": { "auth_ref": [ "r18", "r211" ], "lang": { "en-us": { "role": { "documentation": "Date the debt instrument was offered for sale, in CCYY-MM-DD format.", "label": "Debt Instrument Offering Date1", "terseLabel": "Date of issuance and sale of notes" } } }, "localname": "DebtInstrumentOfferingDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r40", "r473" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument Payment Terms", "terseLabel": "Payment terms" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodStartDate": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Start date of debt instrument redemption period, in CCYY-MM-DD format.", "label": "Debt Instrument Redemption Period Start Date", "terseLabel": "Convertible notes, redemption start date" } } }, "localname": "DebtInstrumentRedemptionPeriodStartDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount of debt redeemed.", "label": "Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed", "terseLabel": "Redemption price as percentage of the principal amount" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument Repurchase Amount", "terseLabel": "Reacquisition price of outstanding debt" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r42", "r93", "r211", "r215", "r216", "r217", "r384", "r385", "r387", "r475" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument Term", "terseLabel": "Loan agreement term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r32", "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges Policy [Text Block]", "terseLabel": "Amortization of Debt Issuance Costs and Discount" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCosts": { "auth_ref": [ "r15", "r458", "r478" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.", "label": "Deferred Costs", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r32", "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Deferred Finance Costs Net", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r311" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r313" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets Liabilities Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r318", "r319" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10070.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration", "terseLabel": "NOLs subject not to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration", "terseLabel": "NOLs subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r316", "r318", "r319" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10080.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards Research", "terseLabel": "Research and development credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r312" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Valuation allowances" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan Employer Discretionary Contribution Amount", "terseLabel": "Contribution amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match", "terseLabel": "Employer matching percent" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.", "label": "Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Percent", "terseLabel": "Maximum percentage of contributions per employee" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r78", "r188" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Derivative Fair Value Of Derivative Net", "terseLabel": "Derivative, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative Liability Measurement Input", "terseLabel": "Derivative liabilities, unobservable inputs rate" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeMember": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).", "label": "Derivative [Member]", "terseLabel": "Derivative liabilities" } } }, "localname": "DerivativeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Country [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r87", "r117", "r118" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Basic and Diluted Net Loss per Share of Common Stock" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r299" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "totalLabel": "Total income tax benefit" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]", "terseLabel": "Percent of Pretax Income" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r299", "r329" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10010.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Income taxes from continuing operations at statutory rate", "verboseLabel": "Corporate income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r299", "r329" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10100.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Increase in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r299", "r329" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10050.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate", "terseLabel": "Deferred rate change" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r299", "r329" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10040.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r299", "r329" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10070.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation Other Adjustments", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r299", "r329" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10020.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes", "terseLabel": "State income taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r299", "r329" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10090.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation Tax Credits Research", "terseLabel": "R&D credit adjustment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [ "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "label": "Embedded Derivative Fair Value Of Embedded Derivative Liability", "terseLabel": "Bifurcated embedded conversion option derivative liability" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": { "auth_ref": [ "r351" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.", "label": "Embedded Derivative Gain Loss On Embedded Derivative Net", "terseLabel": "Gain (loss) on fair value adjustment of derivative liability" } } }, "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity": { "auth_ref": [ "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the liability for the conversion option reclassified to stockholders' equity when the embedded option no longer required separation from the host instrument.", "label": "Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity", "terseLabel": "Bifurcated embedded conversion option associated with Notes" } } }, "localname": "EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Total unrecognized compensation cost related to unvested share-based compensation arrangements, recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options", "terseLabel": "Total unrecognized compensation cost related to unvested RSU share-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Total unrecognized compensation cost related to unvested share-based compensation arrangements" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Tax Benefit From Compensation Expense", "terseLabel": "Tax benefit from compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCompensationCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Outstanding stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r95", "r96", "r97", "r100", "r107", "r109", "r119", "r173", "r210", "r218", "r283", "r284", "r285", "r324", "r325", "r376", "r377", "r378", "r379", "r380", "r381", "r492", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r78", "r205" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10110.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment Of Warrants", "terseLabel": "Warrant liabilities fair value adjustment" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value Assets Measured On Recurring Basis [Text Block]", "terseLabel": "Summary of Financial Instruments Measured on a Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]", "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r357", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value By Balance Sheet Grouping [Table]", "terseLabel": "Fair Value By Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r358", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r357", "r358", "r360", "r361", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r230", "r231", "r236", "r238", "r358", "r411" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r230", "r231", "r236", "r238", "r358", "r412" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r358", "r413" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation Calculation Roll Forward" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r362", "r365" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r362", "r365" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]", "terseLabel": "Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues", "terseLabel": "December 2020 Public Offering" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r364", "r366" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r87", "r367", "r369" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Of Financial Instruments Policy", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r159", "r163", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r347" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10120.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain Loss On Derivative Instruments Net Pretax", "negatedLabel": "Derivative liability fair value adjustment" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r78", "r202", "r203" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10050.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gains Losses On Extinguishment Of Debt", "negatedLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecurities": { "auth_ref": [ "r151", "r154", "r463" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Held To Maturity Securities", "totalLabel": "Amortized Cost" } } }, "localname": "HeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": { "auth_ref": [ "r156", "r161" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails": { "order": 10010.0, "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Held To Maturity Securities Accumulated Unrecognized Holding Gain", "terseLabel": "Unrealized Gains" } } }, "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": { "auth_ref": [ "r157", "r162" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails": { "order": 10020.0, "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Held To Maturity Securities Accumulated Unrecognized Holding Loss", "negatedLabel": "Unrealized Losses" } } }, "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesCurrent": { "auth_ref": [ "r153" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.", "label": "Held To Maturity Securities Current", "terseLabel": "Short-term investments" } } }, "localname": "HeldToMaturitySecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount": { "auth_ref": [ "r158", "r470" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount", "terseLabel": "Held-to-maturity investments" } } }, "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "auth_ref": [ "r155", "r160", "r463" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails": { "order": 10030.0, "parentTag": "us-gaap_HeldToMaturitySecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Held To Maturity Securities Fair Value", "terseLabel": "Fair Value" } } }, "localname": "HeldToMaturitySecuritiesFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesTextBlock": { "auth_ref": [ "r159", "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).", "label": "Held To Maturity Securities [Text Block]", "terseLabel": "Held-to-maturity Securities" } } }, "localname": "HeldToMaturitySecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r56", "r129", "r137", "r140", "r143", "r145", "r455", "r465", "r468", "r485" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "negatedLabel": "Loss before taxes", "totalLabel": "Loss before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Income Loss From Continuing Operations Per Basic And Diluted Share", "terseLabel": "Net loss per share \u2013 basic and diluted" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseRelatedToStockOptionsDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseRelatedToStockOptionsDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r300", "r309", "r315", "r327", "r330", "r332", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination Penalties And Interest Accrued", "terseLabel": "Income tax examination, penalties and interest accrued" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r91", "r108", "r109", "r128", "r298", "r328", "r331", "r486" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "negatedLabel": "Income tax benefit", "totalLabel": "Total income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Expense Benefit Continuing Operations Income Tax Reconciliation [Abstract]", "terseLabel": "Amount" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r54", "r87", "r296", "r297", "r309", "r310", "r314", "r320", "r520" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r299" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10200.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Increase in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r295", "r299" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10150.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Income Tax Reconciliation Change In Enacted Tax Rate", "terseLabel": "Deferred rate change" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r299" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10110.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate", "terseLabel": "Income taxes from continuing operations at statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r299" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10140.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r299" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10170.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Income Tax Reconciliation Other Adjustments", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r299" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10120.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Income Tax Reconciliation State And Local Income Taxes", "terseLabel": "State income taxes" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r299" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "order": 10190.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Income Tax Reconciliation Tax Credits Research", "negatedLabel": "R&D credit adjustment" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r77" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase Decrease In Accounts Payable And Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r77" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Other Operating Assets And Liabilities Net [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r77" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase Decrease In Prepaid Expenses Other", "negatedLabel": "Prepaid expenses, other assets, and deferred costs" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSecurityDeposits": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in security deposits.", "label": "Increase Decrease In Security Deposits", "terseLabel": "Decrease in security deposit" } } }, "localname": "IncreaseDecreaseInSecurityDeposits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r55", "r127", "r383", "r386", "r467" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10080.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10070.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income Other", "negatedLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r72", "r75", "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r61" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income Net Amortization Of Discount And Premium", "negatedLabel": "Accretion of investment discount" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Debt And Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r165", "r456", "r472", "r517" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]", "terseLabel": "Short-term Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r399", "r401" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInCondensedConsolidatedFinancialStatementsForLeaseDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease Cost", "totalLabel": "Total operating lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInCondensedConsolidatedFinancialStatementsForLeaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Summary of Quantitative Information Associated with Amounts Recognized in Condensed Consolidated Financial Statements for Lease" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee Operating Lease Existence Of Option To Extend", "terseLabel": "Lessee, operating lease, existence of option to extend" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Future Minimum Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r400" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r400" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail": { "order": 10060.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r400" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r400" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r400" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail": { "order": 10040.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r400" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail": { "order": 10030.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r400" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "terseLabel": "Difference between future minimum lease payments and discounted cash flows" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityAndRightOfUseAssetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Option To Extend", "terseLabel": "Renewal term, description" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Renewal Term", "terseLabel": "Renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Term Of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35", "r90", "r139", "r166", "r338", "r341", "r342", "r373" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r90", "r166", "r373", "r462", "r481" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r37", "r90", "r166", "r338", "r341", "r342", "r373" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r357" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities Fair Value Disclosure", "terseLabel": "Fair value of financial liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate L I B O R [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtMeasurementInput": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure long-term debt.", "label": "Long Term Debt Measurement Input", "terseLabel": "Senior convertible notes, unobservable inputs rate" } } }, "localname": "LongTermDebtMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Longterm Debt Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r42", "r199" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities Policy", "terseLabel": "Short-Term Investments" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputCreditSpreadMember": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using amount above (below) yield between two debt instruments similar in maturity, but different in credit quality.", "label": "Measurement Input Credit Spread [Member]", "terseLabel": "Market Credit Spread" } } }, "localname": "MeasurementInputCreditSpreadMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly.", "label": "Measurement Input Discount For Lack Of Marketability [Member]", "terseLabel": "Discounts for Lack of Marketability" } } }, "localname": "MeasurementInputDiscountForLackOfMarketabilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input Expected Dividend Rate [Member]", "terseLabel": "Estimated Yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input Expected Term [Member]", "terseLabel": "Weighted Average Expected Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input Price Volatility [Member]", "terseLabel": "Stock Price Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r74", "r76", "r79" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r52", "r53", "r57", "r79", "r90", "r99", "r103", "r104", "r105", "r106", "r108", "r109", "r114", "r129", "r137", "r140", "r143", "r145", "r166", "r373", "r466", "r484" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r60" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10040.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "negatedTotalLabel": "Total other expense:" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other expense (income):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Operating segments (number)" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10140.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r129", "r137", "r140", "r143", "r145" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10030.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r393", "r401" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInCondensedConsolidatedFinancialStatementsForLeaseDetail": { "order": 10010.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInCondensedConsolidatedFinancialStatementsForLeaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r390" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityAndRightOfUseAssetDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "totalLabel": "Total operating lease liability", "verboseLabel": "Present value of future minimum lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityAndRightOfUseAssetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r390" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityAndRightOfUseAssetDetail": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Operating lease liability, current portion (Note 8)", "verboseLabel": "Operating lease liability, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityAndRightOfUseAssetDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r390" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityAndRightOfUseAssetDetail": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liability (Note 8)", "verboseLabel": "Operating lease liability, long-term portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityAndRightOfUseAssetDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r391", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Total lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInCondensedConsolidatedFinancialStatementsForLeaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r389" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use asset (Note 8)", "verboseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityAndRightOfUseAssetDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r398", "r401" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInCondensedConsolidatedFinancialStatementsForLeaseDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r397", "r401" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Remaining Lease term (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInCondensedConsolidatedFinancialStatementsForLeaseDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforward" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsExpirationDate": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.", "label": "Operating Loss Carryforwards Expiration Date", "terseLabel": "NOLs expiration date" } } }, "localname": "OperatingLossCarryforwardsExpirationDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "auth_ref": [ "r206", "r353", "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Information by type of options indexed to an issuer's equity.", "label": "Option Indexed To Issuers Equity Equity [Axis]", "terseLabel": "Option Indexed to Issuer's Equity" } } }, "localname": "OptionIndexedToIssuersEquityEquityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed To Issuers Equity Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]", "terseLabel": "Description of Business and Basis of Preparation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r11", "r36" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 10030.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10050.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other Expense" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r62" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10100.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "terseLabel": "Other expense" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r58" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10090.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income", "negatedLabel": "Other income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r3", "r6", "r187" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10030.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense Current", "terseLabel": "Other prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r48" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10040.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables", "terseLabel": "Other receivable" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over Allotment Option [Member]", "terseLabel": "Underwriters" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables And Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r70" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments Of Debt Issuance Costs", "negatedLabel": "Payments of senior convertible notes issuance costs", "terseLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r68" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Repurchase of shares to satisfy tax withholdings" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": { "auth_ref": [ "r64", "r152" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.", "label": "Payments To Acquire Held To Maturity Securities", "negatedLabel": "Purchase of investments" } } }, "localname": "PaymentsToAcquireHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r65" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r246", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2015InducementPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2015InducementPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValueOutstanding": { "auth_ref": [ "r20" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.", "label": "Preferred Stock Value Outstanding", "terseLabel": "Preferred stock, $0.001 par value, authorized 5,000,000 shares as of December 31, 2020 and December 31, 2019; 0 shares issued and outstanding as of December 31, 2020 and December 31, 2019" } } }, "localname": "PreferredStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r27", "r28" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10240.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r4", "r6", "r186", "r187" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10020.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r67" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds From Convertible Debt", "terseLabel": "Proceeds from senior convertible notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds From Debt Net Of Issuance Costs", "terseLabel": "Proceeds from debt, net of issuance costs" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInterestReceived": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest received on loans and other debt instruments during the current period.", "label": "Proceeds From Interest Received", "terseLabel": "Cash received for interest" } } }, "localname": "ProceedsFromInterestReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r66" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from common stock issued" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r66", "r278" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans", "terseLabel": "Proceeds from employee stock purchase plan issuances" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r63" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds From Sale Maturity And Collections Of Investments", "terseLabel": "Maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r66", "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Cash received from option exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationCompensationCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds From Warrant Exercises", "terseLabel": "Proceeds from Warrant Exercises" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r52", "r53", "r73", "r90", "r99", "r108", "r109", "r129", "r137", "r140", "r143", "r145", "r166", "r336", "r339", "r340", "r343", "r344", "r373", "r468" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r31", "r191" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r193", "r521", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r30", "r189" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r13", "r14", "r191", "r482" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property Plant And Equipment Other Types [Member]", "terseLabel": "Other" } } }, "localname": "PropertyPlantAndEquipmentOtherTypesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r13", "r191" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r13", "r189" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r237", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r237", "r402", "r404", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r69" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments Of Long Term Debt", "negatedLabel": "Payment of loan payable expected to be refinanced" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r293", "r533" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10150.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and development, net" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseRelatedToStockOptionsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r87", "r293" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r8", "r15", "r86", "r519" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units", "verboseLabel": "Outstanding restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r218", "r286", "r480", "r496", "r501" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r95", "r96", "r97", "r100", "r107", "r109", "r173", "r283", "r284", "r285", "r324", "r325", "r492", "r494" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r125", "r126", "r136", "r141", "r142", "r146", "r147", "r149", "r223", "r224", "r439" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10130.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r396", "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability", "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale Of Stock Number Of Shares Issued In Transaction", "terseLabel": "Common stock shares issued" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale Of Stock Price Per Share", "terseLabel": "Public offering price" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCapitalizationEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Capitalization Equity [Line Items]", "terseLabel": "Schedule Of Capitalization Equity [Line Items]" } } }, "localname": "ScheduleOfCapitalizationEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCapitalizationEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.", "label": "Schedule Of Capitalization Equity [Table]", "terseLabel": "Schedule Of Capitalization Equity [Table]" } } }, "localname": "ScheduleOfCapitalizationEquityTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r245", "r274", "r288" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Stock-Based Compensation Expense Related to Stock Options" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Held To Maturity Securities [Line Items]", "terseLabel": "Schedule of Held-to-maturity Securities [Line Items]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": { "auth_ref": [ "r159", "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).", "label": "Schedule Of Held To Maturity Securities [Table]", "terseLabel": "Schedule Of Held To Maturity Securities [Table]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r31", "r191" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r246", "r277" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2015InducementPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseRelatedToStockOptionsDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]", "terseLabel": "Schedule of Restricted Stock Units (\"RSU\") Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r253", "r263", "r265" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Assumptions Used To Estimate Fair Value of Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r44", "r88", "r120", "r121", "r207", "r208", "r209", "r211", "r212", "r213", "r215", "r216", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r308", "r321" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]", "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit in the form of a standby letter of credit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r87", "r130", "r131", "r132", "r133", "r134", "r135", "r147" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Segment and Geographic Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10160.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling General And Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling General And Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseRelatedToStockOptionsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Vesting period of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Options granted in period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value Roll Forward", "terseLabel": "Aggregate Intrinsic Value ($000)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Ending balance - Outstanding (shares)", "periodStartLabel": "Beginning balance - Outstanding (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance - Outstanding (in dollars per share)", "periodStartLabel": "Beginning balance - Outstanding (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward", "terseLabel": "Weighted Average Grant Date Fair Value Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Weighted average risk-free interest rate, employees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate", "terseLabel": "Weighted average expected volatility, employees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2015InducementPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseRelatedToStockOptionsDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Roll Forward", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized", "terseLabel": "Share-based compensation arrangement by share-based payment award, number of additional shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized", "terseLabel": "Shares authorized under the plan (in shares)", "verboseLabel": "For possible future issuance under employee stock purchase plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2015InducementPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Possible future issuance under equity compensation plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2015InducementPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]", "terseLabel": "Weighted- Average Remaining Contractual Life (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period", "negatedLabel": "Forfeited/expired (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price", "terseLabel": "Forfeited/expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2015InducementPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average value of options granted in period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Balance - Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r255", "r277" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Ending balance - Outstanding (shares)", "periodStartLabel": "Beginning balance - Outstanding (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Ending balance - Outstanding (in dollars per share)", "periodStartLabel": "Beginning balance - Outstanding (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward", "terseLabel": "Weighted- Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r267" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value", "terseLabel": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number", "terseLabel": "Exercisable (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r265" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Vested or expected to vest (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Vested or expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r244", "r250" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r87", "r246", "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.", "label": "Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate", "terseLabel": "Expected dividend yield, non-employees directors" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1", "terseLabel": "Weighted average expected term (in years), non-employees directors" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.", "label": "Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate", "terseLabel": "Weighted average expected volatility, non-employees directors" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.", "label": "Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate", "terseLabel": "Weighted average risk-free interest rate, non-employees directors" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Expiration period of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2009StockOptionPlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EquityIncentivePlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r269", "r287" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Weighted average expected term (in years), employees" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Balance - Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1", "terseLabel": "Vested or expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1", "terseLabel": "Total fair value of shares vested during the year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued Price Per Share", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit", "terseLabel": "Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r19", "r20", "r21", "r88", "r90", "r111", "r112", "r113", "r115", "r116", "r120", "r121", "r122", "r166", "r210", "r373" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r47", "r95", "r96", "r97", "r100", "r107", "r109", "r119", "r173", "r210", "r218", "r283", "r284", "r285", "r324", "r325", "r376", "r377", "r378", "r379", "r380", "r381", "r492", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r95", "r96", "r97", "r119", "r439" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r242", "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Granted During Period Value Sharebased Compensation", "terseLabel": "Aggregate fair value of options granted" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationOptionValuationMethodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r83", "r84", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued1", "terseLabel": "Common stock issued for settlement of senior convertible notes" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r46", "r210", "r211", "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period Shares Conversion Of Convertible Securities", "terseLabel": "Common stock issued for conversion of Notes (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r20", "r21", "r210", "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Common stock issued through employee stock purchase plan and stock option plan (in shares)", "verboseLabel": "Common stock issued through employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensation2014EmployeeStockPurchasePlanDetails", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r20", "r21", "r210", "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Common stock issued, net of expenses (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r210", "r218" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period Shares Restricted Stock Award Gross", "terseLabel": "Common stock issued for vested restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Stock Issued During Period Shares Reverse Stock Splits", "terseLabel": "Stock issued during period as result of reverse stock splits" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r210", "r218", "r256" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Exercised (shares)", "terseLabel": "Common stock issued for exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r47", "r210", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period Value Conversion Of Convertible Securities", "terseLabel": "Common stock issued for conversion" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r20", "r21", "r210", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period Value Employee Stock Purchase Plan", "terseLabel": "Common stock issued through employee stock purchase and stock option plans" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r20", "r21", "r210", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Common stock issued, net of expenses" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r20", "r21", "r210", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period Value Restricted Stock Award Gross", "terseLabel": "Common stock issued for vested restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r47", "r210", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Common stock issued for exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r24", "r25", "r90", "r150", "r166", "r373" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r89", "r218", "r222" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders Equity Note Stock Split Conversion Ratio1", "terseLabel": "Reverse stock split, ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders Equity Reverse Stock Split", "terseLabel": "Common stock, reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r382", "r406" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r382", "r406" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r382", "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r382", "r406" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r405", "r407" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]", "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary Sale Of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward Amount", "terseLabel": "Tax credit carryforward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r159", "r163", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r99", "r100", "r101", "r102", "r170", "r171", "r172", "r173", "r175", "r176", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r322", "r323", "r324", "r325", "r440", "r441", "r442", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type Of Adoption [Member]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r230", "r469" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U S Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "terseLabel": "Unamortized debt issuance cost" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r294", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits", "periodStartLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r306" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions", "terseLabel": "Additions for tax positions of current period" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions", "terseLabel": "Additions for tax positions of prior periods" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r307" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r394", "r401" ], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInCondensedConsolidatedFinancialStatementsForLeaseDetail": { "order": 10020.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInCondensedConsolidatedFinancialStatementsForLeaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant liability", "verboseLabel": "Warrant liabilities" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "calculation": { "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants And Rights Outstanding", "terseLabel": "Warrant liabilities" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.", "label": "Warrants And Rights Outstanding Maturity Date", "terseLabel": "Warrant liabilities, maturity date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants And Rights Outstanding Measurement Input", "terseLabel": "Warrant liabilities, stock price volatility rate" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants And Rights Outstanding Term", "terseLabel": "Warrant liabilities, expected term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted average common shares outstanding \u2013 basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.scynexis.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31010-122693" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r345": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121636179&loc=d3e34841-113949" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "15", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=35708913&loc=d3e50896-113970" }, "r351": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "15", "Topic": "815", "URI": "http://asc.fasb.org/subtopic&trid=2229187" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90198-114008" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519491&loc=d3e90476-114009" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117817908&loc=SL117819236-161440" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r407": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r456": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803" }, "r472": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r517": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r534": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r535": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r536": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r537": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r538": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r539": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r540": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r541": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r542": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3337-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 88 0001564590-21-015962-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-015962-xbrl.zip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�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end